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People falling ill will always want to get treatment for their ailment in the hope of becoming
well again. The great advances in medical science have changed our outlook on the possibil‐
ities to conquer diseases and of life expectancy, especially in the western world. The devel‐
opments that have led to this include the mapping of the human genome and the rapidly
expanding application of this genetic knowledge to preventive medicine, the increasing
knowledge of the role of hormones, the rapid pace of advancement in the field of immune-
related diseases and their treatment, stem cell research, information technology and robotic
techniques in surgery. A valuable approach is also provided by targeted therapies that are
based on the gene environment and drugs that specifically target the diseases; it offers excit‐
ing new possibilities for understanding and managing health and disease.
Like all human skills the practice of medicine has evolved gradually, and from a craft using
rather crude or ineffective measures it has transformed to include modern experimentally
driven medicine and controlled standards of care. The completion of the Human Genome
Project was a major landmark in this evolution. The collaborative efforts have realized the
potential for a paradigm shift in clinical medicine. However, scientists soon found out that
the sequenced genome was not the end point. The genetic code was no solution as such, and
its implications were much more complex than could have been foreseen. Though some dis‐
eases can now be linked to a definitive genetic cause, other diseases are considered complex
and multifactorial. As understanding of human biological variation deepens, hopes for a
practice of medicine tailored for the individual and his genome grow stronger. The ideas
behind such individualized medicine, widely called personalized medicine, are based on the
understanding that individuals differ from each other genetically in ways that significantly
impact disease processes. Though it is generally understood that individuals vary genetical‐
ly more within a given continental population than between populations, different popula‐
tions may have different predispositions for certain diseases. In addition, the efficacy of
medications may vary by population.
DNA is identical up to 99% in the human population, yet each individual has a unique set of
DNA. This uniqueness is maintained by over 30 million variants constituting a platform for
researchers to discover, study and document their implications on our health and behavior.
One field of this type of research aims to personalize the dosage of medicine according to
the patient's unique genetic structure. Furthermore, drugs in standard dosages cannot be
guaranteed to yield normal metabolic responses, and one of the important tasks of pharma‐
cogenetics is to help end cases of adverse drug reactions that in the worst cases can result in
death. DNA is constantly subject to mutations, i.e. accidental changes in its code. Mutations
can lead to missing or malformed proteins, and that can lead to disease. Clinical studies
have shown that molecular targeted therapies in lung cancer, such as EGFR tyrosine kinase
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and multifactorial. As understanding of human biological variation deepens, hopes for a
practice of medicine tailored for the individual and his genome grow stronger. The ideas
behind such individualized medicine, widely called personalized medicine, are based on the
understanding that individuals differ from each other genetically in ways that significantly
impact disease processes. Though it is generally understood that individuals vary genetical‐
ly more within a given continental population than between populations, different popula‐
tions may have different predispositions for certain diseases. In addition, the efficacy of
medications may vary by population.
DNA is identical up to 99% in the human population, yet each individual has a unique set of
DNA. This uniqueness is maintained by over 30 million variants constituting a platform for
researchers to discover, study and document their implications on our health and behavior.
One field of this type of research aims to personalize the dosage of medicine according to
the patient's unique genetic structure. Furthermore, drugs in standard dosages cannot be
guaranteed to yield normal metabolic responses, and one of the important tasks of pharma‐
cogenetics is to help end cases of adverse drug reactions that in the worst cases can result in
death. DNA is constantly subject to mutations, i.e. accidental changes in its code. Mutations
can lead to missing or malformed proteins, and that can lead to disease. Clinical studies
have shown that molecular targeted therapies in lung cancer, such as EGFR tyrosine kinase
inhibitors (TKIs), increase survival, lower toxicity and improve the quality of life in patients.
Despite these advances, the realisation of personalized therapies for the non-small cell lung
cancer (NSCLC) still faces a number of challenges. These include effective integration of
clinical and genetic data and a lack of clinical decision support tools to assist physicians
with patient selection.
Research in personalized medicine is producing new exciting information about the predic‐
tion and prevention of disease with respect to a particular patient and how to find the best
possible treatment for this individual. The goal of this book, “Personalized Medicine, in Re‐
lation to Redox State, Diet and Lifestyle”, was to function as an introduction to this field of
research by describing the general principles and concepts and by reviewing the pertaining
literature. We also tried to make the reading lighter by adding topics of general interest and
curiosity.
Traditional medicines (TM) have been advised by World Health Organization (WHO) to be
considered complementary or alternative to current classic medicine. Recently, targeted
therapy has been proposed to be medical model for individualized healthcare, including all
preventive, diagnostic, and therapeutic medical interventions according to genetic context.
Personalized medicine is an evolving field in which physicians use diagnostic tests to deter‐
mine which medical treatments will work best for each patient. By combining the data from
those tests with an individual's medical history, circumstances and values, healthcare pro‐
viders can develop targeted treatment and prevention plans. ersonalied medicine may revo‐
lutionize healthcare; it will, however, require great efforts.
Certain medications may cure or prevent the disease, whereas some drug interactions can
even be harmful. Thus, for instance, administering too little of a drug or toxin can be harm‐
ful if poor results are achieved in the tumor cells targeted. Variation in drug metabolizing
enzymes can lead to a situation in which individuals who are slow metabolizers are getting
a lower dose and fast metabolizers a higher dose of the drug than required for optimal effi‐
cacy and reduced toxicity. Warfarin, for example, serves as a good example of how pharma‐
cogenetics can be utilized before starting the therapy in order to achieve maximum efficacy
and maximum toxicity (Holbrook et al. 2005, Arch. Intern. Med. 165 (10): 1095). Pharmaco‐
genetics is a potential approach for establishing the guidelines for optimal quality in the use
of medicines, and thus to improve the efficacy and safety of both prospective and licensed
drugs. Pharmacogenetics and pharmacogenomics have been widely recognized as funda‐
mental steps towards personalied medicine. They deal with genetically determined variants
that affect the way in which individuals respond to drugs, and hold the promise to revolu‐
tionize drug therapy by tailoring it according to individual genotypes. Moreover, the appli‐
cation of pharmacogenetics and pharmacogenomics to therapies used in the treatment of
osteoarticular diseases (e.g. rheumatoid arthritis, osteoporosis) is a respective method for
tailoring therapies based on clinically relevant drugs (e.g. disease-modifying anti-rheumatic
drugs, vitamin D, and estrogens).
This book also addresses differences and similarities among drugs, as well as the role of nu‐
trients and dietary supplements. Advice on diet, exercise and cleanliness is found through‐
out the works of Hippocrates – the ancient Greeks understood some of the beneficial links
between lifestyle, environment and health. Pharmacogenetics has the potential to produce
knowledge for optimal quality use of medicines, and to improve the efficacy and safety of
XII Preface
both prospective and licensed drugs. Pharmacogenetics and pharmacogenomics have been
widely recognized as fundamental steps toward personalized medicine.
This book is intended to draw attention to the roles of food and nutrition in human/animal
metabolism. Food and nutrition, which have a central role in maintaining health and pre‐
venting deficiencies, also play an intimate and inextricable role in all aspects of drug metab‐
olism, effectiveness, and safety. Pharmacotherapy, on the other hand, is usually applied to
combat some form of disease, trauma, or at least a medical complaint. However, the borders
between these two disciplines are not always clear, and tend to dissolve. The role of specific
foods of physiologically-active food components called functional foods as many fruits, veg‐
etables, and unprocessed whole foods was introduced in Japan in the 1980s and these foods
have properties that can benefit our health. Hippocrates, nearly 2,500 years ago, stressed the
tent “Let food be thy medicine and medicine be thy food,”. He taught that the first and fore‐
most principle of medicine must be to respect nature's healing forces, which inhabit each
living organism. Certain medications may cure or prevent the disease, whereas some drug
interactions can even be harmful. William Gull said “I do not say no drugs are useful, but
there is not enough discrimination in their use” (Pearce JMS. Sir William Gull (1816-1890)).
“I think for the history of man people have always wanted to see something about their fu‐
ture, and now, through the power of genetics and genomics, we are able to look into the
future in a science-based way” (Lord J.U. Health, University of Miami, Miller School of
Medicine, 01.11.2016.)
I wish to acknowledge the help of a number of people in the preparation of this book. First‐
ly, I wish to thank Allan Atroshi, a Director at the Global Society for Nutrition, Environment
and Health (GSNEH), for the innumerable time he spent helping me edit this book. Second‐
ly I must certainly express my gratitude towards Ilkka Linnankoski, PhD and Mrs Brenda
Linnankoski, for their interest, as well as thoughtful reading and suggestions that helped to
strengthen the book. Last, but certainly not least, this book would not have been possible
without the support of the authors who contributed to this book. Thank you so very much
for all your help in making the book a success.
Faik Atroshi
Pharmacology and Toxicology at the University of Helsinki
Helsinki, Finland
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Abstract
The purpose of this chapter is to clarify the prevalence of Helicobacter pylori infection (HPI)
and atrophic corpus gastritis (ACG) in patients with intellectual disability (ID) and review
the literature surrounding them. We measured the levels of pepsinogen I, pepsinogen II,
gastrin-17b (basal), and Helicobacter pylori antibodies from 243 patients with intellectual
disability living in Rinnekoti Research Centre at Lakisto area during 2009–2011. We
determined the levels of hemoglobin, mean cell volume (MCV), hematocrit, and the mean
amount (MCH) and concentration (MCHC) of red cell hemoglobin, the counts of erythro-
cytes, leucocytes, and thrombocytes. About 43% had high level of Helicobacter pylori
antibodies and 6% ACG. Our results show that Helicobacter pylori infection occurs
approximately twice the rate it appears in the normal population. Also, the incidence of
ACG was higher among patients with ID than normal population. ID may be a risk of
getting the Helicobacter pylori infection (HPI) and ACG. In addition, it was found that the
level of thrombocytes was increased in HPI group compared to normal group and
decreased in ACG group compared to normal group. This study shows that there is
clearly a need to investigate (test) more stomach condition in patients with ID.
Keywords: helicobacter, Helicobacter pylori, pepsinogen, gastritis, atrophic corpus gastritis,
intellectual disability, personalized medicine
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gastrin-17b (basal), and Helicobacter pylori antibodies from 243 patients with intellectual
disability living in Rinnekoti Research Centre at Lakisto area during 2009–2011. We
determined the levels of hemoglobin, mean cell volume (MCV), hematocrit, and the mean
amount (MCH) and concentration (MCHC) of red cell hemoglobin, the counts of erythro-
cytes, leucocytes, and thrombocytes. About 43% had high level of Helicobacter pylori
antibodies and 6% ACG. Our results show that Helicobacter pylori infection occurs
approximately twice the rate it appears in the normal population. Also, the incidence of
ACG was higher among patients with ID than normal population. ID may be a risk of
getting the Helicobacter pylori infection (HPI) and ACG. In addition, it was found that the
level of thrombocytes was increased in HPI group compared to normal group and
decreased in ACG group compared to normal group. This study shows that there is
clearly a need to investigate (test) more stomach condition in patients with ID.
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1. Literature review
1.1. Helicobacter pylori infection
Helicobacter pylori is a common Gram-negative bacterium, which may colonize the human
stomach, wherein it can induce various gastroduodenal disorders (chronic gastritis, ulceration,
atrophic corpus gastritis, and gastric cancer). However, only a small part of the people, who
are colonized, develops associated diseases. It is estimated that H. pylori infection (HPI) affects
more than half of the adult population worldwide [1] and is responsible for 75% of all gastric
cancer cases [2]. In Finland and many other countries, the prevalence of H. pylori is decreased
in last decades, in Finland to the level of approximately 15% of population [3]. Intellectually
disabled children are a vulnerable subgroup and may experience higher rates of infections and
morbidities [4]. H. pylori infection and gastric cancer occur at higher rates in subjects with ID
than in the general population [5]. In institutionalized patients with intellectual disability (ID),
Helicobacter pylori infection (HPI) occurs twice the rate it appears in the normal population [6–8].
It is suggested that the transmission of HPI occur via an oral-oral or fecal-oral pathway. Ohwada
et al. [9] concluded that a high frequency of mild norm chromic anemia in institutionalized
people with ID was observed. According to them, medications and chronic inflammation may
increase the risk of anemia. Telaranta-Keerie et al. [10] noted the prevalence of 3.5 % of popula-
tion for atrophic corpus gastritis (ACG) and also found that ACG may cause impairment in
secretion of intrinsic factor, resulting in vitamin B12 deficiency. Because of these observations, we
decided to evaluate the hematological values of our patients with ID. ACG can be autoimmune
in origin or it can appear as multifocal atrophic gastritis (MAG) [11, 12]. According to Telaranta-
Keerie et al. [10], MAG is always HPI-initiated. Achlorhydric or hypochlorhydric stomach with
ACG may result in malabsorption of vitamin B12, micronutrients, and medicines [13]. It is well
known that the stomach must be acid in order to absorb B12. Many people already suffer from
borderline B12 deficiency—this is a difficult vitamin for the body to assimilate, but essential for
normal biochemistry. Therefore, achlorhydria may be associated with vitamin B12 deficiency in
the setting of pernicious anemia. Parenteral vitamin B12 may be important in selected patients.
Achlorhydria is associated with thiamine deficiency in the setting of bacterial overgrowth
[14–16]. In addition, increasing evidence accumulates that H. pylori infection may interfere with
many biological processes and have a role in birth of several other extra-gastroduodenal mani-
festations including among others iron deficiency anemia, immune thrombocytopenic purpura,
metabolic syndrome and diabetes mellitus, nonalcoholic fatty liver disease, coronary artery
disease and cerebrovascular disorders [17]. Because of these facts, ACG is important disease to
be diagnosed and recognized [18, 19]. It has been observed that Helicobacter pylori infection can
cause rumination and numerous other behavioral disorders [20].Helicobacter pylori are associated
with gastric atrophy and gastric carcinoma [21].
1.2. The role of epidemiology in understanding the health effects of Helicobacter pylori in
intellectual disability
H. pylori infection appears to be almost universal among certain groups of people with intel-
lectual disability and appears to be a relatively silent condition in this population, even in
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those with more virulent strains [22]. The ID is potentially at risk of significant but preventable
morbidity and mortality from the disease consequences of this infection [23]. The efficacy of
standard treatment protocols appear lower than that in the general population, and in some,
the side effects are more prominent [24]. The diagnosis of H. pylori infection can be made with
reasonable clinical certainty using the fecal antigen test (and serology under some conditions)
or, in those with greater abilities, using the urea breath test [25]. Although eradication of
infection does not change the level of maladaptive behavior or intellectual disability, it may
reduce the risk of the disease consequences of H. pylori. Given the clinical silence of the
infection, the virulence of the strains, the acceptability of the diagnostic tests, and knowledge
of the risk factors for infection, despite a possible lower eradication rate and higher rate of side
effects, a strong argument can be made to proactively screen for and treat H. pylori infection
among groups of people with intellectual disability who have a history of institutionalization,
greater levels of intellectual disability or maladaptive behavior, or live with flatmates with
hypersalivation or fecal incontinence [5].
Intellectually disabled children are a vulnerable subgroup and may experience higher rates of
infections and morbidities [4]. H. pylori infection and gastric cancer occur at higher rates in
subjects with ID than in the general population [5, 7]. Many children with ID and neurological
impairments are not able to co-operate with performance of noninvasive test such as UBT [7].
In addition, because of limitations in their intellectual and adaptive functioning, such children
are unable to report their symptoms. Behavior of people with ID is often difficult to explain
and reactions may be similar on physical and emotional stress that is why they may be
misunderstood and over medicated. One of the main reasons to begin this research study in
our research center—Rinnekoti Research Centre—was the fact that patients with ID very often
have difficulties to recognize, localize and indicate their symptoms. Although life-long
H. pylori associated morbidities are well known, relatively few studies have addressed the
status of H. pylori infection in people with ID [5].
1.3. Helicobacter infection and gastric neoplasia
As discussed above, Helicobacter pylori are one of the world’s most common pathogens with a
colonization of about 60% of the general population [26, 27]. It is estimated that H. pylori
infection affects more than half of the adult population worldwide [1] and is responsible for
75% of all gastric cancer cases [2]. No mode of transmission is fully known, however, many
factors may contribute such as socio-economic and poor living standards, poor nutrition and
physical activity, and possibly poor access to health services. However, most individuals never
develop clinical disease [28].
Gastrointestinal problems in handicapped children with neurodevelopmental disabilities are
chronic and present long-term management problems. These conditions include dysphagia
(60%), chronic pulmonary aspiration (41%), gastroesophageal reflux (32%), abdominal pain and
gastritis (32%), constipation (74%), and malnutrition (33%) [29]. Growth failure and malnutrition
are common in children with cerebral palsy, particularly in those with spastic quadriplegia, of
which 85% report feeding problems [30, 31]. In addition, 20–30% of hemiplegic and diplegic
cerebral palsy children are underweight for age [26, 32]. There are multifactorial causes:
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insufficient food intake, feeding problems, increased nutrient losses from vomiting or
diarrhea, and alterations in energy requirements in epileptic or metabolic syndromes where
increased muscle tone or involuntary movements are seen. What is now clear is that undernu-
trition in cerebral palsy is often correctable and that providing a balanced diet and better
nutrition can result in improvement in long-term spasticity, appearance, and effect of these
children [33].
Good number of studies have been published in persons with intellectual disability, however,
large-scale scientific studies have not been publishedwith a population case-control study [22, 32,
34]. Harris et al. [35] (10) reported that hospital residents under 40 years of age had a 87%
prevalence of HP compared with 24% for controls, whereas the overall prevalence for all ages
was 87% for residents, and 43% for controls in hospital residents with severe learning disabilities.
A larger study including 338 intellectually disabled and 254 controls from Holland (12) found a
prevalence of 5% in children and 50% in the elderly in the general population, whereas 83% of the
disabled and 27% of the healthy employees were infected. The presence of HP was significantly
associated with male gender, longer duration of institutionalization, an IQ below 50, rumination,
and a history of upper abdominal symptoms. Another study was conducted to determine the
occurrence of HP infection in persons, who presented with severe dyspeptic symptoms and to
monitor clinically the effect of treatment [36]. Over a 1-year period, a total of 43 persons (total
population in care was 224) had severe dyspeptic symptoms and 42 persons (98%, 26 males, 16
females, mean age 45 years, mean institutionalization 20 years) had HP.
1.4. Treatment regimens used for H. pylori eradication
H. pylori infection is most likely acquired by ingesting contaminated food and water, and
through person to person contact. H. pylori infections are usually treated with antibiotics to
help prevent the bacteria from developing a resistance to any particular antibiotic. Helicobacter
pylori infection causes progressive damage to gastric mucosa and results in serious disease
such as peptic ulcer disease, MALT lymphoma, or gastric adenocarcinoma in 20–30% of
patients [37]. Most persons who are infected with H. pylori never suffer any symptoms related
to the infection; however, H. pylori causes chronic active, chronic persistent, and atrophic
gastritis in adults and children. Infection withH. pylori also causes duodenal and gastric ulcers.
Infected persons have a two- to six-fold increased risk of developing gastric cancer and
mucosal-associated-lymphoid-type (MALT) lymphoma compared with their uninfected coun-
terparts. The role of H. pylori in nonulcer dyspepsia remains unclear [38]. Therapy for H. pylori
infection consists of 10 days to 2 weeks of one or two effective antibiotics, such as amoxicillin,
tetracycline (not to be used for children <12 years), metronidazole, or clarithromycin, plus
either ranitidine bismuth citrate, bismuth subsalicylate, or a proton pump inhibitor [39, 40]. H
pylori eradication rates were higher for a 7-day antibiotic regimen containing lansoprazole,
amoxicillin, and clarithromycin (LAC), when used as first-line therapy compared with
levofloxacin, amoxicillin, and lansoprazole (LAL) [39]. Yoon et al. [40] investigated the efficacy
of a moxifloxacin-containing triple therapy as second-line therapy forH. pylori infection as well
as the effect of treatment duration and antibiotic resistance on the eradication rate [40].
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Combination drug therapy regimens commonly used to treat H. pylori infection includes a
proton pump inhibitor (PPI) plus clarithromycin plus amoxicillin or metronidazole and a
proton pump inhibitor plus a bismuth compound plus metronidazole plus tetracycline. How-
ever, all medicines have side effects. But many people don’t feel the side effects or they are able
to deal with them [38, 41, 42].
1.5. Helicobacter pylori infection and oxidative stress
Oxidative stress results from the damaging action of reactive oxygen species. These molecules
react with proteins, lipids, or DNA, altering their structure and causing oxidative damage to the
cells. Reactive oxygen species (ROS) are produced during normal and physiological process,
which inevitably leads to the generation of oxidative molecules: superoxide (O2•
_), hydrogen
peroxide (H2O2), or hydroxyl radical (•OH). Oxidative stress is implicated in a large number of
diseases: cancer (oxidative damage to DNA causes mutations that can lead to carcinogenesis),
atherosclerosis (atherosclerotic plaques are made from oxidized fat), and neurodegenerative
diseases (oxidative damage is a central component of nerve cell destruction). Indicators of oxida-
tive stress have been detected inmuscles and blood of IDpatients. Oxidative damage can alter the
blood-brain barrier, which could explain some of the cognitive problems experienced by patients.
There is an increasing evidence that microbial pathogens induce oxidative stress in infected
host cells [43–45] and this may represent an important mechanism leading to epithelial injury
in H. pylori infection [46].
Oxidative stress could well play a role in the altered epithelial proliferation, increased apopto-
sis, and increased oxidative DNA damage [47–49] associated with H. pylori infection.
Evidence for this includes increased levels of reactive oxygen species (ROS) measured in the
mucosae of infected patients [48, 50, 51]. While activated, ROS-releasing phagocytic leukocytes
recruited to the gastric mucosa during infection represent one obvious source of oxidative
stress [43, 50].
The mechanism of tissue damage and cell proliferation in H. Pylori infection remains unknown,
although cytokines, chemokines, growth factors, including nitric oxide synthase and potent
neutrophil. Derive reactive oxygen metabolism have all been proposed to contribute to such
damage [52–54]. HP infection is associated with the increased production of free radicals in the
gastric mucosa [50]. Accumulated free radicals in the tissue initiate lipid peroxidation of cell
membranes and threaten cell integrity. Antioxidant may be useful in HP-related mucosal disease
[47]. Evidence suggests that microbial pathogens induce oxidative stress in infected host cells
[43–45], which represents an important mechanism causing damage to the epithelial in H. pylori
infection [55]. Helicobacter pylori is the major cause of acute and chronic gastritis, gastric, and
duodenal ulcer and increased incidence of gastric adenocarcinoma and elevated gastric mucosa
lymph proliferation. Reactive oxygen species have been suggested as one of the main causes of
cell injury in H. pylori associated gastritis. H. pylori mutants that are defective in RuvC have
increased sensitivity to DNA-damaging agents and to oxidative stress, exhibit reduced survival
within macrophages, and are unable to establish successful infection in a mouse model [56].
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2.1. Material and methods
GastroPanel test (Biohit Oyj, Helsinki) was used. The test consisted of measurement of plasma
pepsinogen I, pepsinogen II (PG I, PG II and PG I/PG II ratio), H. pylori IgG antibodies (HpAb)
and gastrin-17-basal by the ELISA method. Test results, together with a short interpretation of
the results are created by the GastroSoft software. The GastroSoft software uses an algorithm
that is based on the levels of PG I, PG II, HpAb, and gastrin-17-basal in plasma as measured by
GastroPanel. When the results showed a low PG I level (<30 μg/l) and/or a low PG I/PG II ratio
(<3), the GastroSoft interpretation was “moderate or severe atrophic corpus gastritis”. Cases
fulfilling these criteria were considered to have advanced ACG. If PG I level and PG I/PG II
ratio were normal but the patient had an elevated HpAb result (≥30 EIU), this was interpreted
as “nonatrophic H. pylori gastritis”. When the levels of all the biomarkers were within their
reference ranges (PG I ≥ 30 μg/l and PG I/PG II ratio ≥ 3, HpAb below 30 EIU), the GastroSoft
interpretation was “healthy, normal stomach mucosa”.
2.2. Laboratory determinations and reagents
Vacuette serum tubes were used to obtain serum samples and vacuette K2EDTA tubes were
used to obtain hematological samples. Hemoglobin, mean cell volume (MCV), hematocrit,
erythrocytes, thrombocytes, and leukocytes were assayed with Sysmex KX-21 N analyzer. All
used reagents were reagent grade. All laboratory determinations were controlled with the
control samples from Labquality Ltd., Helsinki, Finland. All enzyme immunoassays were
done with BP 800 reader.
2.3. Study population
The study material consisted of blood samples from patients with intellectual disability (243
individuals). Patients with ID lived in groups containing 6–8 persons during 2009–2011. Age
was from 10 to 80. The whole group consisted 157 male and 86 female patients with ID.
Sanitary facilities were common for each group as normal family living. The personnel taking
care of these patients was living with them for 24 hours per day with 8–10 hours shifts.
3. Results
We measured the levels of pepsinogen I, pepsinogen II, gastrin 17-beta, and Helicobacter pylori
antibodies from 243 patients with intellectual disability (157 male patients and 86 female
patients). Results are shown in Tables 1 and 2 and Figures 1–4. The prevalence of subjects
with ACG, HPI, and normal stomach mucosa is shown in Table 1. Among male patients, 7%
had ACG, while among female patients, 4.7% had ACG. 6.2% of all patients had ACG. Among
male patients, 45.2% had HPI, while among female patients, 39.5% had HPI. About 43.2% of all
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patients had HPI. Among male patients, 47.8% had normal stomach mucosa, while among
female patients, 55.8% had normal stomach mucosa. About 50.6% of all patients had normal
stomach mucosa (Table 1). Differences in the levels of pepsinogen II, PG I/PG II, and
Helicobacter pylori antibodies between HPI group and normal group were statistically
extremely significant. Differences in the levels of pepsinogen I, PG I/PG II, and Helicobacter
pylori antibodies between ACG group and normal group were also statistically extremely
significant. Differences in the levels of hemoglobin, hematocrit, erythrocytes, and leucocytes
between HPI group and normal group were not statistically significant. The level of thrombo-
cytes was increased in HPI group compared to normal group and decreased in ACG group
compared to normal group. These differences were statistically significant. Differences in the
MCHC, MCH, and MCV were not statistically significant between these groups. Same results
were between ACG group and normal group (Table 2).
Table 2. Five gastro and eight hematological parameters in groups with advanced corpus gastritis (ACG), Helicobacter
pylori antibodies (HPI), and healthy stomach mucosa (normal).
Table 1. Prevalence of subjects with advanced atrophic corpus gastritis (ACG), elevated Helicobacter pylori antibodies,
and normal stomach mucosa in male and female patients with ID.
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(<3), the GastroSoft interpretation was “moderate or severe atrophic corpus gastritis”. Cases
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ratio were normal but the patient had an elevated HpAb result (≥30 EIU), this was interpreted
as “nonatrophic H. pylori gastritis”. When the levels of all the biomarkers were within their
reference ranges (PG I ≥ 30 μg/l and PG I/PG II ratio ≥ 3, HpAb below 30 EIU), the GastroSoft
interpretation was “healthy, normal stomach mucosa”.
2.2. Laboratory determinations and reagents
Vacuette serum tubes were used to obtain serum samples and vacuette K2EDTA tubes were
used to obtain hematological samples. Hemoglobin, mean cell volume (MCV), hematocrit,
erythrocytes, thrombocytes, and leukocytes were assayed with Sysmex KX-21 N analyzer. All
used reagents were reagent grade. All laboratory determinations were controlled with the
control samples from Labquality Ltd., Helsinki, Finland. All enzyme immunoassays were
done with BP 800 reader.
2.3. Study population
The study material consisted of blood samples from patients with intellectual disability (243
individuals). Patients with ID lived in groups containing 6–8 persons during 2009–2011. Age
was from 10 to 80. The whole group consisted 157 male and 86 female patients with ID.
Sanitary facilities were common for each group as normal family living. The personnel taking
care of these patients was living with them for 24 hours per day with 8–10 hours shifts.
3. Results
We measured the levels of pepsinogen I, pepsinogen II, gastrin 17-beta, and Helicobacter pylori
antibodies from 243 patients with intellectual disability (157 male patients and 86 female
patients). Results are shown in Tables 1 and 2 and Figures 1–4. The prevalence of subjects
with ACG, HPI, and normal stomach mucosa is shown in Table 1. Among male patients, 7%
had ACG, while among female patients, 4.7% had ACG. 6.2% of all patients had ACG. Among
male patients, 45.2% had HPI, while among female patients, 39.5% had HPI. About 43.2% of all
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patients had HPI. Among male patients, 47.8% had normal stomach mucosa, while among
female patients, 55.8% had normal stomach mucosa. About 50.6% of all patients had normal
stomach mucosa (Table 1). Differences in the levels of pepsinogen II, PG I/PG II, and
Helicobacter pylori antibodies between HPI group and normal group were statistically
extremely significant. Differences in the levels of pepsinogen I, PG I/PG II, and Helicobacter
pylori antibodies between ACG group and normal group were also statistically extremely
significant. Differences in the levels of hemoglobin, hematocrit, erythrocytes, and leucocytes
between HPI group and normal group were not statistically significant. The level of thrombo-
cytes was increased in HPI group compared to normal group and decreased in ACG group
compared to normal group. These differences were statistically significant. Differences in the
MCHC, MCH, and MCV were not statistically significant between these groups. Same results
were between ACG group and normal group (Table 2).
Table 2. Five gastro and eight hematological parameters in groups with advanced corpus gastritis (ACG), Helicobacter
pylori antibodies (HPI), and healthy stomach mucosa (normal).
Table 1. Prevalence of subjects with advanced atrophic corpus gastritis (ACG), elevated Helicobacter pylori antibodies,
and normal stomach mucosa in male and female patients with ID.
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Figure 2. The levels of pepsinogen II on 243 patients with ID.
Figure 1. The levels of pepsinogen I on 243 patients with ID.
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Figure 4. The levels of H. pylori antibodies on 243 patients with ID.
Figure 3. The levels of Gastrin 17-b on 243 patients with ID.
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This study provides an overview of the best available evidence on the prevalence of H. pylori
infection obtained from patients with intellectual disability.
The level of ID and environmental factors may be related to the risk of infection with H. pylori [7].
According to Merrick, 43 persons (total population in care was 224) had severe dyspeptic symp-
toms.Wallace et al. [7] showed that adultswith IDmaybe at risk of infectionwithHPI.According to
their results, a long period of institutionalization living with other patients predisposes to HPI.
Helicobacter pylori among patients with ID living in hospitals are common [7]. In institutionalized
patients with intellectual disability (ID), Helicobacter pylori infection (HPI) occur twice the rate it
appears in the normal population [6–8]. However, this trend has not been before observed in
Finland. The patients with ID lived in groups containing 6–8 persons. Sanitary facilities were
common for each group as normal family living. It is suggested that the transmission of HPI occur
via anoral-oral or fecal-oral pathway. Themechanismof transmissionof this pathogen is not known
exactly. But it is known that the rate of this disease is increasedwith age and other living conditions.
According to our findings, patients with ID and age of 50 and living for a long time in group
residences are high at risk to get Helicobacter pylori infection and also so atrophic corpus gastritis.
Becausewell-beingof patientswith ID is important,wedecided todetermine also the hematological
values of these people. We did not find any big differences between the patients with healthy and
sick stomach mucosa. The count of thrombocytes was increased in HPI group and decreased in
ACG group. Thrombocytes have an important role in inflammation [57]. They participate in
inflammatory response to H. pylori infection by activation and aggregation as well as acting as a
source of inflammatory mediators and modulating the activity of other inflammatory cells in
stomach mucosa [58]. The volume of thrombocytes may be increased during infection. Their
persistent activation and enhanced destruction production process during infection may lead to
decreased amounts of them [59]. However, it seems that there lacks association between H. pylori
infection and various markers of systemic inflammation including thrombocyte/lymphocyte ratio
in adults with chronic asymptomatic H. pylori infection [60]. Helicobacter pylori infection and its
consequences may be severe to people with ID. Wallace et al. [7] concluded that if this infection
leads to increased levels of maladaptive behavior, this could result in loss of social opportunities,
sedativedruguse and sodecrease ofwell-being. Themental pressure amongworkers in institutions
for people with ID will increase. Böhmer et al. [61] and Schryver et al. [62] found that Helicobacter
pylori infection is an occupational risk in healthcareworkersworking in institutions for peoplewith
ID. This observation gives the reason to also investigate all workers taking care of patients with ID.
Proujansky et al. [20] stated that rumination may be a possible symptom of Helicobacter pylori
infection. Rumination occurs more frequently in patients with ID. Dentists play the important
role in finding patients with rumination. From these patients, it is important to investigate
Helicobacter pylori infection and treat it. Ohwada et al. [9] found that the prevalence of anemia
was increased on patients with ID. According to their results, most patients showed a
normocytic norm chromic anemia pattern. They say that medications and inflammation may
increase the risk of anemia. We did not find differences on hemoglobin levels between the
patients with normal and sick mucosa of stomach. We need more research on this field.
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Wallace et al. [63, 64] reported that 7% of institutionalized adults with ID treated for
Helicobacter pylori infection and test negative at the end of treatment are at risk of reinfection.
They suggest that patients with ID should retest at an interval of approximately 3–5 years after
apparent eradication. More research is needed to evaluate the effects of Helicobacter pylori
infection on pain and use of drugs on patients with ID. Taking care of this infection, we can
probably increase the level of well-being of these patients and so to decrease the physical and
physiological pressure of workers in institutions for people with ID. Many studies have
explored the association of H. pylori with hypermethylation of specific genes [65, 66] as well
as hypomethylation of genes [67, 68]. Further research is required to elucidate the exact
mechanisms of inflammation and tumor suppression, which might provide new opportunities
for personalized treatment options.
The poor prognosis of patients with a negative H. pylori status might be the result of a more
aggressive form of gastric cancer [69, 70]. The present study demonstrates that H. pylori positiv-
ity is a beneficial prognostic indicator in patients with intellectual disability, independent of
other clinic pathologic variables. In clinical practice, patients with curatively resected gastric
cancer who are negative for H. pylori may need more careful follow-up and more aggressive
antitumor treatment to prolong life expectancy. Further research is required to elucidate the
exact mechanisms of inflammation and tumor suppression, which might provide new opportu-
nities for personalized treatment options. We believe that the current prospective study is the
first to confirm H. pylori status as a favorable prognostic factor in a large number of intellectual
disability patients with Helicobacter pylori infection and atrophic corpus gastritis in Finland, thus
validating the effect of H. pylori infection status on survival in intellectual disability patients.
Antibiotic susceptibility should be checked in all patients, ideally, before the start of eradication
treatment. The knowledge of local antibiotic resistance and consumption pattern is important in
selecting a reliable regimen [71–73]. Future development forH.pylori therapy shouldbedirected to
overcome individualized antibiotic resistance.Warneke et al. [74] investigated various phenotypic
and genotypic biomarkers of gastric cancer (GC) and concluded whether these biomarkers are
suitable for the identification of GC subtypes, are they of prognostic significance, and should any
of these biomarkers be considered to tailor patient treatment in the future. There remains a need to
better understand theprognostic factors affecting the cure rate ofHelicobacter pylori infectionmight
lead to the development of novel prevention strategies and therapeutic targets. Therefore, person-
alizedmedical approachwill likely increase the cure rate ofH. pylori infection [75].
A complete history could also do away with the need for additional testing and increased
medical expenses for the patient and the healthcare system as a whole.
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Abstract
Antisocial personality disorder (ASPD) is a persistent psychiatric disorder. Behaviors 
and emotions deviate from the norm. Inherent impulsivity, comorbid alcohol depen-
dence, and violation of laws cause severe challenges at individual and societal levels. 
Both environment and heritability alter the risk for ASPD. Research shows that specific 
biologic changes predispose to this disorder. Biological factors may lead to novel possi-
bilities to treat and alleviate symptoms with medications or nutritional means. However, 
treatment of ASPD meets particular challenges due to the inherent symptoms of the dis-
order, and firm evidence-based personalized treatments are scant. This chapter describes 
the disorder and associated adverse outcomes in life such as recurrent violent behavior 
and increased mortality. Moreover, treatment possibilities are discussed covering risk 
assessment, medication, psychotherapy, and nutrition.
Keywords: antisocial personality disorder, ASPD, alcoholism, impulsivity, violent 
behavior
1. Introduction
Antisocial personality disorder (ASPD) is a psychiatric disorder, which despite being prob-
ably heavily under diagnosed has at least a prevalence of 1 in 100 persons [1]. The golden 
standard of treatment of psychiatric disorders is a combination of pharmacological treatment 
and psychotherapy. To date, there are no specific golden standards of pharmacological or 
psychotherapeutic treatments of ASPD, but in the future, treatment results may improve 
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after careful selection of whom to treat. ASPD forms a patient group, which has a poor treat-
ment compliance in general due to inherent diagnostic symptoms of unplanned lifestyle and 
impulsive decision-making.
2. What is ASPD: what to treat
The core symptoms of ASPD are antisocial attitudes that lead to generally destructive behavior 
in part due to the inherent impulsive behavior and severe alcoholism (early-onset type II alco-
holism) associated with this disorder. ASPD is diagnosed among adults, but it is preceded by 
conduct disorder symptoms before age 15, symptoms such as running away from home, initia-
tion of physical fights, usage of weapons in fights, forcing others into sexual activity, cruelty to 
animals, destruction of other persons’ property, deliberately engaged in fire-setting, frequent 
lying, and stealing. An extensive description of conduct disorder, however, is beyond the scope 
of this article.
Diagnostic symptoms of ASPD have not changed much over time. The symptom cluster 
includes the following type of items [2]:
• Inability to sustain consistent work or studies due to lack of motivation, repeated absence 
from work, impulsive abandonment of several jobs without realistic plans of future jobs or 
education.
• Failure to conform to social norms with respect to lawful behavior, as indicated by repeat-
edly performing acts that are grounds for arrest (whether arrested or not), e.g., destroying 
property, harassing others, stealing, and pursuing an illegal occupation.
• Irritability and aggressiveness, as indicated by repeated physical fights or assaults.
• Repeatedly failing to honor financial obligations, as indicated by defaulting on debts or 
failing to provide child support on regular basis.
• Impulsive behavior and inability to plan ahead, as indicated by, e.g., traveling from place 
to place without a prearranged job or clear goal for the period of travel or clear idea about 
when the travel will terminate and lack of a fixed address for a long period.
• No respect for the truth as indicated by repeated lying, use of aliases, and “conning” others 
for personal profit or pleasure.
• Recklessness regarding own or others’ safety, as indicated by driving while intoxicated or 
recurrent speeding.
• If being a parent or guardian, lacks ability to function as a responsible parent, as indi-
cated by, for instance, malnutrition of child, child’s illness resulting from lack of minimal 
hygiene, child’s dependence on neighbors or nonresident relative for food or shelter, 
failure to arrange for a caretaker for your child when parent is away from home, and 
repeated squandering on personal items or of money required for household necessities.
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• Never sustained a totally monogamous relationship for more than 1 year.
• Lacks remorse (feels justified in having hurt, mistreated, or stolen from others).
Realistic foci of treatment for persons diagnosed with ASPD are (i) modulation of attitudes, 
(ii) decrease of impulsive behavior, and (iii) treatment of alcoholism.
3. Personalized focus and selection of whom to treat
As patient care resources and skills to treat specifically ASPD are limited, there is a strong 
rationale to carefully choose the target groups of individuals suffering from ASPD, whom 
should persistently be encouraged and motivated to treatment. For this, two separate ways 
of selective approach may be adapted, each focusing on different criteria. One alternative for 
selection of whom to treat in this patient group would be a focus in primary prevention when 
the first symptoms appear and accumulate (early interventions). Another focus is secondary 
prevention and treatment when the first tangible severe consequences of having ASPD appear.
Some of the more obvious measurement tools that could be considered for the decision-
making on whether to start an intervention or not would be presence of persistent alcohol 
consumption and conduct disorder symptoms appearing at an early age (age 10–14) or acts 
leading to a prison sentence. An act of violence that leads to a prison sentence is unfortunately 
frequent among ASPD patients in early adulthood preceded by several smaller violations of 
the law not leading to incarceration. However, in the incarcerated environment, a meaning-
ful secondary prevention effort can be arranged. As 50% of prison populations are diagnosed 
with ASPD [3], it is unrealistic to provide treatment for all ASPD patients, but a good rationale 
for focus would be those individuals who are at an increased risk for reoffenses.
Decisions for offering treatments are dichotomous but symptoms and risk are often measured 
on a continuum from mild to severe. However, scales of symptom and risk severity can easily 
be constructed, and often a meaningful cutoff point, depending on the size of the selection 
population, is the 75–90% percentile. Continuums such as alcohol consumption quantity, trait 
impulsivity, and accumulation of acts of violent can be transformed into categories of high-
low expected efficacy of treatment for the individual or high-low expectancy of benefit for 
society. Both interests are often in line with each other.
4. Risk assessment for recurrent violent behavior or premature death
The tools for assessing risk for future acts of violence in previously violent populations have 
been criticized as an inexact science [4]. Many attempts of constructing assessment tools have 
been made, but their accuracy is far from satisfactory. For instance, the risk assessment tools 
HCR-20 and PCL-R rely on psychological assessments and historical data on life events, 
which may be difficult to assess. Moreover, application of such tool needs highly trained 
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after careful selection of whom to treat. ASPD forms a patient group, which has a poor treat-
ment compliance in general due to inherent diagnostic symptoms of unplanned lifestyle and 
impulsive decision-making.
2. What is ASPD: what to treat
The core symptoms of ASPD are antisocial attitudes that lead to generally destructive behavior 
in part due to the inherent impulsive behavior and severe alcoholism (early-onset type II alco-
holism) associated with this disorder. ASPD is diagnosed among adults, but it is preceded by 
conduct disorder symptoms before age 15, symptoms such as running away from home, initia-
tion of physical fights, usage of weapons in fights, forcing others into sexual activity, cruelty to 
animals, destruction of other persons’ property, deliberately engaged in fire-setting, frequent 
lying, and stealing. An extensive description of conduct disorder, however, is beyond the scope 
of this article.
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from work, impulsive abandonment of several jobs without realistic plans of future jobs or 
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• Failure to conform to social norms with respect to lawful behavior, as indicated by repeat-
edly performing acts that are grounds for arrest (whether arrested or not), e.g., destroying 
property, harassing others, stealing, and pursuing an illegal occupation.
• Irritability and aggressiveness, as indicated by repeated physical fights or assaults.
• Repeatedly failing to honor financial obligations, as indicated by defaulting on debts or 
failing to provide child support on regular basis.
• Impulsive behavior and inability to plan ahead, as indicated by, e.g., traveling from place 
to place without a prearranged job or clear goal for the period of travel or clear idea about 
when the travel will terminate and lack of a fixed address for a long period.
• No respect for the truth as indicated by repeated lying, use of aliases, and “conning” others 
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• If being a parent or guardian, lacks ability to function as a responsible parent, as indi-
cated by, for instance, malnutrition of child, child’s illness resulting from lack of minimal 
hygiene, child’s dependence on neighbors or nonresident relative for food or shelter, 
failure to arrange for a caretaker for your child when parent is away from home, and 
repeated squandering on personal items or of money required for household necessities.
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• Never sustained a totally monogamous relationship for more than 1 year.
• Lacks remorse (feels justified in having hurt, mistreated, or stolen from others).
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low expected efficacy of treatment for the individual or high-low expectancy of benefit for 
society. Both interests are often in line with each other.
4. Risk assessment for recurrent violent behavior or premature death
The tools for assessing risk for future acts of violence in previously violent populations have 
been criticized as an inexact science [4]. Many attempts of constructing assessment tools have 
been made, but their accuracy is far from satisfactory. For instance, the risk assessment tools 
HCR-20 and PCL-R rely on psychological assessments and historical data on life events, 
which may be difficult to assess. Moreover, application of such tool needs highly trained 
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professionals. The accuracy of such assessments suffers from several sources of bias such 
as underlying biologic individual variation [5]. Likewise, childhood maltreatment may also 
have ambiguous inter-rater variations and compromised data source reliability. However, 
childhood maltreatment has been unambiguously assessed to increase the risk for antisocial 
behavior, recurrent violent behavior, and premature death at the age of 40, especially in com-
binations with biological variations (e.g., different monoamine oxidase A genotypes) leading 
to alteration of risk [6–8]. Alcohol consumption has shown a positive correlation with increase 
in risk for recurrent acts of violence, whereas aging has shown to have a negative correlation 
to this outcome measure [9]. The biologic field of research may have most new tools to con-
tribute to risk assessments in the future.
The biological research in violent reconvictions may reveal new possibilities to pharmacologi-
cal treatments of ASPD and support decisions on whom to treat. The method for obtaining 
reliable scientific evidence of causalities leading to recurrent violent behavior is conducting 
long follow-up study settings in large cohorts. Both ASPD and severe alcoholism are consid-
ered hereditary. A consensus approximation of the hereditary component of alcoholism is 
50% [10]. Impulsivity, composed of a persistent tendency to act on the spur of the moment 
and locomotive restlessness, is also partly hereditary [11]. Detection of genetic causalities 
underlying ASPD, severe alcoholism, and impulsivity has to date resulted in a handful of 
robust findings mainly through utilization of violent alcoholics in a young Finnish founder 
population. Genetic research in founder population allows an increased power to detect spe-
cific genetic risk for complex disorders due to a relatively homogenous gene pool caused by 
geographic isolation [12]. Six functional genetic loci associated with ASPD, impulsivity, alco-
holism, and violent behavior, have been detected in the Finnish founder population. These 
genes comprise the serotonin 2B receptor (HTR2B) [13], tryptophan hydroxylase 2 (TPH2) 
[14], serotonin 1B receptor (HTR1B) [15], serotonin 3B receptor (HTR3B) [16], monoamine 
oxidase A (MAOA) [7, 9, 17], and T-cadherin [17].
Apart from specific genes, variation in glucose and insulin metabolism, which could be 
regarded as biomarkers, has also been shown to robustly predict recurrent violent behavior 
[18, 19]. Likewise, low serotonin levels have also been robustly associated with impulsive-
aggressive behavior [20, 21].
Detection of individuals with high risk, especially due to biologic reasons, may raise ethical 
issues whether to treat or isolate individuals with increased risk for recurrent violent behav-
ior. However, for medical professionals, the importance of treatment efforts of the psychiatric 
disorder ASPD, alcoholism, and overt impulsivity is clear as treatment is offered for other 
diseases with underlying biologic causalities such as diabetes or strokes, as well.
5. Medication
Impulsivity and alcoholism frequently coexist. Consequently, treatment of either symptom or 
disorder alleviates the other. The treatment of alcoholism is more advanced compared with 
treatment of impulsivity. At best, specific genetic data may reveal who will benefit from a 
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specific treatment in a dichotomous manner. A prime example of this is that individuals having 
a specific gene variant (Asp40) in the μ-opioid receptor (OPRM1) seem to clearly benefit from 
naltrexone treatment of alcoholism, whereas individuals with another genetic variant do not 
benefit from this medication [22]. Although there is a paucity of studies with such clear evi-
dence of one gene’s effect on a particular pharmacological treatment, this is the direction 
research should move into. Kupila et al. [23] recently found that the severity of alcoholism 
(Cloninger’s type I vs. type II) alters pharmacological binding to the glutamate system, which 
is associated with addictions. Such findings give clues for meaningful study-setting which 
could contribute to future evidence-based personalized medical management. The severity of 
alcoholism has also been examined as a predictor in some pharmacological studies. It seems 
that patients with severe alcohol dependence (type II), which is associated with ASPD, may 
react differently to medications as compared with patients with the less severe form of alco-
holism (type I), which is the type of alcohol dependence that the majority of “alcoholics” suf-
fer from. For instance, antagonism of the serotonin 3 receptor with ondansetron has shown 
beneficial in the treatment of early onset severe alcoholism (type II), whereas no considerable 
therapeutic effect appears among patients with less severe alcoholism [24].
Moreover, carriers of a loss-of-function point mutation allele of the serotonin 2B receptor 
(HTR2B Q20*) may benefit from focused treatment of alcoholism and impulsivity as this 
mutation has been shown to make the carriers of this mutation more susceptible for problem-
behavior especially while under the influence of alcohol, but also while sober [25]. However, 
this point mutation in the serotonin 2B receptor has only been found among Finns at this 
point, but this may serve as an example of a functional genetic discovery, which may lead to 
development of personalized treatments. Widely used serotonin selective reuptake inhibitors 
(SSRIs), such as fluoxetine and citalopram, do not seem to decrease depression or suicide rates 
among human HTR2B Q20* carriers or Htr2b knockout mice [26, 27]. Therefore, SSRIs likely 
show no effect on HTR2B Q20* ASPD carriers, but new pharmacological strategies are being 
currently developed [28].
Due to a lack of highly efficient pharmacological treatment of impulsivity and aggression, 
a vast variety of psychotropic medications have been used for treatment of impulsivity and 
aggression. However, recent research both in animal study settings [29] and large human 
follow-up cohorts [30] suggests that lithium could be the drug of choice for preventative treat-
ment of impulsive behavior, due to the associated lower risk of suicide attempts and signifi-
cantly decreased suicide mortality, in comparison to valproic acid and benzodiazepines, in 
high-risk bipolar patients [30].
6. Psychotherapy
Psychotherapy aims at alleviating various symptoms, modulate thought constructs, and to 
gain control of behavior such as antisocial attitudes, drinking alcohol, or acting impulsively. 
A slight pessimism regarding the efficacy of psychotherapy in treating ASPD is frequent 
among clinicians, which is partly justified as antisocial thought constructs and impulsive 
behavior decrease treatment compliance. Persons suffering from personality disorders tend 
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50% [10]. Impulsivity, composed of a persistent tendency to act on the spur of the moment 
and locomotive restlessness, is also partly hereditary [11]. Detection of genetic causalities 
underlying ASPD, severe alcoholism, and impulsivity has to date resulted in a handful of 
robust findings mainly through utilization of violent alcoholics in a young Finnish founder 
population. Genetic research in founder population allows an increased power to detect spe-
cific genetic risk for complex disorders due to a relatively homogenous gene pool caused by 
geographic isolation [12]. Six functional genetic loci associated with ASPD, impulsivity, alco-
holism, and violent behavior, have been detected in the Finnish founder population. These 
genes comprise the serotonin 2B receptor (HTR2B) [13], tryptophan hydroxylase 2 (TPH2) 
[14], serotonin 1B receptor (HTR1B) [15], serotonin 3B receptor (HTR3B) [16], monoamine 
oxidase A (MAOA) [7, 9, 17], and T-cadherin [17].
Apart from specific genes, variation in glucose and insulin metabolism, which could be 
regarded as biomarkers, has also been shown to robustly predict recurrent violent behavior 
[18, 19]. Likewise, low serotonin levels have also been robustly associated with impulsive-
aggressive behavior [20, 21].
Detection of individuals with high risk, especially due to biologic reasons, may raise ethical 
issues whether to treat or isolate individuals with increased risk for recurrent violent behav-
ior. However, for medical professionals, the importance of treatment efforts of the psychiatric 
disorder ASPD, alcoholism, and overt impulsivity is clear as treatment is offered for other 
diseases with underlying biologic causalities such as diabetes or strokes, as well.
5. Medication
Impulsivity and alcoholism frequently coexist. Consequently, treatment of either symptom or 
disorder alleviates the other. The treatment of alcoholism is more advanced compared with 
treatment of impulsivity. At best, specific genetic data may reveal who will benefit from a 
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benefit from this medication [22]. Although there is a paucity of studies with such clear evi-
dence of one gene’s effect on a particular pharmacological treatment, this is the direction 
research should move into. Kupila et al. [23] recently found that the severity of alcoholism 
(Cloninger’s type I vs. type II) alters pharmacological binding to the glutamate system, which 
is associated with addictions. Such findings give clues for meaningful study-setting which 
could contribute to future evidence-based personalized medical management. The severity of 
alcoholism has also been examined as a predictor in some pharmacological studies. It seems 
that patients with severe alcohol dependence (type II), which is associated with ASPD, may 
react differently to medications as compared with patients with the less severe form of alco-
holism (type I), which is the type of alcohol dependence that the majority of “alcoholics” suf-
fer from. For instance, antagonism of the serotonin 3 receptor with ondansetron has shown 
beneficial in the treatment of early onset severe alcoholism (type II), whereas no considerable 
therapeutic effect appears among patients with less severe alcoholism [24].
Moreover, carriers of a loss-of-function point mutation allele of the serotonin 2B receptor 
(HTR2B Q20*) may benefit from focused treatment of alcoholism and impulsivity as this 
mutation has been shown to make the carriers of this mutation more susceptible for problem-
behavior especially while under the influence of alcohol, but also while sober [25]. However, 
this point mutation in the serotonin 2B receptor has only been found among Finns at this 
point, but this may serve as an example of a functional genetic discovery, which may lead to 
development of personalized treatments. Widely used serotonin selective reuptake inhibitors 
(SSRIs), such as fluoxetine and citalopram, do not seem to decrease depression or suicide rates 
among human HTR2B Q20* carriers or Htr2b knockout mice [26, 27]. Therefore, SSRIs likely 
show no effect on HTR2B Q20* ASPD carriers, but new pharmacological strategies are being 
currently developed [28].
Due to a lack of highly efficient pharmacological treatment of impulsivity and aggression, 
a vast variety of psychotropic medications have been used for treatment of impulsivity and 
aggression. However, recent research both in animal study settings [29] and large human 
follow-up cohorts [30] suggests that lithium could be the drug of choice for preventative treat-
ment of impulsive behavior, due to the associated lower risk of suicide attempts and signifi-
cantly decreased suicide mortality, in comparison to valproic acid and benzodiazepines, in 
high-risk bipolar patients [30].
6. Psychotherapy
Psychotherapy aims at alleviating various symptoms, modulate thought constructs, and to 
gain control of behavior such as antisocial attitudes, drinking alcohol, or acting impulsively. 
A slight pessimism regarding the efficacy of psychotherapy in treating ASPD is frequent 
among clinicians, which is partly justified as antisocial thought constructs and impulsive 
behavior decrease treatment compliance. Persons suffering from personality disorders tend 
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to have difficulties to realize or admit that they have a mental health problem that would 
need treatment. This is especially true for ASPD. However, this pessimism for the efficacy 
of treatment is not justified for all ASPD patients. For instance, group-based cognitive and 
behavioral interventions focused on reducing offending and other antisocial behaviors in an 
optimistic and trusting context have shown some good results [31]. It is also important not to 
have to ambitious goals, but to aim at alleviating some symptoms such as impulsive behavior, 
decrease in alcohol consumption, and decrease in disrespect of the rights of others. Clinical 
experience in the field of forensic psychiatry suggests that life events such as coming into 
religious faith and commitment to a strong-willed spouse would represent a “natural” psy-
chotherapy altering thought constructs and behavior, and it has proved to be helpful for some 
ASPD patients. Consequently, simple psychotherapeutic themes in treatment of ASPD would 
be discussing religious interests and the benefits of being in a stable long-term relationship.
7. Nutrition
There is no convincing robust scientific evidence for treating ASPD with specific diets alone, but 
the inherent impulsivity and lack of persistence in ASPD certainly cause poor dietary habits. 
Many vitamins and other compounds received through food are vital for the proper biologic 
and physiologic functioning of the body. Thus, it is likely—and a fair hypothesis—that specific 
diets and supplements may show beneficiary for the treatment of ASPD with associated symp-
toms in the future as a part of the treatment strategy. One randomized placebo- controlled 
study suggests that the influence of supplementary vitamins, minerals, and essential fatty acid 
would decrease antisocial behavior and violence in an incarcerated context [32]. These kinds of 
study settings should be replicated and performed in outpatient study settings.
Some general advice, although speculative, on what diet to recommend for ASPD individu-
als could be mentioned. As low serotonin levels have been coupled with impulsivity and 
aggression [20, 21], a tangible means of ensuring a sufficient supply of tryptophan in the 
diet would be consumption of cheese and peanuts. When an alcoholic is being in a pro-
longed relapse period of drinking, it may be a good advice to make sure to eat glucose-rich 
food, as low glucose levels have been associated to violent and irritable behavior [20]. On 
the other hand, a glucose-rich diet may be harmful in the long run as it increases the risk 
for type 2 diabetes, and high insulin levels have been associated with increased risk for acts 
of violence [18].
8. Conclusions and future direction
As most of the acts of violence in the western world are attributable to individuals having 
ASPD, enhancement of the treatment of ASPD will have tangible effects in terms of reduc-
tion of violence in society. Most new ground is expected to be gained through an increasing 
understanding of biological causalities underlying ASPD will help to personalize treatments, 
including the therapeutic areas such as redox state and diet. Combination of several treatment 
strategies likely amounts in best treatment results. As treatment is challenging, professionals 
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should be trained to treat this specific patient group. Furthermore, clinicians—including gen-
eral practitioners—would need education in recognizing symptoms associated with ASPD 
and encouragement to refer these patients to specialized treatment, although the problem 
remains that ASPD patients rarely seek treatment due to the inherent nature of the disorder. 
Conclusively, it should be noted that research supporting evidence-based personalized treat-
ment of ASPD is sparse. This review therefore reflects the clinical and theoretical expertise of 
the author, which hopefully could initiate further research.
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and physiologic functioning of the body. Thus, it is likely—and a fair hypothesis—that specific 
diets and supplements may show beneficiary for the treatment of ASPD with associated symp-
toms in the future as a part of the treatment strategy. One randomized placebo- controlled 
study suggests that the influence of supplementary vitamins, minerals, and essential fatty acid 
would decrease antisocial behavior and violence in an incarcerated context [32]. These kinds of 
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diet would be consumption of cheese and peanuts. When an alcoholic is being in a pro-
longed relapse period of drinking, it may be a good advice to make sure to eat glucose-rich 
food, as low glucose levels have been associated to violent and irritable behavior [20]. On 
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Conclusively, it should be noted that research supporting evidence-based personalized treat-
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Abstract
Alzheimer’s and Parkinson’s diseases are neurodegenerative diseases where several 
biomarkers have suggested that a single measurement is not a sufficient biomarker. The 
observation of increased concentration of cadmium (Cd), lead (Pb), and silver (Ag) in 
erythrocytes by inductively coupled plasma mass spectrometry (ICP-MS) shows a need 
to look for new approaches to understand the complex synchronistic effects of the cell 
metabolism. We have used a simplified scheme to follow some of the effects by following 
a hierarchy of reactions simplified to monitor elements in peripheral blood cells, e.g., 
erythrocytes. Erythrocytes carry oxygen to cells and carbon dioxide and waste to the 
lungs and back when passing from different organs including the brain. Erythrocytes 
also have the capacity to carry metal ions, which may be transferred to other organs, e.g., 
brain, despite the blood-brain barrier (BBB) and choroid plexus filter. If transfer of Cd, 
Pb, and Ag is continued too long, the repair systems may not be sufficient, and epigenetic 
effects on DNA and RNA may begin. Peripheral blood cells, e.g., erythrocytes, may help 
get earlier individual indications of changes at the cell level by using ICP-MS.
Keywords: hierarchy, cells, Cd, Pb, Ag, erythrocytes, Alzheimer’s disease, Parkinson’s 
disease, epigenetic changes, element profile, ICP-MS
1. Introduction
The cell metabolism is a complex balance of proteins, fatty acids, carbohydrates, metal ions, 
and trace elements regulated by DNA and RNA in nucleus. The metabolism of proteins is 
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further influenced by a noncoding RNA, e.g., siRNA, which involves molecular reactions and 
metal ions. Reactions involving metal ions and molecules may create difficulties in interpret-
ing which components are involved due to similar symptoms that may be created by different 
reactions at the cellular level, masking symptoms. A simplified summary of reactions is given 
in Figure 1.
In Figure 1, it is suggested that cell reactions proceed in a hierarchical manner, along with 
three main pathways [1]. The first pathway involves metal ions associated with ligands with 
different strengths due to properties of metal ions, binding compounds, pH, redox state, and 
medium where this reaction takes place. The second pathway involves organic compounds 
with nucleophilic or electrophilic properties resulting in products favoring the most reactive 
partner. The third pathway involves radical reactions which may be fast or slow depending 
on cell demand. The brain has high needs for oxygen and uses about 20% of the total oxygen. 
Oxygen is important for many reactions but can produce H2O2 or OH*− radicals that can 
cause severe damage when not under control. The reaction pathway used for processing a 
component will be dependent on DNA, RNA, and cell demand.
According to the Food and Drug Administration (FDA) [2], as many as 70% of drugs for 
Alzheimer’s disease, 75% cancer diseases, 50% arthritis diseases, and 40% asthma diseases are 
Figure 1. The flow of compounds and metal ions between cells is dependent on the three main chemical pathways in a 
hierarchy. The first path involves free radical-induced production of compounds where hydroxyl radical and solvated 
electron reactions may be involved. The second path involves electrophilic and nucleophilic compounds forming 
products adequate to the cells. The third path involves metal ions and ligands dependent on the previous two pathways 
but adapted to cell demand. The symbolic schedule indicates that compounds and metal ions may reach DNA and 
RNA not controlled by evolutionary developed genome adapted to cell demand. Small changes of DNA and RNA may 
take place, an epigenetic change, which may be restored or adapted, but large damages will present symptoms and are 
difficult to restore.
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not effective. The report may indicate compliance problems and difficulties with translating 
symptoms from reactions, but above all there is a need of more sensitive and selective systems 
to handle diseases.
Personalized medicine may be one way to improve systems by better diagnostic tools, design-
ing drugs, etc. Peripheral blood has been used in medical diagnosis for a very long time, 
because, among other things, it is easily accessible. In the search for signs of lack or excess 
of minerals and trace elements in the disease, the interest has been focused mainly on blood, 
plasma, or serum. The utilization of blood cells as a marker model is proposed here. The ele-
ment profile of blood cells may be one part to improve the present systems.
It is a challenge to separate normal reactions of cell metabolism from early pathophysiological 
differences. The identification of early changes in cells is important for correct diagnosis and 
optimal treatment when symptoms indicate the beginning of a disease. Blood cells which 
pass through several organs may be useful as they exchange information between systems 
involved. One example is the erythrocytes which transport oxygen from the lungs to differ-
ent recipients and waste products back, e.g., CO2 and hemoglobin, for decomposition and 
excretion. Besides the important transport of oxygen to oxygen-dependent organs, e.g., the 
brain, liver, and kidneys, they carry metal ions. When cells are growing old or have accumu-
lated metal ions, the metabolism capacity of oxygen or transfer process of metal ions may be 
changed. By following the variations in the metal concentrations of the erythrocytes, sum-
marized in an element profile, multifactorial diseases may be identified earlier. Observations 
of increased concentrations of metal ions, e.g., lead (Pb), (cadmium) Cd, and (silver) Ag, in the 
erythrocytes of patients with Alzheimer’s and Parkinson’s diseases by inductively coupled 
plasma mass spectrometry (ICP-MS) indicate possibilities to observe early steps in the patho-
physiological processes and early epigenetic changes [3–5].
An early indication of changed metal ion homeostasis by an element profile is the change of 
important cell reactions. The element profile may be looked upon as the integrated results 
of reactions of metal ions and ligands. Cells with different life span, e.g., erythrocytes and 
platelets, help in the interpretation of possible changes. Changes in the element profile may 
give early biochemical, physiological, and pathophysiological information of changed cell 
metabolism and indicate defects in vulnerable organs.
2. Comparison of significant increased concentrations of Pb, Cd, and 
Ag in the erythrocytes of patients with Alzheimer’s and Parkinson’s 
diseases
Patients with Alzheimer’s disease were selected in Finland [3] and patients with Parkinson’s 
disease in Sweden [4, 5]. The mean concentrations of Pb in patients with Alzheimer’ disease 
[3] and Parkinson’s disease were 157 μg/kg (wet weight) and 67.8 μg/kg, respectively, about 
two times higher than that of Parkinson’s disease [5]. The concentration of Cd in erythrocytes 
of patients with Alzheimer’s disease was 11.5 μg/kg (wet weight) and 1.9 μg/kg in Parkinson’s 
disease, about five times higher in Alzheimer’s disease. An increased concentration of Ag was 
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ment profile of blood cells may be one part to improve the present systems.
It is a challenge to separate normal reactions of cell metabolism from early pathophysiological 
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optimal treatment when symptoms indicate the beginning of a disease. Blood cells which 
pass through several organs may be useful as they exchange information between systems 
involved. One example is the erythrocytes which transport oxygen from the lungs to differ-
ent recipients and waste products back, e.g., CO2 and hemoglobin, for decomposition and 
excretion. Besides the important transport of oxygen to oxygen-dependent organs, e.g., the 
brain, liver, and kidneys, they carry metal ions. When cells are growing old or have accumu-
lated metal ions, the metabolism capacity of oxygen or transfer process of metal ions may be 
changed. By following the variations in the metal concentrations of the erythrocytes, sum-
marized in an element profile, multifactorial diseases may be identified earlier. Observations 
of increased concentrations of metal ions, e.g., lead (Pb), (cadmium) Cd, and (silver) Ag, in the 
erythrocytes of patients with Alzheimer’s and Parkinson’s diseases by inductively coupled 
plasma mass spectrometry (ICP-MS) indicate possibilities to observe early steps in the patho-
physiological processes and early epigenetic changes [3–5].
An early indication of changed metal ion homeostasis by an element profile is the change of 
important cell reactions. The element profile may be looked upon as the integrated results 
of reactions of metal ions and ligands. Cells with different life span, e.g., erythrocytes and 
platelets, help in the interpretation of possible changes. Changes in the element profile may 
give early biochemical, physiological, and pathophysiological information of changed cell 
metabolism and indicate defects in vulnerable organs.
2. Comparison of significant increased concentrations of Pb, Cd, and 
Ag in the erythrocytes of patients with Alzheimer’s and Parkinson’s 
diseases
Patients with Alzheimer’s disease were selected in Finland [3] and patients with Parkinson’s 
disease in Sweden [4, 5]. The mean concentrations of Pb in patients with Alzheimer’ disease 
[3] and Parkinson’s disease were 157 μg/kg (wet weight) and 67.8 μg/kg, respectively, about 
two times higher than that of Parkinson’s disease [5]. The concentration of Cd in erythrocytes 
of patients with Alzheimer’s disease was 11.5 μg/kg (wet weight) and 1.9 μg/kg in Parkinson’s 
disease, about five times higher in Alzheimer’s disease. An increased concentration of Ag was 
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observed in both Alzheimer’s and Parkinson’s diseases 7.4 μg/kg (wet weight) and 2.8 μg/kg, 
respectively, about two times higher in Alzheimer’s disease. Pb, Cd, and Ag maintain the 
hierarchical effects on weaker associated metal ions in relation to association constants 
and not to DNA control when the balance of metal ions or binding compounds cannot be 
 controlled [1]. It is important to identify early changes to understand the pathophysiological 
mechanisms and find proper treatments. Some effects will be discussed in relation to the 
imbalance of metal ion homeostasis and significant concentration changes of Pb, Cd, and Ag 
in the erythrocytes.
3. Reduced filter capacity of the kidneys and control of adrenal 
glands may promote the uptake of Pb, Cd, and Ag in erythrocytes
The reasons for the significant increased concentration of Pb, Cd, and Ag in erythrocytes of 
patients with Alzheimer’s and Parkinson’s diseases are not well understood. The absorption 
of essential elements starts in the small intestine, e.g., duodenum, less in the jejunum, and 
ileum, and large intestine. It is a complex interplay between intestinal bacteria and the liver, 
kidneys, pancreas, and bone. It is probable that Pb, Cd, and Ag may use the same carrier 
systems as essential elements in the blood. After the uptake of Pb, Cd, and Ag, they are trans-
ported to other organs for use or storage in the bone and also balanced by the kidneys and 
adrenal glands. The absorbed Pb, Cd, and Ag may not be properly controlled by the kidneys 
and adrenal glands. Excretion of Cd is very low and thus Cd is accumulated. The half-life 
of Cd in humans is about 20–35 years [6]. Most of the Cd is deposited in the kidneys, liver, 
pancreas, and lungs. Excess Pb is also accumulated often in the bone with a half-life of about 
5–19 years [7]. The half-life of Ag in humans is not well documented, but an indicative value 
may be about 50 days [8]. Erythrocytes have a half-life of about 120 days. The accumulated 
silver in the erythrocytes may indicate a leakage of silver from root tips with silver amal-
gam [1, 9]. The contribution of Ag from food, drinking water, and vaccines is probably low. 
An imbalance of metal ion homeostasis in cell membrane carrier systems may interfere with 
essential element metabolism in favor of an epigenetic change. The decreased filter capac-
ity of the kidneys and decreased control by parathyroid and adrenal glands can to some 
extent explain the accumulation of elements in the erythrocytes and the transport to other 
organs, e.g., brain. If imbalance of metal ion homeostasis in the erythrocytes is lasting too 
long, DNA control may decrease. The kidneys and adrenal glands in collaboration with the 
hypothalamus, pineal gland, pituitary glands, and choroid plexus are known to involve in 
the control of electrolyte and water balance [10, 11]. Chronic exposure to low concentrations 
of compounds with Pb, Cd, and Ag and loss of binding compounds, e.g., decreased available 
selenium and compounds with low metal binding capacity, may decrease the filter selectivity 
and disrupt DNA control. The background of decreased filter capacity is of course complex, 
but a part of the problem may be found in nutrition, e.g., lack of adequate selenium, phytate 
(inositol hexakisphosphate), flavonoids, and tannins balancing metal ion flux. In addition, 
environmental exposure, lack of exercise, smoking habit, and genetic factors may contribute. 
The decreased filter capacity of the kidneys and decreased brain control may promote the 
Personalized Medicine, in Relation to Redox State, Diet and Lifestyle32
transport of metal ions and compounds not controlled by DNA, thus opening for epigenetic 
changes. Besides the transport of Pb, Cd, and Ag by erythrocytes in the blood, carriers like 
albumin, metallothionein, transferrin, and ceruloplasmin carry metal ions to recipients in the 
body. It is possible that the kidneys provide Pb, Cd, and Ag to erythrocytes, thus disturbing 
other carrier systems of elements, e.g., Na, K, Mg, Ca, and Se. It is not known if the imbal-
ance of metal ion homeostasis in erythrocytes of patients with Alzheimer’s and Parkinson’s 
diseases starts in the kidneys and adrenal glands or how the imbalance of metal ions in the 
erythrocytes is transferred to other organs. The transport of Pb, Cd, and Ag from the mem-
branes and further selection of metal ions are provided by different systems, e.g., transient 
receptor protein (TRP) channels [12–14], solute carrier (SLC) protein families [15, 16], and 
ATP binding cassette (ABC) families [17, 18] and calmodulin families [19, 20]. Interestingly, 
difference in binding capacity of the membranes gives an additional way to regulate metal ion 
flow controlled by DNA.
4. Increased concentration of Pb, Cd, and Ag in the erythrocytes and 
effects of messengers and cellular overload in metal ion homeostasis 
with reference to calcium homeostasis
The discussion will be limited to some effects of elements, which involve the important mes-
sengers in Alzheimer’s and Parkinson’s diseases: calcium, selenium, and inosine 1,4,5-tri-
phosphate (IP3), the latter being an example of an organic messenger [21]. Calcium is an 
important intracellular messenger involved in the release of, e.g., [Ca2+], from the rough and 
smooth endoplasmic reticulum (ER), ryanodine receptor, TRP, mitochondria, and calmodulin 
family, and apoptosis. Alterations in [Ca2+] homeostasis have been suggested in neurological 
diseases, such as Parkinson’s and Alzheimer’s diseases [22–24]. The metabolism and flux of 
calcium in the ER are suggested to be dependent on, e.g., selenoprotein N, selenoprotein 
S, and selenoprotein T, critical for maintaining [Ca2+] [25–27]. Microglia were implicated in 
Alzheimer’s disease [28]. If Pb, Cd, and Ag enter in the microglia local defense systems, they 
may be decreased. Sodium and potassium ions are important for nerve signals and in glu-
cose metabolism [29]. O’Brien and Legge [30] showed that erythrocytes may be mapped by 
using potassium ions with μ-PIXE technique resulting in a disclike structure indicating high 
concentration of potassium in the erythrocytes. Erythrocytes and neuron cells carry insulin 
receptors [31, 32]. Insulin facilitates the introduction of sodium-potassium pumps, indicating 
that insulin and insulin receptors also support the distribution of Na and K in membranes 
[33]. As Li, Na, and K often have lower affinity to receptors and carriers than Pb, Cd, and Ag, 
interactions can be expected in the uptake and transport of channels. In many cells, transport 
of K can be made in Ca channels, e.g., Gardos channels [34, 35], by SLC family [36]. Insulin 
facilitates the introduction of sodium-potassium pumps indicating that insulin and insulin 
receptors also support the distribution of these elements in neuron cells. Cd may interact with 
Na and K-ATPase, indicating a possible interaction with Na and K ions [37]. Ca and Mg in 
cells often are carried by members of calmodulin families [38]. Similar size of ionic radius of 
cadmium 0.97 A and Ca 0.99 A may explain competition of binding sites. Cd in calmodulin 
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observed in both Alzheimer’s and Parkinson’s diseases 7.4 μg/kg (wet weight) and 2.8 μg/kg, 
respectively, about two times higher in Alzheimer’s disease. Pb, Cd, and Ag maintain the 
hierarchical effects on weaker associated metal ions in relation to association constants 
and not to DNA control when the balance of metal ions or binding compounds cannot be 
 controlled [1]. It is important to identify early changes to understand the pathophysiological 
mechanisms and find proper treatments. Some effects will be discussed in relation to the 
imbalance of metal ion homeostasis and significant concentration changes of Pb, Cd, and Ag 
in the erythrocytes.
3. Reduced filter capacity of the kidneys and control of adrenal 
glands may promote the uptake of Pb, Cd, and Ag in erythrocytes
The reasons for the significant increased concentration of Pb, Cd, and Ag in erythrocytes of 
patients with Alzheimer’s and Parkinson’s diseases are not well understood. The absorption 
of essential elements starts in the small intestine, e.g., duodenum, less in the jejunum, and 
ileum, and large intestine. It is a complex interplay between intestinal bacteria and the liver, 
kidneys, pancreas, and bone. It is probable that Pb, Cd, and Ag may use the same carrier 
systems as essential elements in the blood. After the uptake of Pb, Cd, and Ag, they are trans-
ported to other organs for use or storage in the bone and also balanced by the kidneys and 
adrenal glands. The absorbed Pb, Cd, and Ag may not be properly controlled by the kidneys 
and adrenal glands. Excretion of Cd is very low and thus Cd is accumulated. The half-life 
of Cd in humans is about 20–35 years [6]. Most of the Cd is deposited in the kidneys, liver, 
pancreas, and lungs. Excess Pb is also accumulated often in the bone with a half-life of about 
5–19 years [7]. The half-life of Ag in humans is not well documented, but an indicative value 
may be about 50 days [8]. Erythrocytes have a half-life of about 120 days. The accumulated 
silver in the erythrocytes may indicate a leakage of silver from root tips with silver amal-
gam [1, 9]. The contribution of Ag from food, drinking water, and vaccines is probably low. 
An imbalance of metal ion homeostasis in cell membrane carrier systems may interfere with 
essential element metabolism in favor of an epigenetic change. The decreased filter capac-
ity of the kidneys and decreased control by parathyroid and adrenal glands can to some 
extent explain the accumulation of elements in the erythrocytes and the transport to other 
organs, e.g., brain. If imbalance of metal ion homeostasis in the erythrocytes is lasting too 
long, DNA control may decrease. The kidneys and adrenal glands in collaboration with the 
hypothalamus, pineal gland, pituitary glands, and choroid plexus are known to involve in 
the control of electrolyte and water balance [10, 11]. Chronic exposure to low concentrations 
of compounds with Pb, Cd, and Ag and loss of binding compounds, e.g., decreased available 
selenium and compounds with low metal binding capacity, may decrease the filter selectivity 
and disrupt DNA control. The background of decreased filter capacity is of course complex, 
but a part of the problem may be found in nutrition, e.g., lack of adequate selenium, phytate 
(inositol hexakisphosphate), flavonoids, and tannins balancing metal ion flux. In addition, 
environmental exposure, lack of exercise, smoking habit, and genetic factors may contribute. 
The decreased filter capacity of the kidneys and decreased brain control may promote the 
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transport of metal ions and compounds not controlled by DNA, thus opening for epigenetic 
changes. Besides the transport of Pb, Cd, and Ag by erythrocytes in the blood, carriers like 
albumin, metallothionein, transferrin, and ceruloplasmin carry metal ions to recipients in the 
body. It is possible that the kidneys provide Pb, Cd, and Ag to erythrocytes, thus disturbing 
other carrier systems of elements, e.g., Na, K, Mg, Ca, and Se. It is not known if the imbal-
ance of metal ion homeostasis in erythrocytes of patients with Alzheimer’s and Parkinson’s 
diseases starts in the kidneys and adrenal glands or how the imbalance of metal ions in the 
erythrocytes is transferred to other organs. The transport of Pb, Cd, and Ag from the mem-
branes and further selection of metal ions are provided by different systems, e.g., transient 
receptor protein (TRP) channels [12–14], solute carrier (SLC) protein families [15, 16], and 
ATP binding cassette (ABC) families [17, 18] and calmodulin families [19, 20]. Interestingly, 
difference in binding capacity of the membranes gives an additional way to regulate metal ion 
flow controlled by DNA.
4. Increased concentration of Pb, Cd, and Ag in the erythrocytes and 
effects of messengers and cellular overload in metal ion homeostasis 
with reference to calcium homeostasis
The discussion will be limited to some effects of elements, which involve the important mes-
sengers in Alzheimer’s and Parkinson’s diseases: calcium, selenium, and inosine 1,4,5-tri-
phosphate (IP3), the latter being an example of an organic messenger [21]. Calcium is an 
important intracellular messenger involved in the release of, e.g., [Ca2+], from the rough and 
smooth endoplasmic reticulum (ER), ryanodine receptor, TRP, mitochondria, and calmodulin 
family, and apoptosis. Alterations in [Ca2+] homeostasis have been suggested in neurological 
diseases, such as Parkinson’s and Alzheimer’s diseases [22–24]. The metabolism and flux of 
calcium in the ER are suggested to be dependent on, e.g., selenoprotein N, selenoprotein 
S, and selenoprotein T, critical for maintaining [Ca2+] [25–27]. Microglia were implicated in 
Alzheimer’s disease [28]. If Pb, Cd, and Ag enter in the microglia local defense systems, they 
may be decreased. Sodium and potassium ions are important for nerve signals and in glu-
cose metabolism [29]. O’Brien and Legge [30] showed that erythrocytes may be mapped by 
using potassium ions with μ-PIXE technique resulting in a disclike structure indicating high 
concentration of potassium in the erythrocytes. Erythrocytes and neuron cells carry insulin 
receptors [31, 32]. Insulin facilitates the introduction of sodium-potassium pumps, indicating 
that insulin and insulin receptors also support the distribution of Na and K in membranes 
[33]. As Li, Na, and K often have lower affinity to receptors and carriers than Pb, Cd, and Ag, 
interactions can be expected in the uptake and transport of channels. In many cells, transport 
of K can be made in Ca channels, e.g., Gardos channels [34, 35], by SLC family [36]. Insulin 
facilitates the introduction of sodium-potassium pumps indicating that insulin and insulin 
receptors also support the distribution of these elements in neuron cells. Cd may interact with 
Na and K-ATPase, indicating a possible interaction with Na and K ions [37]. Ca and Mg in 
cells often are carried by members of calmodulin families [38]. Similar size of ionic radius of 
cadmium 0.97 A and Ca 0.99 A may explain competition of binding sites. Cd in calmodulin 
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molecule causes conformational changes of calmodulin [39]. The binding constants for Pb 
and Cd in calmodulin are higher than those of Mg and Ca. When cells are not controlled by 
DNA, Pb, Cd, and Ag may change the metabolism of Mg and Ca. It is not known if and how 
Pb, Cd, and Ag of erythrocytes compete with carrier systems of patients with Alzheimer’s 
and Parkinson’s diseases. In Alzheimer’s disease acetylcholine receptors involve Ca [21, 40] 
which may be repressed by Pb, Cd, and Ag. In cells the calcium concentration is low and 
kept under strong control because correct concentration of Ca is important for the regula-
tion of ATP synthesis in mitochondria and organelle functions. Uncontrolled release of Ca in 
cells disturbs ATP synthesis and apoptosis regulation. Cellular overload of Pb, Cd, and Ag is 
interesting in view of possible interactions of cell metabolism in three ways: (1) competition of 
Pb, Cd, and Ag with weaker associated metal ions as K, Mg, and Ca; (2) interaction of Pb, Cd, 
and Ag with selenium compounds in mitochondria and ER; and (3) reaction with phosphate 
groups in ATP and IP3. Reactive selenium compounds may be identified in different parts of 
ER important in the regulation of Ca [25]. Studies on harmful effects of metal ions often refer 
to one element at a time; very little is known about the effects of accumulated Pb, Cd, and Ag 
and their synchronistic damage. Dementia in Alzheimer’s and Parkinson’s diseases has been 
demonstrated in several studies [41]. The effects of Pb and Cd were demonstrated in mentally 
retarded children [42]. Pb, Cd, and Ag may also “hitchhike” endogenous carriers of essential 
metal ions making the interpretation of metal ion homeostasis not controlled by DNA reac-
tions more complex. It is likely that Pb, Cd, and Ag may be able to repress Mg and Ca in cell 
DNA and disrupt DNA and RNA control due to synchronistic damaging effects.
5. Possible effects of Pb, Cd, and Ag on blood-brain barrier (BBB) 
filter and choroid plexus in relation to metal ion imbalance and 
selenium homeostasis
In Alzheimer’s and Parkinson’s diseases, malfunctions may be attributed to damage in differ-
ent regions. The transport of compounds and metal ions to the brain is controlled by blood-
brain barrier and by CSF in the choroid plexus [43–45]. The blood-brain barrier is constructed 
of endothelial cells, astrocyte end-feet, and pericytes forming diffuse barriers, tight junctions, 
receptors, and channels for carrier-mediated transport [46]. Leukocytes and larger molecules 
cannot pass into the BBB as well as in other vessels, but, e.g., oxygen, carbon dioxide, iron, 
glucose, and certain amino acids can pass. If Pb, Cd, and Ag from erythrocytes enter the 
BBB, an imbalance may be expected of metal ions and compounds in regions of, e.g., the 
hippocampus, hypothalamus, pituitary gland, pineal gland, and cortex. Part of Pb, Cd, and 
Ag in the erythrocytes may “hitchhike” tight junctions, channels, and carriers for essential 
elements in BBB and enter neuron cells, astrocytes, and microglia in a way not controlled by 
DNA. Pericytes and endothelial cells have mitochondria and ER which need selenium for 
proper function of, e.g., Ca and Mg. Mitochondria synthesize ATP, and lowered selenium 
and Mg may decrease the production of ATP and complicate synthesis systems in ER for the 
control of Ca and Mg. Activated neutrophil granulocytes can produce (H2O2) damage in tight 
junctions and receptors in membranes of pericytes and endothelial cells when there are local 
Personalized Medicine, in Relation to Redox State, Diet and Lifestyle34
low selenium status and low activity of protecting GSH-Px (GPx1 and GPx4). The ER stores 
selenium [25] and metal ions for maintaining calcium metabolism. Imbalance in metal ion 
homeostasis and selenium homeostasis can hamper DNA control of metal flux to different 
organelles, e.g., ER, mitochondria, Golgi, and nuclei. Besides erythrocyte transport of Pb, Cd, 
and Ag, albumin may carry Pb, Cd, and Ag which can react with tight junctions and receptors 
on pericytes and pass, loaded with Pb, Cd, and Ag producing reactive oxygen species (ROS). 
Pb, Cd, and Ag can interact with elements in mitochondria, e.g., Mg, Ca, Mn, and Se, and 
disturb ER storage of calcium and action of selenophosphate synthetase. The introduction 
of selenium in amino acids and UGA (stop codon) is very important for cell metabolism. 
Albumin may carry heme groups having an antioxidant effect, which decreases the risk of 
ROS production [47]. Microglia can attack receptors and tight junctions on pericytes around 
the endothelial cells producing ROS damage and perhaps open for albumin entrance carrying 
Pb, Cd, and Ag. The brain is composed of 80% water and uses aquaporin, AQ1, AQ4, and 
AQ9, for water balance [10]. Apart from water control, Pb, Cd, and Ag can use aquaporin for 
passage [11]. If Pb and Cd can pass into the mitochondria, Mn may be displaced and trigger 
SOD to produce ROS. Pb, Ca, and Ag may use the SLC system [48], “hitchhike,” and transfer 
elements through the BBB in a way not controlled by DNA. Choroid plexus epithelial cells 
are rich in selenium [25] and may act as an additional barrier against metal ions and toxic 
compounds [43]. If erythrocytes are overloaded with Cd, Pb, and Ag, some ions may pass the 
BBB in other regions of the brain, e.g., hippocampus and cortex, and produce local imbalance 
of metal ions and selenium homeostasis in the brain.
6. Effects of Pb, Cd, and Ag on insulin receptors in brain cells and 
energy homeostasis
Increased concentrations of Pb, Cd, and Ag do not only affect the transfer of metal ions but 
also may influence the metabolism of proteins and peptides [49–51]. In plasma about 30% of 
Ca and about 40% Zn may be carried by albumin, but albumin also carries other elements and 
organic compounds [47, 52–54]. In the study of albumin, Pb and Cd decreased the transport of 
taxifolin [55]. Albumin in the blood carries 1–10% of glucose. If Pb, Cd, and Ag bind to albumin, 
transport of organic compounds, e.g., glucose, may be decreased. Many peptides and proteins 
in the BBB are transported by carrier in membranes, e.g., SLC and ABC families, which can be 
blocked by Pb, Cd, and Ag. T4 (thyroxin) in the blood is transported by transthyretin to the 
BBB [56]. T4 is dependent on selenium deiodinases for transfer to active T3 (thyronine) [57]. 
As both deiodinases and T4 and T3 have reactive selenium and iodine groups can Pb, Cd, 
and Ag disturb selenium homeostasis. Insulin present in the brain is not known to be directly 
involved in glucose metabolism but may assist in the regulation of energy homeostasis [49, 50]. 
The brain has many insulin receptors, which is highest in the hippocampus. The association 
of metal ions to insulin receptors in neuron cells may be similar as that of erythrocytes when 
Cd, Pb, and Ag interact with K+ and Na+ ions with insulin receptors [32]. Insulin binding 
sites to insulin receptor may be occupied by Pb, Cd, and Ag and decrease transport. Memory 
problems connected to the hippocampus may be explained to some extent by a decreased 
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molecule causes conformational changes of calmodulin [39]. The binding constants for Pb 
and Cd in calmodulin are higher than those of Mg and Ca. When cells are not controlled by 
DNA, Pb, Cd, and Ag may change the metabolism of Mg and Ca. It is not known if and how 
Pb, Cd, and Ag of erythrocytes compete with carrier systems of patients with Alzheimer’s 
and Parkinson’s diseases. In Alzheimer’s disease acetylcholine receptors involve Ca [21, 40] 
which may be repressed by Pb, Cd, and Ag. In cells the calcium concentration is low and 
kept under strong control because correct concentration of Ca is important for the regula-
tion of ATP synthesis in mitochondria and organelle functions. Uncontrolled release of Ca in 
cells disturbs ATP synthesis and apoptosis regulation. Cellular overload of Pb, Cd, and Ag is 
interesting in view of possible interactions of cell metabolism in three ways: (1) competition of 
Pb, Cd, and Ag with weaker associated metal ions as K, Mg, and Ca; (2) interaction of Pb, Cd, 
and Ag with selenium compounds in mitochondria and ER; and (3) reaction with phosphate 
groups in ATP and IP3. Reactive selenium compounds may be identified in different parts of 
ER important in the regulation of Ca [25]. Studies on harmful effects of metal ions often refer 
to one element at a time; very little is known about the effects of accumulated Pb, Cd, and Ag 
and their synchronistic damage. Dementia in Alzheimer’s and Parkinson’s diseases has been 
demonstrated in several studies [41]. The effects of Pb and Cd were demonstrated in mentally 
retarded children [42]. Pb, Cd, and Ag may also “hitchhike” endogenous carriers of essential 
metal ions making the interpretation of metal ion homeostasis not controlled by DNA reac-
tions more complex. It is likely that Pb, Cd, and Ag may be able to repress Mg and Ca in cell 
DNA and disrupt DNA and RNA control due to synchronistic damaging effects.
5. Possible effects of Pb, Cd, and Ag on blood-brain barrier (BBB) 
filter and choroid plexus in relation to metal ion imbalance and 
selenium homeostasis
In Alzheimer’s and Parkinson’s diseases, malfunctions may be attributed to damage in differ-
ent regions. The transport of compounds and metal ions to the brain is controlled by blood-
brain barrier and by CSF in the choroid plexus [43–45]. The blood-brain barrier is constructed 
of endothelial cells, astrocyte end-feet, and pericytes forming diffuse barriers, tight junctions, 
receptors, and channels for carrier-mediated transport [46]. Leukocytes and larger molecules 
cannot pass into the BBB as well as in other vessels, but, e.g., oxygen, carbon dioxide, iron, 
glucose, and certain amino acids can pass. If Pb, Cd, and Ag from erythrocytes enter the 
BBB, an imbalance may be expected of metal ions and compounds in regions of, e.g., the 
hippocampus, hypothalamus, pituitary gland, pineal gland, and cortex. Part of Pb, Cd, and 
Ag in the erythrocytes may “hitchhike” tight junctions, channels, and carriers for essential 
elements in BBB and enter neuron cells, astrocytes, and microglia in a way not controlled by 
DNA. Pericytes and endothelial cells have mitochondria and ER which need selenium for 
proper function of, e.g., Ca and Mg. Mitochondria synthesize ATP, and lowered selenium 
and Mg may decrease the production of ATP and complicate synthesis systems in ER for the 
control of Ca and Mg. Activated neutrophil granulocytes can produce (H2O2) damage in tight 
junctions and receptors in membranes of pericytes and endothelial cells when there are local 
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low selenium status and low activity of protecting GSH-Px (GPx1 and GPx4). The ER stores 
selenium [25] and metal ions for maintaining calcium metabolism. Imbalance in metal ion 
homeostasis and selenium homeostasis can hamper DNA control of metal flux to different 
organelles, e.g., ER, mitochondria, Golgi, and nuclei. Besides erythrocyte transport of Pb, Cd, 
and Ag, albumin may carry Pb, Cd, and Ag which can react with tight junctions and receptors 
on pericytes and pass, loaded with Pb, Cd, and Ag producing reactive oxygen species (ROS). 
Pb, Cd, and Ag can interact with elements in mitochondria, e.g., Mg, Ca, Mn, and Se, and 
disturb ER storage of calcium and action of selenophosphate synthetase. The introduction 
of selenium in amino acids and UGA (stop codon) is very important for cell metabolism. 
Albumin may carry heme groups having an antioxidant effect, which decreases the risk of 
ROS production [47]. Microglia can attack receptors and tight junctions on pericytes around 
the endothelial cells producing ROS damage and perhaps open for albumin entrance carrying 
Pb, Cd, and Ag. The brain is composed of 80% water and uses aquaporin, AQ1, AQ4, and 
AQ9, for water balance [10]. Apart from water control, Pb, Cd, and Ag can use aquaporin for 
passage [11]. If Pb and Cd can pass into the mitochondria, Mn may be displaced and trigger 
SOD to produce ROS. Pb, Ca, and Ag may use the SLC system [48], “hitchhike,” and transfer 
elements through the BBB in a way not controlled by DNA. Choroid plexus epithelial cells 
are rich in selenium [25] and may act as an additional barrier against metal ions and toxic 
compounds [43]. If erythrocytes are overloaded with Cd, Pb, and Ag, some ions may pass the 
BBB in other regions of the brain, e.g., hippocampus and cortex, and produce local imbalance 
of metal ions and selenium homeostasis in the brain.
6. Effects of Pb, Cd, and Ag on insulin receptors in brain cells and 
energy homeostasis
Increased concentrations of Pb, Cd, and Ag do not only affect the transfer of metal ions but 
also may influence the metabolism of proteins and peptides [49–51]. In plasma about 30% of 
Ca and about 40% Zn may be carried by albumin, but albumin also carries other elements and 
organic compounds [47, 52–54]. In the study of albumin, Pb and Cd decreased the transport of 
taxifolin [55]. Albumin in the blood carries 1–10% of glucose. If Pb, Cd, and Ag bind to albumin, 
transport of organic compounds, e.g., glucose, may be decreased. Many peptides and proteins 
in the BBB are transported by carrier in membranes, e.g., SLC and ABC families, which can be 
blocked by Pb, Cd, and Ag. T4 (thyroxin) in the blood is transported by transthyretin to the 
BBB [56]. T4 is dependent on selenium deiodinases for transfer to active T3 (thyronine) [57]. 
As both deiodinases and T4 and T3 have reactive selenium and iodine groups can Pb, Cd, 
and Ag disturb selenium homeostasis. Insulin present in the brain is not known to be directly 
involved in glucose metabolism but may assist in the regulation of energy homeostasis [49, 50]. 
The brain has many insulin receptors, which is highest in the hippocampus. The association 
of metal ions to insulin receptors in neuron cells may be similar as that of erythrocytes when 
Cd, Pb, and Ag interact with K+ and Na+ ions with insulin receptors [32]. Insulin binding 
sites to insulin receptor may be occupied by Pb, Cd, and Ag and decrease transport. Memory 
problems connected to the hippocampus may be explained to some extent by a decreased 
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transport of insulin, availability of glucose, and the antioxidant capacity of the brain involved 
in energy homeostasis [49, 50]. If the concentration of Pb, Cd, and Ag of the erythrocytes is 
too high, insulin transport in the brain may be decreased with less capacity to control energy 
homeostasis and hormone balance of insulin, leptin, and serotonin [49].
7. Axonal transport and possible interactions of Pb, Cd, and Ag
The axonal transport of mitochondria [58, 59] may be blocked by Pb, Cd, and Ag. Mitochondria 
were transported by kinesin, dynein, and myosin motors. Accumulation of Pb, Cd, and Ag in 
the erythrocytes may interact with transport in neurons due to carry-over effects.
In the synapse dopamine and acetylcholine are transported in the vesicles. The observed 
accumulation of Pb, Cd, and Ag in the erythrocytes may present two problems: (1) lowered 
dopamine production and (2) blocking acetylcholine.
Dopamine synthesis may be disturbed by Cd, Pb, and Ag in the medulla of adrenal glands, 
neuron cells, and substantia nigra. Transport of molecules, e.g., dopamine, may be blocked by 
Pb, Cd, and Ag. Interactions with aldosterone formed in cortex (adrenal glands) are known 
as an important regulator of Na, K may be disturbed. The high concentration of Cd, Pb, and 
Ag may interact with the hormone controlled by, e.g., hypothalamus, thalamus, and adrenal 
glands.
8. Changed metal ion and selenium homeostasis by overloaded 
Pb, Cd, and Ag in erythrocytes related to receptor functions in 
Alzheimer’s and Parkinson’s diseases
Important calcium-dependent receptors were reported in Section 3. Receptors may respond 
to metal ions and compounds but in a hierarchy to respond correctly. Receptors in the dif-
ferent brain regions may need to be restored; excess Pb, Cd, and Ag may block restoring 
procedures. Receptor feasibility is dependent on metal ions and organic compounds to main-
tain hierarchy in selectivity and efficacy. If receptors are exposed to overload of Pb, Cd, and 
Ag in erythrocytes, receptor activity may be destroyed or renewal not be possible. Patients 
with Alzheimer’s and Parkinson’s diseases with changed metal ion homeostasis meet incom-
plete selenium proteins or not properly adapted proteins [60, 61]. In Parkinson’s disease, 
dopamine synthesis in neuron cells, e.g., substantia nigra and hypothalamus, is decreased. 
In parkinsonian patient’s postmortem substantia nigra, increased concentration of iron was 
observed [62]. Transport of iron by SLC41 (membrane iron carrier) to the substantia nigra 
can be disrupted by erythrocytes overloaded with Pb, Cd, and Ag and decrease the synthesis 
of dopamine. Lowered Ca homeostasis is coupled with selenium deficiency in ER in both 
Parkinson’s and Alzheimer’s diseases [26, 63–69]. In Alzheimer’s disease increased produc-
tion of β-amyloid is implicated. Patients with Alzheimer’s and Parkinson’s diseases may have 
in common increased Pb, Cd, and Ag in the erythrocytes with possible interactions with 
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selenoproteins and phosphate groups in nuclei, ER, mitochondrial ATP, and IP3 [27]. SelP 
(selenoprotein P) in the brain with about 10 Se atoms is important to support different brain 
regions with selenium. As SelP is very reactive, Pb, Cd, and Ag and their protective role may 
be blocked [70]. A more basic work is necessary to understand how the regulation of metal ion 
homeostasis in cells is related to selenium homeostasis at the local level.
9. Epigenetic effects on DNA and RNA repair systems after exposure 
to Cd, Pb, and Ag from erythrocytes
Cells exposed to Cd, Pb, and Ag can disturb the genomic stability which is dependent on Mg 
[71, 72]. DNA is dependent on efficient repair systems due to as many as 10,000 errors/cell/day 
[73]. If Cd, Pb, and Ag from erythrocytes are introduced to cells, repair systems will not work 
properly [74]. Deformed molecules or decreased production of important protective com-
pounds may initiate problems in cell metabolism, e.g., it starts wrong apoptosis signals and Cd, 
Pb, and Ag may compete with repair systems, e.g., enzymes and ligases of DNA polymerases 
[75, 76]. Excess Cd, Pb, and Ag can also impair Zn-dependent RNA polymerases by competing 
with the active center in the binding domain and also create cross-linking of DNA [77–79].
10. Conclusions
ICP-MS may be used for the determination of the element profile of erythrocytes as a bio-
marker in Alzheimer’s and Parkinson’s diseases. The increased concentration of Pb, Cd, and 
Ag in erythrocytes in Alzheimer’s and Parkinson’s diseases indicates changes in the filter 
capacity of the kidneys combined with the changes of the adrenal glands. Studying multifac-
torial problems using element profiles in diseases may help to identify early changes in the 
pathophysiological process and epigenetic progress. The increase of Pb, Cd, and Ag in the 
erythrocytes may indicate changes in metal ion homeostasis at the cellular level in other parts 
of the body, e.g., the brain.
Parkinson’s and Alzheimer’s diseases are neurodegenerative diseases. A variety of treatment 
recommendations in the treatment guidelines have been proposed, including physical activ-
ity and disease-modifying medication, which should be initiated at the early stage of the 
disease. The complex synchronistic effects at the cellular level when Cd, Pb, and Ag enter in 
a noncontrolled way may be approached by using ICP-MS. It is hoped that this knowledge 
will allow the identification of novel therapeutic targets that will eventually lead to a more 
efficient treatment, based on the patient’s individual genetic predispositions.
Many candidate biomarkers of the neurodegenerative diseases have been proposed in the 
scientific literature, but in all cases, their variability in cross-sectional studies is considerable, 
and therefore no single measurement has proven to serve a useful marker, possibly lacking 
the power of directly predicting disease risk, as the underlying physiological change may per 
se be harmless and without functional compromise.
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transport of insulin, availability of glucose, and the antioxidant capacity of the brain involved 
in energy homeostasis [49, 50]. If the concentration of Pb, Cd, and Ag of the erythrocytes is 
too high, insulin transport in the brain may be decreased with less capacity to control energy 
homeostasis and hormone balance of insulin, leptin, and serotonin [49].
7. Axonal transport and possible interactions of Pb, Cd, and Ag
The axonal transport of mitochondria [58, 59] may be blocked by Pb, Cd, and Ag. Mitochondria 
were transported by kinesin, dynein, and myosin motors. Accumulation of Pb, Cd, and Ag in 
the erythrocytes may interact with transport in neurons due to carry-over effects.
In the synapse dopamine and acetylcholine are transported in the vesicles. The observed 
accumulation of Pb, Cd, and Ag in the erythrocytes may present two problems: (1) lowered 
dopamine production and (2) blocking acetylcholine.
Dopamine synthesis may be disturbed by Cd, Pb, and Ag in the medulla of adrenal glands, 
neuron cells, and substantia nigra. Transport of molecules, e.g., dopamine, may be blocked by 
Pb, Cd, and Ag. Interactions with aldosterone formed in cortex (adrenal glands) are known 
as an important regulator of Na, K may be disturbed. The high concentration of Cd, Pb, and 
Ag may interact with the hormone controlled by, e.g., hypothalamus, thalamus, and adrenal 
glands.
8. Changed metal ion and selenium homeostasis by overloaded 
Pb, Cd, and Ag in erythrocytes related to receptor functions in 
Alzheimer’s and Parkinson’s diseases
Important calcium-dependent receptors were reported in Section 3. Receptors may respond 
to metal ions and compounds but in a hierarchy to respond correctly. Receptors in the dif-
ferent brain regions may need to be restored; excess Pb, Cd, and Ag may block restoring 
procedures. Receptor feasibility is dependent on metal ions and organic compounds to main-
tain hierarchy in selectivity and efficacy. If receptors are exposed to overload of Pb, Cd, and 
Ag in erythrocytes, receptor activity may be destroyed or renewal not be possible. Patients 
with Alzheimer’s and Parkinson’s diseases with changed metal ion homeostasis meet incom-
plete selenium proteins or not properly adapted proteins [60, 61]. In Parkinson’s disease, 
dopamine synthesis in neuron cells, e.g., substantia nigra and hypothalamus, is decreased. 
In parkinsonian patient’s postmortem substantia nigra, increased concentration of iron was 
observed [62]. Transport of iron by SLC41 (membrane iron carrier) to the substantia nigra 
can be disrupted by erythrocytes overloaded with Pb, Cd, and Ag and decrease the synthesis 
of dopamine. Lowered Ca homeostasis is coupled with selenium deficiency in ER in both 
Parkinson’s and Alzheimer’s diseases [26, 63–69]. In Alzheimer’s disease increased produc-
tion of β-amyloid is implicated. Patients with Alzheimer’s and Parkinson’s diseases may have 
in common increased Pb, Cd, and Ag in the erythrocytes with possible interactions with 
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selenoproteins and phosphate groups in nuclei, ER, mitochondrial ATP, and IP3 [27]. SelP 
(selenoprotein P) in the brain with about 10 Se atoms is important to support different brain 
regions with selenium. As SelP is very reactive, Pb, Cd, and Ag and their protective role may 
be blocked [70]. A more basic work is necessary to understand how the regulation of metal ion 
homeostasis in cells is related to selenium homeostasis at the local level.
9. Epigenetic effects on DNA and RNA repair systems after exposure 
to Cd, Pb, and Ag from erythrocytes
Cells exposed to Cd, Pb, and Ag can disturb the genomic stability which is dependent on Mg 
[71, 72]. DNA is dependent on efficient repair systems due to as many as 10,000 errors/cell/day 
[73]. If Cd, Pb, and Ag from erythrocytes are introduced to cells, repair systems will not work 
properly [74]. Deformed molecules or decreased production of important protective com-
pounds may initiate problems in cell metabolism, e.g., it starts wrong apoptosis signals and Cd, 
Pb, and Ag may compete with repair systems, e.g., enzymes and ligases of DNA polymerases 
[75, 76]. Excess Cd, Pb, and Ag can also impair Zn-dependent RNA polymerases by competing 
with the active center in the binding domain and also create cross-linking of DNA [77–79].
10. Conclusions
ICP-MS may be used for the determination of the element profile of erythrocytes as a bio-
marker in Alzheimer’s and Parkinson’s diseases. The increased concentration of Pb, Cd, and 
Ag in erythrocytes in Alzheimer’s and Parkinson’s diseases indicates changes in the filter 
capacity of the kidneys combined with the changes of the adrenal glands. Studying multifac-
torial problems using element profiles in diseases may help to identify early changes in the 
pathophysiological process and epigenetic progress. The increase of Pb, Cd, and Ag in the 
erythrocytes may indicate changes in metal ion homeostasis at the cellular level in other parts 
of the body, e.g., the brain.
Parkinson’s and Alzheimer’s diseases are neurodegenerative diseases. A variety of treatment 
recommendations in the treatment guidelines have been proposed, including physical activ-
ity and disease-modifying medication, which should be initiated at the early stage of the 
disease. The complex synchronistic effects at the cellular level when Cd, Pb, and Ag enter in 
a noncontrolled way may be approached by using ICP-MS. It is hoped that this knowledge 
will allow the identification of novel therapeutic targets that will eventually lead to a more 
efficient treatment, based on the patient’s individual genetic predispositions.
Many candidate biomarkers of the neurodegenerative diseases have been proposed in the 
scientific literature, but in all cases, their variability in cross-sectional studies is considerable, 
and therefore no single measurement has proven to serve a useful marker, possibly lacking 
the power of directly predicting disease risk, as the underlying physiological change may per 
se be harmless and without functional compromise.
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This necessitates the development of new effective strategies for the prevention and early 
diagnosis of such conditions. Contrary to the common perception that personalized medicine 
is completely based on a genetic approach, clinical subtypes, personality, lifestyle, aging, and 
comorbidities constitute the true personalized medicine.
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Abstract
Over the past few decades, researchers have established that the human body has a 
complex ecosystem. It is a social network between our own cells and bacteria and other 
microorganisms. Bacteria cells in the human body outnumber our own cells by 10 to 1. 
Despite this huge number, they are usually no threat to us. They offer vital help to many 
of our basic physiological processes. It is becoming increasingly clear that the microbes 
in our gut play crucial roles in health and disease. It is likely that the bacterial flora in 
our body may also influence the aging process. Apart from the influence of bacterial flora 
in our bodies and the diet we consume, there are certain pharmacological substances 
such as rapamycin, metformin, and resveratrol that are shown to influence longevity in 
animals and humans. Calorie restriction is known to increase life span in many animal 
species. Other factors that influence aging include the role of free radicals, gene modifica-
tions, chronic inflammation, and certain spices such as curcumin and capsaicin. Modern 
life style that promotes obesity and social isolation are other factors that contribute to a 
number of human illnesses. This paper will present some of the latest findings related to 
gut flora, aging, and social well-being.
Keywords: diet, microbiome, gut flora, social well-being, health
1. Introduction
The relation between our body and the food we eat on a regular basis throughout our lifespan 
is a very close and intimate one when compared to all other human relationships. Therefore, 
many researchers in the field of nutrition have often proclaimed “we are what we eat.” 
According to anthropologists, our ancestors cultivated the art of cooking more than a mil-
lion years ago, and the hot and cooked meals made us what we are today [1]. The oversized 
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brain, shrunken teeth, guts, and other peculiar traits of our race arose as Homo sapiens turned 
to cooking in order to improve the quality of the food and easy digestion. Unlike our close 
cousins, the apes, our race cannot survive on raw food in the wild for a long time. On the 
other hand, the lifespan of our species is much higher than that of the primates. It is often 
thought that the increased lifespan of humans during the last couple of centuries is due to the 
advent of antibiotics and other medical advances, the development of modern urban sanita-
tion systems, and the availability of fresh, nutritious vegetables and fruits round the year. 
This assumption, however, is being challenged by the findings from the study of mummies a 
few thousand years ago [2, 3]. These studies indicate that the trend in the increase of lifespan 
actually started much earlier than what was considered a few decades ago. Compelling data 
from fields as diverse as physical anthropology, primatology, genetics, and medicine indicate 
another mechanism for the increased life span. The trend toward slower aging and increased 
life span started when our ancestors developed defense systems that could ward against the 
threat from pathogens and irritants in the immediate environment [3]. As human ancestors 
ate more meat, they evolved defenses against its attendant pathogens. These defense systems 
may also have contributed to an increased life span as well as diseases of old age. Research is 
going on at present, and if the above theory is proven correct, it may open new avenues for 
the development of drugs that may prolong the life span as well as fight the old-age diseases. 
The new abundance of calories and protein helped to fuel brain growth, and at the same time, 
such nutritional advances also made it unavoidable to the exposure to various pathogens. The 
risk of exposure to early pathogens and the subsequent development of immunity favored the 
rise and spread of adaptations that allowed our ancestors to survive attacks by disease-caus-
ing organisms such as bacteria, viruses, and other microbes that seek to invade our tissues.
Agriculture was probably developed by humans around the Nile valley, Indus basin, 
Mesopotamia, and other regions of early civilizations around 10,000–12,000 years ago. It all 
started when our ancestors noticed that new plants arise from other plant species. In other 
words, they learned the secret of seeds. This was probably the starting point of agriculture. 
Before this new era in human history, the diet of our ancestors was composed of fruits, nuts, 
and tubers. The hunter-gatherer consumed meat whenever they succeeded in hunting. The 
early Homo sapiens kept moving in order to find food and survive. Once they learned the 
secret of seeds, they quickly learned to domesticate crops, ultimately crossbreeding different 
plants to create such staples as wheat, rye, and barley. This in turn resulted in a change in the 
nomadic way of living. They developed a modern way of living by building villages, towns, 
and cities. Sugarcane was domesticated in New Guinea around 10,000 years ago. It was a kind 
of food revolution at that time, and according to New Guinean myths, sugar was an elixir that 
cured almost everything. The domestication of sugarcane spread slowly from island to island 
and reached the Asian mainland, the Middle East, and Europe. In India, in olden days, sugar 
was used as a medicine for headaches, gut flutters, and impotence. Finally, Columbus planted 
sugar cane in Hispaniola. The slave trade in North and South America is a consequence of 
sugar plantation.
The eating habits of our hunter-gather ancestors changed drastically since they discovered the 
secrets and potentials of seeds and plants. Along with the advances in technology and 
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instrumentation, the early practice of agriculture improved tremendously, and our ances-
tors quickly learned to domesticate crops and animals as mentioned earlier. The percentage 
of carbohydrates in the diets of our ancestors after the introduction of agriculture increased 
to as much as 40% compared to fats and proteins. With the advance of industrial revolution 
about two centuries ago, our dietary habits changed further. The fast-food business became 
very lucrative, and currently, it is being introduced even in the remote corners of the globe. 
Alcoholic beverages mainly beer and wine were introduced to human diets around 6000 years 
ago. The distillation process discovered by the Alchemists in the Middle East several centuries 
ago led to the production of strong alcoholic beverages such as whiskey and brandy. The intro-
duction of fertilizers and other chemicals in recent decades to boost the production of crops 
has resulted in the contamination of soil and water. The percentage of heavy metals and other 
contaminants in the soil and water increased significantly, and this in turn affected plants and 
aquatic ecology. The future of agricultural practices is likely to be changed drastically in the 
coming years with increasing population burden. How food is going to transform the future 
generations is a challenging situation for scientists and politicians. Genetic engineering might 
be a partial solution. Genetically modified vegetables and grains are already available in many 
food stores. With the current trend in population explosion, it is crucial to find ways to improve 
agriculture without destroying the ecology.
For thousands of years, humans shared the planet with Neanderthals, primates, and a large 
number of other species which are extinct. Our species were also at a risk of extinction about 
74,000 years ago when a super volcanic eruption took place in Indonesia. The human popu-
lation at that time was only a few thousands. The heroic ascent of man took place around 
35,000–50,000 years ago. At around the time of introduction of agriculture, the human popula-
tion was around one million [4]. During the industrial revolution about 150–200 years ago, 
the human population became one billion. After the Second World War, dramatic changes 
took place in the history of Homo sapiens. This included population expansion, globalization, 
mass production, technological and communication revolutions, improved farming methods, 
and advances in health sciences. It is predicted that by 2050, the human population would be 
increased to 9 billion. It is the age of man: the Anthropocene [4].
In this mini-review, I would describe the current knowledge about human aging and the 
importance of bacterial flora in our bodies that have profound influence in our health and 
social well-being. It will also describe some of the latest advances in order to deal with the 
aging populations throughout our globe.
2. Diet, pharmaceuticals, and aging
Any comparative study of diet and aging depends on the availability of accurate criteria for 
defining and assessing the aging processes. Currently, a lot of information is available about 
human aging. Burnet in 1974 indicated a linear relation between age and logarithmic values for 
total death rates in different populations [5]. The exponential increase in mortality rates with 
age was first noted by Gompertz in 1825 [6]. Research on aging in the late 1960s in Sweden and 
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another mechanism for the increased life span. The trend toward slower aging and increased 
life span started when our ancestors developed defense systems that could ward against the 
threat from pathogens and irritants in the immediate environment [3]. As human ancestors 
ate more meat, they evolved defenses against its attendant pathogens. These defense systems 
may also have contributed to an increased life span as well as diseases of old age. Research is 
going on at present, and if the above theory is proven correct, it may open new avenues for 
the development of drugs that may prolong the life span as well as fight the old-age diseases. 
The new abundance of calories and protein helped to fuel brain growth, and at the same time, 
such nutritional advances also made it unavoidable to the exposure to various pathogens. The 
risk of exposure to early pathogens and the subsequent development of immunity favored the 
rise and spread of adaptations that allowed our ancestors to survive attacks by disease-caus-
ing organisms such as bacteria, viruses, and other microbes that seek to invade our tissues.
Agriculture was probably developed by humans around the Nile valley, Indus basin, 
Mesopotamia, and other regions of early civilizations around 10,000–12,000 years ago. It all 
started when our ancestors noticed that new plants arise from other plant species. In other 
words, they learned the secret of seeds. This was probably the starting point of agriculture. 
Before this new era in human history, the diet of our ancestors was composed of fruits, nuts, 
and tubers. The hunter-gatherer consumed meat whenever they succeeded in hunting. The 
early Homo sapiens kept moving in order to find food and survive. Once they learned the 
secret of seeds, they quickly learned to domesticate crops, ultimately crossbreeding different 
plants to create such staples as wheat, rye, and barley. This in turn resulted in a change in the 
nomadic way of living. They developed a modern way of living by building villages, towns, 
and cities. Sugarcane was domesticated in New Guinea around 10,000 years ago. It was a kind 
of food revolution at that time, and according to New Guinean myths, sugar was an elixir that 
cured almost everything. The domestication of sugarcane spread slowly from island to island 
and reached the Asian mainland, the Middle East, and Europe. In India, in olden days, sugar 
was used as a medicine for headaches, gut flutters, and impotence. Finally, Columbus planted 
sugar cane in Hispaniola. The slave trade in North and South America is a consequence of 
sugar plantation.
The eating habits of our hunter-gather ancestors changed drastically since they discovered the 
secrets and potentials of seeds and plants. Along with the advances in technology and 
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to as much as 40% compared to fats and proteins. With the advance of industrial revolution 
about two centuries ago, our dietary habits changed further. The fast-food business became 
very lucrative, and currently, it is being introduced even in the remote corners of the globe. 
Alcoholic beverages mainly beer and wine were introduced to human diets around 6000 years 
ago. The distillation process discovered by the Alchemists in the Middle East several centuries 
ago led to the production of strong alcoholic beverages such as whiskey and brandy. The intro-
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aquatic ecology. The future of agricultural practices is likely to be changed drastically in the 
coming years with increasing population burden. How food is going to transform the future 
generations is a challenging situation for scientists and politicians. Genetic engineering might 
be a partial solution. Genetically modified vegetables and grains are already available in many 
food stores. With the current trend in population explosion, it is crucial to find ways to improve 
agriculture without destroying the ecology.
For thousands of years, humans shared the planet with Neanderthals, primates, and a large 
number of other species which are extinct. Our species were also at a risk of extinction about 
74,000 years ago when a super volcanic eruption took place in Indonesia. The human popu-
lation at that time was only a few thousands. The heroic ascent of man took place around 
35,000–50,000 years ago. At around the time of introduction of agriculture, the human popula-
tion was around one million [4]. During the industrial revolution about 150–200 years ago, 
the human population became one billion. After the Second World War, dramatic changes 
took place in the history of Homo sapiens. This included population expansion, globalization, 
mass production, technological and communication revolutions, improved farming methods, 
and advances in health sciences. It is predicted that by 2050, the human population would be 
increased to 9 billion. It is the age of man: the Anthropocene [4].
In this mini-review, I would describe the current knowledge about human aging and the 
importance of bacterial flora in our bodies that have profound influence in our health and 
social well-being. It will also describe some of the latest advances in order to deal with the 
aging populations throughout our globe.
2. Diet, pharmaceuticals, and aging
Any comparative study of diet and aging depends on the availability of accurate criteria for 
defining and assessing the aging processes. Currently, a lot of information is available about 
human aging. Burnet in 1974 indicated a linear relation between age and logarithmic values for 
total death rates in different populations [5]. The exponential increase in mortality rates with 
age was first noted by Gompertz in 1825 [6]. Research on aging in the late 1960s in Sweden and 
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the United States showed similar patterns. Mortality for both countries was higher for men 
from birth up to the highest ages, whereas the mortality rate at age 10 shows for both men and 
women the lowest figures of all age groups. At age 20, there is a limited additional increase 
that is more pronounced in males than in females. It may have a special significance when it 
is realized that the blood pressure in normal populations exhibits an almost identical plateau 
at age 20 [7]. These data are consistent with a genetic control hypothesis for aging which is in 
turn under environmental influence.
During the 1960s and 1970s, tobacco, alcohol, sugar, coffee, and some other constituents have 
been singled out as factors increasing the risk of developing diseases of the old age including 
cardiovascular diseases, diabetes, and cancer. Mormons in Utah, USA, and other parts of 
the world are forbidden to drink alcoholic beverages and coffee and to smoke. It seemed of 
interest to compare the mortality rates for Mormons and other groups. Studies by Brown and 
Forbes in 1976 showed that mortality rates of Mormons in Utah (USA) and a control group 
in Montreal (Canada) showed an identical pattern [8]. The similarity was pronounced after 
the age of 40 when cancer and cardiovascular diseases are the dominating cause of death [8]. 
Similar results were found in Sweden. Does this mean that smoking habits and drinking alco-
holic beverages and coffee are less important than other factors? Later studies, however, have 
proven that drinking, smoking, and the consumption of fatty foods have a profound negative 
influence in the development of diseases of the old age. Studies in Sweden and other countries 
during the 1970s suggest two separate selection processes: one from conception until the age 
of 10 and the other from 10 until death. The early selection period may be more susceptible to 
social and general living conditions than the second. Those surviving the first 20–30 years of 
age in Australia 100 years ago showed a lower rise in mortality rate with age than the case in 
the general population today [5, 9]. These findings indicate that aging might be a continuous 
process [10]. In China arteriosclerosis was not considered to be a clinical problem in the 1930s, 
but today there is a high incidence of cardiovascular disease in China [11]. The Chinese diet 
was considered to be “non-atherogenic.” The diet at the present time is basically unchanged, 
but the life expectancy, which 60–70 years ago was 33 years or less, is now 70 years. Some 
decades ago, chronic alcoholism appeared to protect against cardiovascular diseases until it 
was found that the low incidence of the diseases related to the shorter life span of alcoholics 
[12, 13]. Another paradox related to alcohol consumption is the high level of high-density 
lipoprotein (HDL) found in the blood of alcoholics [12, 13]. HDL is found to have some protec-
tive effect against the development of cardiovascular diseases.
It was only during the latter part of the nineteenth century that the mean life expectancy at 
birth in Sweden and some other European countries reached 50 years. The decreasing infant 
mortality, which still contributes to a prolonged life expectancy in Sweden and other affluent 
countries, suggests that the diet consumed by the mothers during the most susceptible phase 
of life has no obvious inadequacies. With the exception of infections and toxic agents, most 
environmental factors are assumed to affect human genes only slowly. Can the prevailing 
causes of death due to cardiovascular diseases and cancer be eliminated? The latest research 
indicates that they cannot be eliminated, but can be postponed. Hayflick in 1976 estimated 
the increase in life expectancy when the old-age diseases are eliminated [14]. According to 
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his estimate, a total elimination of cardiovascular diseases would lead to an increase in life 
expectancy at birth of 10.9 years. The elimination of cancer on the other hand would lead life 
expectancy by only 2–3 years. Studies by Pearce and Dayton in 1971 showed that populations 
consuming a diet that is high in polyunsaturated fatty acids died less frequently from cardio-
vascular diseases than people on normal diets [15].
In order to understand the interaction between the genetic basis and the environmental fac-
tors at different age levels, it seemed desirable to develop a “biological age indicator” system. 
Burnet’s hypothesis mentioned earlier indicating a genetic control of aging giving the thymus 
and the circulating lymphocytes a leading role seems to be in agreement with the findings 
described above. At the present time, based on a number of studies employing modern tech-
nology, it is doubtful whether genes alone are involved in the aging process. Genes alone are 
unlikely to explain all the secrets of longevity. Genes account for only 25% of longevity. It is 
the environment too, but that does not explain all factors involved in the aging process either. 
Table 1 shows some of the relevant factors associated with aging.
Retardation of growth in experimental animals by calorie restriction was first described by 
McCay and his co-workers in 1939 [16]. Tannebaum and Silverstone showed that diet restric-
tion retards the appearance of various types of cancer and thus the diet slows down the aging 
process [17–20]. Ross and his co-workers in 1976 showed that a food intake in grams was 
negatively correlated with age [21]. They concluded that the conditions in early life seem to 
govern the life span and to interweave with factors that regulate susceptibility to age-related 
diseases. So far, nobody has established a particular nutrient such as an amino acid, a mineral, 
a trace element, a vitamin, or total energy as the limiting factor. Although eating sparingly 
may have been less a choice than an involuntary circumstance of poverty in a number of places 
in the world during the nineteenth and twentieth centuries, early research has suggested that 
Agent/process Known mechanism
Calorie restriction Gene modification
Rapamycin and related compounds mTOR modification
Metformin Glycation of proteins
Resveratrol Antioxidant, acts on sirtuins
Free radicals Damage DNA and proteins
Gene modification Acts on regulating genes
Chronic inflammation Cytokine excretion
Young blood Restoration of GDF 11
Drugs Gene/hormone activation
Spices (e.g., curcumin, capsaicin) Antioxidants, act on sirtuins
Table 1. Factors associated with aging process.
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at age 20 [7]. These data are consistent with a genetic control hypothesis for aging which is in 
turn under environmental influence.
During the 1960s and 1970s, tobacco, alcohol, sugar, coffee, and some other constituents have 
been singled out as factors increasing the risk of developing diseases of the old age including 
cardiovascular diseases, diabetes, and cancer. Mormons in Utah, USA, and other parts of 
the world are forbidden to drink alcoholic beverages and coffee and to smoke. It seemed of 
interest to compare the mortality rates for Mormons and other groups. Studies by Brown and 
Forbes in 1976 showed that mortality rates of Mormons in Utah (USA) and a control group 
in Montreal (Canada) showed an identical pattern [8]. The similarity was pronounced after 
the age of 40 when cancer and cardiovascular diseases are the dominating cause of death [8]. 
Similar results were found in Sweden. Does this mean that smoking habits and drinking alco-
holic beverages and coffee are less important than other factors? Later studies, however, have 
proven that drinking, smoking, and the consumption of fatty foods have a profound negative 
influence in the development of diseases of the old age. Studies in Sweden and other countries 
during the 1970s suggest two separate selection processes: one from conception until the age 
of 10 and the other from 10 until death. The early selection period may be more susceptible to 
social and general living conditions than the second. Those surviving the first 20–30 years of 
age in Australia 100 years ago showed a lower rise in mortality rate with age than the case in 
the general population today [5, 9]. These findings indicate that aging might be a continuous 
process [10]. In China arteriosclerosis was not considered to be a clinical problem in the 1930s, 
but today there is a high incidence of cardiovascular disease in China [11]. The Chinese diet 
was considered to be “non-atherogenic.” The diet at the present time is basically unchanged, 
but the life expectancy, which 60–70 years ago was 33 years or less, is now 70 years. Some 
decades ago, chronic alcoholism appeared to protect against cardiovascular diseases until it 
was found that the low incidence of the diseases related to the shorter life span of alcoholics 
[12, 13]. Another paradox related to alcohol consumption is the high level of high-density 
lipoprotein (HDL) found in the blood of alcoholics [12, 13]. HDL is found to have some protec-
tive effect against the development of cardiovascular diseases.
It was only during the latter part of the nineteenth century that the mean life expectancy at 
birth in Sweden and some other European countries reached 50 years. The decreasing infant 
mortality, which still contributes to a prolonged life expectancy in Sweden and other affluent 
countries, suggests that the diet consumed by the mothers during the most susceptible phase 
of life has no obvious inadequacies. With the exception of infections and toxic agents, most 
environmental factors are assumed to affect human genes only slowly. Can the prevailing 
causes of death due to cardiovascular diseases and cancer be eliminated? The latest research 
indicates that they cannot be eliminated, but can be postponed. Hayflick in 1976 estimated 
the increase in life expectancy when the old-age diseases are eliminated [14]. According to 
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his estimate, a total elimination of cardiovascular diseases would lead to an increase in life 
expectancy at birth of 10.9 years. The elimination of cancer on the other hand would lead life 
expectancy by only 2–3 years. Studies by Pearce and Dayton in 1971 showed that populations 
consuming a diet that is high in polyunsaturated fatty acids died less frequently from cardio-
vascular diseases than people on normal diets [15].
In order to understand the interaction between the genetic basis and the environmental fac-
tors at different age levels, it seemed desirable to develop a “biological age indicator” system. 
Burnet’s hypothesis mentioned earlier indicating a genetic control of aging giving the thymus 
and the circulating lymphocytes a leading role seems to be in agreement with the findings 
described above. At the present time, based on a number of studies employing modern tech-
nology, it is doubtful whether genes alone are involved in the aging process. Genes alone are 
unlikely to explain all the secrets of longevity. Genes account for only 25% of longevity. It is 
the environment too, but that does not explain all factors involved in the aging process either. 
Table 1 shows some of the relevant factors associated with aging.
Retardation of growth in experimental animals by calorie restriction was first described by 
McCay and his co-workers in 1939 [16]. Tannebaum and Silverstone showed that diet restric-
tion retards the appearance of various types of cancer and thus the diet slows down the aging 
process [17–20]. Ross and his co-workers in 1976 showed that a food intake in grams was 
negatively correlated with age [21]. They concluded that the conditions in early life seem to 
govern the life span and to interweave with factors that regulate susceptibility to age-related 
diseases. So far, nobody has established a particular nutrient such as an amino acid, a mineral, 
a trace element, a vitamin, or total energy as the limiting factor. Although eating sparingly 
may have been less a choice than an involuntary circumstance of poverty in a number of places 
in the world during the nineteenth and twentieth centuries, early research has suggested that 
Agent/process Known mechanism
Calorie restriction Gene modification
Rapamycin and related compounds mTOR modification
Metformin Glycation of proteins
Resveratrol Antioxidant, acts on sirtuins
Free radicals Damage DNA and proteins
Gene modification Acts on regulating genes
Chronic inflammation Cytokine excretion
Young blood Restoration of GDF 11
Drugs Gene/hormone activation
Spices (e.g., curcumin, capsaicin) Antioxidants, act on sirtuins
Table 1. Factors associated with aging process.
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a severely restricted diet is associated with a long life. Recent research, however, has under-
mined the link between longevity and caloric restriction.
Rapamycin was isolated from the soil of Easter Islands during the late 1960s. The soil con-
tained a bacterium that made a defensive chemical that was shown to prolong the life span 
of several animal species. This substance has been shown to interfere with the activity of a 
protein called target of rapamycin (TOR) [22–25]. This protein is a now a subject of intensive 
research around the world. A number of recent studies have shown that suppressing the 
activity of the mammalian version of the protein (mTOR) in cells can lower the risk of major 
age-related diseases, especially neurological disorders such as dementia [19]. Researchers 
at Harvard University, USA, have found this protein also acts as a nutrient sensor [22–25]. 
When food is abundant, its activity rises, prompting cells to increase their overall production 
of proteins and to divide. On the other hand, when food is scarce, it helps to conserve the 
resources. Thus, inhibiting the functions of mTOR may oppose the aging process. Rapamycin, 
unfortunately, has many side effects in humans, and a few drug companies are developing 
molecules like rapamycin that have fewer side effects. The discovery that the aging process, 
previously thought to be intractably complex, could be dramatically slowed by altering one 
or several genes (gerontogenes) had helped make gerontology a very exciting and hot topic. It 
also suggests that aging can be retarded by drugs as mentioned above. Such drugs that slow 
aging could act as preventive medicines that could postpone or retard the late-life disorders 
including dementia, osteoporosis, cancer, and cataracts. They can be compared with modern 
drugs for cardiovascular diseases that have pushed off conditions such as early myocardial 
infarcts [22–25].
Metformin is a very common drug that is prescribed to patients with diabetes throughout 
the world. Millions of people have taken it for long periods in order to control blood glucose. 
Considerable efforts have been made since the 1950s to understand the cellular and molecu-
lar mechanisms of the action of metformin. The main effect of this drug from the biguanide 
family is to decrease hepatic glucose production, mainly through the inhibition of mitochon-
drial respiratory-chain complex 1. In addition, it activates the AMP-activated protein kinase 
(AMPK) [26]. Its mechanism of action is not yet absolutely very clear at present. It has, how-
ever, been shown that metformin inhibits the TOR pathway. It also activates another aging-
related enzyme called AMPK, which is likewise stimulated by calorie restriction. Metformin 
also has been shown to activate certain genes associated with aging in experimental animals. 
Recent studies at the university in Cardiff University in Wales, UK, showed that patients with 
type 2 diabetes who took the drug lived on an average 15% longer than a group of healthy 
controls [26, 27]. Scientists speculate that metformin interferes with a normal aging process 
called glycation in which glucose combines with proteins and other molecules gumming up 
their normal functions. This finding is interesting because people who have diabetes, even if it 
is well controlled, have somewhat shorter life span than their healthy counterparts. Only time 
can tell us if metformin can retard aging.
Resveratrol is a molecule that is found in grapes, other berries, and red wine. This molecule 
has attracted considerable attention in recent years in research concerned with aging process. 
Researchers have found that this molecule can activate enzymes such as sirtuins that regulate 
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some of the genes that control aging process. In animal models, resveratrol appears to acti-
vate one of the sirtuins, STRT1, which switches on multiple chemical pathways that mediate 
hormetic effects [28]. It also guarded the brain and spinal cord against damaging effects from 
the cutting off of blood flow that occurs in some types of stroke [28]. Not all of the research is 
uniformly positive. Scientists are uncertain about the specific pathway that resveratrol may be 
involved in the death of neurons. Moreover, recent studies in rodents have failed to show an 
anti-aging effect. It is possible that resveratrol and similar molecules modify genes associated 
with aging. Further studies are in progress.
Reactive oxygen species (ROS) have attracted considerable attention in scientific circles dur-
ing the last few decades. Metabolites of dioxygen such as superoxide, hydrogen peroxide, 
and hydroxyl ions are potentially damaging to biological systems. Univalent reduction of 
dioxygen produces superoxide which can be converted to hydrogen peroxide and hydroxyl 
radical. Superoxide dismutase which is a zinc-containing enzyme and other antioxidants may 
be useful in combating cell damage. A few important trace elements such as zinc, copper, iron, 
and selenium are important components of enzymes that deactivate the damaging effects of 
ROS and other free radicals. Although the first paper showing the association between trace 
elements such as manganese and disorders of the central nervous system appeared more 
than a century ago, much new information has accumulated in recent years concerning the 
role of free radicals in the etiology and pathogenesis of several neurological diseases. These 
include Parkinson’s disease, dementia, amyotrophic lateral sclerosis, Down syndrome, and 
Huntington’s disease. The similarities in the histopathological changes and the coexistence of 
these diseases implicate close relationships among the mechanisms of these illnesses. Age is 
certainly one of the deciding factors in the appearances of degenerative diseases of the central 
nervous system. The causes of these, diseases, however, are multifactorial. The reduction in 
the volume of brain is the most evident abnormality in most of the degenerative diseases 
mentioned above although the distinction between the changes due to the normal aging of 
the brain and the pathological changes observed in many degenerative diseases of the brain is 
arbitrary. The role of ROS and other free radicals in the premature aging process and the sub-
sequent increase in the incidence of a number of degenerative diseases has attracted consider-
able attention during the last few decades. Oxidant stress caused by free radicals is known 
to disturb calcium homeostasis by altering the calcium transport across the cell and mito-
chondrial membranes. Mitochondrial DNA is particularly susceptible to oxidative stress, and 
there is evidence of age-dependent damage and deterioration of respiratory enzyme activi-
ties with normal aging. If free radicals are associated with deterioration of neurons and the 
aging process, it is probable that high levels of antioxidants may prevent such damage. Fruits, 
vegetables, and nuts are very rich in many antioxidants, and people who regularly consume 
a diet rich in antioxidants are known to have healthier brains and to be less likely to suf-
fer from neurodegenerative diseases [29]. On the other hand, supplementations of synthetic 
antioxidants such as vitamin C, E, and A in experimental animals have failed to prevent or 
ameliorate diseases. Recent studies by Mattson have shown that the beneficial effect of fruits 
and vegetables are due to the natural pesticides that plants produce [29]. Plants have devel-
oped an elaborate set of chemical defenses to ward off insects. When we consume fruits and 
vegetables, we are exposed to such chemicals in very low doses. Exposures to these chemicals 
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a severely restricted diet is associated with a long life. Recent research, however, has under-
mined the link between longevity and caloric restriction.
Rapamycin was isolated from the soil of Easter Islands during the late 1960s. The soil con-
tained a bacterium that made a defensive chemical that was shown to prolong the life span 
of several animal species. This substance has been shown to interfere with the activity of a 
protein called target of rapamycin (TOR) [22–25]. This protein is a now a subject of intensive 
research around the world. A number of recent studies have shown that suppressing the 
activity of the mammalian version of the protein (mTOR) in cells can lower the risk of major 
age-related diseases, especially neurological disorders such as dementia [19]. Researchers 
at Harvard University, USA, have found this protein also acts as a nutrient sensor [22–25]. 
When food is abundant, its activity rises, prompting cells to increase their overall production 
of proteins and to divide. On the other hand, when food is scarce, it helps to conserve the 
resources. Thus, inhibiting the functions of mTOR may oppose the aging process. Rapamycin, 
unfortunately, has many side effects in humans, and a few drug companies are developing 
molecules like rapamycin that have fewer side effects. The discovery that the aging process, 
previously thought to be intractably complex, could be dramatically slowed by altering one 
or several genes (gerontogenes) had helped make gerontology a very exciting and hot topic. It 
also suggests that aging can be retarded by drugs as mentioned above. Such drugs that slow 
aging could act as preventive medicines that could postpone or retard the late-life disorders 
including dementia, osteoporosis, cancer, and cataracts. They can be compared with modern 
drugs for cardiovascular diseases that have pushed off conditions such as early myocardial 
infarcts [22–25].
Metformin is a very common drug that is prescribed to patients with diabetes throughout 
the world. Millions of people have taken it for long periods in order to control blood glucose. 
Considerable efforts have been made since the 1950s to understand the cellular and molecu-
lar mechanisms of the action of metformin. The main effect of this drug from the biguanide 
family is to decrease hepatic glucose production, mainly through the inhibition of mitochon-
drial respiratory-chain complex 1. In addition, it activates the AMP-activated protein kinase 
(AMPK) [26]. Its mechanism of action is not yet absolutely very clear at present. It has, how-
ever, been shown that metformin inhibits the TOR pathway. It also activates another aging-
related enzyme called AMPK, which is likewise stimulated by calorie restriction. Metformin 
also has been shown to activate certain genes associated with aging in experimental animals. 
Recent studies at the university in Cardiff University in Wales, UK, showed that patients with 
type 2 diabetes who took the drug lived on an average 15% longer than a group of healthy 
controls [26, 27]. Scientists speculate that metformin interferes with a normal aging process 
called glycation in which glucose combines with proteins and other molecules gumming up 
their normal functions. This finding is interesting because people who have diabetes, even if it 
is well controlled, have somewhat shorter life span than their healthy counterparts. Only time 
can tell us if metformin can retard aging.
Resveratrol is a molecule that is found in grapes, other berries, and red wine. This molecule 
has attracted considerable attention in recent years in research concerned with aging process. 
Researchers have found that this molecule can activate enzymes such as sirtuins that regulate 
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some of the genes that control aging process. In animal models, resveratrol appears to acti-
vate one of the sirtuins, STRT1, which switches on multiple chemical pathways that mediate 
hormetic effects [28]. It also guarded the brain and spinal cord against damaging effects from 
the cutting off of blood flow that occurs in some types of stroke [28]. Not all of the research is 
uniformly positive. Scientists are uncertain about the specific pathway that resveratrol may be 
involved in the death of neurons. Moreover, recent studies in rodents have failed to show an 
anti-aging effect. It is possible that resveratrol and similar molecules modify genes associated 
with aging. Further studies are in progress.
Reactive oxygen species (ROS) have attracted considerable attention in scientific circles dur-
ing the last few decades. Metabolites of dioxygen such as superoxide, hydrogen peroxide, 
and hydroxyl ions are potentially damaging to biological systems. Univalent reduction of 
dioxygen produces superoxide which can be converted to hydrogen peroxide and hydroxyl 
radical. Superoxide dismutase which is a zinc-containing enzyme and other antioxidants may 
be useful in combating cell damage. A few important trace elements such as zinc, copper, iron, 
and selenium are important components of enzymes that deactivate the damaging effects of 
ROS and other free radicals. Although the first paper showing the association between trace 
elements such as manganese and disorders of the central nervous system appeared more 
than a century ago, much new information has accumulated in recent years concerning the 
role of free radicals in the etiology and pathogenesis of several neurological diseases. These 
include Parkinson’s disease, dementia, amyotrophic lateral sclerosis, Down syndrome, and 
Huntington’s disease. The similarities in the histopathological changes and the coexistence of 
these diseases implicate close relationships among the mechanisms of these illnesses. Age is 
certainly one of the deciding factors in the appearances of degenerative diseases of the central 
nervous system. The causes of these, diseases, however, are multifactorial. The reduction in 
the volume of brain is the most evident abnormality in most of the degenerative diseases 
mentioned above although the distinction between the changes due to the normal aging of 
the brain and the pathological changes observed in many degenerative diseases of the brain is 
arbitrary. The role of ROS and other free radicals in the premature aging process and the sub-
sequent increase in the incidence of a number of degenerative diseases has attracted consider-
able attention during the last few decades. Oxidant stress caused by free radicals is known 
to disturb calcium homeostasis by altering the calcium transport across the cell and mito-
chondrial membranes. Mitochondrial DNA is particularly susceptible to oxidative stress, and 
there is evidence of age-dependent damage and deterioration of respiratory enzyme activi-
ties with normal aging. If free radicals are associated with deterioration of neurons and the 
aging process, it is probable that high levels of antioxidants may prevent such damage. Fruits, 
vegetables, and nuts are very rich in many antioxidants, and people who regularly consume 
a diet rich in antioxidants are known to have healthier brains and to be less likely to suf-
fer from neurodegenerative diseases [29]. On the other hand, supplementations of synthetic 
antioxidants such as vitamin C, E, and A in experimental animals have failed to prevent or 
ameliorate diseases. Recent studies by Mattson have shown that the beneficial effect of fruits 
and vegetables are due to the natural pesticides that plants produce [29]. Plants have devel-
oped an elaborate set of chemical defenses to ward off insects. When we consume fruits and 
vegetables, we are exposed to such chemicals in very low doses. Exposures to these chemicals 
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cause a mild stress reaction that lends resilience to cells in our bodies [29]. Adaptation to these 
stresses accounts for a number of health benefits, including healthy aging. This is currently a 
very exciting area of research.
A number of genes that control the body’s defenses can dramatically improve health and 
prolong life. Recent studies indicate that a family of genes involved in an organism’s ability 
to withstand a stressful environment has the power to keep its natural defense and repair sys-
tems going strong, regardless of age [29]. Many recently discovered genes have been found 
to affect stress resistance and life span in many laboratory organisms suggesting that they 
could be part of a fundamental mechanism for surviving unfavorable environment. Scientists 
studying groups of people genetically isolated by location or culture have found gene muta-
tions that seem to prevent diseases that most often shorten life. Table 2 shows some of the 
most important genes associated with aging.
All the known genes associated with the aging process are not included in the table. Along 
with the recent advances in gene technology, we are definitely going to find more genes that 
will influence aging.
Chronic inflammation is another component associated with aging. It is stress-related and 
associated with anxiety. It is well-known that stress modulates the sympathetic nervous 
system and results in the secretion of hormones such as epinephrine and cortisol. These hor-
mones signal the immune system to release cytokines. These molecules alert leucocytes and 
other cells to deal with inflammatory process. When one is chronically stressed, the body is 
flooded with inflammatory chemicals. The chronic inflammation may lead to the develop-
ment of cardiovascular diseases, cancer, and brain deterioration. Meditation and mindfulness 
exercises have recently been shown to have positive effect to combat chronic stress. Regular 
meditation may also reduce the loss of gray matter in the brain [29, 30].
Gene code Known function
SIR2 (sirtuin family) Master regulators of survival
CETP Reduces risk of dementia and hypertension
APOC-3 Lowers risk of CVD and dementia
GHR Suppresses insulin-like growth factor
Lowers fat in the blood
FOXO3a Lowers the incidence of cancer and heart disease
CAT (catalase) Detoxification of hydrogen peroxide
AMPK Metabolism and stress response
KLOTHO Insulin, IGF 1, and vitamin D regulation
DAF/FOXO proteins Growth and glucose metabolism
Telomerase genes Effect on chromosomes
Table 2. Some genes that are currently known to be associated with aging and disease.
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A recent discovery in mice shows that young blood contains a protein called GD11 [31]. This 
protein has been shown to rejuvenate an aging animal by stimulating nerve cell growth and 
retarding myocardial enlargement. No such studies are done in humans. It is interesting to 
see if people with long life span have increased levels of GD11 in their blood. It is likely that 
people with low levels of this protein may be at risk of developing chronic diseases at an early 
stage and this shortens the life span.
As mentioned earlier, a number of pharmaceutical companies are involved in the develop-
ment of drugs that may influence the aging process. Molecules similar to rapamycin are of 
great interest. Novartis has already shown that a molecule called everolimus that is chemi-
cally similar to rapamycin may retard the age-related chronic diseases in humans. Side effects 
and cost are the limiting factors. With current state of knowledge concerned with human 
aging, it is likely that many new drugs may be available in the future for postponing the aging 
process. The trend is already visible. Lower calorie intake, regular exercise, eating a variety 
of fruits and vegetables, and getting proper sleep are probably better than drugs to enjoy a 
healthy old age.
3. Diet and microbiome
Scientists in the past believed that the human body is capable of regulating the metabolic 
functions through complex network of enzymes and the immune system. Over the last few 
years, researchers have found out that the human body has a complex ecosystem. It is a social 
network between our own cells and bacteria and other microorganisms. Trillions of bacteria 
inhabit our skin, genital areas, mouth, and intestine. Bacterial cells in the human body out-
number our own cells by 10 to 1. Despite this huge number, they are usually no threat to us. 
Instead, they offer vital help to many of our basic physiological processes [31]. Employing 
the latest gene technology, researchers have characterized most prevalent species of microbes 
in our body. It is becoming increasingly evident that the microbes, mainly bacteria, in our 
guts play crucial roles in health and diseases. Modern lifestyle has definitely contributed in 
upsetting the normal flora of our guts, and many diseases such as certain autoimmune disor-
ders, obesity, and gastrointestinal problems are probably due to this imbalance. Compared 
to many developing and poor countries of our planet, the bacterial flora of the people living 
in affluent countries is certainly different, especially women. This is especially the case in the 
microbiota of the genital tract. Urinary tract infections are far more common in the females 
of industrialized countries than that of women living in poor countries in Asia, Africa, and 
South America.
Newborns through normal delivery are sterile at the time of birth. While passing through 
the birth canal, babies pick up some of the bacteria from the mother, and they are gradually 
exposed to other members in the family including pets and other domesticated animals. During 
the last few decades, Caesarian deliveries have become very common in both developed and 
developing countries, and this practice has definitely contributed to the difference in quality 
and quantity of microbes in infants. By late infancy, our bodies support one of the most complex 
microbial ecosystems on our planet. As mentioned earlier, modern gene technology has helped 
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cause a mild stress reaction that lends resilience to cells in our bodies [29]. Adaptation to these 
stresses accounts for a number of health benefits, including healthy aging. This is currently a 
very exciting area of research.
A number of genes that control the body’s defenses can dramatically improve health and 
prolong life. Recent studies indicate that a family of genes involved in an organism’s ability 
to withstand a stressful environment has the power to keep its natural defense and repair sys-
tems going strong, regardless of age [29]. Many recently discovered genes have been found 
to affect stress resistance and life span in many laboratory organisms suggesting that they 
could be part of a fundamental mechanism for surviving unfavorable environment. Scientists 
studying groups of people genetically isolated by location or culture have found gene muta-
tions that seem to prevent diseases that most often shorten life. Table 2 shows some of the 
most important genes associated with aging.
All the known genes associated with the aging process are not included in the table. Along 
with the recent advances in gene technology, we are definitely going to find more genes that 
will influence aging.
Chronic inflammation is another component associated with aging. It is stress-related and 
associated with anxiety. It is well-known that stress modulates the sympathetic nervous 
system and results in the secretion of hormones such as epinephrine and cortisol. These hor-
mones signal the immune system to release cytokines. These molecules alert leucocytes and 
other cells to deal with inflammatory process. When one is chronically stressed, the body is 
flooded with inflammatory chemicals. The chronic inflammation may lead to the develop-
ment of cardiovascular diseases, cancer, and brain deterioration. Meditation and mindfulness 
exercises have recently been shown to have positive effect to combat chronic stress. Regular 
meditation may also reduce the loss of gray matter in the brain [29, 30].
Gene code Known function
SIR2 (sirtuin family) Master regulators of survival
CETP Reduces risk of dementia and hypertension
APOC-3 Lowers risk of CVD and dementia
GHR Suppresses insulin-like growth factor
Lowers fat in the blood
FOXO3a Lowers the incidence of cancer and heart disease
CAT (catalase) Detoxification of hydrogen peroxide
AMPK Metabolism and stress response
KLOTHO Insulin, IGF 1, and vitamin D regulation
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A recent discovery in mice shows that young blood contains a protein called GD11 [31]. This 
protein has been shown to rejuvenate an aging animal by stimulating nerve cell growth and 
retarding myocardial enlargement. No such studies are done in humans. It is interesting to 
see if people with long life span have increased levels of GD11 in their blood. It is likely that 
people with low levels of this protein may be at risk of developing chronic diseases at an early 
stage and this shortens the life span.
As mentioned earlier, a number of pharmaceutical companies are involved in the develop-
ment of drugs that may influence the aging process. Molecules similar to rapamycin are of 
great interest. Novartis has already shown that a molecule called everolimus that is chemi-
cally similar to rapamycin may retard the age-related chronic diseases in humans. Side effects 
and cost are the limiting factors. With current state of knowledge concerned with human 
aging, it is likely that many new drugs may be available in the future for postponing the aging 
process. The trend is already visible. Lower calorie intake, regular exercise, eating a variety 
of fruits and vegetables, and getting proper sleep are probably better than drugs to enjoy a 
healthy old age.
3. Diet and microbiome
Scientists in the past believed that the human body is capable of regulating the metabolic 
functions through complex network of enzymes and the immune system. Over the last few 
years, researchers have found out that the human body has a complex ecosystem. It is a social 
network between our own cells and bacteria and other microorganisms. Trillions of bacteria 
inhabit our skin, genital areas, mouth, and intestine. Bacterial cells in the human body out-
number our own cells by 10 to 1. Despite this huge number, they are usually no threat to us. 
Instead, they offer vital help to many of our basic physiological processes [31]. Employing 
the latest gene technology, researchers have characterized most prevalent species of microbes 
in our body. It is becoming increasingly evident that the microbes, mainly bacteria, in our 
guts play crucial roles in health and diseases. Modern lifestyle has definitely contributed in 
upsetting the normal flora of our guts, and many diseases such as certain autoimmune disor-
ders, obesity, and gastrointestinal problems are probably due to this imbalance. Compared 
to many developing and poor countries of our planet, the bacterial flora of the people living 
in affluent countries is certainly different, especially women. This is especially the case in the 
microbiota of the genital tract. Urinary tract infections are far more common in the females 
of industrialized countries than that of women living in poor countries in Asia, Africa, and 
South America.
Newborns through normal delivery are sterile at the time of birth. While passing through 
the birth canal, babies pick up some of the bacteria from the mother, and they are gradually 
exposed to other members in the family including pets and other domesticated animals. During 
the last few decades, Caesarian deliveries have become very common in both developed and 
developing countries, and this practice has definitely contributed to the difference in quality 
and quantity of microbes in infants. By late infancy, our bodies support one of the most complex 
microbial ecosystems on our planet. As mentioned earlier, modern gene technology has helped 
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to create a catalogue of the entire human microbiome. It has turned out that the bacterial genes 
outnumber our own genes by a factor of 1–150. The latest studies also reveal that each individ-
ual belonging to the human race has his/her own bacterial make-up [32]. Most people associate 
bacteria with diseases such as respiratory tract and urinary tract infections. It is only during the 
last few decades that we have learned that we host to a number of friendly microbes as well.
Most bacteria found in the healthy guts of humans are beneficial to us. For example, the 
gut bacteria help to produce vitamins such as cobalamins and break down indigestible food 
components so that we can make use of them. Humans need vitamin B12 for cellular energy 
production, DNA synthesis, and the manufacture of fatty acids. Gut bacteria can also break 
down starch and fiber. They are normally called as commensals. Our own cells in the gas-
trointestinal tract cannot handle indigestible food components such as starch. At the same 
time, it must be pointed out that even the most beneficial bacteria in the gut can cause serious 
disease if they are translocated to some other parts of the body than where they are supposed 
to be. I shall describe the influence of the two commensals in order to show their importance 
in human health and social well-being.
Two bacterial species, namely, Bacteroides thetaiotaomicron and Helicobacter pylori, play cru-
cial roles in digestion and the regulation of appetite. The first one degrades complex carbo-
hydrates. The human genome lacks most of the genes required to synthesize enzymes that 
degrade carbohydrates as mentioned earlier. The second one H. pylori is notorious in the sense 
that they cause dyspepsia, a dysfunction discovered already in the 1980s by the Australian 
physicians Marshall and Warren. This is one of the few bacteria that seem to thrive in the 
acidic environment of our stomachs. After this discovery, it was common to treat peptic ulcers 
by antibiotics, and the incidence of bacteria-induced peptic ulcers dropped to 50%. Apart 
from regulating the acidity in the stomach, this bacterium also regulates appetite. The stom-
ach of our species produces two hormones, namely, ghrelin and leptin, that regulate appetite 
[32]. Patients who are treated with antibiotics and proton-pump inhibitors to eliminate these 
bacteria from the stomach usually gain weight gradually, and it has been suggested that the 
obesity seen even in children in affluent countries like the United States is related to elimina-
tion of this bacteria from our stomachs. A recent study in the United States shows that only 
6% of children have these bacteria. Repeated prescription of penicillin and other antibiotics 
for minor respiratory illnesses and ear infections is probably the main reason for this imbal-
ance. Eradication of this bacteria from the stomach by proton-pump inhibitors and antibiotics 
has become the common practice in most countries at the present time, and with time, it is 
likely that this beneficial bacteria is totally eradicated. It is uncertain at the moment whether 
the elimination of these bacteria alone will be one of the major causes of obesity in the future.
So far, I have only described the influence of two commensals in our body. What about the 
trillions of others? A healthy, mature, immune system depends on the constant intervention of 
beneficial bacteria in the gastrointestinal tract. Bacteroides fragilis and the Lactobacillus species are 
another group of gut bacteria found in a majority of human population [32, 33]. These microbes 
are known to help to keep the immune system in balance by boosting its anti-inflammatory 
arm. Because of lifestyle changes, especially after the introduction of fast foods over the last few 
decades, a number of beneficial bacteria species in our guts are disappearing. The microbiota 
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of Westerners is significantly reduced in comparison to rural individuals living similar lifestyle 
to our Paleolithic ancestors and other free-living primates [34]. What has happened to modern 
lifestyle during a short period of time has completely changed our association with the micro-
bial world. The rise in a number of autoimmune disorders and obesity is closely associated with 
the imbalance in our gut flora. Despite the advances in health sciences during the last century, 
we are still far away from understanding the role of microbiome in health and disease. Intensive 
research is taking place throughout the world to learn more about the microbiota and health.
4. Food and social well-being
According to the World Health Organization (WHO), the fundamental cause of obesity 
and overweight is an energy imbalance between calories consumed and calories expended. 
Physicians and other health personnel throughout the world have advised their overweight 
patients to eat less and exercise more. In spite of such efforts, the prevalence of obesity or the 
accumulation of unhealthy amounts of body fat has climbed to unprecedented levels. Currently, 
30% of the US populations are overweight, and the health budget has increased to astronomi-
cal levels to treat diseases associated with obesity. Similar trends are noted in other affluent 
countries. Even in fast-growing countries such as China, India, Brazil, Russia, and South Africa 
(the so-called BRICS), overweight-associated diseases are on the increase. In the good old days, 
fat babies were considered to be healthier than the thin ones. Even at the present time, many 
mothers who attend the child care centers in the Western countries are worried when their kids 
are underweight according to the current growth charts. In many Asian countries, a round belly 
is considered to be a sign of opulence. The fast-food revolution mentioned earlier is probably 
the most dominant cause of overweight in affluent countries. If the current trend continues, 
obesity will soon surpass smoking in most countries as the biggest contributing factor in the 
development of chronic diseases and early death. For a species that evolved to consume energy-
rich food in the environment where starvation was a constant threat, losing weight and staying 
trimmer in an affluent world fueled by marketing messages and cheap empty calories is, in fact, 
very difficult. Recent research findings are yielding new and important insights about social 
and behavioral factors that influence diet, physical activity, and sedentary life. The general pub-
lic love to believe and react to neat and cheap fixes, and the mass media oblige by playing up 
new scientific findings in headline after headline as if they were the solutions. Behavior-focused 
studies of obesity and diets have identified some basic conditions that seem correlated with 
greater chance of losing weight and keeping it off. These include initial assessment, self-moni-
toring, behavior shifts, and support from others with similar problems. Unfortunately, people 
are getting more and more isolated and live a sedentary life mainly due modern lifestyle.
As mentioned in the earlier section, our body hosts trillions of microorganisms, especially in 
the gut. Bacteria and other microbes dwelling in our body produce molecules that can interact 
with our central nervous system in ways that appear to affect our anxiety and stress response. 
Some of these molecules resemble hormones and neurotransmitters. Gut microbiome appear 
to alter gene activity, especially in the brain, as mentioned earlier. These molecules may also 
be involved in memory and learning. The mood changes in an individual are known to relate 
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to create a catalogue of the entire human microbiome. It has turned out that the bacterial genes 
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ual belonging to the human race has his/her own bacterial make-up [32]. Most people associate 
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by antibiotics, and the incidence of bacteria-induced peptic ulcers dropped to 50%. Apart 
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patients to eat less and exercise more. In spite of such efforts, the prevalence of obesity or the 
accumulation of unhealthy amounts of body fat has climbed to unprecedented levels. Currently, 
30% of the US populations are overweight, and the health budget has increased to astronomi-
cal levels to treat diseases associated with obesity. Similar trends are noted in other affluent 
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are underweight according to the current growth charts. In many Asian countries, a round belly 
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very difficult. Recent research findings are yielding new and important insights about social 
and behavioral factors that influence diet, physical activity, and sedentary life. The general pub-
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to alter gene activity, especially in the brain, as mentioned earlier. These molecules may also 
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to the activity of the gut microbiota. This again depends on the type and quantity of diet we 
consume on an everyday basis. Evidence supporting a connection between gut ecology and 
human brain is trickling in. It is very likely that the microbes on our skin interact with those 
in the gut and thereby influence our behavior.
The final question is about the kind of diet that could provide a healthy long life. Apart from 
healthy aging, an ideal diet should have components that can prevent illnesses such as car-
diovascular disease and diabetes. Such a diet should be rich in vegetables, fruits, and whole 
grains, with moderate amounts of protein and less added sugars and bad fats. It is impossible 
to point out one single nutrient in certain diets that provides health benefits such as reduced 
death from cardiovascular diseases, and many experts on human nutrition think that it is the 
result of various foods in combination that provide the most benefit. The important thing is 
to cut back on how much we eat overall. Therefore, a diet low in added sugars and bad fats, 
with moderate protein intake, and high in plants, nuts, and fruit, can currently be considered 
good for healthy aging and social well-being.
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Abstract
Thalassemia is an inherited disease caused by the genetic disorder of α- and β-globin 
genes, resulting in ineffective erythropoiesis and chronic anemia. Transfusion-dependent 
β-thalassemia patients require red cell transfusion to maintain their blood hemoglobin level 
in the normal range, whereas non-transfusion-dependent thalassemia patients increase duo-
denal absorption of dietary iron in an attempt to accelerate erythropoiesis. These changes 
give rise to iron overload, oxidative stress, organ dysfunction, and other complications. 
Effective iron chelators are necessary to achieve negative iron balance and to relieve such 
complications associated with iron overload. Some pharmaceuticals such as hydroxyurea, 
N-acetylcysteine, ascorbic acid, vitamin E, and glutathione are also given to thalassemia 
patients in order to overcome oxidative cell and tissue damage and to generate a better qual-
ity of life. Interestingly, functional natural products (such as mango, tea, caffeine, and cur-
cumin), vegetables, and cereal (e.g., rice) are helpful for their health-providing properties by 
supplementing the endogenous antioxidant defensive power in the body. Natural products 
exhibit many pharmacological activities, but they are safer if used in the traditional manner.
Keywords: thalassemia, personalized medicine, antioxidant, green tea, functional fruits, 
iron
1. Introduction
Thailand is one of the countries located in Southeast Asia (SEA) with an ongoing thalassemia 
endemic and has been affected by this inherited disease for a long time. In 2012, we had 
an official meeting for reviewing progression in the field to develop a good clinical practice 
guideline (CPG) for thalassemia management in Thailand.
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1. Introduction
Thailand is one of the countries located in Southeast Asia (SEA) with an ongoing thalassemia 
endemic and has been affected by this inherited disease for a long time. In 2012, we had 
an official meeting for reviewing progression in the field to develop a good clinical practice 
guideline (CPG) for thalassemia management in Thailand.
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2. Etiology of thalassemia
Thalassemia is an inherited autosomal recessive disorder of hemoglobin molecules (ineffective 
erythropoiesis) that is characterized by an imbalanced α- and β-globin chain synthesis. The 
accumulation of unbound α-globin chains in erythroid cells is the major cause of pathology 
in β-thalassemia. Stimulation of γ-globin chain synthesis can relieve disease severity because 
it combines with the α-globin chain to form a fetal hemoglobin (Hb F). The disease occurs 
prevalently from Southeast Asia to the Mediterranean.
2.1. α-Thalassemia
α-Thalassemia is due to an impaired production of α-globin chains from 1, 2, 3, or all 4 of the 
α-globin genes, leading to a relative excess of β-globin chains. The severity of the disease is 
based on how many genes are affected. Four clinical conditions of increased severity are rec-
ognized: two carrier states, α+-thalassemia caused by the deletion or dysfunction of one of the 
four α-globin genes, and α0-thalassemia resulting from deletion or dysfunction of two α-globin 
genes in cis. The two clinically relevant forms are Hb Bart’s hydrops fetalis syndrome and Hb 
H disease. Patients with Hb Bart’s hydrops fetalis syndrome (homozygous α-thalassemia) have 
nonfunctioning α-globin genes (genotype α-thal 1/α-thal 1 or − −/− −) and mostly die before 
birth. Mothers usually suffer hypertension, edema, and toxic pregnancy. Hb H disease patients 
carry only one functioning α-globin gene (genotype α-thal 1/α-thal 2 or − −/− α, and α-thal 1/
Hb Constant Spring (CS) or −/αCSα) and mostly suffer mild-to-severe anemia, jaundice, febrile, 
and splenomegaly and hepatomegaly. α-Thalassemia is prevalent in tropical and subtropical 
regions similar to other common globin gene disorders such as β-thalassemia and sickle cell 
anemia where malaria was and still is an epidemic. As a consequence of massive population 
migrations, α-thalassemia has become a relatively common clinical problem in North America, 
Europe, and Australia [1–3].
In northeast Thailand, thalassemia patients suffered with Hb H disease mostly due to the inter-
action of α-thalassemia 1 (SEA type) with the Hb CS, the deletion of three α-globin genes with the 
SEA type α-thalassemia 1 and the 3.7- or 4.2-kb deletion of α-thalassemia 2, and the interaction of 
the SEA α-thalassemia 1 with the Hb Pakse [4]. In Cambodia, α-globin gene mutation was mostly 
caused by the α-(3.7) (rightward) deletion (frequency 0.098–0.255), α-thal-1 (– –(SEA)) (frequency 
0.008–0.011), and α-thal-2 [-alpha(4.2) (leftward deletion)] (frequency 0.003–0.008) [5].
2.2. β-Thalassemia
Human β-thalassemia is characterized by the deficient production of the β-globin chains of adult 
hemoglobin (Hb A), typically due to mutations of the β-globin gene. Over 200 mutations have 
been identified in this gene, and the type of mutation can influence the severity of the disease. 
There are three main types of β-thalassemia, listed in order of decreasing severity: homozygous 
β-thalassemia major (TM) (genotype β0/β0) caused by mutations in both alleles, β-thalassemia 
intermedia (TI) (genotype β0/β+, β+/β+, and β+/βE) caused by diverse mutations, and heterozygous 
β-thalassemia minor caused by single mutation, including hereditary persistent fetal hemoglo-
bin (HPFH). TI patients usually become mildly anemic (baseline Hb level 7–10 g/dl) and have 
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widely varying severity. Some patients require blood transfusion and chelation to promote their 
growth in childhood and prevent bone deformities in adults and sometimes get splenectomy 
due to hypersplenism and mechanical encumbrance. Enhancing Hb F synthesis is useful in 
some patients, and anti-oxidative compounds were found not to improve blood Hb levels. Stem 
cell transplantation and gene therapy are possible in well-developed countries but limited in 
developing countries and in some severe cases. Many complications such as pulmonary hyper-
tension, thrombosis, hypercoagulability, pseudoxanthoma elasticum, and osteoporosis are 
reported in TI patients and can affect their treatment [6].
β-Thalassemia hemoglobin E (Hb E) (genotype β0/βE or β +/βE) is most prevalent in SEA 
countries including Thailand where the carrier frequency is around 50%. The interaction of 
thalassemia Hb E and β-thalassemia results in a clinical spectrum ranging from a condition 
indistinguishable from TM to a mild form of TI. Three categories can be identified depending 
on symptoms as followed: asymptomatic (normal Hb level), mild (baseline Hb level <9.0 g/dl), 
moderate (baseline Hb level 7–9 g/dl), and severe (baseline Hb level <7.0 g/dl). In transgenic 
mice, homozygous beta-knockout (BKO) thalassemia shows many clinical features of red 
blood cells (RBC) indices, in particular mild anemia similar to human TI. The abnormalities 
include decreased blood Hb concentration, hematocrit (Hct), numbers and osmotic fragility 
of RBC, and the increase of reticulocyte count. Additionally, Perl’s staining and colorimetric 
assays shows deposition of iron in the spleen, liver, and kidneys but not in the heart [7].
3. Anemia in thalassemia
The accumulation of excess unbound α-globin chains in erythroid cells of β-thalassemia 
patients can result in RBC hemolysis and anemia; nevertheless, stimulation of γ-globin gene 
to produce γ-globin chain which can combine with the α-globin to form Hb F is a therapeutic 
approach. Like cell apoptosis, eryptosis is a programmed cell death or suicidal death of eryth-
rocytes which is characterized by shrinkage, membrane bleb, activation of proteases (e.g., 
caspase and calpain) after oxidative stress, and phosphatidylserine (PS) exposure at the outer 
plasma membrane leaflet of the affected RBC. Eryptosis can be triggered by osmotic shock, 
energy depletion, hyperthermia, curcumin, ceramide, prostaglandin E2, platelet-activating 
factor, valinomycin, amyloid peptide, hemolysin, chlorpromazine, cyclosporine, paclitaxel, 
stressors-induced injury, and iron-induced oxidative stress. In contrast, it is inhibited by 
erythropoietin (EPO), catecholamines, and nitric oxide (NO). Eryptosis is probably a useful 
mechanism to get rid of defective RBC and infectious agents. Nonetheless, excessive eryptosis 
found in iron deficiency, intoxication of metals (such as Al, Cu, Pb, and Hg), xenobiotics, 
β-thalassemia, sickle cell disease (SCD), glucose-6-phosphate dehydrogenase (G6PD) defi-
ciency, hereditary spherocytosis, paroxysmal nocturnal hemoglobinuria, myelodysplastic 
syndrome (MDS), phosphate depletion, sepsis, hemolytic uremic syndrome, renal insuffi-
ciency, diabetes, pathogenic infection (e.g., malaria, mycoplasma, and hemolysin-producing 
bacteria), and Wilson’s disease can result in short lifespan and microvesicles of the RBC, con-
sequently leading to anemia and impaired microcirculation [8–10]. Synthetic compounds and 
natural products of interests need to be investigated to elucidate their therapeutic potential of 
inhibitors of excessive eryptosis in β-thalassemia with chronic anemia.
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4. Iron overload in thalassemia
4.1. Pathophysiology and complications
Iron overload in thalassemia is assessed with an increase of plasma iron and transferrin satura-
tion, the presence of redox iron as non-transferrin-bound iron (NTBI) and labile plasma iron 
(LPI), and a high deposition of tissue iron in the forms of hemosiderin, ferritin, and labile 
iron pools (LIP). Excessive iron accumulation in the vital organs is the cause of liver diseases 
(e.g., hepatitis, hepatic fibrosis, and hepatocellular carcinoma), cardiomyopathies (e.g., car-
diac arrhythmia and heart failure), and endocrinopathies (e.g., diabetes, growth retardation, 
defective puberty, hypopituitarism, hypogonadism, and hypoparathyroidism) [11, 12]. Iron 
overload can be caused by an increase of dietary iron absorption due to chronic anemia and by 
multiple blood transfusions to maintain normal blood Hb level. Under incomplete or partial 
synthesis of β-chains of Hb in β-thalassemia patients, the remaining excessive α-globin chains 
are unstable and eventually precipitate, causing RBC membrane damage [13]. The affected 
RBCs are prematurely hemolyzed in the bone marrow and spleen, resulting in increased RBC 
turnover, ineffective erythropoiesis, and severe anemia, so patients require regular blood 
transfusions to prevent the anemia and ischemia. Though thalassemia patients do not receive 
transfusions, abnormal iron absorption produces an increase in the body iron burden evalu-
ated at 2–5 g per year [14]. Regular blood transfusions (420 ml/unit of donor blood equivalent 
to 200 mg of iron) lead to double this iron accumulation. Consequently, iron accumulation 
introduces progressive damage in the liver, heart, and in endocrine glands. Circulating NTBI 
as well as LPI is detected whenever the capacity of transferrin to incorporate iron derived from 
either gastrointestinal tract or reticuloendothelial (RE) cells becomes a limiting factor. Both 
forms of toxic iron appear primarily in transfused patients where the total iron-binding capac-
ity (TIBC) has been surpassed [15]. Pathologically, the NTBI fraction seems to be translocated 
across cell membrane irregularly, while the LPI is redox active and susceptible to chelation [16].
4.2. Redox iron catalysis
In enzymatic reactions as shown in Figure 1, superoxide (O2−•) which is one of the reactive 
oxygen species (ROS) is normally produced by NADH:ubiquinone oxidoreductase catalysis 
at the complex I (I) in oxidative phosphorylation and will be converted to hydrogen perox-
ide (H2O2) by superoxide dismutase (SOD) catalysis (II). Hydrogen peroxide (H2O2) which is 
another ROS is produced by xanthine oxidase (XO) catalysis of hypoxanthine to xanthine (III) 
and xanthine to uric acid (IV) in purine catabolic pathway. Finally, hydrogen peroxide will 
be degraded or detoxified by peroxidase (POD) and catalase (CAT) to water and oxygen (V).
In Haber-Weiss/Fenton nonenzymatic reactions, iron can participate in the oxidation-reduc-
tion process known to generate ROS including hydrogen peroxide reacts to form hydroxyl 
radical (OH•) and hydroxide anion (OH−) [17] (Figure 2).
ROS can induce cell death through initiating a series of chemical reactions with many signifi-
cant biomolecules, resulting in DNA oxidation, protein damage, and membrane lipids peroxi-
dation [18, 19]. Among these ROS, hydroxyl radicals might be the most harmful to lipid and 
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protein membrane components. The •OH-induced membrane damage can be related directly 
to a membrane-associated Fenton reagent [20]. Oxidative cell damage has been attributed to the 
emergence of excessive levels of LPI that promote the production of ROS exceeding the cellular 
defensive capacity [21]. Cellular LIP is a source of chelatable and redox-active iron, which is tran-
sitory and serves as a crossroad of cell iron metabolism. The nature of the LIP has been revealed 
by its capacity to promote ROS generation in its “rise-and-fall” patterns. LIP plays a role as a 
self-regulatory pool that is sensed by cytosolic iron-regulatory proteins (IRPs) and its feedback 
regulated by an IRP-dependent expression of iron import and storage. LIP is influenced by a 
range of biochemical reactions that are capable of overriding the IRP regulatory loops. Excess 
labile iron can react with unsaturated lipids [22]. Such redox reactions lead to the damage of 
cells, tissues, and organs as demonstrated as the iron overload associated with β-thalassemia.
4.3. Tissue iron deposition
The spleen contains macrophages that digests hemoglobin and stores the resulting iron in 
ferritin. The number of blood transfusions in β-TM patients correlates with their splenic 
Figure 1. Enzymatic production of ROS.
Figure 2. Iron-catalyzed redox reactions of biological importance.
Diet-Related Thalassemia Associated with Iron Overload
http://dx.doi.org/10.5772/intechopen.91998
63
4. Iron overload in thalassemia
4.1. Pathophysiology and complications
Iron overload in thalassemia is assessed with an increase of plasma iron and transferrin satura-
tion, the presence of redox iron as non-transferrin-bound iron (NTBI) and labile plasma iron 
(LPI), and a high deposition of tissue iron in the forms of hemosiderin, ferritin, and labile 
iron pools (LIP). Excessive iron accumulation in the vital organs is the cause of liver diseases 
(e.g., hepatitis, hepatic fibrosis, and hepatocellular carcinoma), cardiomyopathies (e.g., car-
diac arrhythmia and heart failure), and endocrinopathies (e.g., diabetes, growth retardation, 
defective puberty, hypopituitarism, hypogonadism, and hypoparathyroidism) [11, 12]. Iron 
overload can be caused by an increase of dietary iron absorption due to chronic anemia and by 
multiple blood transfusions to maintain normal blood Hb level. Under incomplete or partial 
synthesis of β-chains of Hb in β-thalassemia patients, the remaining excessive α-globin chains 
are unstable and eventually precipitate, causing RBC membrane damage [13]. The affected 
RBCs are prematurely hemolyzed in the bone marrow and spleen, resulting in increased RBC 
turnover, ineffective erythropoiesis, and severe anemia, so patients require regular blood 
transfusions to prevent the anemia and ischemia. Though thalassemia patients do not receive 
transfusions, abnormal iron absorption produces an increase in the body iron burden evalu-
ated at 2–5 g per year [14]. Regular blood transfusions (420 ml/unit of donor blood equivalent 
to 200 mg of iron) lead to double this iron accumulation. Consequently, iron accumulation 
introduces progressive damage in the liver, heart, and in endocrine glands. Circulating NTBI 
as well as LPI is detected whenever the capacity of transferrin to incorporate iron derived from 
either gastrointestinal tract or reticuloendothelial (RE) cells becomes a limiting factor. Both 
forms of toxic iron appear primarily in transfused patients where the total iron-binding capac-
ity (TIBC) has been surpassed [15]. Pathologically, the NTBI fraction seems to be translocated 
across cell membrane irregularly, while the LPI is redox active and susceptible to chelation [16].
4.2. Redox iron catalysis
In enzymatic reactions as shown in Figure 1, superoxide (O2−•) which is one of the reactive 
oxygen species (ROS) is normally produced by NADH:ubiquinone oxidoreductase catalysis 
at the complex I (I) in oxidative phosphorylation and will be converted to hydrogen perox-
ide (H2O2) by superoxide dismutase (SOD) catalysis (II). Hydrogen peroxide (H2O2) which is 
another ROS is produced by xanthine oxidase (XO) catalysis of hypoxanthine to xanthine (III) 
and xanthine to uric acid (IV) in purine catabolic pathway. Finally, hydrogen peroxide will 
be degraded or detoxified by peroxidase (POD) and catalase (CAT) to water and oxygen (V).
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hemosiderosis and weight [23]. Hemosiderin deposition was found to be greater in the iron-
overloaded livers than in the iron-overloaded spleens. Ferritin and hemosiderin increased 
in hepatocytes and splenic RE cells [24]. Splenectomy is one of the clinical complications of 
hypertransfused TM patients to reduce hyperactivity of RE macrophage; nevertheless, it may 
increase the iron overload.
The liver is one of the main storage organs for iron. Iron overload is considered when the fer-
ritin level consistently exceeds 1,000 ng/ml (normal range 20–200 ng/ml). Excess free radicals 
can cause progressive tissue injury and eventually cirrhosis or hepatocellular carcinoma in 
iron overload patients whose iron is sequestrated predominantly in ferritin or hemosiderin 
[25]. When plasma transferrin becomes highly saturated, NTBI is detectable and rapidly 
transported across the hepatocyte membrane via a specific pathway. Likely, ferroportin 1 is 
the only protein that mediates the transport of iron out of hepatocytes and is then oxidized 
by ceruloplasmin and bound to transferrin [26]. Iron deposition affects hepatic parenchymal 
cells (hepatocytes and bile duct cells) and mesenchymal cells (endothelial cells, macrophage, 
and Kupffer cells) and often distributes differently from one area to another [27].
The heart is one of the most mitochondrial-rich tissues in the body, making the iron of par-
ticular importance to cardiac function. Iron as iron-sulfur cluster and cytochromes plays a 
key role for oxidative phosphorylation and superoxide production in the mitochondria. Iron 
deposition in the heart cells can lead to cellular oxidative stress and damage and an altera-
tion of myocardial function. Heart failure is the leading cause of death among hemosiderosis 
β-thalassemia patients, of whom around 60% die from cardiac failure. Harmful effects of iron 
overload on the heart of TM patients can be monitored efficiently by using noninvasive tech-
niques as described below, whereas invasive techniques such as Perl’s stained in biopsied 
heart tissue are rather impossible. Treatment with effective iron chelators can protect these 
patients from iron-loaded cardiomyopathy [28, 29].
Bone marrow iron deposition (186 μg/g wet weight) increases in proportion to the total body iron 
store in dietary iron overload of African Bantu people and Caucasian idiopathic hemochroma-
tosis patients [30]. MDS patients who are a heterogeneous group of clonal hematopoietic stem 
cell malignancies show bone marrow hemosiderosis and may develop systemic iron overload.
Though hematological care is improved in homozygous transfusion-dependent β-thalassemia 
(TDT) patients, multi-endocrine dysfunction is still a common complication. Thyroid dysfunction 
is defined as overt hypothyroidism, subclinical hypothyroidism, and an exaggerated thyroid-
stimulating hormone response was reported in β-thalassemia patients [31]. Possibly, growth retar-
dation, secondary hypogonadotropic hypogonadism and hypothyroidism are originated from 
pituitary damage primarily caused by iron overload and oxidative stress [32, 33]. Approximately 
half of patients’ pituitary gland dysfunction associated with iron overload is irreversible [34].
The redox irons in TDT patients with TM and TE are catalytically harmful to adrenal glands 
and can cause adrenal insufficiency [35]. Though all TM patients were nondiabetic, some of 
them decreased in the oral glucose tolerance test. They showed normal response of corti-
sol to insulin and adrenocorticotropic hormone stimulation. Moreover, the β-cell pancreatic 
function and adrenal cortical function were depressed in the severely iron-loaded. Recently, 
Koonyosying and colleagues have demonstrated green tea extract could reduce cellular the 
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levels of iron and ROS and increase insulin secretion in concentration-dependent manner 
in iron-loaded pancreatic cell line (RINm5F), indicating the amelioration of oxidative stress 
and endocrinal improvement of pancreatic β-cells [36]. They also found that eltrombopag, 
which is a thrombopoietin receptor agonist and potent metal ion-chelating agent, efficiently 
decreased cellular levels of iron and ROS from cultured HuH7, H9C2, and RINm5F cells and 
restored insulin secretion from iron-loaded RINm5F cells [37].
4.4. Assessment of tissue iron content
Serum ferritin level has been used as a surrogate biochemical marker to correlate closely 
with liver iron concentration for a long time and would be a valuable alternative to assess 
visceral iron overload in heavily iron-loaded TM patients [38]. Sophisticated noninvasive 
magnetic resonance imaging, magnetic iron detector susceptometry, superconducting 
quantum interference device, and nuclear resonance scattering techniques can also be used 
to assess iron status in tissues. Alternatively, invasive tissue biopsied needle aspiration 
associated with ferrozine colorimetry or graphite-furnace atomic absorption spectrometry 
is routinely quantitated for nonheme iron in tissues (e.g., myocardium, liver, pancreas, 
adrenal glands, anterior pituitary gland, and skin) [39–41]. These methods are all valuable 
when evaluating iron load in the tissues and monitoring the response of different organs to 
chelation therapy.
5. Thrombotic events in thalassemia
Heart failure and arrhythmia are the main causes of death in TM patients with cardiac sid-
erosis, pulmonary hypertension, and thrombosis and also the major cardiovascular complica-
tions in TI patients possibly due to pro-atherogenic biochemical factors (e.g., iron status and 
lipid profile) [42, 43]. Hypercoagulable pulmonary microthromboembolism in Thai pediatric 
TE patient was previously investigated [44]. After splenectomy TI patients mostly had throm-
bosis, thrombocytosis, and lower levels of anticoagulation inhibitors (e.g., protein S, protein C, 
and antithrombin III) [45]. Splenectomy promotes portal vein thrombosis in TM patients [46]. 
Ineffective erythropoiesis, chronic anemia, iron overload, and polycythemia by erythrocytosis 
and thrombosis are coincidently occurring in β-thalassemia patients. Signs of cerebrovascular 
accident (brain ischemia, hemorrhage, and infarct) and heart disease (congestive heart failure 
and atrial fibrillation) were described in chronically hypercoagulable thromboembolic thalas-
semia patients, so anticoagulant and/or antiplatelet therapy is recommended. Hypoxia and 
iron overload are the two major mechanisms of ROS overproduction [47]. The levels of plasma 
hemostatic and thrombotic markers were significantly higher in splenectomized TE patients 
than non-splenectomized ones, implying splenectomy increases platelet hyperactivity, blood 
hypercoagulability, and risk of thrombosis. ROS-induced activation of vascular endothelial 
cells can cause vasculitis and thrombosis, showing increased levels of many soluble adhesion 
molecules and von Willebrand factor (vWF) in thalassemia blood [48]. Procoagulant activity of 
circulating RBC microvesicles or microparticles (MPs) may contribute to thrombotic events in 
thalassemia hypercoagulability [49]. Carotid artery thrombus is usually associated with severe 
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levels of iron and ROS and increase insulin secretion in concentration-dependent manner 
in iron-loaded pancreatic cell line (RINm5F), indicating the amelioration of oxidative stress 
and endocrinal improvement of pancreatic β-cells [36]. They also found that eltrombopag, 
which is a thrombopoietin receptor agonist and potent metal ion-chelating agent, efficiently 
decreased cellular levels of iron and ROS from cultured HuH7, H9C2, and RINm5F cells and 
restored insulin secretion from iron-loaded RINm5F cells [37].
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with liver iron concentration for a long time and would be a valuable alternative to assess 
visceral iron overload in heavily iron-loaded TM patients [38]. Sophisticated noninvasive 
magnetic resonance imaging, magnetic iron detector susceptometry, superconducting 
quantum interference device, and nuclear resonance scattering techniques can also be used 
to assess iron status in tissues. Alternatively, invasive tissue biopsied needle aspiration 
associated with ferrozine colorimetry or graphite-furnace atomic absorption spectrometry 
is routinely quantitated for nonheme iron in tissues (e.g., myocardium, liver, pancreas, 
adrenal glands, anterior pituitary gland, and skin) [39–41]. These methods are all valuable 
when evaluating iron load in the tissues and monitoring the response of different organs to 
chelation therapy.
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Heart failure and arrhythmia are the main causes of death in TM patients with cardiac sid-
erosis, pulmonary hypertension, and thrombosis and also the major cardiovascular complica-
tions in TI patients possibly due to pro-atherogenic biochemical factors (e.g., iron status and 
lipid profile) [42, 43]. Hypercoagulable pulmonary microthromboembolism in Thai pediatric 
TE patient was previously investigated [44]. After splenectomy TI patients mostly had throm-
bosis, thrombocytosis, and lower levels of anticoagulation inhibitors (e.g., protein S, protein C, 
and antithrombin III) [45]. Splenectomy promotes portal vein thrombosis in TM patients [46]. 
Ineffective erythropoiesis, chronic anemia, iron overload, and polycythemia by erythrocytosis 
and thrombosis are coincidently occurring in β-thalassemia patients. Signs of cerebrovascular 
accident (brain ischemia, hemorrhage, and infarct) and heart disease (congestive heart failure 
and atrial fibrillation) were described in chronically hypercoagulable thromboembolic thalas-
semia patients, so anticoagulant and/or antiplatelet therapy is recommended. Hypoxia and 
iron overload are the two major mechanisms of ROS overproduction [47]. The levels of plasma 
hemostatic and thrombotic markers were significantly higher in splenectomized TE patients 
than non-splenectomized ones, implying splenectomy increases platelet hyperactivity, blood 
hypercoagulability, and risk of thrombosis. ROS-induced activation of vascular endothelial 
cells can cause vasculitis and thrombosis, showing increased levels of many soluble adhesion 
molecules and von Willebrand factor (vWF) in thalassemia blood [48]. Procoagulant activity of 
circulating RBC microvesicles or microparticles (MPs) may contribute to thrombotic events in 
thalassemia hypercoagulability [49]. Carotid artery thrombus is usually associated with severe 
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cardiovascular diseases (CVD), iron deficiency anemia, and thrombocytosis. Thromboembolic 
complications are documented in thalassemia patients, possibly due to aggregation of abnor-
mal RBC and high amounts of RBC membrane-derived MPs [50]. Antioxidant treatment of 
β-thalassemia HbE patients can improve oxidative stress and hypercoagulable state [51]. Iron 
overload, in particular NTBI level, would be one of the risk factors in pulmonary thrombosis 
and hypertension in splenectomized non-transfusion-dependent thalassemia (NTDT) patients 
[52]. Iron chelators are useful and effective in the amelioration of iron overload and oxidative 
stress in thalassemia mice, possibly in the prevention of pulmonary thrombosis [53]. Nitric 
oxide (NO•) synthesized from L-arginine by catalysis of nitric oxide synthase (NOS) species 
is a free-radical, physiologic vasodilator, and potent inhibitor of platelet function. Excessive 
iron-liberated heme degradation contributes to hypercoagulability [54]. Low arginine bio-
availability in β-thalassemia patients can cause pulmonary hypertension and cardiopulmo-
nary dysfunctions [55]. Splenectomy, thrombocytosis, RBC, and platelet MPs may be residual 
hypercoagulable/thrombotic risks in TDT patients [56, 57]. Liver inflammation and cirrhosis 
can involve in hypercoagulability, thrombosis, and reduced fibrinolysis [58, 59].
6. Treatment and implements
Strategy and approach have been suggested for the treatment and support of thalassemia 
patients to have better quality of life and well-being [60]. These approaches include occasional/
regular blood transfusions, iron chelation therapy, antioxidant supplement, Hb F switching 
agents, anti-allergic drugs, antibiotics (such as antibacterial, antiviral, antifungal, and antima-
larial drugs), splenectomy (in the past), dental care, and hemopoietic stem cell transplantation.
6.1. Iron chelation therapy
Iron chelation therapy aims to prevent the accumulation of toxic iron and eliminate the excess 
iron in TDT patients. Effective chelation and good management of the patients have been 
correlated with a decline in early deaths and complications [61]. Reduction of plasma and 
cellular chelatable iron such as NTBI, LPI, and LIP is a slow process and requires aggressive 
chelation therapy. The chelation will maintain the iron balance at safe levels to prevent high 
iron accumulation and oxidative tissue injury. Such non-iron and iron-overloaded models as 
RBC, cell cultures (e.g., hepatocytes, HepG2 cells, and cardiomyocytes), animals (e.g., mice, 
gerbils, rats, and transgenic BKO mice), and even human thalassemia patients are experimen-
tally investigated and clinically tested to assess the safety and efficacy of iron chelators. At 
present, three standard iron chelators including desferrioxamine (DFO), deferiprone (DFP), 
and deferasirox (DFX) are widely used for the treatment of β-thalassemia patients with iron 
overload to prevent oxidative stress-induced organ dysfunctions and such complications 
(Figure 3). Combined DFO/DFP and DFP/DFX treatments can reverse endocrine complica-
tions by improving glucose intolerance and gonadal dysfunction in TDT patients [62].
Under continuous chelation therapy, many TDT patients with moderate-to-severe pituitary 
iron overload had normal volume and function of the pituitary gland, representing a poten-
tial therapeutic window, while some hypogonadal patients preserved their pituitary volumes 
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and functions. Thai clinicians have reported that DFO chelation therapy for 1.5 years largely 
decreased serum ferritin level and improved secretion of prolactin (PRL) and growth hormone 
(GH) but not other pituitary hormones [63].
6.2. Supplementation of antioxidants
Compounds such as vitamins A, C, E, β-carotene, reduced glutathione (GSH), and N-acetylcysteine 
(NAC) and enzymes such as SOD, CAT, glutathione peroxidase (GPx), and glutathione reduc-
tase (GR) can remove free radicals by enzymatic and nonenzymatic antioxidant systems in the 
body (Figure 4). Since β-thalassemia patients have a higher oxidative stress level than normal 
people, effective antioxidants would be a complementary treatment of choice in these patients. 
Ideas for using drug antioxidants to eliminate oxidative tissue damage and empower antioxidant 
systems in thalassemia patients have been applicable for a long time [64]. Commercially avail-
able compounds included vitamin C, vitamin E, NAC, coenzyme Q10, and hydroxyurea (HU) 
which were used for the treatment, with vitamin E being the most popular [65–79]. Importantly, 
treatment with vitamin E significantly lowered the levels of plasma lipid peroxidation products 
and adenosine diphosphate (ADP)-challenged platelet activity in non-splenectomized and sple-
nectomized HbE/β-thalassemia patients [80]. Regarding other anti-oxidative natural products, 
silymarin restored glutathione level in thalassemia patients [81]. Fermented papaya preparation 
(FPP) increased glutathione levels in blood cells and platelets and decreased membrane lipid 
peroxidation products in β-thalassemia patients [82]. Treatment with a cocktail of DFP, NAC, 
vitamin E, and curcumin for 1 year improved antioxidant capacity in HbE/β-thalassemia patients 
[80, 83]. The levels of serum vitamins A and E, Zn, Se, and Cu were lower in young thalassemia 
patients than in controls, whereas serum ferritin and iron levels were inversely correlated with 
Figure 3. Chemical structures of DFO, DFP, and DFX.
Figure 4. Structures of antioxidants.
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iron in TDT patients. Effective chelation and good management of the patients have been 
correlated with a decline in early deaths and complications [61]. Reduction of plasma and 
cellular chelatable iron such as NTBI, LPI, and LIP is a slow process and requires aggressive 
chelation therapy. The chelation will maintain the iron balance at safe levels to prevent high 
iron accumulation and oxidative tissue injury. Such non-iron and iron-overloaded models as 
RBC, cell cultures (e.g., hepatocytes, HepG2 cells, and cardiomyocytes), animals (e.g., mice, 
gerbils, rats, and transgenic BKO mice), and even human thalassemia patients are experimen-
tally investigated and clinically tested to assess the safety and efficacy of iron chelators. At 
present, three standard iron chelators including desferrioxamine (DFO), deferiprone (DFP), 
and deferasirox (DFX) are widely used for the treatment of β-thalassemia patients with iron 
overload to prevent oxidative stress-induced organ dysfunctions and such complications 
(Figure 3). Combined DFO/DFP and DFP/DFX treatments can reverse endocrine complica-
tions by improving glucose intolerance and gonadal dysfunction in TDT patients [62].
Under continuous chelation therapy, many TDT patients with moderate-to-severe pituitary 
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Compounds such as vitamins A, C, E, β-carotene, reduced glutathione (GSH), and N-acetylcysteine 
(NAC) and enzymes such as SOD, CAT, glutathione peroxidase (GPx), and glutathione reduc-
tase (GR) can remove free radicals by enzymatic and nonenzymatic antioxidant systems in the 
body (Figure 4). Since β-thalassemia patients have a higher oxidative stress level than normal 
people, effective antioxidants would be a complementary treatment of choice in these patients. 
Ideas for using drug antioxidants to eliminate oxidative tissue damage and empower antioxidant 
systems in thalassemia patients have been applicable for a long time [64]. Commercially avail-
able compounds included vitamin C, vitamin E, NAC, coenzyme Q10, and hydroxyurea (HU) 
which were used for the treatment, with vitamin E being the most popular [65–79]. Importantly, 
treatment with vitamin E significantly lowered the levels of plasma lipid peroxidation products 
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patients than in controls, whereas serum ferritin and iron levels were inversely correlated with 
Figure 3. Chemical structures of DFO, DFP, and DFX.
Figure 4. Structures of antioxidants.
Diet-Related Thalassemia Associated with Iron Overload
http://dx.doi.org/10.5772/intechopen.91998
67
serum retinol and selenium levels (p < 0.05). Interestingly, vitamin E and polyphenols can abol-
ish increased oxidative stress in thalassemia patients; if given along with iron chelators, then 
they may provide a substantial improvement in chronic anemia and complications [84].
6.3. Vitamin C
Ascorbic acid or vitamin C is a simple water-soluble vitamin which cannot be enzymatically 
synthesized in the human body. The substance normally functions as a cofactor of proline and 
lysine hydroxylase in collagen synthesis. The levels of leukocyte and urinary AA are decreased 
in idiopathic hemochromatosis patients, TDT patients, and Bantu people [85]. Platelet vitamin 
C level is lower in thalassemia patients with iron overload than normal people [86]. When TM 
patients are treated with vitamin C, their levels of serum iron, transferrin saturation, and fer-
ritin are increased [87]; possibly vitamin C would be involved in the mobilization of storage 
iron from tissues and increase oxidative damage in the patients. However, vitamin C plus 
vitamin E supplementation for β-thalassemia patients has benefits more than vitamin E alone 
in promoting their antioxidant activity [66].
6.4. Vitamin E
Vitamin E (α-tocopherol) is considered to be the most important lipid-soluble exogenous 
antioxidant in humans. Low serum level of vitamin E is found in homozygous TM and TE 
patients. Oral administration of high doses of vitamin E effectively decreased plasma lipid 
peroxidation in β-thalassemia patients and prolonged RBC survival in some patients [71, 88]. 
A therapeutic trial with vitamin E was carried out in TM and TI patients with 750–1000 IU/
day for an average period of 16 months. The treated patients showed fourfold increase in 
both serum and RBC vitamin E levels and a reduced level of malonyldialdehyde (MDA) when 
compared with the untreated group [89]. Daily vitamin E supplementation for 3 months sig-
nificantly increased plasma α-tocopherol levels and reduced plasma oxidant levels in splenec-
tomized TE patients [80].
6.5. Glutathione
Glutathione (γ-glutamylcysteinylglycine) is a tripeptide synthesized by the catalysis of 
γ-glutamyl cysteine synthetase and glutathione synthetase in cells and indicated as a very 
important endogenous free-radical scavenger due to the presence of cysteine sulfhydryl 
group in the molecule. In addition, GR, GPx, and glutathione-S-transferase (GST) work 
as antioxidants to get rid of harmful free radicals mostly in the cells. Physiologically, GR 
together with reduced nicotinamide adenine dinucleotide phosphate functions to recycle 
oxidized glutathione (GSSG) back to GSH to scavenge ROS, and GPx converts hydrogen 
peroxide to water and oxygen. GSH is approximately 80% present in the liver. GR activity 
was slightly decreased in TDT patients, whereas GPx activity was not different when com-
pared with healthy persons [90]. Blood GSH levels of α-, β-, and HbE/β-thalassemia patients 
with iron overload were significantly lower than those of the healthy controls [91–95]. 
Importantly, treatment with flavonoid silymarin restored a decreased GSH content in T cells 
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of β-thalassemia major patients [81]. Though endogenous GSH content is unable to be filled 
up with direct consumption due to digestive peptidase activity, oral administration of some 
antioxidants such as vitamin E (10 mg/kg/day), commercially available FFP, silymarin tablet 
(140 mg three times a day), HU (10–20 mg/kg/day), NAC (2,400 mg/day), and curcumin (500 
mg/day)/vitamin E cocktail can increase/restore intracellular GSH content in thalassemia 
patients instead.
6.6. Hydroxyurea
HU (alternatively hydroxycarbamide) is a drug of choice used for enhancing γ-globin gene 
expression and modifying γ-globin chain production, as a consequence of Hb F production in 
SCD and β-thalassemia patients. In controversy, the compound is toxic and suspected to the 
pathogenesis of colonic ulcerative [96]. Indeed, HU effectively increases Hb F production in 
patients with SCD, SCD with α-thalassemia, and TI and results in a decrease in the number 
of blood transfusions required [97–99]. A current clinical study in TI patients has shown HU 
decreased serum ferritin (50 vs. 33%), LIP (20 vs. 13%), apoptotic event (62 vs. 15%), and 
ROS (60 vs. 50%) levels and increased GSH level (66 vs. 25%) in the responders compared 
to the nonresponders [100]. In addition to the increase in Hb F synthesis, treatment with HU 
(30 mg/day) in β-thalassemia patients with Hb E for 3 months decreased SOD activity and 
MDA concentration of the RBC, probably due to inhibition of cytosolic superoxide radical 
and membrane lipid peroxidation [101, 102].
6.7. N-acetylcysteine (NAC)
NAC, an anti-oxidative thiol-containing compound, is able to trap ROS and reactive nitro-
gen species (RNS) and therefore protect cells from such free-radical-mediated damage. 
After crossing the cell membrane, the compound will be hydrolyzed to cysteine used for 
the synthesis of GSH. Importantly, NAC can protect the RBC of SCD patients and of normal 
subjects from oxidative stress condition [65, 103]. In vitro treatment of blood cells includ-
ing RBC, platelets (PLT), and polymorphonuclear leukocytes of β-thalassemia patients with 
N-acetylcysteine amide increased GSH content and reduced ROS level in these cells, possibly 
resulting in a significant reduction in the sensitivity of thalassemia RBC to hemolysis and 
phagocytosis by macrophages [65]. They also showed that the intraperitoneal injection of 
AD4 to β-thalassemia mice (150 mg/kg) significantly reduced all parameters of oxidative 
stress. One β-thalassemia with hemoglobin sickle (Hb S) who received NAC (2400 mg/day) 
for 6 weeks showed an increase in whole-blood GSH levels and a decrease in the RBC mem-
brane PS exposure [104]. Consistently, TDT patients who received NAC (10 mg/kg/day) for 
3 months showed a decrease in total oxidative stress and total oxidative stress index and 
an increase in total antioxidant capacity and blood Hb level [105]. Our group has reported 
that treatment of β-thalassemia HbE with a cocktail of DFP, NAC, and either vitamin E 
or cucumin for 12 months significantly decreased levels of iron overload (e.g., NTBI, LPI, 
erythrocyte membrane nonheme iron) and oxidative stress (e.g., MDA and erythrocyte ROS) 
parameters and increased levels of blood Hb and antioxidant indicators (e.g., CAT, SOD, and 
GSH), suggesting an effective antioxidant property [51].
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compared with the untreated group [89]. Daily vitamin E supplementation for 3 months sig-
nificantly increased plasma α-tocopherol levels and reduced plasma oxidant levels in splenec-
tomized TE patients [80].
6.5. Glutathione
Glutathione (γ-glutamylcysteinylglycine) is a tripeptide synthesized by the catalysis of 
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group in the molecule. In addition, GR, GPx, and glutathione-S-transferase (GST) work 
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together with reduced nicotinamide adenine dinucleotide phosphate functions to recycle 
oxidized glutathione (GSSG) back to GSH to scavenge ROS, and GPx converts hydrogen 
peroxide to water and oxygen. GSH is approximately 80% present in the liver. GR activity 
was slightly decreased in TDT patients, whereas GPx activity was not different when com-
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decreased serum ferritin (50 vs. 33%), LIP (20 vs. 13%), apoptotic event (62 vs. 15%), and 
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(30 mg/day) in β-thalassemia patients with Hb E for 3 months decreased SOD activity and 
MDA concentration of the RBC, probably due to inhibition of cytosolic superoxide radical 
and membrane lipid peroxidation [101, 102].
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NAC, an anti-oxidative thiol-containing compound, is able to trap ROS and reactive nitro-
gen species (RNS) and therefore protect cells from such free-radical-mediated damage. 
After crossing the cell membrane, the compound will be hydrolyzed to cysteine used for 
the synthesis of GSH. Importantly, NAC can protect the RBC of SCD patients and of normal 
subjects from oxidative stress condition [65, 103]. In vitro treatment of blood cells includ-
ing RBC, platelets (PLT), and polymorphonuclear leukocytes of β-thalassemia patients with 
N-acetylcysteine amide increased GSH content and reduced ROS level in these cells, possibly 
resulting in a significant reduction in the sensitivity of thalassemia RBC to hemolysis and 
phagocytosis by macrophages [65]. They also showed that the intraperitoneal injection of 
AD4 to β-thalassemia mice (150 mg/kg) significantly reduced all parameters of oxidative 
stress. One β-thalassemia with hemoglobin sickle (Hb S) who received NAC (2400 mg/day) 
for 6 weeks showed an increase in whole-blood GSH levels and a decrease in the RBC mem-
brane PS exposure [104]. Consistently, TDT patients who received NAC (10 mg/kg/day) for 
3 months showed a decrease in total oxidative stress and total oxidative stress index and 
an increase in total antioxidant capacity and blood Hb level [105]. Our group has reported 
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Figure 5. Structures of ingredients in curcuminoids.
7. Supplementation of functional food
7.1. Curcuminoids
Curcumin (diferuloylmethane) is one of the major phytochemicals (70–80%, w/w) from the 
golden spice turmeric Curcuma longa Linn (family Zingiberaceae). The three main constituents 
of curcuminoids are curcumin, demethoxycurcumin, and bis-demethoxycurcumin, of which 
the important molecular structure for biological activity is diketone moiety (Figure 5).
Apparently, curcumin and its metabolites including di-, tetra-, and hexa-hydrocurcumin 
exhibit strong antioxidant, free-radical scavenging, anti-lipid peroxidative, antithrombotic, 
and anti-inflammatory activities. Many clinical investigations have addressed pharma-
cokinetics, safety (maximum dose 12 g/day over 3 months), and efficacy of this attractive 
nutraceutical against several human diseases including β-thalassemia. Many formulations of 
curcumin including nanoparticles, liposomal encapsulation, emulsions, capsules, tablets, and 
powder are available for a single and adjunctive treatment [106]. Curcumin is claimed to be 
a potential hexadentate iron chelator and found to remove NTBI in thalassemia serum and 
also suppress the ROS generation and lipid peroxidation in thalassemia RBC [83, 107–111]. 
Curcuminoids (particularly bis-demethoxycurcumin) and its metabolite (hexahydrobisdeme-
thoxycurcumin) potentially enhanced the upregulation of γ-globin gene and synthesis of Hb 
F in human erythroid leukemia (K562) and primary erythroid precursor cells [112]. Curcumin 
is reported one of the triggers of eryptosis to allow defective RBC to escape hemolysis [8]. The 
oxidative stress condition in circulating RBC of TE patients is reduced after treatment with a 
curcumin cocktail, leading to improvement in their quality of life [83]. Curcumin markedly 
decreased iron deposition and lipid peroxidation product as MDA in the liver and spleen and 
the liver of iron-loaded rats [113].
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7.2. Green tea
Tea (Camellia sinensis L., Theaceae family) is one of the most popular beverages in the 
world in which the products, depending on duration of fermentation, can be classified into 
green tea (GT), oolong tea, white tea, yellow tea, black tea, pu-erh tea, and Miang tea. GT 
(C. sinensis L. var japonica) is produced without any fermentation (oxidation), so the major 
persisting catechins are not destroyed by naturally occurring polyphenol oxidase (PPO) in 
fresh tea leaves. Oolong tea (C. sinensis var sinensis) is processed from tea leaves under 
semi-fermentation, in which β-glycosidic aroma precursors including 8-hydroxygeranyl β-d-
primeveroside, trans- and cis-linalool 3,6-oxide 6-O-β-d-xylopyranosyl-β-d-glucopyranosides, 
and (2R,3S,4S,4aS,11bS)-3,4,11-trihydroxy-2-(hydroxymethyl)-8-(4-hydroxyphenyl)-3,4,4α, 
11β-tetrahydro-2H,10H-pyrano[2′,3′:4,5]furo[3,2-g]chromen-10-one are the main volatile 
constituents besides the catechin derivatives. Black tea (long fermentation) and Miang tea 
(C. sinensis L. kuntze var assamica) require very long fermentation times depending on the 
manufacturing process. Miang (a northern Thai word) is a chewing tea and commonly used 
for gum chewing in elderly people, relief of skin burn and inflammation, and as an antidiar-
rheal remedy.
In industry, GT is produced from steaming or roasting fresh tea leaves at high temperatures, 
consequentially drying and inactivating the PPO enzymes and leaving polyphenols known as 
flavonols or catechins at 30–40% by weight of dry tea leaves. It contains at least four major cate-
chin derivatives including (−)-epigallocatechin-3-gallate (EGCG), (−)-epigallocatechin (EGC), 
(−)-epicatechin-3-gallate (ECG), and (−)-epicatechin (EC), of which the lipophilic permeable 
EGCG exhibits anti-oxidative and iron-chelating activities (Figure 6) [114]. Additionally, 
other phenolic acids including chlorogenic acid (CGA), caffeic acid (CA), and gallic acid (GA) 
and flavonols including kaempferol, myricetin, and quercetin are present in green tea [115]. 
Green tea extract (GTE) and EGCG, which show iron-chelating and antioxidant properties 
[116, 117] decrease labile iron (e.g., NTBI and LPI) level and consequently deplete lipid per-
oxidation as well as oxidative stress in both iron-loaded rats and thalassemia mice [118, 119]. 
The compounds were effective in the inhibition of RBC hemolysis, resulting in a prolonged 
RBC lifespan and decreased iron deposition and oxidative damage in the liver [119].
TI showed higher intestinal nonheme iron absorption than TM, while tea produced 41–90% 
inhibition of iron absorption in these patients, suggesting that tea consumption would be 
Figure 6. Structures of catechins in green tea.
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Figure 5. Structures of ingredients in curcuminoids.
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oxidative stress condition in circulating RBC of TE patients is reduced after treatment with a 
curcumin cocktail, leading to improvement in their quality of life [83]. Curcumin markedly 
decreased iron deposition and lipid peroxidation product as MDA in the liver and spleen and 
the liver of iron-loaded rats [113].
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recommended to thalassemia patients, particularly TI patients [120]. Logically, anti-oxidative 
GTE interferes duodenal absorption of dietary iron and iron-chelating properties in vitro and 
in vivo [116–119]. The preparation also showed inhibitory effect on catecholamine secretion 
from isolated rabbit adrenal glands, possibly by blocking L-type calcium channels in the 
adrenal medullary glands [121]. Therefore, GTE might be helpful to decrease iron deposi-
tion, reduce ROS levels, and ameliorate functions of targeted endocrine glands (e.g., pancreas 
and adrenal cortex) in β-thalassemia models. In controversy, a study reports development of 
thrombotic thrombocytopenic purpura in a person after consuming a weight-loss product 
containing green tea [122]. Most importantly, green tea showed antithrombosis ex vivo and 
inhibition of cyclooxygenase 1 activity [123, 124].
In our recent study, we have produced a functional GT-CUR concentrate (Figure 7) for inves-
tigating its effects in Thai adult TDT patents. We found that the drink did not affect white 
blood cell and platelet numbers, Hb, and Hct but increased RBC numbers following daily 
consumption for 2 months. The levels of blood urea, serum alanine aminotransferase, aspar-
tate aminotransferase, and alkaline phosphatase activity tended to decrease but neither sig-
nificantly nor dose dependently. In month 1 and 2 of the treatments, there were a decrease of 
serum MDA (−0.07 ± 2.95 and −0.87 ± 1.68 μM, respectively), NTBI (−1.20 ± 8.03 and −3.93 ± 
3.83 μM, respectively), and LPI (1.91 ± 4.99 and −1.10 ± 2.94 μM, respectively) and increase of 
serum antioxidant activity (5.08 ± 8.86 and 0.28 ± 13.39 mg trolox equivalent/ml, respectively). 
These findings suggest GT-CUR drink would increase erythropoiesis, improve liver and kid-
ney function, and diminish oxidative stress and iron overload in thalassemia patients [125]. 
Surprisingly, we demonstrate that treatment of GTE (1–10 μM EGCG equivalent) decreased 
cellular iron approximately 45% and ROS level in a concentration-dependent manner in iron-
loaded pancreatic cell line (RINm5F) when compared with control cells. Secretory insulin 
level was nearly 2.5-fold times the highest safe concentration of the GTE [36]. The results 
imply that catechin-rich GT would indeed be an effective drink to remove iron, decrease ROS, 
and improve pancreatic cell function thereby increasing insulin production, leading to the 
amelioration of diabetic complications in thalassemia patients with iron overload.
Evidently, green tea is abundant with phytonutrient and enriched with active phytochemicals 
that exhibit many biological and pharmacological activities and it can be utilized for a functional 
Figure 7. GT-CUR concentration: from field to nutraceutical product.
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drink and health benefits. Up to now, many green tea products are being marketed worldwide 
for many purposes in different population ages. We are eager to use our multifunctional cock-
tail containing green tea extract, DFP, and vitamin E to examine if the product could diminish 
hypercoagulability and excessive platelet activity in thalassemia patients and thrombosis-related 
diseases, besides iron chelation.
7.3. Coffee
Coffee is also one of the most widely consumed beverages in the world because they contain 
many active ingredients that are a benefit for human health. Coffee (Coffea arabica L., Coffea 
canephora L. family Rubiaceae) is an original crop that will be further processed to roast coffee, 
coffee powder, coffee brew, coffee biscuit, and coffee candy for commercial purposes. Coffee 
is widely naturalized in many parts of the world including Africa, Latin America, the Pacific 
and Caribbean Ocean, Southeast Asia, and China. In Thailand, coffee is usually cultivated on 
the highlands at Doi Chang and Huay Nam Khun of Chiang Rai, Doi Saket District of Chiang 
Mai, and Kraburi District of Ranong (Figure 8).
Caffeine (1,3,7-trimethylxanthine) is a predominant ingredient persisting in tea and coffee, 
which is the most widely used pharmacologic substance showing prooxidant and antioxidant 
and hydroxyl radical scavenger [126–128]. Coffee contains many kinds of monosaccharide 
including sucrose, polysaccharides, d-arabinose, d-mannose, d-glucose, d-galactose, d-rham-
nose, and d-xylose in nearly equal amounts. The amounts of caffeine and CGA are slightly 
higher in raw arabica coffee (0.9–1.2% and 1.6–2.4% w/w, respectively) than in raw robusta 
coffee (5.5–8.0% and 7.0–10.0% w/w, respectively) [129]. Interestingly, only arginine and cys-
teine are much more abundant in the green coffee (3.61% and 2.89% for arabica 2.28% and 
3.87% for robusta) when compared with the roast coffee (0% and 0.76% for arabica 0% and 
0.14% for robusta). Phenolic compounds including mono- and di-caffeoylquinic acids, CA, 
ferulic acid, p-coumaric acid, sinapic acid, 4-hydroxybenzoic acid, and CGA were detected 
in spent coffee by-product [130, 131] (Figure 9). Phenolic compounds, in particular CGA in 
coffee was able to chelate metal ion such as Zn [132]. In controversy for CVD incidence, one 
Figure 8. Coffee crop in Thailand.
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report supports the administration of caffeine augments endothelium-dependent vasodilation 
in young healthy volunteers through an increase in NO production [133]. Approximately one 
third of CGA and almost all of the CA are absorbed in the small intestine of humans, so the 
two antioxidants might have preventive effect of CVD [134]. The 10-kDa or less fractions but 
no other common components (e.g., CGA, CA, caffeine, quinic acid, trigonelline hydrochlo-
ride, and 5-(hydroxymethyl)-2-furfural) in hot-water extract of coffee had antithrombin and 
antiplatelet activity [135]. CGA protected oxidative damage and dose dependently increased 
the production of NO of human aortic endothelial cells [136].
Caffeine increases intracellular calcium-stimulating endothelial NOS to accelerate the produc-
tion of NO which will be diffused to vascular smooth muscle cell to produce vasodilation [137]. 
Tocopherols are found in coffee bean oil [138]. Caffeine (300 mg, equivalent to two to three cups) 
is metabolized in the human body to theophylline (170 ng/ml plasma) 7 hours post-adminis-
tration [139]. Tea and coffee dose dependently inhibited absorption of nonheme iron of either 
animal or plant food [140]. Dihydrocaffeic acid, a metabolite of CA detected in human plasma 
following coffee ingestion, was able to decrease ROS and increase NOS activity in human-derived 
EA.hy926 endothelial cells [141]. Ingestion of green coffee extract for 4 months led to the decrease 
in plasma level of homocysteine and improvement of human vessel reactivity [142]. Coffee 
ground residual has higher phenolic contents than roast coffee bean and shows inhibitory effects 
on the production of NO and pro-inflammatory cytokines in the macrophage [143]. Surprisingly, 
healthy volunteers who consumed coffee for 2 months (420 and 780 mg CGA equivalent/day) 
showed increase of plasma total antioxidant capacity [144]. A recent study has demonstrated 
coffee would counteract cerebral arterial constriction via endothelial NOS induction and smooth 
muscle dilation [145]. Two catechols, particularly CGA and CA which is abundant in coffee, could 
potentially scavenge free radicals and subsequently inhibit the production of pro-inflammatory 
cytokines as interleukin-8 in intestinal epithelial cells [146]. Consistent with our previous study, 
healthy adults consuming CGA-enriched coffee showed a significant increase of plasma anti-
oxidant capacity when compared with the control group [144, 147]. Additionally, CGA-enriched 
green and roast coffee can protect oxidative damage of biomolecules in human consumers [148].
Nowadays, there are varieties of coffee products including green coffee powder, green coffee 
capsules, green coffee extracts, green coffee cleans detox, roast coffee, roast coffee, coffee brew, 
and herbal coffee that are commercially available for all-level consumers. In socioeconomics, 
the coffee beverage business is very popular and a growing industry in Thailand. We are 
Figure 9. Some major constituents in coffee.
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applying the wonderful properties of coffee for health benefits in thalassemia patients regard-
ing anti-oxidation, metal chelation, and antithrombosis.
8. Fruits and vegetables
Epicarp extracts of bergamot (Citrus bergamia Risso) containing “citropten” and “bergapten” 
powerfully induced the expression and differentiation of γ-globin gene in human erythroid 
cells (K562) and consequently the production of Hb F, suggesting a potential therapy appli-
cation in β-thalassemia and sickle cell anemia [149]. Fermented papaya preparation (FPP) 
increased the glutathione levels in blood cells and platelets and also decreased erythrocyte ROS 
level and membrane lipid peroxidation product levels such as MDA and phosphatidylserine 
in β-thalassemia patients [82, 150]. Mango (Mangifera indica L., family Anacardiaceae) is a tropi-
cal edible fruit cultivated globally and is annually produced from March to May. The seasonal 
fruit gives a high yield in Thailand and can be consumed in the forms of green and yellow 
fruits. It was found that aqueous extracts of the stem barks and peel from Vimang mango dis-
played potent antioxidant, free-radical scavenging and divalent metal ion-chelating properties 
due to the presence of a major polyphenol “mangiferin” [151]. Consistently, our group demon-
strated that aqueous and ethanolic extracts of Thai mango (M. indica var Mahachanok and M. 
indica var Kaew) lowered plasma levels of glucose and triglyceride in streptozotocin-induced 
rats. Obviously, the extract showed analgesic, anti-gastric ulcerative, and chemical-induced 
hepatoprotective effects in rats. In addition, the extracts increased plasma antioxidant capacity 
in rats and humans [152]. The results suggest fresh and fermented mangoes would be a poten-
tial functional and therapeutic food against the deleterious action of ROS generated during 
iron overload (e.g., β-thalassemia, Friedreich’s ataxia, hemochromatosis, and inflammation).
Rice (Oryza sativa L.) is the chief economic crop cultivated in every region of Thailand. One 
study demonstrated that consumption of wheatgrass juice and tablets decreased the require-
ment of RBC transfusions in Indian β-thalassemia patients by 25% or more [153, 154]. It was 
possible that pheophytin compound in the wheatgrass would increase hemoglobin synthesis. 
In controversy, another study showed that the juice therapy did not affect the production of 
hemoglobin [155]. Pancytopenia such as leukocytopenia and thrombocytopenia is observed 
in the chelation treatment of thalassemia; however, herbs like wheatgrass, papaya leaves, 
and garlic would be effective in treating single lineage cytopenias [156]. We found that etha-
nol extract of neem (Azadirachta indica var siamensis Valeton) leaves displayed free-radical 
scavenging and iron-binding activities in vitro, and the study of the extract will be extended 
to β-thalassemia mice with iron overload [157].
9. Conclusions
Regular iron chelation therapy with high dietary intake of antioxidants effectively lowers the 
harmfulness of iron overload-mediated oxidative tissue damage and organ dysfunctions in 
thalassemia patients. The supplementation with single nutrients, like antioxidants, is gener-
ally not effective in ameliorating such iron overload conditions or in slowing the progression 
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report supports the administration of caffeine augments endothelium-dependent vasodilation 
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of the disease. It is recommended that these nutrients should be consumed as part of a 
healthy diet/functional fruits in daily meals. Nutritional and herbal strategies for modify-
ing the pathological and clinical courses of thalassemia disease should consider the major 
active ingredients, nutraceuticals, biological activities, and hematological efficacy. Moreover, 
pre-implant/prenatal detections of thalassemia in the fetus using sensitive and specific molec-
ular-biological and ultrasonic techniques could block new cases and problematic carriers of 
hemoglobinopathies. Understanding the genetics underlying the heritable subphenotypes of 
thalassemia would be prognostically useful and inform us further about personalized thera-
peutics as well as help the discovery and development of new pharmacogenomics. An effec-
tive medical regime, adjunctive supplementation of synthetic and natural antioxidants, and 
caregiver education could also be important factors to prevent or treat symptoms/complica-
tions in thalassemia. Selected protocols using single or combined chelators could be designed 
for personalized iron chelation therapy in TDT and NTDT patients, which would effectively 
and safely remove all the excess toxic iron (e.g., NTBI, LPI, and LIP) and prevent cardiac, liver, 
and other organ damage. Finally, a reliable approach based on genomics and proteomics may 
be effective to build a rational personalized medicine framework that can be applied in the 
preclinical, clinical, and therapeutic settings of hypercoagulability in thalassemia.
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Abstract
Introduction: Epileptic seizures and antiepileptic drugs (AEDs) are a source of oxygen 
stress. Oxygen stress can have negative effects. These effects which can be prevented are 
largely unknown in clinical epileptology. Objective: The objective of the study is to dis-
cuss (a) homeostatic oxidant, antioxidant imbalance due to epileptic seizures and AEDs, 
(b) the protective factors that help prevent oxygen stress (OS), and personalized medicine 
based on pharmacogenomics and diet as therapeutic challenges in epilepsy. Discussion: 
Experimental models of epileptic seizures evoked by various means suggest that seizures 
can cause neuronal destruction. This is accompanied by an increased activity of free radi-
cals and a reduction of total antioxidant capacity (in red blood cells, blood serum, and 
cerebrospinal fluid). A number of antioxidants have been found to attenuate the negative 
effects of OS and act neuroprotectively if they are administered prior to seizure occur-
rence: vitamins (C, E), trace elements (Se, Zn), melatonin, erdosteine, or natural herbal 
extracts. New AEDs (GBP, LEV, LTG, and TGB) cause no, or very little, OS as opposed to 
other drugs (CBZ, PHT, PB, VPA, TPM, or OXC), which have pronounced albeit hetero-
geneous and dose-dependent effects. It is suggested that AEDs should be administered 
together with free radical sweepers (vitamins, trace elements, electrolytes, melatonin) 
and other anti-oxidizing substances. Conclusions: (1) Epileptic seizures and AEDs cause 
OS. The effects vary greatly depending, among other things, on the daily drug dose. (2) 
The findings of research using a variety of seizure models are more unequivocal than the 
findings of research on patients with epilepsy. This suggests that the relations among 
seizures, AEDs, OS etiology, and OS consequences are complex. (3) Since existing AEDs 
cause OS, it is necessary to develop a new approach to AED treatment. (4) It is important 
to know the patient’s specific characteristics, including previous history, lifestyle, age, 
gender, weight, diet, environment, etc. They can be valuable tools to improve the quality 
of life of a person suffering from epilepsy. This concept of managing the patient health is 
called targeted medicine or personalized medicine.
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1. Introduction
Within the last three decades, interest in oxygen stress and its role in the development of 
organ pathology has increased considerably, and the importance of this phenomenon has 
been increasingly recognized. Oxygen stress means that the production of free radicals and 
reactive forms of oxygen (RFO) has exceeded the antioxidant defense mechanism capacity 
[1, 2]. Bartosz [3] thinks that RFO research may be the key to a better understanding of cer-
tain biochemical, physiological, and pathological aspects of living organisms and suggests 
that such understanding could be applied to clinical practice. Free radicals, the product of 
oxygen stress, may play an important role as physiological markers that control cell pro-
cess signals. However, when produced in excess, or when the antioxidant defense system is 
weak, they may lead to cell injury.
Excessive free radical production is related to various physiological and pathological states 
such as aging, epileptic seizures, or the use of xenobiotics, including fat-soluble drugs [4, 5]; 
this also applies to antiepileptic drugs (AEDs) [6–8]. A number of nonspecific factors [9] as 
well as dietary habits affect the state of antioxidants in the healthy elderly [10]. This suggests 
that oxidation and anti-oxidation processes are rather ubiquitous and hence nonspecific.
As far as epilepsy is concerned, when the number of free radicals in the neuron increases, 
this interferes with the respiratory chain in the mitochondria, destabilizes the lysosomal 
membranes, and lowers the convulsion threshold [11–13]. Peroxydation of the neuronal mem-
branes modifies their electrophysiological properties and leads to an abnormal bioelectric 
discharge in the neurons.
Epilepsy is frequent in diseases involving dysfunction in the mitochondrial structures. It is 
a sign of energetic anomalies in the ATP synthesis due to ADP phosphorylation [14]. The 
mitochondria have vital functions such as energy production, cellular harm control, neu-
rotransmitter synthesis, and free radical production. It is not clear yet which of these functions 
are affected in epileptic seizures [15]. Liang and Patel found an increase in spontaneous and 
evoked epileptic attacks in a subgroup of mice with a partial inherent mitochondrial SOD 
deficit. This effect correlated with chronic mitochondrial oxygen stress (aconitase enzyme 
deactivation) and reduced oxygen use. They think that oxygen stress caused by free radi-
cal peroxides increases seizure susceptibility in this subgroup of mice. This susceptibility 
increases with age and also with increased environmental stimulation and the use of stimu-
lants. Oxygen stress and mitochondrial dysfunction may both cause and be caused by epi-
leptic attacks [16]. According to Dubenko and Litovchenko [17], the application of energy 
metabolism activators improves the clinical and electroencephalographic course of epilepsy. 
This has been demonstrated experimentally by positive histological changes. According to 
these writers, this treatment prevents neuronal harm and the development of encephalopathy.
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Research on various seizure models, in animals and humans, has shown that not only epilep-
tic seizures but also EEG discharges themselves may cause complex metabolic neural lesions 
and oxidation-antioxidant disequilibrium [18–21].
On the other hand, a number of experimental studies have shown that AEDs can also produce 
free radicals and significantly increase the peroxydation of neuronal membrane lipids and 
reduce the protective effects of antioxidants. These changes may lead to increased seizure and 
idiosyncratic drug effect frequency [7, 22–25]. PHT initiates an oxidation damage to proteins 
and fats in the maternal and embryonic liver tissue organelle in murine rodents [1].
A group of researchers have also found that oxidation stress and resistance to AEDs trigger 
adaptive mechanisms, i.e., production of endogenous antioxidant sweepers, which prevent 
the harmful effects of oxidation [26]. These researchers studied nitrogen oxide and endog-
enous antioxidant GSH sweepers, GSH-Px, complete (T) and superoxide dismutase (T-SOD), 
Mn-SOD, and catalase in the cerebrospinal fluid of children with various neurological dis-
eases. All the antioxidant parameters were the highest in the children with bacterial meningi-
tis compared with the other groups. In the epilepsy group, nitrogen oxide, GSH, and GSH-Px 
were higher than in the aseptic meningitis and control group [26]. The authors think that 
oxygen stress may be related to seizure pathology and that its reduction may lead to a better 
prognosis for the course of epilepsy.
Akarsu et al. [27] came to similar conclusions. They studied the state of oxidation in 21 chil-
dren with febrile seizures and 21 children without febrile seizures. They assessed the level of 
arginase and catalase in the red blood cells, malondialdehyde—an indicator of lipid peroxida-
tion (MDA)—and nitrogen oxide in the plasma and cerebrospinal fluid. The control group 
consisted of 41 children divided into three subgroups: (1) with fever, (2) without convulsions, 
and (3) without fever and without convulsions. Both fever and convulsions had a significant 
effect on the oxidation mechanism. Febrile and afebrile convulsions differed in their genera-
tion of oxygen stress. According to the authors, higher levels of oxygen stress may be a factor 
that protects against neuronal lesion during convulsions in afebrile convulsions.
Not only can oxygen stress initiate epileptogenesis, it can also worsen the course of epilepsy. 
Consistently with these conclusions, using antioxidants in conventional epilepsy therapy and 
hence attenuating oxygen stress could have a positive effect on the course of epilepsy [28]. 
Many researchers share this opinion, but few of them are clinical epileptologists. Earlier, a 
review was published of research on the possible role of oxygen stress in the early stages of 
epileptogenesis, both in animal models and humans [29]. There has also been discussion of 
attempts to use exogenous antioxidants which, according to many writers, have antieplepto-
genic properties (which AEDs do not).
It has been reported that refractory epileptic patients may benefit from pharmacogenetic test-
ing for variations in the genes encoding drug-metabolizing enzymes and drug transporters 
of AEDs [30]. Since the treatment options are limited, the use of personal medication, which 
could have beneficial effects in epilepsy treatment, is indicated [31]. The aim of personalized 
medication is to maximize the likelihood of therapeutic efficacy and to minimize the risk of 
drug toxicity. Specific genes have been linked to adverse drug reactions in the form of a severe 
rash in Stevens-Johnson syndrome [32, 33].
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2. Preventing oxidation stress due to epileptic seizures
Experimental research with animal models and clinical observation have shown that epilep-
tic seizures lead to a number of harmful activities in the brain: disturbed blood circulation, 
increased cerebrospinal fluid pressure, brain edema, and hypoxia, all of which lead to a 
sudden reduction of energy carriers (ADP, ATP, phosphocreatine) and pH neuron reduc-
tion. During seizures, arachidic acid is released in the postsynaptic membranes. This has an 
activating effect on presynaptic neuronal endings and leads to increased glutamate release. 
Arachidic acid also increases the production of free oxygen radicals, leading to increased 
lipid peroxidation. These in turn may activate phospholipase C and then lead to the release of 
arachidic acid from cellular membranes, setting a vicious circle in motion [3].
2.1. The metrazol seizure model (PTZ)
Intraperitoneally induced seizures in rats by means of PTZ rupture the blood-brain barrier. 
This has been demonstrated with Evans dye, used to mark the permeability of this barrier 
[34]. Research suggests that free radicals are involved in the permeability of the blood-brain 
barrier; this permeability leads to albumin extravasation to the thalamic nuclei, brain stem, 
frontal cortex, and occipital cortex. The animals that have been given vitamin E or selenium 
(Se) prior to the seizure induction had less extravasation in these structures. It has also been 
demonstrated that in young rats in normothermic conditions, the barrier permeability was 
greater in males (p < 0.05) [35].
In this convulsion model in mice, prior administration of erdosteine (mucoliticum), which 
acts as an antioxidant, leads to much weaker oxygen stress and much longer latency time 
from pentylenetetrazol (PTZ) administration to convulsion onset (p < 0.05) [36]. On the other 
hand, compared with the control group, the experimental group had lower levels of MDA 
and xanthine oxidase (oxidizers) and a higher level of SOD (p < 0.001). These studies show 
that administration of erdosteine reduces convulsion-induced oxygen stress and therefore 
protects the neurons.
In mice, Nigella sativa oil (NSO), a powerful antioxidant that has been in used in folk medicine 
and the kitchen for thousands of years, prevented epileptic seizures induced by PTZ kindling 
much more effectively than valproic acid (VPA) [20].
2.2. The kainic acid model
Kainic acid (KA) is used as a model substance in the assessment of neurotoxicity. It leads to 
excessive RFT production due to reduced antioxidant activity. When KA was administered 
to rats, lipid peroxidation of the neuronal membrane increased in proportion to seizure pro-
gression [37]. In the same model, SOD and catalase activity increased significantly on day 5 
following KA administration and returned to the base level 3 weeks later; GGH-PX activity 
also increased significantly on day 5 but was still high 3 weeks later [38]. Lipid and protein 
peroxidation, assessed by MDA concentration, increased significantly 8 and 16 h later then 
decreased on day 2 and day 5 following KA injection. The authors attribute the rapid increase 
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in MDA and protein peroxidation to free radicals produced in this phase of the pathological 
KA effect; they think that the changes in the enzymatic scavenger activity and the reduced 
MDA concentration may have been caused by glia proliferation due to neuronal death.
In the KA model in mice, prior or simultaneous administration of melatonin (a powerful 
hydroxyl radical scavenger) (20 mg/kg i.p.) had an anti-oxidizing effect and prevented lipid 
peroxidation, cerebral mitochondria DNA injury, and seizures [39].
In the KA model, prior administration of vineatrol significantly reduced the MDA level in 
rats’ brains but had no effect on the glutation level [40]. Doses exceeding 20 and 40 mg/kg 
lengthened the latency time to that of the first seizures. Additional administration of vineatrol 
30 and 60 min after KA administration significantly reduced seizure incidence. The authors 
suggest that vineatrol could potentially be administered in the epileptic state.
Sok et al. [21] studied the anticonvulsive effects of Petasites japonicum (BMP), a plant grown 
in East Asia and used for both culinary purposes and in folk medicine. Its root extracts are 
still used for headaches and asthma. Prolonged administration of BMP, prior to KA admin-
istration, reduced mortality in mice by one half, and administration of the BMP-I subfraction 
reduced convulsive seizures and also significantly reduced neuronal loss in parts CA1 and 
CA3 of the hippocampus. The authors suggest that BMP-I is the factor responsible for preven-
tion of oxidization lesion in the mouse brain.
Hsieh et al. [41] tested a traditional Chinese herb (Gastrodia elata B1—GE) administered to 
treat epilepsy in a controlled study using the KA seizure model in rats. They found that prior 
administration of GE significantly reduced in vitro lipid peroxydation in the rats’ brains, an 
effect analogous to the effect of phenytoin (PHT—20 mg/kg). The authors think that GE has 
an antiepileptic effect and is a free radical scavenger. This antiepileptic effect may be at least 
partly attributable to the GE’s vanilla component [42].
2.3. The pilocarpine model
Pilocarpine, an imidazole alkaloid extracted from the leaves of the Pilocarpus jaborandi shrub, 
is a parasympathomimetic, cholinergic antagonist that acts similarly to acetylcholine. It is 
often used to evoke epileptic convulsions and epileptic states in animal models. The mecha-
nisms leading to seizures or status epilepticus are unknown. It is thought that oxygen stress 
plays an important role, but we still do not know which brain structures are more sensitive. 
Studies of the activity of catalase, a free radical scavenger, have found different effects of the 
epileptic state on the catalase level in different brain structures [19]. The highest elevation was 
found in the hippocampus (36%), striatum (31%), and frontal cortex (15%); no changes in the 
level of catalase activity were found in the cerebellum. The authors think that the endogenous 
increase in the catalase activity, responsible for removal of free oxygen radicals produced 
during convulsions, may be a compensatory defense mechanism that counteracts the nega-
tive effects of oxygen stress in the status epilepticus. Other researchers have come to similar 
conclusions [26, 43]. Tejada et al. [43] evoked a pilocarpine epileptic state and found that 
MDA increased significantly (64%), suggesting oxygen injury. They found a simultaneous 
increase in the anti-oxidizing activity of catalase enzymes (28%), GSH-Px (28%) and SOD 
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(21%). On the other hand, vitamin E concentration in the cerebral cortex was reduced (15%) 
due to increased lipid peroxydation following pilocarpine administration.
Barros et al. [18] applied the same model and found that administration of vitamin E (200 
mg/g i.p.) 30 min prior to the administration of pilocarpine (400 mg/kg s.c.) led to increased 
(214%) catalase activity in the hippocampus compared with rats given only pilocarpine (67%) 
or physiological saline. The authors think that increased catalase activity may be responsible 
for the regulation of free radicals evoked by the status epilepticus.
In this same model in rats, prior administration of vitamin C (250 mg/kg i.p.) reduced the 
negative effects of oxygen stress and neuronal lesion [44]. The latency time to convulsion 
onset following pilocarpine administration was longer, and mortality in the status epilepticus 
was reduced compared with the group which did not receive vitamin C or received physi-
ological saline. This study also demonstrated that in the group receiving only vitamin C, the 
level of lipid peroxidation was lower than in the group that received (a) pilocarpine and (b) 
pilocarpine and vitamin C. In all the experimental groups, catalase activity in the hippocam-
pus increased compared with the control group which only received physiological saline. 
The authors think that the neuroprotective function of vitamin C in adult rats may be due to 
reduced lipid peroxidation and increased catalase activity following convulsions and status 
epilepticus [44].
2.4. The audiogenic seizure model
Prolonged melatonin administration to rats congenitally predisposed to audiogenic convul-
sions (the Krushinsky-Molodkina model) had no effect on seizures evoked by a 20 times more 
powerful auditory stimulus [45]. VPA administration significantly reduced convulsions, but 
VPA and melatonin combination had a significantly larger anti-seizure effect—it lengthened 
the latency time and reduced seizure severity. However, the rats receiving the combined 
treatment displayed a much more rapid onset of myclonia than the rats receiving either VPA 
or melatonin [45].
3. Counteracting AED-evoked oxygen stress
3.1. AEDs in animal models of epileptic seizures
Researchers using animal models have found a variety of effects of AEDs, administered in 
various doses, on oxidant and antioxidant processes in an astrocyte culture in rats [46]. Here 
is a selected list of studied variables: LDH and GS levels, RFT production, lipid peroxidation, 
and DNA fragmentation. Drugs such as CBZ, TPM, and OXC caused oxygen stress what-
ever their dose. GBP, LEV, LTG, and TGB, on the other hand, caused no significant metabolic 
changes whether given in large or small doses. Cortical astrocytes seem to tolerate this latter 
group of AEDs better than the former group.
In a similar model of rat cortical cell culture, VPA was found to protect against the negative 
effects of oxygen stress [47]. Administration of VPA for 7 days prevented lipid and protein 
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oxidization anomalies. The authors think that by preventing the accumulation of free radicals, 
VPA affects one or more of the neuroprotective processes.
VPA is a relatively safe drug, but it can sometimes be related to allergic idiosyncratic hepa-
topathy, a rare condition but more frequent in children less than 2 years of age taking more 
than one type of AED. The mechanism of toxic hepatopathy is unknown, but it has been 
suggested that it is caused by oxygen stress which leads to excessive RFT production and 
reduction of total antioxidant capacity [48, 49]. Therefore, therapeutic strategies or specific 
medicines that reduce oxygen stress may protect against toxic hepatopathy in patients taking 
VPA. Sabayan et al. [49] have hypothesized that garlic (allium) preparations may prevent this 
liver damage by removing free radicals and preventing the reduction of glutathione activity 
which accompanies the treatment with VPA.
TPM with its many mechanisms of action has undoubted effectiveness in the treatment of 
epilepsy in children. However, TPM administered in rat stomachs for 3 months may lead to 
such adverse effects as toxic liver dysfunction [50]. In a study of young rats, it was found that 
small doses of TPM (40 mg/kg a day) might reduce total antioxidant capacity in the organism 
and lead to a minor liver pathology. Large doses of TPM (80 mg/kg a day) or a combination of 
TPM (40 mg/kg) and VPA (300 mg/kg a day) significantly increased the risk of such adverse 
effects. Glutathione levels in the liver were significantly lower in the rats given large doses of 
TPM and in the rats on the TPM + VPA regime than that in the rats taking small doses of TPM 
and the controls given only distilled water. Histopathological examination also revealed dis-
seminated punctual necrosis as well as lipid and degenerative changes in some hepatocytes.
In this same model, TPM (40 and 80 mg/kg i.p.) had no effect either on rats’ status epilepticus 
or mortality, but larger doses significantly reduced KA-evoked lipid peroxidation [51].
LEV (2000 mg/kg i.p.) administered prior to pilocarpine administration (400 mg/kg s.c.) in 
mice prevented peroxidation increase in the hippocampus (but did not increase the nitrate 
level or reduce catalase activity in the hippocampus or cortical glutation) [52]. Perhaps the 
anti-oxidizing, neuroprotective effect of LEV and the consequent reduction of oxygen stress 
can be attributed to a different mechanism than the one which is active in the case of other 
AEDs.
In the KA convulsion model in rats, pre-convulsion administration of zonisamide led to an 
increased antioxidant level in the hippocampus [53]. The authors think that zonisamide has 
neuroprotective properties against free radicals.
LTG does not lead to detectable increases in lipid peroxydation in rats in vivo [54]. The antiep-
ileptic effectiveness of LTG in the partial complex epilepsy model (stimulation of the dentate 
gyrus) in rats was in reverse proportion to the level of activity of nitrogen oxide [55].
3.2. AEDs in human epilepsy
When used in human epilepsy, AEDs have various but equivocal effects on the oxidization 
processes [7, 22]. The authors studied the effects of epilepsy and prolonged AED treatment 
(CBZ, PHT, and VPA) on the levels of trace elements, electrolytes, and oxidization and 
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(21%). On the other hand, vitamin E concentration in the cerebral cortex was reduced (15%) 
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oxidization anomalies. The authors think that by preventing the accumulation of free radicals, 
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LTG does not lead to detectable increases in lipid peroxydation in rats in vivo [54]. The antiep-
ileptic effectiveness of LTG in the partial complex epilepsy model (stimulation of the dentate 
gyrus) in rats was in reverse proportion to the level of activity of nitrogen oxide [55].
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When used in human epilepsy, AEDs have various but equivocal effects on the oxidization 
processes [7, 22]. The authors studied the effects of epilepsy and prolonged AED treatment 
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anti-oxidization activity in the blood serum in 70 patients with epilepsy and 14 untreated 
patients with epilepsy (controls) [7, 22]. They found increased Zn, Ca, Na, MDA, and GSH-Px 
and reduced copper, ceruloplasmin, and total antioxidant capacity in the treated patients 
(especially in those treated with VPA); treatment had no effect on the levels of Se, Mg, and 
K. In the untreated patients with epilepsy, uric acid (a powerful free oxygen radical scaven-
ger) was elevated but the total antioxidant capacity in the serum was reduced, suggesting that 
different antioxidants had different activities in this epileptic group.
According to these authors, some nutrients may have a positive effect on the reduction of sei-
zure frequency (vitamin B6, vitamin E, Mg, Mn, taurine, glycine, omega-3 fatty acids; vitamin 
B1 may improve cognitive functioning in patients with epilepsy).
In order to prevent the negative effects of LPP, prophylactic or therapeutic replenishment 
of folic acid, vitamin B6, vitamin D, and l-carnitine may be advisable. Vitamin K is recom-
mended toward the end of pregnancy in women taking AEDs. In some cases melatonin may 
reduce seizure frequency. However, supplementation can very seldom substitute AEDs com-
pletely [56].
Mahle and Dasgupta [1] found that PHT monotherapy significantly increased lipid hydro-
peroxidase in blood serum concentration compared with the control group. The total blood 
serum antioxidant capacity was lower in patients than in healthy controls. These researchers 
found a weak correlation between lipid hydroperoxidase concentrations, trygliceridemia, and 
cholesterol level in the serum of patients with epilepsy.
The negative consequences of oxygen stress in the serum were significantly larger in women 
with epilepsy treated with PHT monotherapy than in healthy women and women with 
untreated epilepsy [57]. According to the authors, as an addition to glutathione to PHT treat-
ment, modification of the activity of CuZn-SOD enzymes and reduction of copper absorption 
during pregnancy may prevent the incidence of the aforementioned, albeit somewhat con-
troversial, fetal phenytoin syndrome [58]. PHT is very rarely administered to patients with 
epilepsy in Poland (1–2%) and probably only exceptionally to epileptic women in reproduc-
tive (childbearing) age.
Comparative studies of the effects of PHT and CBZ monotherapies found a significant 
increase in the blood serum level of MDA and CuZn-SOD and a significant reduction of glu-
tathione in patients treated with PHT compared with a healthy control group and a group 
with untreated epilepsy [59]. No differences were found for CBZ except for a slight increase 
in CuZn-SOD activity. All in all compared with PTH, CBZ caused fewer interferences with 
antioxidant activity, lipid peroxidation, and level of trace elements (Cu, Zn).
VPA used in monotherapy for 60 days in 50 children with epilepsy (mean age 8.5 ± 3.6 years) 
led to liver dysfunction, free radical production, and DNA oxidation injury in the liver cells 
and neurons. The general oxidation state, measured by the level of 8-hydroxy-2-deoxyguano-
sine (8-OHdG), depended on the drug dose [60]. A linear relation was found between the 
VPA serum level and the lipid peroxidation magnitude. In a group of children with a VPA 
concentration 114 ± 9.7 μg/ml, peroxidation was significantly higher than in a control group 
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of children with a VPA concentration 81.0 ± 8 μg/ml. Free radicals caused DNA oxygen injury 
due to a significant increase in the serum level of 8-OHdG, which may be a good biological 
indicator of increased risk of VPA-evoked degeneration.
Other researchers have also found a linear relation between lipid peroxidation and the VPA 
level in the plasmas of patients with epilepsy [4]. They measured lipid peroxidation spec-
trofluorometrically, before and after Fenton reaction evocation, in 75 patients and 4 healthy 
controls. Interestingly, lipid peroxidation was higher in patients with partial epilepsy than 
in patients with generalized epilepsy and higher in women than men. Gender differences in 
oxygen stress effects have also been found in PHT-treated patients with epilepsy [57], PTZ rat 
models [35], and hippocampal sections in patients [61].
A comparative study of the effect of 2-year VPA and CBZ monotherapies on changes in the 
antioxidant system in children with epilepsy found significant differences in the effects of 
both AEDs [62]. The researchers measured the level of glutation, GSH-Px, red blood cell SOD, 
and serum lipid peroxidation. They studied two groups: (1) 25 healthy children and (2) 27 
children with epilepsy untreated prior to the study onset, 14 of whom were treated with VPA 
and 13 with CBZ. The treatment lasted 2 years. Laboratory tests were conducted in treatment 
months 13 and 24. The antioxidant systems in the children taking VPA for 2 years were more 
altered than the antioxidant systems of the children taking CBZ.
Another comparative study of the effects of CBZ and VPA on epileptic children found no dif-
ferences in the serum concentrations of Cu, Zn, Mn, Se, and Mg [24]. The only difference was 
found for the GSH-Px activity which was significantly higher in the VPA group. There were 
no differences in the SOD levels.
A more recent comparative study of the effect of VPA, CBZ, and PB monotherapies on the oxi-
dation and anti-oxidation systems in children with epilepsy yielded slightly different results 
[6]. The control groups consisted of children with untreated epilepsy and healthy children. 
The researchers found that the level of total antioxidant capacity in the serum was signifi-
cantly reduced in the group with untreated epilepsy compared with the healthy group. The 
level of peroxidation was significantly elevated in both the untreated group with epilepsy 
and the CBZ treatment group compared with the healthy controls. The pattern of results was 
similar for the children treated with PB and for the control group. According to the authors, 
children with epilepsy are at risk of oxygen stress due to seizures and AEDs. Their oxidation 
and anti-oxidation processes are unbalanced. VPA restores this balance more effectively than 
CBZ or PB.
Bolayir et al. [63] studied the effect of OXC on anti-oxidation processes in 13 adult patients 
with epilepsy prior to monotherapy and after 1 year of monotherapy. They also studied 15 
healthy controls. They measured lipid peroxidation activity, SOD, GSH-Px, and catalase in 
the red blood cells. The patients had significant differences in the levels of GSH-Px and SOD 
after 1 year of treatment compared with the pre-treatment levels. The MDA level was also 
significantly different from the level of the control group and from that assessed before the 
treatment. These findings suggest that the anti-oxidation systems in patients treated with 
OXC are negatively affected after 1 year of treatment.
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peroxidase in blood serum concentration compared with the control group. The total blood 
serum antioxidant capacity was lower in patients than in healthy controls. These researchers 
found a weak correlation between lipid hydroperoxidase concentrations, trygliceridemia, and 
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with epilepsy treated with PHT monotherapy than in healthy women and women with 
untreated epilepsy [57]. According to the authors, as an addition to glutathione to PHT treat-
ment, modification of the activity of CuZn-SOD enzymes and reduction of copper absorption 
during pregnancy may prevent the incidence of the aforementioned, albeit somewhat con-
troversial, fetal phenytoin syndrome [58]. PHT is very rarely administered to patients with 
epilepsy in Poland (1–2%) and probably only exceptionally to epileptic women in reproduc-
tive (childbearing) age.
Comparative studies of the effects of PHT and CBZ monotherapies found a significant 
increase in the blood serum level of MDA and CuZn-SOD and a significant reduction of glu-
tathione in patients treated with PHT compared with a healthy control group and a group 
with untreated epilepsy [59]. No differences were found for CBZ except for a slight increase 
in CuZn-SOD activity. All in all compared with PTH, CBZ caused fewer interferences with 
antioxidant activity, lipid peroxidation, and level of trace elements (Cu, Zn).
VPA used in monotherapy for 60 days in 50 children with epilepsy (mean age 8.5 ± 3.6 years) 
led to liver dysfunction, free radical production, and DNA oxidation injury in the liver cells 
and neurons. The general oxidation state, measured by the level of 8-hydroxy-2-deoxyguano-
sine (8-OHdG), depended on the drug dose [60]. A linear relation was found between the 
VPA serum level and the lipid peroxidation magnitude. In a group of children with a VPA 
concentration 114 ± 9.7 μg/ml, peroxidation was significantly higher than in a control group 
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oxygen stress effects have also been found in PHT-treated patients with epilepsy [57], PTZ rat 
models [35], and hippocampal sections in patients [61].
A comparative study of the effect of 2-year VPA and CBZ monotherapies on changes in the 
antioxidant system in children with epilepsy found significant differences in the effects of 
both AEDs [62]. The researchers measured the level of glutation, GSH-Px, red blood cell SOD, 
and serum lipid peroxidation. They studied two groups: (1) 25 healthy children and (2) 27 
children with epilepsy untreated prior to the study onset, 14 of whom were treated with VPA 
and 13 with CBZ. The treatment lasted 2 years. Laboratory tests were conducted in treatment 
months 13 and 24. The antioxidant systems in the children taking VPA for 2 years were more 
altered than the antioxidant systems of the children taking CBZ.
Another comparative study of the effects of CBZ and VPA on epileptic children found no dif-
ferences in the serum concentrations of Cu, Zn, Mn, Se, and Mg [24]. The only difference was 
found for the GSH-Px activity which was significantly higher in the VPA group. There were 
no differences in the SOD levels.
A more recent comparative study of the effect of VPA, CBZ, and PB monotherapies on the oxi-
dation and anti-oxidation systems in children with epilepsy yielded slightly different results 
[6]. The control groups consisted of children with untreated epilepsy and healthy children. 
The researchers found that the level of total antioxidant capacity in the serum was signifi-
cantly reduced in the group with untreated epilepsy compared with the healthy group. The 
level of peroxidation was significantly elevated in both the untreated group with epilepsy 
and the CBZ treatment group compared with the healthy controls. The pattern of results was 
similar for the children treated with PB and for the control group. According to the authors, 
children with epilepsy are at risk of oxygen stress due to seizures and AEDs. Their oxidation 
and anti-oxidation processes are unbalanced. VPA restores this balance more effectively than 
CBZ or PB.
Bolayir et al. [63] studied the effect of OXC on anti-oxidation processes in 13 adult patients 
with epilepsy prior to monotherapy and after 1 year of monotherapy. They also studied 15 
healthy controls. They measured lipid peroxidation activity, SOD, GSH-Px, and catalase in 
the red blood cells. The patients had significant differences in the levels of GSH-Px and SOD 
after 1 year of treatment compared with the pre-treatment levels. The MDA level was also 
significantly different from the level of the control group and from that assessed before the 
treatment. These findings suggest that the anti-oxidation systems in patients treated with 
OXC are negatively affected after 1 year of treatment.
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3.3. Dietary management in epilepsy
The idea that a specific way of eating can affect epilepsy was (recognized) first postulated by 
Hippocrates, who noticed that fasting could prevent convulsions [64]. All forms of dietary 
therapy that can be used for epilepsy involve ketogenic [65–68] medium-chain triglyceride, 
modified Atkins, and low-glycemic index diets that restrict carbohydrates and increase fat in 
the diet. However, most of these metabolic treatments for epilepsy can cause some side effects 
and nutritional deficiencies such as diarrhea, constipation, nausea, vomiting, and increased 
acid reflux. There is growing interest in ketogenic diet and it is available in many countries. 
The reasons why ketogenic diet prevents seizure are not fully understood. One hypothesis 
is that the ketones produced by the diet are able to enter the brain and reduce the levels of 
reactive oxygen species and make the brain use energy more efficiently, resulting in fewer 
seizures [69, 70]. It has been shown that ketogenic diet can produce a significant reduction in 
seizure frequency in the elderly as well [66, 71, 72].
3.4. Vitamins and minerals
Long-term use of antiepileptic drugs can affect the vitamin and mineral status in epilepsy 
patients. Antiepileptic drugs have been shown to decrease the levels of the B group vitamins 
such as folate and vitamins B6 and B12 [73, 74], which are important for controlling the metabo-
lism. For example, the low folate levels caused by AEDs lead to high levels of homocysteine, 
a risk factor for heart disease [74–76]. Epileptic patients have reduced folic acid levels due 
to the use of AEDs [77]. It has been reported that epileptic patient using AEDs should be 
supplemented with B vitamins, especially with the metabolically active form of folic acid, 
l-methylfolate, to reduce the homocysteine levels [78].
Significantly lower levels of vitamin D are found in the blood of patients taking antiepileptic 
drugs. The explanation is that the use of AEDs increases the liver enzyme activity of cyto-
chrome P450, which is involved in breaking down of vitamin D [79–83]. Therefore, patients 
who are taking AEDs may need to take vitamin D and calcium supplements [84].
Pyridoxine-dependent epilepsy is a rare autosomal recessive disorder characterized by a 
combination of various seizure types that usually occurs during the first hours of life and 
is unresponsive to standard anticonvulsants, responding only to immediate administration 
of pyridoxine hydrochloride (vitamin B6) [85–87]. However, not all types of seizures can be 
treated with pyridoxine, but a potentially effective option is the biologically active form of 
vitamin B6 (pyridoxal-5-phosphate) [88–90].
Other antioxidants that have been reported to have the capacity to mitigate mitochondrial 
oxidative stress in the brain and lower seizure frequency in epilepsy include vitamin E, vita-
min C, and selenium [91–97]. Vitamin E is shown to prevent several types of seizures in ani-
mal models [98, 99]. Epileptics are also more likely to have low vitamin E levels, though this 
may be a result of taking antiepileptic drugs [100].
Magnesium is essential for enzyme function including ATP-generating reactions [101]. It 
stimulates the production of prostacyclin and nitric oxide [102], supports mitochondrial 
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integrity, and modulates ion transport [103, 104]. Magnesium has been shown to be associated 
with many health conditions; for example, it is essential for brain function and development 
[105, 106]. Epileptics have significantly lowered serum magnesium levels, and the seizure 
activity correlates with the level of hypomagnesemia [107–109].
3.5. Melatonin
Numerous studies on melatonin conducted over the last 30 years have confirmed that this 
neurohormone is susceptible to circadian rhythms, has antioxidant properties, and modulates 
immunological activity [110]. Melatonin affects the blood platelets and prolongs their life. It is 
transported by platelets to all body tissues. Thanks to its lipophilic function, it crosses the cell 
membranes easily, regulates blood-tissue exchange, and interacts with the endothelial cells. 
Platelets can behave like mobile and wandering serotonergic and/or melatonergic elements, 
comparable with cerebral neurotransmitter release [111].
Melatonin was found to be a potent free radical scavenger, and therefore it reduces oxygen 
stress and prevents excessive arousal from injured neurons as demonstrated with various 
animal models and humans.
The neuroprotective effect of melatonin was confirmed in a randomized, double-blind trial 
with epileptic children receiving VPA monotherapy [112]. The researchers administered VPA 
+ melatonin to 15 children and VPA + placebo to 14 children for 14 days. The posttest GSS-R 
level was significantly higher (p = 0.05) in the VPA + melatonin group, and the percentile dif-
ference in the value of this enzyme was also significant (p = 0.005).
Gupta et al. [113] found that CBZ and VPA administered in monotherapy to 22 children with 
epilepsy had differential effects on the blood serum levels of melatonin. In both groups the 
researchers measured endogenous and exogenous melatonin 30 min after administration. The 
serum level of melatonin was higher in the CBZ group (165 pg/ml ± 50–350) than in the VPA 
group (78 pg/ml ± 13–260). The authors think that these differences in the level of melato-
nin can be attributed to different effects of these two AEDs, additional epilepsy and CBZ-
dependent RFT increase, or differences in melatonin kinetics in conditions of oxygen stress. In 
a study by the present author [29], adding melatonin to the patients’ regular AED for several 
weeks did not affect seizure frequency in cases in which the course of the epilepsy was severe.
3.6. Selenium
The neuroprotective effect of selenium, one of the trace elements, is related to selenoproteins 
which are antioxidants [114]. Selenium insufficiency has been found in young children with 
severe mental retardation and drug-resistant epilepsy [115]. Oral administration of selenium 
(3–5 μg/kg m.c.) reduced seizure frequency, improved EEG recordings, and normalized liver 
activity. In another study, the serum level of selenium in 30 patients with intractable epilepsy 
was also lower (66.88 ng/ml ± 17.58) than in healthy controls matched for age, socioeconomic 
status, and place of residence (85.93 ng/ml ± 13.93) (p < 0.05) [116]. However, the low selenium 
level in the blood serum did not correlate with the measured risk factors for drug-resistant 
epilepsy: age of onset, infant seizures, neurological disorder, or etiology of epilepsy.
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group (78 pg/ml ± 13–260). The authors think that these differences in the level of melato-
nin can be attributed to different effects of these two AEDs, additional epilepsy and CBZ-
dependent RFT increase, or differences in melatonin kinetics in conditions of oxygen stress. In 
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3.6. Selenium
The neuroprotective effect of selenium, one of the trace elements, is related to selenoproteins 
which are antioxidants [114]. Selenium insufficiency has been found in young children with 
severe mental retardation and drug-resistant epilepsy [115]. Oral administration of selenium 
(3–5 μg/kg m.c.) reduced seizure frequency, improved EEG recordings, and normalized liver 
activity. In another study, the serum level of selenium in 30 patients with intractable epilepsy 
was also lower (66.88 ng/ml ± 17.58) than in healthy controls matched for age, socioeconomic 
status, and place of residence (85.93 ng/ml ± 13.93) (p < 0.05) [116]. However, the low selenium 
level in the blood serum did not correlate with the measured risk factors for drug-resistant 
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The clinical implications of these results, and those quoted above, should be interpreted care-
fully because epilepsy is such a complex and heterogeneous disease, as suggested by the 
findings reviewed in this article.
3.7. Drug-resistant epilepsy: polytherapy
Drug-resistant seizures force the physician to use polytherapy with various AEDs. Polytherapy 
increases the production of free radicals and disturbs mineral balance to a greater extent than 
monotherapy, leading to increased oxygen stress. Both increased free radical production and 
inhibition of the enzymes that remove scavengers lead to adverse states and aggravation of 
the morbid process [22, 117].
Patients with epilepsy and on long-term AED therapy are at greater risk of atherosclerotic 
changes in the arteries [118]. Metabolic dysfunctions in these patients have been attributed 
to altered homocysteine, lipid and lipoprotein metabolism, and uric acid. According to the 
authors, these dysfunctions are indications for routine antioxidant multivitamin supplemen-
tation (folic acid, B12, B6, C and E, and beta-carotene). The protective, anti-atheromatic effect 
of vitamins is based on their antioxidant and anti-inflammatory properties. However, in the 
other research quoted above, increased lipid hydroperoxidase concentration had only weak 
correlations with the risk factors for vascular changes (triglyceridemia, cholesterolemia) [1].
Tupeev et al. [119] found a positive effect of prolonged vitamin E treatment (600 mg/day) 
in patients with generalized seizures: seizure frequency was reduced, EEG improved, and 
antioxidant activity increased.
Assuming that AEDs can trigger free radical production and lipid peroxydation, Hung-Ming 
et al. [23] studied the effects of TW970, a modified version of the Chinese herbal specific 
chaihu-longu-muli-tang which has antiepileptic and antioxidant properties. They administered 
it for 4 months to 3 groups of patients: (1) 20 patients with drug-resistant epilepsy (at least 4 
attacks a month), (2) 20 patients with mild epilepsy (fewer than 4 attacks a month), and (3) 
a control group of 20 healthy adults matched for age. The patients were tested prior to the 
introduction of TW970 and 4 months after the introduction. In the resistant group, seizure 
frequency dropped from 13.4 ± 3.4 to 10.7 ± 2.5 a month, but the difference was not significant 
(p = 0.084). Prior to the TW970 introduction, the resistant epilepsy group had significantly 
higher lipid peroxidation and increased MDA and CuZn-SOD activity, including reduced 
glutathione, compared with the healthy control group. After 4 months of TW970 treatment, 
the levels of MDA and CuZn-SOD normalized in the resistant epilepsy group, whereas no 
significant changes in the parameters were found in the mild epilepsy group, either prior to 
or following TW970 therapy. The authors suggest that TW970 may reduce seizure frequency 
in resistant epilepsy and that antioxidants may be responsible for this effect.
Many Native American plants are valued by local medical practitioners for their positive 
effects on health and a number of diseases, including epilepsy: Celastrus paniculatus L. (CP), 
Picrorhiza kurroa (PK), and Withania somnifera L. (WS). It has been found that extracts of these 
plants are dose-dependent free radical scavengers and that they prevent DNA injury due to 
oxygen stress. PK extract had a more powerful effect than CP or WS. These favorable biological 
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properties have been attributed to anti-stress, immune-modulating, anti-inflammatory, and 
antiaging effects [120].
3.8. The effects of surgery on AED-resistant temporal lobe epilepsy
López et al. [121] studied the activity of antioxidant enzymes (SOD, catalase, and GSH-Px) 
and markers of oxygen stress-induced molecular neuronal injury (MDA and RFT) before 
and at various moments after epileptic focus resection in 9 patients and a control group 
of 32 healthy individuals. All the studied variables normalized postoperatively except the 
SOD activity. Several other interesting observations seem to be somewhat related to these 
findings. Turkdogan et al. [122] found that increased lipid peroxidation in the plasma may 
be causally related to the presence of abnormal structural changes of the brain, as assessed 
by magnetic resonance (MR) rather than to the treatment of epilepsy, focal or generalized 
epileptic discharges in the EEG, duration of epilepsy, or to seizure frequency (more or fewer 
than 1 seizure a month). The authors found an increase in serum lipid peroxidation in 52 
children with epilepsy, treated with one or more AEDs and with an abnormal brain MR, 
compared with 16 healthy children (the difference was significant, p < 0.05). No significant 
differences in antioxidant enzymes were found in either group. The children with well-con-
trolled seizures and the ones with drug-resistant seizures but normal MRs had higher SOD 
activity than the children in the control group (p < 0.05). GSH-Px (an antioxidant) activity 
was not significantly different among the children with epilepsy and the control group [123]. 
This interesting and heterogeneous picture of enzymatic activity in children with epilepsy 
and control children suggests that the relations between various laboratory tests and numer-
ous variables associated with the heterogeneity and treatment of epilepsy are very complex. 
Although the authors took seizure frequency into consideration, they did not specify when 
the blood tests were taken relative to the experienced or imminent seizure nor did they 
report EEG recording of epileptic activity prior to the blood test. This makes it very difficult 
to interpret the causal relations among the results of the various tests and their epileptic 
correlates.
4. Conclusions
Epilepsy is a brain disease that has been linked with abnormal brain oxidation processes. 
Despite a vast spectrum of anticonvulsant therapies toward halting abnormal electrical activ-
ity in the brain, it may be suggested that antioxidants can perhaps in the future play a role 
in controlling seizures. Therefore, further study is necessary, in order to display whether 
widely accessible antioxidants such as vitamin C or vitamin E in fact possess the ability to 
synergistically act with anticonvulsant medications and whether this combination can result 
in improved control of epilepsy.
1. Research on animal models and patients with epilepsy suggests that both epileptic sei-
zures and AEDs (especially polytherapy), as well as other factors evoking oxygen stress, 
have a negative effect on the oxidation-anti-oxidation balance.
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the levels of MDA and CuZn-SOD normalized in the resistant epilepsy group, whereas no 
significant changes in the parameters were found in the mild epilepsy group, either prior to 
or following TW970 therapy. The authors suggest that TW970 may reduce seizure frequency 
in resistant epilepsy and that antioxidants may be responsible for this effect.
Many Native American plants are valued by local medical practitioners for their positive 
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Picrorhiza kurroa (PK), and Withania somnifera L. (WS). It has been found that extracts of these 
plants are dose-dependent free radical scavengers and that they prevent DNA injury due to 
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of 32 healthy individuals. All the studied variables normalized postoperatively except the 
SOD activity. Several other interesting observations seem to be somewhat related to these 
findings. Turkdogan et al. [122] found that increased lipid peroxidation in the plasma may 
be causally related to the presence of abnormal structural changes of the brain, as assessed 
by magnetic resonance (MR) rather than to the treatment of epilepsy, focal or generalized 
epileptic discharges in the EEG, duration of epilepsy, or to seizure frequency (more or fewer 
than 1 seizure a month). The authors found an increase in serum lipid peroxidation in 52 
children with epilepsy, treated with one or more AEDs and with an abnormal brain MR, 
compared with 16 healthy children (the difference was significant, p < 0.05). No significant 
differences in antioxidant enzymes were found in either group. The children with well-con-
trolled seizures and the ones with drug-resistant seizures but normal MRs had higher SOD 
activity than the children in the control group (p < 0.05). GSH-Px (an antioxidant) activity 
was not significantly different among the children with epilepsy and the control group [123]. 
This interesting and heterogeneous picture of enzymatic activity in children with epilepsy 
and control children suggests that the relations between various laboratory tests and numer-
ous variables associated with the heterogeneity and treatment of epilepsy are very complex. 
Although the authors took seizure frequency into consideration, they did not specify when 
the blood tests were taken relative to the experienced or imminent seizure nor did they 
report EEG recording of epileptic activity prior to the blood test. This makes it very difficult 
to interpret the causal relations among the results of the various tests and their epileptic 
correlates.
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Epilepsy is a brain disease that has been linked with abnormal brain oxidation processes. 
Despite a vast spectrum of anticonvulsant therapies toward halting abnormal electrical activ-
ity in the brain, it may be suggested that antioxidants can perhaps in the future play a role 
in controlling seizures. Therefore, further study is necessary, in order to display whether 
widely accessible antioxidants such as vitamin C or vitamin E in fact possess the ability to 
synergistically act with anticonvulsant medications and whether this combination can result 
in improved control of epilepsy.
1. Research on animal models and patients with epilepsy suggests that both epileptic sei-
zures and AEDs (especially polytherapy), as well as other factors evoking oxygen stress, 
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2. AEDs and drug dosage have a differential effect on oxygen stress. The research findings 
are equivocal or even contradictory, however, with respect to the different AEDs. New 
AEDs usually have a more favorable effect on the oxidation and anti-oxidation enzyme 
balance and trace element and electrolytic homeostasis.
3. Neuroprotectors (trace elements, vitamins, and other antioxidants) help to reduce seizure-
induced oxygen stress, and therefore it is suggested that they should be used to supple-
ment AED treatment.
4. The fact that AEDs can lead to oxidation-anti-oxidation imbalance suggests that we need 
to adopt a new approach to the treatment of epilepsy and AED synthesis. We need to take 
the negative effects of oxygen stress into consideration.
5. No drug is completely safe and effective, and considering the complex and heterogeneous 
nature of epilepsy, it is evident that the optimal treatment of each individual case requires 
a carefully performed diagnosis and the application of research-based therapy, which 
includes the use of personalized medicine as well as drugs. Genes are influenced by the envi-
ronment and therapy. The value of food as medicine was acknowledged several centuries 
ago. Therefore, monitoring genomic information, pharmacogenomics, and the food-drug 
interactions is important as it helps to personalize the treatment to meet the patient’s needs.
6. It is important to know the patient’s specific characteristics including previous history, life-
style, age, gender, weight, diet, environment, etc. They can be valuable tools to improve the 
quality of life of the epileptic. Targeted medicine/personalized medicine is the concept of 
managing the patients’ health. It is believed that Hippocrates (c. 460 BC–c. 370 BC) was the 
one who applied this idea to medicine. He is best remembered today for his famous Oath “It’s 
far more important to know what person the disease has than what disease the person has.”
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Abstract
Personalized care, which includes personalized medicine, personalized nutrition, and 
even personalized exercise, is a useful and a more effective method for the treatment 
and control of lifestyle diseases such as type 2 diabetes and cardiovascular diseases. The 
relationship between nutrients, diet and gene expression (commonly called as nutritional 
genomics or nutrigenomics) and precision or personalized medicine have received con-
siderable attention of researchers, clinicians, drug developers, practitioners of traditional 
system of medicine, and regulatory agencies over the years. Many, if not all, of the com-
mon human debilitating conditions including cancer, obesity, cardiovascular diseases 
and diabetes are related directly or indirectly to an individual’s nutritional status and 
its genetic make up. Understanding the interplay between diet and genes may help 
provide direction upon which personalized therapy can be used for the treatment and 
management of these catastrophic life-threatening conditions, including strategies for 
their prevention. In this era of human healthcare where the diagnosis of the disease and 
treatment of the patient are perceived to be patient-tailored, due to the differences in the 
genetic make-up of individuals and their lifestyle, personalized human healthcare could 
be the most effective method for the treatment and prevention of debilitating diseases 
with a high morbidity and mortality. This chapter provides an insight into the potential 
of individualized care in life-threatening complications.
Keywords: individualized care, precision medicine, lifestyle diseases, chronic 
inflammatory diseases
1. Introduction
Personalized or individualized care, which includes personalized medicine, as well as person-
alized nutrition and even personalized exercise, is an individual (patient)-centric, integrative, 
and holistic approach for the treatment and management of lifestyle diseases. Personalized 
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care, a term often used interchangeably with precision medicine (an essential piece of personal-
ized care which specifically refers to the medical treatment of the patient) is a more comprehen-
sive term (than personalized or precision medicine) that represents an overarching philosophy 
for patient care, taking the advantage of personalized medicine and pharmacogenomics, as 
well as personalized nutrition and exercise. Personalized medicine, as defined by Schleidgen 
et al. [1] as an emerging area of medical care seeking to improve stratification and timing of 
healthcare by utilizing biological information and biomarkers on the level of molecular disease 
pathways, genetics, proteomics, as well as metabolomics, is an essential piece of personalized 
care. The key issue of personalized or individualized medicine remains how a targeted therapy 
can be used to tackle rapidly increasing chronic health burden by maximizing therapeutic effi-
cacy and minimizing drug toxicity risks for an individual. Since the completion of the human 
genome project in the year 2000, the field has continued to evolve over the years especially 
from pharmacogenetics to pharmacogenomics so as to effectively monitor the multigenic effect 
on drug response [2]. Realization of the limitation of pharmacogenetics leads to the emergence 
of pharmacogenomics, which determines how genes affect a person’s response to drugs. This 
has opened up avenues for individualized identification of genetic variants using wide genome 
approaches through the use of latest and most recent methods, thus providing ways for deter-
mining molecular targets with the help of available DNA-based diagnostic screening tools [3].
A growing body of evidence has shown that chronic human diseases and conditions such as 
type 2 diabetes (T2D), cardiovascular diseases (CVD), atherosclerosis, obesity, and metabolic 
syndrome are associated with unhealthy lifestyle, which includes bad eating habits, physi-
cal inactivity, smoking, and exposure to stress [4]. A lifestyle modification with personalized 
nutrition and personalized physical activity is believed to play a central role in the prevention, 
management, and treatment of these life-threatening conditions [5]. Currently over 2500 genetic 
tests are available for the detection of diseases [6]. Ongoing efforts are being made to determine 
genetic risk of individuals to some of these diet-related conditions, like T2D and obesity, through 
available testing and screening methods so as to minimize the public health burden [7, 8]. Newer 
methods involving nanodiagnostic tools such as the DNA-based bionanosensors have recently 
emerged and are presumed to be safe and cost-effective with high specificity for early detection 
of the disease [9]. There is a vital need to educate the patients by the physicians and healthcare 
workers including the dietitians on the benefits of a well-balanced diet since failure to meet the 
nutritional requirements results in an array of conditions that occur due to the deficiency of 
certain nutrients. For example, the deficiencies of vitamins and minerals such as zinc, selenium, 
magnesium, chromium, and iron deficiencies have been reported in conditions like diabetes [10] 
and cystic fibrosis [11], especially among children. More recently, boron is getting recognition as 
an important trace element that may contribute significantly by mitigating the harmful effects 
in at least some of these diseases by augmenting the innate immune response and other mecha-
nisms, such as stabilizing the complex membrane and macromolecular structures. Nutrient, 
especially the micronutrient deficiencies in early childhood or at a later stage may result in great 
economic burden that can lower a country’s GDP [12]. Individualized nutrition and personal-
ized care have the potential of a positive impact on the healthcare sector with certain changes in 
the system [13]. Some of the required changes may involve largely policy issues and healthcare 
infrastructural changes [14], as well as economic changes [15, 16] to lower the cost of medication.
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2. Lifestyle diseases
Lifestyle factors such as bad eating habits, sedentary lifestyle, high-calorie diet and excessive 
alcohol intake increase the rate at which some or most chronic human diseases develop. Most 
of these diseases, which include cancer, diabetes and atherosclerosis, are a leading cause of 
death and pose great health and economic burden to the country [17]. Prevalence of diabe-
tes, in particular, continues to increase in the world. Diabetes is projected to be the seventh 
leading cause of death by the year 2030 [18]. Lifestyle changes such as personalized exercise 
(physical activity), personalized diet (nutrigenomics), and relaxation techniques (meditation 
and yoga) can help prevent or at least minimize the occurrence, as well as the prevalence, of 
these diseases [4].
Lifestyle changes and somewhat drug intervention have profound effect on the development 
and progression of chronic human diseases, including the disease progress, for example, from 
the prediabetes stage to diabetes, or even diabetes-associated complications. However, it is 
not clear who may or may not respond appropriately to a particular therapy. This is because 
individuals are different. Lifestyle changes like healthy eating and physical activity can do a lot 
of wonder in preventing chronic diseases when coupled with individual awareness to disease 
through genetic risk testing and other methods. Personalized or individualized nutrition holds 
great promise in the future and can be used to identify associations between genes, nutrients, 
and a disease so as to improve public health [19].
3. Diet-related chronic conditions
3.1. Diet and physical activity
Diet and (lack of) physical activity constitute some of the major contributory factors for 
the development of chronic illnesses, both noncommunicable and communicable, directly 
impacting the immune system of the body and metabolism. Diseases like tuberculosis fail to 
develop if an individual’s lifestyle is healthy with respect to diet and physical activity. In diet-
related complications such as obesity and T2D, a complex interplay of several factors includ-
ing both genetic predisposition and lifestyle of an individual has been reported [5, 19]. These 
factors can have serious devastating effects on health, as the appearance of one disease may 
increase the chance for another disease; for example, obesity alone may lead to an increase in 
T2D and CVD [20].
Diet-related diseases are generally chronic in nature and are often associated with age 
and type of diet (nutrition) [21]. Personalizing diet, i.e., increasing the nutritional qual-
ity of diet and genotyping (nutrigenomics), leads to achieving a better health [22]. Earlier, 
global guidelines on food, certain food groups, and other nutrient requirements of the 
population were recommended with the overall view of preventing or delaying the onset 
of diet-related diseases. Nowadays, with an increased understanding of genetic differences 
pertaining to nutritional requirements among individuals, scientists are making efforts to 
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categorize these guidelines based on inter-individual variation in dietary response result-
ing in a personalized diet, thus preventing chronic diet-related conditions [21]. Over the 
years, a number of clinicians and researchers have tried to demonstrate the importance of 
dietary modifications to achieve healthy and sustainable weight loss among overweight 
and obese individuals. However, these attempts could not yield positive results because 
of different metabolic roles of macromolecules such as the lipid, protein and carbohydrate 
in energy homeostasis and differences in metabolism. These molecules have a great effect 
on metabolism, appetite, and thermogenesis, which support the idea of considering the 
fuel value provided by each macromolecule separately. At times, even when considered 
separately, nature and kind of food constituents matter. For example, a diet which can 
reduce the risk of T2D and CVD is important for people who already have the disease. In 
this case, a fiber-rich or nonstarch polysaccharide diet, like whole grain, legumes, fruits and 
vegetables, is the most appropriate diet.
A sedentary lifestyle equally contributes to lifestyle diseases. It has been identified as a link 
between obesity, diabetes, metabolic syndrome, CVD, and death [23]. Physical inactivity is 
widely believed to be the primary cause of most preventable chronic conditions including 
diabetes, obesity and CVD. Therefore, physical activity may delay or prevent these and other 
chronic conditions [24]. Weight loss is recognized as one of the baseline strategies employed 
to deal with chronic inflammatory diseases like diabetes and CVD [25]. Obese individuals are 
overweight and prone to develop chronic inflammatory diseases. A holistic approach focus-
ing on changes in lifestyle including changes in diet to suit individual’s needs, and physical 
activity, together with compatible precision medicine and ridding of the bad habits is bound 
to have beneficial effect on the management and prevention of life-threatening diseases and 
associated complications.
3.2. Type 2 diabetes
Individuals with type 2 diabetes are often faced with insulin resistance (IR) challenge arising 
from an accumulation of triglycerides in adipose tissues. Studies have shown that weight loss 
can bring significant improvement in IR both in T2D and in those with impaired glucose toler-
ance [26]. Nonetheless, there is an array of inter-individual variations with regard to improve-
ment in insulin sensitivity and glycemia because of the individual response to changes in 
lifestyle factors such as the weight, diet and physical activity [5].
Increasing evidence has shown that single-nucleotide polymorphisms (SNPs) exist in diabe-
tes [27, 28], which gives a lot of scope for the treatment based on genetic characteristics of an 
individual. These genetic differences are considered as markers of diabetes risk as they can 
be used to predict the disease and also to determine diabetes onset [29]. Nearly 80 genetic 
loci are thought to influence genetic susceptibility to both types of diabetes. An integral part 
of diabetes management and self-management education, medical nutrition therapy (MNT), 
was designed to provide patients with specific care as well as guidelines on lifestyle changes 
an individual can make and maintain in order to improve health [30]. Once individuals’ basic 
nutritional requirements have been achieved, chances of developing disease are rare even for 
diabetics where nutrient supplementation may be an issue of concern [31].
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3.3. Obesity
Management of obesity consists of the ability to lose weight either through exercise or person-
alized nutrition (non-pharmacological), or may involve the use of drugs. Due to individual 
genetic makeup and myriad of environmental factors, different individuals respond differ-
ently to exercise; some may even show resistance [32, 33]. Personalized exercise may help 
prevent unwanted individual response. In addition, identification of specific polymorphisms 
such as obesity-related SNPs may help find differences in dietary response to caloric restric-
tion. Personalized nutrition is, therefore, expected to play a role in determining the kind and 
nature of diet suitable for different individuals owing to the environmental and genetic dif-
ferences. Many of the diet-associated health burdens have been linked to SNPs, which is used 
to predict individual response to drugs in a population [34]. The most common examples 
of these polymorphisms are leptin/leptin receptor polymorphism (related to obesity gene), 
apolipoprotein (E and A1), which is related to CVD, and methylenetetrahydrofolate reductase 
(MTHR) related to folate metabolism [35].
3.4. Cardiovascular diseases
Cardiovascular diseases (CVDs) are a group of metabolic diseases arising from atherosclero-
sis [36]. CVDs account for the most common cause of morbidity and mortality in the world 
[36], with poorly controlled diabetes as one of the promoting factors. Newer technologies 
involving large-scale genotyping and sequencing have allowed for identification of heri-
table CVD risks which can be used in personalized treatment. Epigenetics and personalized 
attempts are increasingly proving beneficial and providing a new way to treat CVDs [37]. In 
the near future, it is hoped that the DNA sequence variants associated with CVD or which 
show association with the beneficial or adverse effects of medication and used to predict 
CVD risk may be identified and guide the decision of choosing the best medication and dose 
to individual patients.
3.5. Cancer
Much of the successful personalized treatments have been recorded in the area of oncology 
with many tumors and cancers being targeted with individualized regimens. Today, the 
world is witnessing a rapid progress in the upcoming field of personalized medicine with 
the emergence of genotyping industry for screening/testing, leading to an increased use of 
of precision medicines for cancer therapy. Many of these drugs are already available in the 
market and include kinase inhibitors [38]. Imatinib, lapatinib and erlotinib are some selective 
kinase inhibitors which are used to target anaplastic lymphoma [38].
3.6. Oral health and related diseases
Genomic information is increasing our understanding of oral health by providing an under-
standing of the disease etiology, thereby allowing easier diagnostic and a chance to take 
preventive measures to avoid the onset of oral diseases [39]. This is possible when genome 
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categorize these guidelines based on inter-individual variation in dietary response result-
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3.3. Obesity
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analysis and disease risk assessment is started at childhood, as it gives room for proper plan-
ning for individualized prevention and monitoring strategies. By doing so, oral health and 
related problems like dental caries, periodontitis, and oral cancers may be detected at the 
onset and treated.
3.7. Osteoporosis
Osteoporosis is a complicated preventable syndrome that affects millions of peoples, espe-
cially women, in the world. Several personalized medicine intervention procedures are being 
investigated to identify the individuals with a high tendency to the disease. For instance, 
FRAX(R) is an algorithm that enables physicians to calculate the tendency for an individual 
patient risk for osteoporosis for 10 years, as well as helps in the selection of appropriate drug 
taking into consideration the choice of the patient [40]. Prognosis, treatment, and prevention 
of fractures would be easier when gene variants associated with osteoporosis are identified, 
leading to a more personalized approach/therapy [41].
4. Conclusion
Personalized care is at the verge of a revolution in healthcare sector, with potential to revolu-
tionize the treatment, care and prevention of a number of debilitating life threatening diseases, 
some of which have been discussed in this chapter (Figure 1). When fully implemented, the 
treatment of patients can be individualized in strict accordance with their individual genetic 
make-up, rather than traditional “one-size-fits-all” pharmacology. A person’s lifestyle, which 
decides the overall well-being of an individual, is crucial while implementing the approach 
Figure 1. Diet-related conditions where personalized care can revolutionize the treatment, control and prevention of 
lifestyle diseases in human.
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of personalized care of patients suffering from long-term lifestyle debilitating and morbid 
diseases through individualized nutrition, personal hygiene/oral health, and individualized 
needs that may be combined with relaxation techniques, such as meditation and yoga.
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Abstract
Neurological disorders are medically complex diseases that affect the central and peripheral 
nervous systems. They can affect an entire neurological pathway or a single neuron. Some neu-
rological problems can present years after a causative event. The World Health Organization 
reports that various types of neurological disorders affect millions of people around the 
world. So far, there are no therapies available to cure these disorders. Pharmacological and 
non-pharmacological interventions can at best relieve symptoms and perhaps delay the pro-
gression of the disease. However, there are a wide variety of helpful treatments for different 
disorders that may help an individual to learn better social skills and communication cues, 
in order to help them be able to interact socially, in a more natural fashion. For some neu-
rological issues, the outlook can be quite good with treatment and adequate rehabilitation. 
Diet also plays an important role in the prevention of late-life cognitive decline. Deficits in 
cognition, low dietary quality and physical functioning, and cardio-metabolic risk factors are 
frequently reported in patients with neurological disorders. In this chapter we will briefly 
discuss research, as well as current opportunities and future prospects towards personalized 
medicine in relation to selected neurological disorders and diseases such as Down syndrome, 
neuronal ceroid lipofuscinoses (NCLs), and multiple sclerosis (MS).
Keywords: neurological disorders, free radicals, antioxidants, personalized medicine
1. Introduction
Genes are responsible for forming all of the neurons. However, they are certainly not 
the only factor determining how our brain develops and forms its inner connections. A 
combination of hereditary factors and environmental factors plays an important role in 
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world. So far, there are no therapies available to cure these disorders. Pharmacological and 
non-pharmacological interventions can at best relieve symptoms and perhaps delay the pro-
gression of the disease. However, there are a wide variety of helpful treatments for different 
disorders that may help an individual to learn better social skills and communication cues, 
in order to help them be able to interact socially, in a more natural fashion. For some neu-
rological issues, the outlook can be quite good with treatment and adequate rehabilitation. 
Diet also plays an important role in the prevention of late-life cognitive decline. Deficits in 
cognition, low dietary quality and physical functioning, and cardio-metabolic risk factors are 
frequently reported in patients with neurological disorders. In this chapter we will briefly 
discuss research, as well as current opportunities and future prospects towards personalized 
medicine in relation to selected neurological disorders and diseases such as Down syndrome, 
neuronal ceroid lipofuscinoses (NCLs), and multiple sclerosis (MS).
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1. Introduction
Genes are responsible for forming all of the neurons. However, they are certainly not 
the only factor determining how our brain develops and forms its inner connections. A 
combination of hereditary factors and environmental factors plays an important role in 
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determining a neuron’s final location [1]. Studies confirm that an active lifestyle maintains 
brain function [2]; thus, new research aims to develop lifestyle behaviors and medications 
that could improve normal brain development as well as repair damaged brains. Many neu-
rological disorders emerge during the early years of development and may be diagnosed at 
birth or later, and their causes include congenital, chromosomal, and gene abnormalities, 
infections, immune disorders, and environmental factors such as nutritional deficiencies 
and toxins. The effectiveness of self-management interventions for people with long-term 
neurological conditions, in particular, Down syndrome (DS), neuronal ceroid lipofuscino-
sis (NCL), Duchenne muscular dystrophy (DMD), and multiple sclerosis (MS), has been 
reported. The effectiveness of various antioxidants on several neurodegenerative diseases 
in clinical trials has increasingly demonstrated that reactive oxygen species (ROS) and 
oxidative damage are important factors in the processes involved. Imbalanced defense 
mechanism of antioxidants and overproduction of free radicals from environment to living 
system lead to serious penalty resulting in neurodegeneration [3]. The current need for bet-
ter interventions is highlighted, particularly the importance of providing condition-specific 
information. As the overall life expectancy across the globe has increased, the global com-
munity is now facing new challenges of improving quality of life and healthcare; however, 
advancements in medical technology have benefits and improved healthcare [4, 5]. This 
chapter provides an overview of the evidence of current findings; research limitations and 
future directions of research efforts are discussed in some neurological conditions such as 
DS, DMD, NCL, and MS.
2. Free radicals in the brain
Unlike many other tissues, the brain is a highly aerobic and totally oxygen-dependent tissue. 
Oxygen reduction produces reactive radical intermediates, such as superoxide and hydroxyl 
radicals which are thought to be the major agents of oxygen toxicity [6, 7]. Hydrogen peroxide 
is formed through dismutation of superoxide anion catalyzed by Cu-Zn and Mn forms of 
superoxide dismutase (SOD), both found in the central nervous system. In addition to Cu-Zn 
SOD (SOD-1), the activity of which is increased in DS, and hydrogen peroxide (H2O2) is gener-
ated in association with D- and L-amino acid oxidase, monoamine oxidase, α-hydroxyacid 
oxidase, xanthine oxidase, and cytochrome P-450 system.
Unlike charged oxygen radicals, H2O2, being rather unreactive and stable, rapidly crosses cell 
membranes. Cellular damage is accomplished when H2O2 decomposes to the highly reactive 
hydroxyl radical in reactions catalyzed by iron (II) or copper (I). If the scavenging of H2O2 
and the contemporaneous prevention of hydroxyl radical formation do not take place, the 
hydroxyl radical may attack, e.g., fatty acid side chains, and start a chain reaction of lipid 
peroxidation. Lipid peroxidation causes gradual loss of membrane fluidity and membrane 
potential and increases membrane permeability to ions [6, 7]. Abnormalities in the fatty acid 
composition found in fetal DS brain phospholipids suggest that from the early stage of onto-
genesis, lipoperoxidation may have a pathological significance [8, 9]. Oxidative degradation 
and polymerization of lipids lead to the accumulation of lipofuscin, the age pigment. Current 
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evidence permits the interpretation that a high proportion of DS subjects later develop the 
neuropathological changes resembling Alzheimer’s disease [10–12].
Considerable evidence has emerged in recent years implicating a role for oxygen free radi-
cals in the initiation of cellular injury that leads to the development of several neurological 
disorders. The neonatal brain, with its high concentrations of unsaturated fatty acids (lipid 
content), high rate of oxygen consumption, and low concentrations of antioxidants, is particu-
larly vulnerable to oxidative damage. Thus, increased oxidative stress has been implicated in 
various neurological disorders such as seizures, ischemia-reperfusion injury, and neurode-
generative diseases [13] such as Alzheimer’s, Parkinson’s, and amyotrophic lateral sclerosis 
(ALS, Lou Gehrig’s disease). Free radical damage has been implicated in the initiation and 
propagation of seizure activity as well as the accompanying seizure-induced neuronal dam-
age [14]. Therefore, antioxidants could play an important role in modulating susceptibility to 
seizure activity and seizure-induced neuronal injury.
Radical attack may also destroy membrane-bound enzymes and receptors, e.g., the binding 
of serotonin is decreased. However, the brain tends to need radical reactions for the gen-
eration of physiological responses. Cellular redox adjustments generally regulate functional 
sulfhydryl groups of proteins. There is evidence supporting the suggestion that free radical 
intermediates are involved, e.g., in the coupling between depolarization of the plasma mem-
brane Ca2+ fluxes and neurotransmitter release [15, 16]. It has also been hypothesized that 
the elimination of neurofilaments at nerve terminals is regulated by oxygen radicals and 
that a contact of a growing neurite with a neighboring neuron induces the production of 
oxygen radicals. Rapid elimination of oxygen radicals during synaptogenesis would result 
in a reduced number of synaptic connections [17]. Accordingly, transgenic mice bearing the 
human SOD gene develop abnormalities in neuromuscular junctions of the tongue which 
closely resemble those of DS patients [18]. However, these abnormalities may be explained by 
a decreased level of superoxide anion as well as by increased formation of highly active and 
toxic hydroxyl radicals and singlet oxygen.
The regulation of glutathione (GSH) level (GSH/GSSG) through pentose phosphate pathway 
producing nicotinamide adenine dinucleotide phosphate (NADPH), GSH reductase, and glu-
tathione peroxidase (GSHPx) contributes to the overall redox state of cells in brain [19]. The 
brain tends to need radical reactions as well as to possess specific or high endogenous levels 
of free radical scavengers such as dopamine, norepinephrine, catechol estrogens, taurine, and 
carnosine [20] in neurons. Carnosine is involved with GABA activity in the brain, and brain 
tissue contains high levels of carnosine, which is capable of reducing the oxidative, nitrosa-
tive, and glycemic stress to which the brain is especially vulnerable [21–23]. Oxidation and 
glycation produce inflammation and also contribute to cross-linking of proteins, including 
the Alzheimer’s disease protein called amyloid-beta [24]. A study by Takahashi [25] demon-
strated that homocarnosine levels were high in patients who responded to antileptic drugs. 
The functional balance between various free radical scavenger systems in the brain seems 
reasonable. Significant positive correlations between catalase and SOD levels have been 
reported in tissues of normal subjects excluding erythrocytes. Factors concomitantly influenc-
ing the variation of the activities of SOD, catalase, and GSHPx have been reported. Enzymes 
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determining a neuron’s final location [1]. Studies confirm that an active lifestyle maintains 
brain function [2]; thus, new research aims to develop lifestyle behaviors and medications 
that could improve normal brain development as well as repair damaged brains. Many neu-
rological disorders emerge during the early years of development and may be diagnosed at 
birth or later, and their causes include congenital, chromosomal, and gene abnormalities, 
infections, immune disorders, and environmental factors such as nutritional deficiencies 
and toxins. The effectiveness of self-management interventions for people with long-term 
neurological conditions, in particular, Down syndrome (DS), neuronal ceroid lipofuscino-
sis (NCL), Duchenne muscular dystrophy (DMD), and multiple sclerosis (MS), has been 
reported. The effectiveness of various antioxidants on several neurodegenerative diseases 
in clinical trials has increasingly demonstrated that reactive oxygen species (ROS) and 
oxidative damage are important factors in the processes involved. Imbalanced defense 
mechanism of antioxidants and overproduction of free radicals from environment to living 
system lead to serious penalty resulting in neurodegeneration [3]. The current need for bet-
ter interventions is highlighted, particularly the importance of providing condition-specific 
information. As the overall life expectancy across the globe has increased, the global com-
munity is now facing new challenges of improving quality of life and healthcare; however, 
advancements in medical technology have benefits and improved healthcare [4, 5]. This 
chapter provides an overview of the evidence of current findings; research limitations and 
future directions of research efforts are discussed in some neurological conditions such as 
DS, DMD, NCL, and MS.
2. Free radicals in the brain
Unlike many other tissues, the brain is a highly aerobic and totally oxygen-dependent tissue. 
Oxygen reduction produces reactive radical intermediates, such as superoxide and hydroxyl 
radicals which are thought to be the major agents of oxygen toxicity [6, 7]. Hydrogen peroxide 
is formed through dismutation of superoxide anion catalyzed by Cu-Zn and Mn forms of 
superoxide dismutase (SOD), both found in the central nervous system. In addition to Cu-Zn 
SOD (SOD-1), the activity of which is increased in DS, and hydrogen peroxide (H2O2) is gener-
ated in association with D- and L-amino acid oxidase, monoamine oxidase, α-hydroxyacid 
oxidase, xanthine oxidase, and cytochrome P-450 system.
Unlike charged oxygen radicals, H2O2, being rather unreactive and stable, rapidly crosses cell 
membranes. Cellular damage is accomplished when H2O2 decomposes to the highly reactive 
hydroxyl radical in reactions catalyzed by iron (II) or copper (I). If the scavenging of H2O2 
and the contemporaneous prevention of hydroxyl radical formation do not take place, the 
hydroxyl radical may attack, e.g., fatty acid side chains, and start a chain reaction of lipid 
peroxidation. Lipid peroxidation causes gradual loss of membrane fluidity and membrane 
potential and increases membrane permeability to ions [6, 7]. Abnormalities in the fatty acid 
composition found in fetal DS brain phospholipids suggest that from the early stage of onto-
genesis, lipoperoxidation may have a pathological significance [8, 9]. Oxidative degradation 
and polymerization of lipids lead to the accumulation of lipofuscin, the age pigment. Current 
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evidence permits the interpretation that a high proportion of DS subjects later develop the 
neuropathological changes resembling Alzheimer’s disease [10–12].
Considerable evidence has emerged in recent years implicating a role for oxygen free radi-
cals in the initiation of cellular injury that leads to the development of several neurological 
disorders. The neonatal brain, with its high concentrations of unsaturated fatty acids (lipid 
content), high rate of oxygen consumption, and low concentrations of antioxidants, is particu-
larly vulnerable to oxidative damage. Thus, increased oxidative stress has been implicated in 
various neurological disorders such as seizures, ischemia-reperfusion injury, and neurode-
generative diseases [13] such as Alzheimer’s, Parkinson’s, and amyotrophic lateral sclerosis 
(ALS, Lou Gehrig’s disease). Free radical damage has been implicated in the initiation and 
propagation of seizure activity as well as the accompanying seizure-induced neuronal dam-
age [14]. Therefore, antioxidants could play an important role in modulating susceptibility to 
seizure activity and seizure-induced neuronal injury.
Radical attack may also destroy membrane-bound enzymes and receptors, e.g., the binding 
of serotonin is decreased. However, the brain tends to need radical reactions for the gen-
eration of physiological responses. Cellular redox adjustments generally regulate functional 
sulfhydryl groups of proteins. There is evidence supporting the suggestion that free radical 
intermediates are involved, e.g., in the coupling between depolarization of the plasma mem-
brane Ca2+ fluxes and neurotransmitter release [15, 16]. It has also been hypothesized that 
the elimination of neurofilaments at nerve terminals is regulated by oxygen radicals and 
that a contact of a growing neurite with a neighboring neuron induces the production of 
oxygen radicals. Rapid elimination of oxygen radicals during synaptogenesis would result 
in a reduced number of synaptic connections [17]. Accordingly, transgenic mice bearing the 
human SOD gene develop abnormalities in neuromuscular junctions of the tongue which 
closely resemble those of DS patients [18]. However, these abnormalities may be explained by 
a decreased level of superoxide anion as well as by increased formation of highly active and 
toxic hydroxyl radicals and singlet oxygen.
The regulation of glutathione (GSH) level (GSH/GSSG) through pentose phosphate pathway 
producing nicotinamide adenine dinucleotide phosphate (NADPH), GSH reductase, and glu-
tathione peroxidase (GSHPx) contributes to the overall redox state of cells in brain [19]. The 
brain tends to need radical reactions as well as to possess specific or high endogenous levels 
of free radical scavengers such as dopamine, norepinephrine, catechol estrogens, taurine, and 
carnosine [20] in neurons. Carnosine is involved with GABA activity in the brain, and brain 
tissue contains high levels of carnosine, which is capable of reducing the oxidative, nitrosa-
tive, and glycemic stress to which the brain is especially vulnerable [21–23]. Oxidation and 
glycation produce inflammation and also contribute to cross-linking of proteins, including 
the Alzheimer’s disease protein called amyloid-beta [24]. A study by Takahashi [25] demon-
strated that homocarnosine levels were high in patients who responded to antileptic drugs. 
The functional balance between various free radical scavenger systems in the brain seems 
reasonable. Significant positive correlations between catalase and SOD levels have been 
reported in tissues of normal subjects excluding erythrocytes. Factors concomitantly influenc-
ing the variation of the activities of SOD, catalase, and GSHPx have been reported. Enzymes 
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frequently called protective should rather be envisaged as being regulatory, controlling the 
levels of different states of oxygen reduction, phorbol esters, and strong superoxide produc-
ers through NADPH oxidase activation [26–29], inducing biosynthesis of polyamines [30, 31]. 
The role of polyamines is also associated with the architectural modeling of brain regions and 
generation of synaptic connections [32–34]. Thus effective scavenging of superoxide by excess 
SOD-1 may contribute even to the polyamine biosynthesis.
In addition to the complex enzyme systems, biochemical defenses include low molecular weight 
free radical scavengers and antioxidants. Lipid soluble vitamin E lowers the steady-state con-
centrations of many free radical species [35–39]. Ubiquinone may exert, similarly to vitamin E, 
a protective effect against lipid peroxidation [40]. The concentration of vitamin E in a fetal DS 
brain does not significantly differ from that of controls [41]. We have found the serum vitamin E 
concentrations of Down syndrome patients to be normal (1.01 + 0.35 vs. 1.13 + 0.39 mg/100 ml) 
[42]. In addition to conventional antioxidant systems, the brain has been found to contain specific 
or high endogenous levels of free radical scavengers such as dopamine, norepinephrine [43–45], 
catechol estrogens [20], carnosine [46], and taurine [47, 48]. The transport of taurine to platelets 
is impaired in DS [49]. Taurine and hypotaurine, found in high concentrations in the brain [50], 
could act as intracellular superoxide scavengers which would inhibit not only lipid peroxidation 
but also inactivation of SOD by both superoxide and H2O2 [51, 52]. The presence of 1–10 mM 
taurine protects cultured lymphoblastoid cells from the injurious effect of iron-ascorbate [48].
The role of dietary beta-carotene in the central nervous system is not elucidated. Beta-
carotene acts as an antioxidant at low oxygen pressures [53–55]. Being converted to retinol or 
retinoic acid, it causes a marked decrease in superoxide generation. Through a still unknown 
mechanism, retinoic acid induces human neuroblastoma cell differentiation in vitro [56–58], 
and it also contributes to neural differentiation of embryonal  carcinoma cells in vitro [59].
Serum β-carotene and vitamin A levels are generally normal in DS, although vitamin A levels 
lower than in normal subjects have also been reported. Relatively high carotene/vitamin A 
ratio suggests decreased efficiency in converting carotene to vitamin A. In addition the utili-
zation of vitamin A in DS may be impaired at its site of action [60–62].
Thyroid hormones improve the cleaving of beta-carotene to vitamin A. This conversion to 
retinol is decreased in hypothyroidism. Thus, in hypothyroidism the vitamin A concentration 
decreases even when the dietary β-carotene remains the same or rises [63, 64].
3. Down syndrome
Down syndrome (DS), also known as trisomy 21, is a genetic disorder caused by the presence 
of all or part of a third copy of chromosome 21 [65]. It is one of the most common chromosome 
abnormalities in humans [66]. Globally, as of 2010, DS occurs in about 1 per 1000 births [67] 
and results in about 17,000 deaths [68].
In spite of the intensified antenatal diagnostics and termination of affected pregnancies, the 
prevalence of DS, first described in 1866, is still so high that it constitutes an important health-
care problem. DS phenotype is readily recognized at birth. Karyotype analysis confirms the 
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diagnosis of DS associated with trisomy of chromosome 21. Since the further development 
of the child is predestined to be hampered by a multitude of clinical symptoms including 
mental retardation, premature aging, and immunological disorders such as hypothyroid 
states, attempts have been made to increase the understanding of the etiopathogenesis of the 
syndrome and to influence its progress.
The genetic imbalance due to an extra set of normal genes located in chromosome 21 means 
that the expression of these or actually of only some genes in the q arm leads to the disturbed 
development. Cumulative effects of increased amounts of primary gene products may be 
deleterious if no compensatory mechanisms exist. Genes of the q arm in chromosome 21, 
which may contribute to the DS pathology, include α/β interferon receptor, phosphoribosyl-
glycinamide synthetase [69–72], cystathionine beta synthase [73], and cytoplasmic Cu-Zn 
superoxide dismutase (SOD-1) [74, 75].
DS, described in a karyotypically normal 18-month-old boy, has been explained by a micro-
duplication of a chromosome 21 fragment (not exceeding 2000–3000 kilobase pairs) contain-
ing the SOD-1 gene [76, 77]. Further evidence of the involvement of additional SOD-1 gene 
in the neuropathological symptoms of DS has been derived from studies performed with 
transgenic cell lines and from mice carrying the human SOD gene [18, 78].
Consistent with the gene dosage effect, SOD-1 activity is increased in the cerebral cortex of DS 
fetuses as well as in erythrocytes, blood platelets, leukocytes, and fibroblasts of DS patients [79] 
(Thilakavathy et al. 2008). According to Sinet [75], elevated SOD-1 activity may constitute an 
oxygen free radical “stress.” Usually SOD-1 protects cells from the harmful effects of oxygen 
radicals by catalyzing formation of H2O2 from O2− enzymes that remove excessive peroxides 
like catalase and glutathione peroxidase (GSHPx) [74]. NADPH is needed for the regeneration 
by glutathione reductase of glutathione (GSH), the utilization of which is increased via GSHPx 
as a defense against peroxide formation. Thus several enzymes with structural loci other than 
those of chromosome 21, including glutathione reductase, glutathione peroxidase, and glucose-
6-phosphate dehydrogenase, show elevated activity in erythrocytes of DS patients [80, 81].
Some reports suggest that Both SOD GSHPx activities are increased in Down syndrome chil-
dren [82]. It remains to be seen whether oxidative damage will still be related to the accumu-
lation of aluminum silicates in the brain as well as to that of the senile plaques and tangles. 
Experiments have indicated that aluminum salts may not only accelerate Fe (II)-induced 
peroxidation of membrane lipids but do this especially in the brain [83]. Interestingly a high 
proportion of Down syndrome patients develop the neuropathological and clinical changes of 
AD suggesting a close pathogenetic relationship between these disorders. Thus the correction 
of antioxidant balance in AD by Se supplementation should be demonstrated by other means 
so as to direct it preventatively to those with a high risk of developing AD.
Balazs and Brooksbank [8] noticed that the adaptive response to elevated SOD-1 activity, 
i.e., increased GSHPx activity found in other tissues, is not detected in the fetal DS brain. 
The level of GSHPx activity in neural tissues seems to be as such too low to provide protec-
tion from peroxide-induced lesions [84]. Furthermore, if H2O2 production is high, catalase 
might be a superior scavenger, because restoration of glutathione becomes a limiting factor 
for the activity of GSHPx [85]. However, catalase level is normal in DS erythrocytes [72, 86], 
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frequently called protective should rather be envisaged as being regulatory, controlling the 
levels of different states of oxygen reduction, phorbol esters, and strong superoxide produc-
ers through NADPH oxidase activation [26–29], inducing biosynthesis of polyamines [30, 31]. 
The role of polyamines is also associated with the architectural modeling of brain regions and 
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SOD-1 may contribute even to the polyamine biosynthesis.
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but also inactivation of SOD by both superoxide and H2O2 [51, 52]. The presence of 1–10 mM 
taurine protects cultured lymphoblastoid cells from the injurious effect of iron-ascorbate [48].
The role of dietary beta-carotene in the central nervous system is not elucidated. Beta-
carotene acts as an antioxidant at low oxygen pressures [53–55]. Being converted to retinol or 
retinoic acid, it causes a marked decrease in superoxide generation. Through a still unknown 
mechanism, retinoic acid induces human neuroblastoma cell differentiation in vitro [56–58], 
and it also contributes to neural differentiation of embryonal  carcinoma cells in vitro [59].
Serum β-carotene and vitamin A levels are generally normal in DS, although vitamin A levels 
lower than in normal subjects have also been reported. Relatively high carotene/vitamin A 
ratio suggests decreased efficiency in converting carotene to vitamin A. In addition the utili-
zation of vitamin A in DS may be impaired at its site of action [60–62].
Thyroid hormones improve the cleaving of beta-carotene to vitamin A. This conversion to 
retinol is decreased in hypothyroidism. Thus, in hypothyroidism the vitamin A concentration 
decreases even when the dietary β-carotene remains the same or rises [63, 64].
3. Down syndrome
Down syndrome (DS), also known as trisomy 21, is a genetic disorder caused by the presence 
of all or part of a third copy of chromosome 21 [65]. It is one of the most common chromosome 
abnormalities in humans [66]. Globally, as of 2010, DS occurs in about 1 per 1000 births [67] 
and results in about 17,000 deaths [68].
In spite of the intensified antenatal diagnostics and termination of affected pregnancies, the 
prevalence of DS, first described in 1866, is still so high that it constitutes an important health-
care problem. DS phenotype is readily recognized at birth. Karyotype analysis confirms the 
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diagnosis of DS associated with trisomy of chromosome 21. Since the further development 
of the child is predestined to be hampered by a multitude of clinical symptoms including 
mental retardation, premature aging, and immunological disorders such as hypothyroid 
states, attempts have been made to increase the understanding of the etiopathogenesis of the 
syndrome and to influence its progress.
The genetic imbalance due to an extra set of normal genes located in chromosome 21 means 
that the expression of these or actually of only some genes in the q arm leads to the disturbed 
development. Cumulative effects of increased amounts of primary gene products may be 
deleterious if no compensatory mechanisms exist. Genes of the q arm in chromosome 21, 
which may contribute to the DS pathology, include α/β interferon receptor, phosphoribosyl-
glycinamide synthetase [69–72], cystathionine beta synthase [73], and cytoplasmic Cu-Zn 
superoxide dismutase (SOD-1) [74, 75].
DS, described in a karyotypically normal 18-month-old boy, has been explained by a micro-
duplication of a chromosome 21 fragment (not exceeding 2000–3000 kilobase pairs) contain-
ing the SOD-1 gene [76, 77]. Further evidence of the involvement of additional SOD-1 gene 
in the neuropathological symptoms of DS has been derived from studies performed with 
transgenic cell lines and from mice carrying the human SOD gene [18, 78].
Consistent with the gene dosage effect, SOD-1 activity is increased in the cerebral cortex of DS 
fetuses as well as in erythrocytes, blood platelets, leukocytes, and fibroblasts of DS patients [79] 
(Thilakavathy et al. 2008). According to Sinet [75], elevated SOD-1 activity may constitute an 
oxygen free radical “stress.” Usually SOD-1 protects cells from the harmful effects of oxygen 
radicals by catalyzing formation of H2O2 from O2− enzymes that remove excessive peroxides 
like catalase and glutathione peroxidase (GSHPx) [74]. NADPH is needed for the regeneration 
by glutathione reductase of glutathione (GSH), the utilization of which is increased via GSHPx 
as a defense against peroxide formation. Thus several enzymes with structural loci other than 
those of chromosome 21, including glutathione reductase, glutathione peroxidase, and glucose-
6-phosphate dehydrogenase, show elevated activity in erythrocytes of DS patients [80, 81].
Some reports suggest that Both SOD GSHPx activities are increased in Down syndrome chil-
dren [82]. It remains to be seen whether oxidative damage will still be related to the accumu-
lation of aluminum silicates in the brain as well as to that of the senile plaques and tangles. 
Experiments have indicated that aluminum salts may not only accelerate Fe (II)-induced 
peroxidation of membrane lipids but do this especially in the brain [83]. Interestingly a high 
proportion of Down syndrome patients develop the neuropathological and clinical changes of 
AD suggesting a close pathogenetic relationship between these disorders. Thus the correction 
of antioxidant balance in AD by Se supplementation should be demonstrated by other means 
so as to direct it preventatively to those with a high risk of developing AD.
Balazs and Brooksbank [8] noticed that the adaptive response to elevated SOD-1 activity, 
i.e., increased GSHPx activity found in other tissues, is not detected in the fetal DS brain. 
The level of GSHPx activity in neural tissues seems to be as such too low to provide protec-
tion from peroxide-induced lesions [84]. Furthermore, if H2O2 production is high, catalase 
might be a superior scavenger, because restoration of glutathione becomes a limiting factor 
for the activity of GSHPx [85]. However, catalase level is normal in DS erythrocytes [72, 86], 
Personalized Management of Selected Neurological Disorders
http://dx.doi.org/10.5772/intechopen.92002
127
and its activity is practically absent in the brain tissue [87]. Consequently brain cells may be 
extremely susceptible to oxygen free radicals.
3.1. The pathophysiology of Down syndrome and the role of the thyroid gland
Thyroid hormone has a regulatory function on mitosis and differentiation of neural cells; 
hence, it is intimately involved in normal brain maturation [88–91]. Experimentally trijodo-
thyronine enhances neural outgrowth in vitro [92, 94]. Even subclinical hypothyreosis during 
the postnatal period may contribute to the delayed and incomplete maturation of the cerebral 
and cerebellar cortices.
Increased prevalence of thyroid dysfunction is associated with DS in infants as well as in 
older children and adults [95–98]. Hypothyroidism is reported in 17–50% of the DS patients 
studied depending on the age and sex distribution of the population [98]. The relatively high 
incidence of autoimmune thyroiditis suggests that impaired immune surveillance is the 
primary mechanism in hypothyroidism [99]. Pueschel and Pezullo [98] conducted a study 
which showed that approximately 28% of their 151 DS patients had elevated antimicrosomal 
antibodies, and a highly significant correlation of antimicrosomal antibodies to T4 and to 
TSH was found. Recent studies indicate that antimicrosomal antibodies are mainly, if not 
exclusively, against thyroid peroxidase [100].
Thyroid peroxidase is a membrane-bound enzyme associated with the endoplasmic reticu-
lum and the apical membrane of the thyroid cell. lmmunoelectron microscopical observations 
of the thyroid microsomal antigen in the apical plasma membrane are compatible with the 
notion that microsomal antigen is identical with thyroid peroxidase [101–104].
SOD-1 system, which generates H2O2, is essential in the iodination and coupling reactions 
catalyzed by thyroid peroxidase [105–107]. However, an excess of H2O2 may inactivate the 
peroxidase complex [105–108]. The irreversible loss of catalytic activity, caused by H2O2 or by 
the reactive oxygen species generated, may result from oxidation of functionally important 
amino acid residues to carbonyl derivatives. This may also render the protein susceptible to 
proteolytic attack and to detachment of its cellular compartment. If so, the maintenance of the 
thyroid peroxidase function and its integrity would require correct steady-state production of 
H2O2 and strict control of its level. This requirement is mainly met with by GSHPx and catalase.
Antigenicity of the modified and disintegrated thyroid peroxidase should be recognized by 
helper lymphocytes only in the context of MHC Class 11 products coded by genes in the 
HLA-D region. This region normally expressed only by a restricted variety of cell types is 
found in autoimmune disorders in target cells. Thus an aberrant expression of HLA-DR anti-
gen found on thyrocytes in Graves’ and Hashimoto’s disease indicates its potential impor-
tance in antigen presentation of thyroid autoimmune disorders [109, 110].
The presence and intensity of DR expression in Graves’ thyroids correlate positively with 
the titer of microsomal antibodies. Curiously, in cultured thyroid cells, plant lectins are 
able to induce the expression of HLA-DR by a mechanism unrelated to the known mito-
genic effects. On the other hand, the inducing effect of gamma-interferon (IFN-γ) could 
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have a physiological significance (IFN-α and IFN-β did not induce Class II expression in 
thyrocytes) [111–113]:
• Release of IFNs and lymphokines, best candidates for inducers, must be triggered by other 
factors [111–113].
On the basis of the gene dosage effect, we suggest possible mechanisms for the sensitization 
of DS thyroids to autoimmunization:
• Viral challenge including enhanced production of oxygen radicals due to macrophage and 
neutrophil activity may exert additional requirement for GSHPx and selenium. If these 
needs are not met with overproduction of oxygen radicals and constitutive excess of both 
LFA-1 and its beta-chain, it may hinder normal immune response [111–114].
• Excess H2O2 causes fragmentation of thyroid peroxidase which detaches from the cell 
membrane and turns into an autoantigen.
• Increased expression of IFN-α/IFN-P receptors, the gene of which is found in chromosome 
21, may sensitize thyrocytes to the induction of HLA-DR antigen by γ-IFN [111–113].
3.2. The impact of early hearing loss on language
Down syndrome occurs in approximately 1 in 600–800 live births [115] and remains the most 
common genetic abnormality seen in most otolaryngology practices. Down syndrome has 
a number of clinical problems associated with it [116–118]. The symptoms of DS vary from 
person to person, and people with the syndrome may have different problems at different 
times of their lives [119]. Hearing loss will affect many people with Down syndrome at some 
point in their lives. It has been reported that children with Down syndrome are at particular 
risk of some degree of hearing impairment due to a number of physiological differences. The 
authors concluded that there are a range of middle ear problems that can be treated success-
fully if the children are taken for routine cleaning and examination from birth [120]. Hearing 
losses affect 40–80% of individuals with DS [121–124]. In young children, the most common 
cause is conductive loss due to episodes of ear infection and otitis media with effusion (OME).
To determine the prevalence of hearing loss in newborn with Down syndrome, Tedeschi 
et al. [125] reported that newborn with Down syndrome have a higher prevalence of con-
genital hearing loss than the total neonatal population (15 vs. 0.25%). Individuals with Down 
syndrome are prone to otolaryngologic anomalies that complicate the diagnosis and classifi-
cation of hearing impairment [126]. In children, hearing loss can affect educational, language-
related, and emotional development. Even mild hearing loss can affect a child’s articulation. 
It is reported that as many as 80% of people with Down syndrome will have some problem 
with hearing [127]. A retrospective and cross-sectional analysis was performed to evaluate the 
prevalence of OME in children with DS for consecutive age categories between 6 months and 
12 years [128]. The authors concluded that a high prevalence of OME was found at the age of 
1 year (66.7%), with a second peak prevalence of 60% at 6–7 years. A declining trend was seen 
in older children [128].
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and its activity is practically absent in the brain tissue [87]. Consequently brain cells may be 
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genic effects. On the other hand, the inducing effect of gamma-interferon (IFN-γ) could 
Personalized Medicine, in Relation to Redox State, Diet and Lifestyle128
have a physiological significance (IFN-α and IFN-β did not induce Class II expression in 
thyrocytes) [111–113]:
• Release of IFNs and lymphokines, best candidates for inducers, must be triggered by other 
factors [111–113].
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needs are not met with overproduction of oxygen radicals and constitutive excess of both 
LFA-1 and its beta-chain, it may hinder normal immune response [111–114].
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• Increased expression of IFN-α/IFN-P receptors, the gene of which is found in chromosome 
21, may sensitize thyrocytes to the induction of HLA-DR antigen by γ-IFN [111–113].
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Down syndrome occurs in approximately 1 in 600–800 live births [115] and remains the most 
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a number of clinical problems associated with it [116–118]. The symptoms of DS vary from 
person to person, and people with the syndrome may have different problems at different 
times of their lives [119]. Hearing loss will affect many people with Down syndrome at some 
point in their lives. It has been reported that children with Down syndrome are at particular 
risk of some degree of hearing impairment due to a number of physiological differences. The 
authors concluded that there are a range of middle ear problems that can be treated success-
fully if the children are taken for routine cleaning and examination from birth [120]. Hearing 
losses affect 40–80% of individuals with DS [121–124]. In young children, the most common 
cause is conductive loss due to episodes of ear infection and otitis media with effusion (OME).
To determine the prevalence of hearing loss in newborn with Down syndrome, Tedeschi 
et al. [125] reported that newborn with Down syndrome have a higher prevalence of con-
genital hearing loss than the total neonatal population (15 vs. 0.25%). Individuals with Down 
syndrome are prone to otolaryngologic anomalies that complicate the diagnosis and classifi-
cation of hearing impairment [126]. In children, hearing loss can affect educational, language-
related, and emotional development. Even mild hearing loss can affect a child’s articulation. 
It is reported that as many as 80% of people with Down syndrome will have some problem 
with hearing [127]. A retrospective and cross-sectional analysis was performed to evaluate the 
prevalence of OME in children with DS for consecutive age categories between 6 months and 
12 years [128]. The authors concluded that a high prevalence of OME was found at the age of 
1 year (66.7%), with a second peak prevalence of 60% at 6–7 years. A declining trend was seen 
in older children [128].
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As with children, adults with DS may experience hearing loss due to glue ear. Picciotti et al. 
[129] assessed auditory function in adults with DS to evaluate the prevalence of hearing loss. 
The authors concluded that hearing loss is common in adults with DS and shows a pattern 
compatible with precocious aging of the hearing system.
3.3. Hearing and spoken language
Disorders impairing a patient’s communication abilities may involve voice, speech, language, 
hearing, and/or cognition [130]. The effect of hearing difficulties on spoken language develop-
ment has been demonstrated in many studies of the speech and language skills of children 
and teenagers with Down syndrome [131, 132].
Most individuals with DS also experience speech and language impairments although the 
severity of these is variable [133, 134]. Researchers studying language development in DS 
have measured hearing either directly tested or using pure tone audiometry to establish hear-
ing thresholds [135] or, indirectly, using speech discrimination tasks [136–138]. Therefore, it 
suggested that speech and language therapy should be provided when children are found to 
have ongoing hearing difficulties and that joint audiology and speech and language therapy 
clinics could be considered for preschool children [138].
4. Duchenne muscular dystrophy
Duchenne muscular dystrophy (DMD) is one of the most severe myopathies, usually obvi-
ous by the age of 5, and evolves progressively until it causes disablement and death, around 
the age of 20 [139]. In young boys, DMD is caused by deletions or point mutations in the 
pre-mRNA for dystrophin that result in out-of-frame transcripts and hence a nonfunctional 
truncated dystrophin protein [140]. It is recessively inherited, linked to sex, and the gene 
determining DMD has been mapped in the Xp-21 locus [141]. It has an incidence of 1/3000–
1/3500 male births and 1/3 of the cases coming from new mutation. Some affected individuals 
may develop intellectual disturbance due to unknown mechanism, so far. The sister of an 
affected individual has a 50% chance of carrying the defective gene [141]. The result of the 
dystrophic locus on the gene is the absence of dystrophin, a rod-shaped protein that is part of 
the muscle cytoskeleton. Death commonly results from involvement of the respiratory mus-
cles. Dystrophin is present in the muscle of normal individuals and has been rarely, or not at 
all, detected in patients with DMD [142, 143]. The genetic alteration produces abnormality in 
the membrane of the muscular fibers that consists of a disturbance in the calcium transport 
(Ca2+), inside the muscular fibers, which is the base mechanism of cellular degeneration and 
necrosis. There is fiber necrosis and replacement of fibers by fat. A nucleotide degradation 
and decreased muscle ATP and ADP content have been reported. The ATP is necessary to 
drive the Na+/K+ pump which maintains ionic gradients across the sarcolemma; resequester 
the Ca++ into the cisternae; and power contraction [144–146]. The production of ATP can be 
the result of anaerobic respiration, which breaks glucose down into ATP and lactic acid, or 
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aerobic respiration when ATP, carbon dioxide, and water are formed. A second immediate 
reserve of energy exists in the form of creatine phosphate, which can donate phosphate to 
ADP to form ATP, becoming itself a creatine. In the resting muscle, glucose is stored as gly-
cogen, and in such a muscle aerobic respiration synthesizes ATP from glucose or fatty acids.
Muscle dystrophy and mitochondrial dysfunction give rise to an amplification of stress-
induced cytosolic calcium signals and an amplification of stress-induced reactive oxygen 
species (ROS) production, and increased oxidative stress within the cell damages the sar-
colemma and eventually results in the death of the cell. Muscle fibers undergo necrosis and 
are ultimately replaced with adipose and connective tissue. In recent years, synthetic splice-
switching oligonucleotides (SSO) have been developed as new treatments for DMD whereby 
an SSO is targeted to the pre-mRNA and mediates splicing redirection to restore the reading 
frame of the dystrophin gene via exon skipping and thus to generate a shorter but functional 
dystrophin protein isoform [140, 147–155]. Several SSO chemistries have been developed for 
exon skipping in DMD and other neuromuscular diseases [156, 157], but of these only two 
SSO chemical types have been used in clinical trials, namely, 2′-O-methyl phosphorothioates 
(2′-OMe/PS) [158] and phosphorodiamidate morpholino oligonucleotides (PMO) [159, 160].
Therapy of DMD has been an elusive goal. Studies with isolated myocytes have shown that 
lipid peroxidation with an enhanced free radical production can be activated by increasing 
Ca concentration [161–163]. Thus, several kinds of antioxidants have been proposed as a treat-
ment since increased levels of thiobarbituric acid (TBA) reactive material has been found in 
the muscles and blood of DMD males [164]. We have previously reported that the biological 
half-life of 75Se in DMD patients was significantly shorter than in healthy controls [165]. Low 
oxygen saturation in the muscle tissue may stimulate the Il-6 production, a cytokine, which 
is produced by contracting muscles and released into the blood. The blood circulation of the 
older Duchenne patients is particularly disturbed. Pedersen et al. [166] have demonstrated 
that Il-6 affects the metabolic genes, induction of lipolysis, inhibition of insulin resistance, 
and stimulation of cortisol production. In addition, carbohydrate supplementation during 
exercise was shown to inhibit the release of Il-6 from contracting muscles. Thus carnitine 
supplementation is indicated to the Duchenne patients, to make sure that the energy supply 
will be good [167].
Shimomura et al. [168] observed that a group of trained animals, part of which were coen-
zyme Q10 (CoQ10)-treated, had to exercise for 30 min on treadmill, in downhill position. 
CoQ10-treated animals had a higher level of CoQ10 in their muscles, and the early rise in 
creatine kinase and lactic dehydrogenase plasma levels, due to the exercise, was evident 
at a remarkably significant lower extent, in the treated ones. Similar observations were 
also made in humans [169, 170]. Therefore we have been treating the Duchenne patients 
with CoQ10. In our earlier work, we gave DMD patients sodium selenite, 0.05–0.1 mg Se 
kg−1 BW day−1; α-tocopherol, 10–20 mg kg−1 BW day−1; vitamin B2, 0.2 mg kg−1 BW day−1; 
vitamin B6, 5 mg kg−1 BW day−1; carnitine, 10–20 mg kg−1 BW day−1; and ubiquinone-10 
(CoQ10), 3 mg kg−1 BW day−1 [171]. We reported two siblings of whom the elder one got 
practically no antioxidants and the younger one has antioxidant treatment starting at the 
age of 6 years. The first one was wheelchair bound at the age of 8 years and deceased at 
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ment has been demonstrated in many studies of the speech and language skills of children 
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suggested that speech and language therapy should be provided when children are found to 
have ongoing hearing difficulties and that joint audiology and speech and language therapy 
clinics could be considered for preschool children [138].
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ous by the age of 5, and evolves progressively until it causes disablement and death, around 
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pre-mRNA for dystrophin that result in out-of-frame transcripts and hence a nonfunctional 
truncated dystrophin protein [140]. It is recessively inherited, linked to sex, and the gene 
determining DMD has been mapped in the Xp-21 locus [141]. It has an incidence of 1/3000–
1/3500 male births and 1/3 of the cases coming from new mutation. Some affected individuals 
may develop intellectual disturbance due to unknown mechanism, so far. The sister of an 
affected individual has a 50% chance of carrying the defective gene [141]. The result of the 
dystrophic locus on the gene is the absence of dystrophin, a rod-shaped protein that is part of 
the muscle cytoskeleton. Death commonly results from involvement of the respiratory mus-
cles. Dystrophin is present in the muscle of normal individuals and has been rarely, or not at 
all, detected in patients with DMD [142, 143]. The genetic alteration produces abnormality in 
the membrane of the muscular fibers that consists of a disturbance in the calcium transport 
(Ca2+), inside the muscular fibers, which is the base mechanism of cellular degeneration and 
necrosis. There is fiber necrosis and replacement of fibers by fat. A nucleotide degradation 
and decreased muscle ATP and ADP content have been reported. The ATP is necessary to 
drive the Na+/K+ pump which maintains ionic gradients across the sarcolemma; resequester 
the Ca++ into the cisternae; and power contraction [144–146]. The production of ATP can be 
the result of anaerobic respiration, which breaks glucose down into ATP and lactic acid, or 
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Therapy of DMD has been an elusive goal. Studies with isolated myocytes have shown that 
lipid peroxidation with an enhanced free radical production can be activated by increasing 
Ca concentration [161–163]. Thus, several kinds of antioxidants have been proposed as a treat-
ment since increased levels of thiobarbituric acid (TBA) reactive material has been found in 
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is produced by contracting muscles and released into the blood. The blood circulation of the 
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and stimulation of cortisol production. In addition, carbohydrate supplementation during 
exercise was shown to inhibit the release of Il-6 from contracting muscles. Thus carnitine 
supplementation is indicated to the Duchenne patients, to make sure that the energy supply 
will be good [167].
Shimomura et al. [168] observed that a group of trained animals, part of which were coen-
zyme Q10 (CoQ10)-treated, had to exercise for 30 min on treadmill, in downhill position. 
CoQ10-treated animals had a higher level of CoQ10 in their muscles, and the early rise in 
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at a remarkably significant lower extent, in the treated ones. Similar observations were 
also made in humans [169, 170]. Therefore we have been treating the Duchenne patients 
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the age of 17 years. However, at the age of 15 years, the younger brother was still able to 
walk without any assistance. At the age 19 years, he was to be a graduate student with the 
best scores of all seven subjects that he participated. At the age of 21 years, he was still 
able to swim a distance of 50 m without any assistance. At age of 30 years, he is still able 
to make computer art and to have art exhibitions of his own. There are also mothers who 
have made observations that the odor of lard characteristic of their DMD sons was cured 
during the antioxidant supplementation. Potential future developments therapy may be 
to produce functional amounts of dystrophin by skipping the mutated exon like what has 
been done in mdx dystrophic mouse [172–174].
5. Neuronal ceroid lipofuscinosis
Neuronal ceroid lipofuscinoses (NCLs) are clinically heterogeneous neurodegenerative lyso-
somal diseases [175–179]. NCLs are recessively inherited neurodegenerative lysosomal stor-
age diseases. The neuronal ceroid lipofuscinoses are with a prevalence of 1 in 12,500 in some 
populations such as the USA and Northern Europe. Currently the classification is based on 
genetic defects, with 14 clinical subtypes and genetically separate neurodegenerative disor-
ders that result from excessive accumulation of lipopigments (lipofuscin) in the body’s tis-
sues, and the most prevalent NCLs are CLN3 disease, classic juvenile and CLN2 disease, and 
classic late infantile [39, 176, 180–182]. Characteristics of the diseases are deposits of ceroid 
and lipofuscin pigments in the tissues, particularly in the neural tissue, visual failure, and 
progressive mental retardation; depending on the age of onset and clinical, electrophysiologi-
cal, and neuropathological features, the NCLs can be subdivided into the infantile the late 
infantile, the juvenile and the adult type of NCL; however, the pathogenesis of NCL is still 
unknown.
5.1. Management of neuronal ceroid lipofuscinosis
Neuronal ceroid lipofuscinoses are a group of hereditary diseases caused by mutations 
in at least eight genes (CLN1-CLN8) [183, 184]. They are characterized by massive accu-
mulation of autofluorescent lysosomal storage bodies in most cells and associated severe 
degeneration of the CNS [183]. There is no single, standard treatment for neuronal ceroid 
lipofuscinoses (NCLs), as there is currently no cure; however, a number of different treat-
ments can be used to ease symptoms and encourage independence and better standards 
of general health [185]. Also there are certain medical problems that can affect someone 
with neuronal ceroid lipofuscinosis. However, a number of different treatments can be 
used to ease the symptoms and encourage independence and better standards of general 
health. These treatments are based on each individual’s physical and intellectual needs 
as well as their personal strengths and limitations: enzyme replacement therapy, gene 
therapy, stem cells including tissue engineering, and medicine or metabolic therapy such 
as dietary restriction and immune biotherapy [186–190]. These modes of treatments have 
been used in many genetic diseases. Acetyl-L-carnitine (ALC) has been shown to be thera-
peutic in treatment of NCLs [191]. It was reported that ALC might rebalance the disorders 
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underlying neuronal ceroid lipofuscinosis disease which are related to a disturbance in pH 
homeostasis [191].
The polyenic acid level with low levels of linoleic acid and an inverse relationship between 
GSHPx activity and the level of eicosatrienoic acid have been observed in juvenile neu-
ronal ceroid lipofuscinosis (JNCL) [192]. The occurrence of the fluorescent pigments 
suggested the peroxidation of lipids in the etiology of NCL. It is likely that the diseased 
tissues peroxidized cause secondary damage more rapidly than normal tissues and cyto-
toxic end products of lipoperoxidation. On a weight basis, ceroid seen in JNCL patients 
binds five times more iron than the lipofuscin seen in normal elderly individuals. The 
increased levels of aluminum salts greatly enhance iron-dependent damage to membranes. 
Heiskala et al. [193] has confirmed the presence of complexable iron and copper in the CSF 
of patients with NCL and other neurological disorders, and when the pH value of the assay 
for iron was lowered, the NCL group had substantially more complexable iron in their 
CSFs. Interestingly aluminum has been observed in CSF and in ceroid lipofuscin pigments 
of the brain of NCL patients [194]. It is well established that damaged tissue release metals 
from protein-bound sites and these metals stimulate peroxidative damage to lipids and 
other biomolecules.
One of the most essential enzymes counteracting lipoperoxidation is the selenium-containing 
GSHPx. Two independent reports have demonstrated that erythrocyte GSHPx activity is 
decreased in JNCL patients [195]. This low GSHPx activity was reversed to normal level by 
selenium supplementation. The evaluation of sodium selenite absorption and losses before 
supplementation of JNCL patients has been studied by using total body counting for 75Se 
detection. These studies showed that in three JNCL patients, about 55% of the administered 
75Se was eliminated during the first 11 days in the feces and about 10% in the urine [39]. 
Compared to healthy controls (42 and 7%, respectively), findings indicate a reduced absorp-
tion of selenium in JNCL patients contrary to a previous report. The low GSHPx activity in 
NCL patients may indeed reflect a low selenium intake most probably due to a disturbed 
absorption of selenium and secondary phenomena due to an inborn error of metabolism. 
Apart from the low selenium status, also very low vitamin E levels are found in the serum 
of advanced and hospitalized NCL patients. This can be explained by the recent finding of a 
pronounced reduction of apolipoprotein B as well as the whole fraction of very low-density 
lipoprotein (VLDL) in JNCL patients.
JNCL patients (genetically subgroups) have been given daily supplementation of sodium 
selenite (0.05–0.1 mg/Se/kg of BW), vitamin E (α-tocopherol acetate 0.014–0.05 g/kg BW), and 
vitamins B2 (0.025–0.05 mg/kg BW) and B6 (0.63–0.8 mg/kg BW). The benefits of the therapy 
are corroborated by the significant negative correlation of GSHPx activity with neurological 
dysfunction of motor performance, balance, coordination, and speech [196]. The mean age at 
death has been extended by 4 years as compared to that at the beginning of the century. As the 
best responders to antioxidant therapy show no neurological dysfunction at the age of over 
20 years, there is no doubt that the life expectancy of JNCL patients receiving antioxidants, 
including selenium, will be significantly prolonged in the future [197]. Complications of the 
antioxidant therapy have been few and not severe. Six patients have experienced vomiting and 
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in at least eight genes (CLN1-CLN8) [183, 184]. They are characterized by massive accu-
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degeneration of the CNS [183]. There is no single, standard treatment for neuronal ceroid 
lipofuscinoses (NCLs), as there is currently no cure; however, a number of different treat-
ments can be used to ease symptoms and encourage independence and better standards 
of general health [185]. Also there are certain medical problems that can affect someone 
with neuronal ceroid lipofuscinosis. However, a number of different treatments can be 
used to ease the symptoms and encourage independence and better standards of general 
health. These treatments are based on each individual’s physical and intellectual needs 
as well as their personal strengths and limitations: enzyme replacement therapy, gene 
therapy, stem cells including tissue engineering, and medicine or metabolic therapy such 
as dietary restriction and immune biotherapy [186–190]. These modes of treatments have 
been used in many genetic diseases. Acetyl-L-carnitine (ALC) has been shown to be thera-
peutic in treatment of NCLs [191]. It was reported that ALC might rebalance the disorders 
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underlying neuronal ceroid lipofuscinosis disease which are related to a disturbance in pH 
homeostasis [191].
The polyenic acid level with low levels of linoleic acid and an inverse relationship between 
GSHPx activity and the level of eicosatrienoic acid have been observed in juvenile neu-
ronal ceroid lipofuscinosis (JNCL) [192]. The occurrence of the fluorescent pigments 
suggested the peroxidation of lipids in the etiology of NCL. It is likely that the diseased 
tissues peroxidized cause secondary damage more rapidly than normal tissues and cyto-
toxic end products of lipoperoxidation. On a weight basis, ceroid seen in JNCL patients 
binds five times more iron than the lipofuscin seen in normal elderly individuals. The 
increased levels of aluminum salts greatly enhance iron-dependent damage to membranes. 
Heiskala et al. [193] has confirmed the presence of complexable iron and copper in the CSF 
of patients with NCL and other neurological disorders, and when the pH value of the assay 
for iron was lowered, the NCL group had substantially more complexable iron in their 
CSFs. Interestingly aluminum has been observed in CSF and in ceroid lipofuscin pigments 
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from protein-bound sites and these metals stimulate peroxidative damage to lipids and 
other biomolecules.
One of the most essential enzymes counteracting lipoperoxidation is the selenium-containing 
GSHPx. Two independent reports have demonstrated that erythrocyte GSHPx activity is 
decreased in JNCL patients [195]. This low GSHPx activity was reversed to normal level by 
selenium supplementation. The evaluation of sodium selenite absorption and losses before 
supplementation of JNCL patients has been studied by using total body counting for 75Se 
detection. These studies showed that in three JNCL patients, about 55% of the administered 
75Se was eliminated during the first 11 days in the feces and about 10% in the urine [39]. 
Compared to healthy controls (42 and 7%, respectively), findings indicate a reduced absorp-
tion of selenium in JNCL patients contrary to a previous report. The low GSHPx activity in 
NCL patients may indeed reflect a low selenium intake most probably due to a disturbed 
absorption of selenium and secondary phenomena due to an inborn error of metabolism. 
Apart from the low selenium status, also very low vitamin E levels are found in the serum 
of advanced and hospitalized NCL patients. This can be explained by the recent finding of a 
pronounced reduction of apolipoprotein B as well as the whole fraction of very low-density 
lipoprotein (VLDL) in JNCL patients.
JNCL patients (genetically subgroups) have been given daily supplementation of sodium 
selenite (0.05–0.1 mg/Se/kg of BW), vitamin E (α-tocopherol acetate 0.014–0.05 g/kg BW), and 
vitamins B2 (0.025–0.05 mg/kg BW) and B6 (0.63–0.8 mg/kg BW). The benefits of the therapy 
are corroborated by the significant negative correlation of GSHPx activity with neurological 
dysfunction of motor performance, balance, coordination, and speech [196]. The mean age at 
death has been extended by 4 years as compared to that at the beginning of the century. As the 
best responders to antioxidant therapy show no neurological dysfunction at the age of over 
20 years, there is no doubt that the life expectancy of JNCL patients receiving antioxidants, 
including selenium, will be significantly prolonged in the future [197]. Complications of the 
antioxidant therapy have been few and not severe. Six patients have experienced vomiting and 
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nausea when the serum concentration of selenium reached the level of 0.45 to 0.5 mM. Serum 
levels up to 4.0 mM were usually well tolerated, as well as when the sodium selenite was 
changed to ebselen (2-phenyl-1,2,-benzisoselenazol-3(2H)-one).
6. Multiple sclerosis
Multiple sclerosis (MS) is a chronic autoimmune disease of the central nervous system, 
where suspected autoimmune attack causes nerve demyelination and progressive neuro-
degeneration and should benefit from both anti-inflammatory and neuroprotective strate-
gies [198]. MS affects an estimated 4.3 cases per 100,000 in Europe with a higher rate in 
Northern Europe [199]. Often it appears in individuals between 20 and 40 years of age and 
has a strong genetic component [200]. The disease course is benign in 10–15% of patients, 
and they do not need an assistive device for walking even after 20 years of MS [201, 202]. 
Low levels of polyenic acids are involved in the pathogenesis of both MS and JNCL. Earlier 
a decrease level of serum linoleate as well as unsaturated fatty acids of brain phospholipids 
in MS patients was shown [203, 204]. It has also been argued that supplementation with 
essential fatty acids may improve the clinical status of MS patients [205]. And as in NCL, 
the selenium may, by activating GSHPx (scavenger of organic peroxides), regulate the 
metabolic transformation of essential fatty acids and biotransformation of these to pros-
taglandins, thromboxanes, and leukotrienes [206]. Curiously decreased GSHPx activities 
in erythrocytes have been found in female but not in male MS patients [207]. A significant 
association between the two haplotypes of the dopamine D2 receptor gene (DRD2) and the 
age of onset and/or diagnosis of MS was reported [208].
Current treatments for MS mainly target inflammatory processes, and there has been scant 
progress in treatments that enhance neuronal or glial regeneration. Can we predict the risk 
of serious side effects? This asks for the development of biomarkers, clinical, genetic, imag-
ing, or immunological, that allow for a better stratification of patients [209]. The need for 
tailored therapeutics is especially imperative, as the consequences of an ineffective medica-
tion might be irreversible dysfunction. However, it is obvious that treatment decisions in 
clinical practice must be made on an individual basis. This requires a personalized medicine 
approach in predicting disease activity in multiple sclerosis. Biomarkers that could predict 
disease course, treatment response, and risk of side effects would be highly appreciated. 
Despite extensive research over the last years, few biomarkers have made their way into 
clinical practice.
7. Advances in the development of novel antioxidant therapies
Earlier, through intervention efforts, patients with DS have received medical treatment and 
stimulation of sensory, motor, and cognitive areas [210]. In 1981, Harrell et al. [211] reported that 
the administration of a megavitamin mineral supplement to a heterogenous group of 16 men-
tally retarded children, 4 of which had DS, had led to encouraging results. However, controlled 
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double-blind studies on somewhat larger groups using similar megadoses of vitamins and miner-
als but no thyroid supplementation did not result in any beneficial effects [212–216]. However, 
these studies were devoid of a detailed theory of the mechanism of action, and the age distribution 
of the patients was disadvantageous in relation to possible targets in the developing brains.
Our primary survey and theory of antioxidant therapy in DS [42, 217] rest on the present 
concepts of the etiopathogenesis of DS [8, 79]. Earlier, selected antioxidants have been used, 
e.g., in the therapy of neuronal ceroid lipofuscinosis [218]. Prevention of free radical damage 
should be executed by agents focused on the tissue and cellular compartments and processes 
where the generation of free radicals is critical. In DS, elevated cytoplasmic SOD-1 activity 
causes free radical stress through H2O2. An excess of H2O2 may be activated in iron- or copper-
catalyzed reactions to generate highly reactive hydroxyl radical (–OH) or singlet oxygen. The 
extent and nature of the damage depend on the precise site of the •OH production, which in 
turn depends on the intra- or extracellular location of the critical metal ions [7, 219].
However, GSHPx, which gives protection against elevated H2O2, is low in brains with intensive 
oxygen metabolism. Histochemical studies by Slivka and co-workers [220] are indicative of 
the relative absence of GSH in neuronal somata and locate GSH to non-neuronal elements 
and fibrous and terminal regions of neurons. Furthermore, in normal newborn infants, the 
activity of GSHPx is physiologically low [221, 222]. Just a reflection of this condition could be 
the low blood selenium level found in neonates [223]. Controversial results have been pub-
lished on the level of selenium in plasma and erythrocytes of DS patients [79]. Peripherally 
decreased GSHPx activity may be corrected by selenium supplementation [224, 225]. Unlike 
catalase, benefit of optimal GSHPx activity is gained through its capability to reduce both H2O2 
and organic hydroperoxides including lipid peroxides. The mean plasma selenium concentra-
tion in DS patients has been shown not to differ significantly from that of the control subjects 
although the GSHPx activity is 130% of the normal [226]. Neve and co-workers [227] reported 
normal erythrocyte but significantly decreased plasma selenium levels in 29 DS patients. These 
discrepancies may be explained by the differences in the population groups studied and by 
the distribution of the blood selenium pool. Only 10–15% of the erythrocyte selenium in man 
is reported to be incorporated into the GSHPx, whereas the corresponding value in rat is 
75–85% [228].
We noticed in DS patients of different ages that the mean compensatory increase of erythro-
cyte GSHPx was lower than expected, 33.4 vs. 50%. The finding that the erythrocyte SOD/
GSHPx ratio was higher than in healthy controls confirmed our belief of insufficient com-
pensation [42, 217]. In DS the whole body retention of 5–8 kBq, 75Se-sodium selenite, with 
0.4 ug Se as carrier/kg BW, is estimated to be 53.3 ± 21.1%. Stable selenium supplementation 
increased 75Se elimination indicating a saturated selenium pool in the body [229]. Selenium 
supplementation 0.025 mg Se/kg/d in the form of sodium selenite increased E-GSHPx activ-
ity by 28 (59.9% above normal). This was also demonstrated by the 23.9% decrease of SOD/
GSHPx ratio (P < 0.01) [42, 217].
The consequences of selenium supplementation on the brain antioxidant balance, and thus 
its therapeutic value, are difficult to monitor. However, certain clinical, experimental, and 
in vitro observations may be indicative [230]. A highly positive correlation has been reported 
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and they do not need an assistive device for walking even after 20 years of MS [201, 202]. 
Low levels of polyenic acids are involved in the pathogenesis of both MS and JNCL. Earlier 
a decrease level of serum linoleate as well as unsaturated fatty acids of brain phospholipids 
in MS patients was shown [203, 204]. It has also been argued that supplementation with 
essential fatty acids may improve the clinical status of MS patients [205]. And as in NCL, 
the selenium may, by activating GSHPx (scavenger of organic peroxides), regulate the 
metabolic transformation of essential fatty acids and biotransformation of these to pros-
taglandins, thromboxanes, and leukotrienes [206]. Curiously decreased GSHPx activities 
in erythrocytes have been found in female but not in male MS patients [207]. A significant 
association between the two haplotypes of the dopamine D2 receptor gene (DRD2) and the 
age of onset and/or diagnosis of MS was reported [208].
Current treatments for MS mainly target inflammatory processes, and there has been scant 
progress in treatments that enhance neuronal or glial regeneration. Can we predict the risk 
of serious side effects? This asks for the development of biomarkers, clinical, genetic, imag-
ing, or immunological, that allow for a better stratification of patients [209]. The need for 
tailored therapeutics is especially imperative, as the consequences of an ineffective medica-
tion might be irreversible dysfunction. However, it is obvious that treatment decisions in 
clinical practice must be made on an individual basis. This requires a personalized medicine 
approach in predicting disease activity in multiple sclerosis. Biomarkers that could predict 
disease course, treatment response, and risk of side effects would be highly appreciated. 
Despite extensive research over the last years, few biomarkers have made their way into 
clinical practice.
7. Advances in the development of novel antioxidant therapies
Earlier, through intervention efforts, patients with DS have received medical treatment and 
stimulation of sensory, motor, and cognitive areas [210]. In 1981, Harrell et al. [211] reported that 
the administration of a megavitamin mineral supplement to a heterogenous group of 16 men-
tally retarded children, 4 of which had DS, had led to encouraging results. However, controlled 
Personalized Medicine, in Relation to Redox State, Diet and Lifestyle134
double-blind studies on somewhat larger groups using similar megadoses of vitamins and miner-
als but no thyroid supplementation did not result in any beneficial effects [212–216]. However, 
these studies were devoid of a detailed theory of the mechanism of action, and the age distribution 
of the patients was disadvantageous in relation to possible targets in the developing brains.
Our primary survey and theory of antioxidant therapy in DS [42, 217] rest on the present 
concepts of the etiopathogenesis of DS [8, 79]. Earlier, selected antioxidants have been used, 
e.g., in the therapy of neuronal ceroid lipofuscinosis [218]. Prevention of free radical damage 
should be executed by agents focused on the tissue and cellular compartments and processes 
where the generation of free radicals is critical. In DS, elevated cytoplasmic SOD-1 activity 
causes free radical stress through H2O2. An excess of H2O2 may be activated in iron- or copper-
catalyzed reactions to generate highly reactive hydroxyl radical (–OH) or singlet oxygen. The 
extent and nature of the damage depend on the precise site of the •OH production, which in 
turn depends on the intra- or extracellular location of the critical metal ions [7, 219].
However, GSHPx, which gives protection against elevated H2O2, is low in brains with intensive 
oxygen metabolism. Histochemical studies by Slivka and co-workers [220] are indicative of 
the relative absence of GSH in neuronal somata and locate GSH to non-neuronal elements 
and fibrous and terminal regions of neurons. Furthermore, in normal newborn infants, the 
activity of GSHPx is physiologically low [221, 222]. Just a reflection of this condition could be 
the low blood selenium level found in neonates [223]. Controversial results have been pub-
lished on the level of selenium in plasma and erythrocytes of DS patients [79]. Peripherally 
decreased GSHPx activity may be corrected by selenium supplementation [224, 225]. Unlike 
catalase, benefit of optimal GSHPx activity is gained through its capability to reduce both H2O2 
and organic hydroperoxides including lipid peroxides. The mean plasma selenium concentra-
tion in DS patients has been shown not to differ significantly from that of the control subjects 
although the GSHPx activity is 130% of the normal [226]. Neve and co-workers [227] reported 
normal erythrocyte but significantly decreased plasma selenium levels in 29 DS patients. These 
discrepancies may be explained by the differences in the population groups studied and by 
the distribution of the blood selenium pool. Only 10–15% of the erythrocyte selenium in man 
is reported to be incorporated into the GSHPx, whereas the corresponding value in rat is 
75–85% [228].
We noticed in DS patients of different ages that the mean compensatory increase of erythro-
cyte GSHPx was lower than expected, 33.4 vs. 50%. The finding that the erythrocyte SOD/
GSHPx ratio was higher than in healthy controls confirmed our belief of insufficient com-
pensation [42, 217]. In DS the whole body retention of 5–8 kBq, 75Se-sodium selenite, with 
0.4 ug Se as carrier/kg BW, is estimated to be 53.3 ± 21.1%. Stable selenium supplementation 
increased 75Se elimination indicating a saturated selenium pool in the body [229]. Selenium 
supplementation 0.025 mg Se/kg/d in the form of sodium selenite increased E-GSHPx activ-
ity by 28 (59.9% above normal). This was also demonstrated by the 23.9% decrease of SOD/
GSHPx ratio (P < 0.01) [42, 217].
The consequences of selenium supplementation on the brain antioxidant balance, and thus 
its therapeutic value, are difficult to monitor. However, certain clinical, experimental, and 
in vitro observations may be indicative [230]. A highly positive correlation has been reported 
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between erythrocyte GSHPx values and IQ in DS [231]. The plasma selenium concentration 
and erythrocyte GSHPx activity were found to be higher in DS girls than in DS boys, which 
is consistent with the finding of significantly higher IQ scores for female than for male DS 
patients. The positive correlation of E-GSHPx activity between DS subjects and their siblings 
suggests the influence of environmental and/or additional genetic factors [26, 230].
Estimates of the amount of selenium in the rat brain indicate that the GSHPx may account for 
only ⅕ of the total selenium in the brain [232]. The finding that selenoproteins other than GSHPx 
are distributed mainly in the brain and endocrine organs raises a question of their physiologi-
cal role. After the administration of very small amounts of selenium, severely depleted rats 
retained in the brain and in the reproductive and several endocrine organs (including thyroid) 
a dose which was 20–50 times the dose found in adequately fed control animals. This indicates 
the existence of regulatory mechanisms which ensure a sufficient level of selenium in critical 
organs, above all in the brain and the thyroid even during depletion [91, 233].
In concentrations of 6 x 10-7 M, selenite induces a 30-fold increase of GSHPx activity in neu-
roblast cells in vitro [234]. Earlier studies on the rat liver suggested that selenium regulates 
the level of GSHPx mRNA as well as GSHPx protein concentration and GSHPx activity [235]. 
Concentrations of 10-5 M exert obvious toxic effects on nerve fibers in vitro [236]. Trace elements, 
as “doping impurities” in organic material, could be key variables that regulate conductivity 
in biological semiconduction structures [237]. We suggest that the abnormally high levels of 
copper and iron and the low level of zinc ion in erythrocytes and blood mononuclear cells are 
reflections of disturbed oxygen radical metabolism in DS. However, increased concentration 
of copper can be explained as gene dosage evident by the increased activity of SOD-1 [238]. 
Except for the decreased iron content in erythrocytes, the results were in accordance with an 
earlier study [239]. Ferrous-ion (Fe II) and copper-ion (Cu I) react with H2O2 producing •OH 
radicals [240, 241]. Titanium in erythrocytes may indicate insufficient protection by GSHPx. If 
titanium is present as Ti (IV), stable compounds may be formed with hydrogen peroxides and 
probably with superoxide anions to give 1:1 adducts [238]. The low plasma zinc concentration 
in DS children has been recognized in earlier studies as well [242, 243]. The homeostasis of 
zinc is regulated by the intestine. The absorption of zinc seems to be decreased in DS, mean 
retention of zinc being 30% compared with 58% in healthy adults. Stable zinc supplementa-
tion in one DS patient did not increase the 65Zn elimination, indicating an unsaturated zinc 
pool [229].
Interestingly, the primarily high blood mononuclear cell levels of copper decreased, whereas 
the concentration of iron and zinc was not affected during selenium supplementation [244]. 
No significant alterations were observed in the erythrocyte concentrations of magnesium, 
calcium, iron, copper, zinc, sulfur, titanium, and manganese. Aluminum was not found in 
erythrocytes nor in neutrophils of DS patients [238].
8. Brain antioxidant homeostasis in relation to selenium and GSHPx
In nature the availability of selenium, as a trace element, may be limited. GSHPx activity 
has been shown to reflect selenium status in deficient and adequate states [245]. On the 
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other hand, protection against toxicity is likely to involve the alterations in GSH metabo-
lism that occur in nutritional Se deficiency. A high concentration of erythrocyte glutathione 
in patients with neurological disorders has been reported [246–248]. However, regulatory 
mechanisms apparently exist which ensure that during periods of insufficient selenium 
intake, the content of the element is kept up above all in the brain and the reproductive and 
the endocrine organs.
Selenium seems to be somehow involved in the regulation of oxygen metabolism through its 
influence on a variety of enzymes. In concentrations of 6 × 10−7 to ×10−6 M, selenite induces a 
30-fold increase of GSHPx activity in neuroblast cells in vitro. Other studies with the rat liver 
have suggested that Se status regulates the level of GSHPx mRNA as well as GSHPx protein 
concentration and GSHPx activity [235]. In concentrations of 0.7 − 2 × 10−5 M, Se in the rat liver 
increases the activities of γ-glutamylcysteine synthetase, the first rate-limiting enzyme in GSH 
biosynthesis, and GSSG reductase, which catalyzes the reduction of GSSG to GSH [249]. In some 
species the induction of GSH S-transferase has been shown to occur as a result of Se deficiency. 
Hydrogen peroxide as the most stable and diffusible of the oxygen reduction intermediates may 
exert an influence on the expression of SOD, catalase, and GSHPx activities. The homeostasis 
in the oxidative metabolism and oxygen reduction may be distorted by different means either 
inherent or acquired. Depending on the spatial and temporal occurrence of the distortion, vari-
ous neurological states are expressed. The developing brain is particularly susceptible to oxida-
tive stress more so than the mature brain [250]. H2O2 accumulation has also been associated 
with increased injury in the superoxide dismutase-overexpressing neonatal murine brain, and 
greater cell death is seen when immature neurons are exposed to H2O2 than with mature neu-
rons. Increased H2O2 accumulation may be the result of relative insufficiency of the endogenous 
enzyme GSHPx.
Under physiologic circumstances, the brain has efficient antioxidant defense mechanisms, 
including GSHPx, which converts potentially harmful H2O2 to oxygen and water at the 
expense of reduced GSH. Under oxidative stress, in the immature brain, endogenous levels 
of GSHPx may be inadequate for converting excess H2O2. Transgenic mice that overexpress 
GSHPx (hGPx-tg), when subjected to hypoxia-ischemia (HI), have less histologic brain injury 
than their WT littermates [19]. In addition, the cortex exhibits increased GSHPx enzyme activ-
ity at 24 h, whereas GSHPx activity remains unaltered in the WT brain. In addition, neu-
rons cultured from the hGPx-tg brain are resistant to injury from exogenously applied H2O2 
[251]. Neurons cultured from the hippocampus and cortex that are transfected (transfection 
describes the introduction of foreign material into eukaryotic cells) with genes for catalase 
and GSHPx also show protection from neurotoxic insults and a corresponding decrease in 
H2O2 accumulation [252]. These findings indicate that adequate GSHPx activity can amelio-
rate injury to the immature brain from oxidative stress due to H2O2.
It is well established that a previous stress to the brain can induce tolerance to subsequent injury, 
a phenomenon called personality change (PC). In neonatal rodents, protection against HI brain 
injury has been induced by PC with a period of hypoxia before the induction of HI [253]. The 
mechanisms of this protection have yet to be fully determined, but it has been established that a 
large number of genes are induced in response to hypoxia [254]. Many of these genes are regu-
lated by the transcription factor hypoxia-inducible factor-1α (HIF-1α), perhaps most importantly 
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between erythrocyte GSHPx values and IQ in DS [231]. The plasma selenium concentration 
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Concentrations of 10-5 M exert obvious toxic effects on nerve fibers in vitro [236]. Trace elements, 
as “doping impurities” in organic material, could be key variables that regulate conductivity 
in biological semiconduction structures [237]. We suggest that the abnormally high levels of 
copper and iron and the low level of zinc ion in erythrocytes and blood mononuclear cells are 
reflections of disturbed oxygen radical metabolism in DS. However, increased concentration 
of copper can be explained as gene dosage evident by the increased activity of SOD-1 [238]. 
Except for the decreased iron content in erythrocytes, the results were in accordance with an 
earlier study [239]. Ferrous-ion (Fe II) and copper-ion (Cu I) react with H2O2 producing •OH 
radicals [240, 241]. Titanium in erythrocytes may indicate insufficient protection by GSHPx. If 
titanium is present as Ti (IV), stable compounds may be formed with hydrogen peroxides and 
probably with superoxide anions to give 1:1 adducts [238]. The low plasma zinc concentration 
in DS children has been recognized in earlier studies as well [242, 243]. The homeostasis of 
zinc is regulated by the intestine. The absorption of zinc seems to be decreased in DS, mean 
retention of zinc being 30% compared with 58% in healthy adults. Stable zinc supplementa-
tion in one DS patient did not increase the 65Zn elimination, indicating an unsaturated zinc 
pool [229].
Interestingly, the primarily high blood mononuclear cell levels of copper decreased, whereas 
the concentration of iron and zinc was not affected during selenium supplementation [244]. 
No significant alterations were observed in the erythrocyte concentrations of magnesium, 
calcium, iron, copper, zinc, sulfur, titanium, and manganese. Aluminum was not found in 
erythrocytes nor in neutrophils of DS patients [238].
8. Brain antioxidant homeostasis in relation to selenium and GSHPx
In nature the availability of selenium, as a trace element, may be limited. GSHPx activity 
has been shown to reflect selenium status in deficient and adequate states [245]. On the 
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lism that occur in nutritional Se deficiency. A high concentration of erythrocyte glutathione 
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mechanisms apparently exist which ensure that during periods of insufficient selenium 
intake, the content of the element is kept up above all in the brain and the reproductive and 
the endocrine organs.
Selenium seems to be somehow involved in the regulation of oxygen metabolism through its 
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30-fold increase of GSHPx activity in neuroblast cells in vitro. Other studies with the rat liver 
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increases the activities of γ-glutamylcysteine synthetase, the first rate-limiting enzyme in GSH 
biosynthesis, and GSSG reductase, which catalyzes the reduction of GSSG to GSH [249]. In some 
species the induction of GSH S-transferase has been shown to occur as a result of Se deficiency. 
Hydrogen peroxide as the most stable and diffusible of the oxygen reduction intermediates may 
exert an influence on the expression of SOD, catalase, and GSHPx activities. The homeostasis 
in the oxidative metabolism and oxygen reduction may be distorted by different means either 
inherent or acquired. Depending on the spatial and temporal occurrence of the distortion, vari-
ous neurological states are expressed. The developing brain is particularly susceptible to oxida-
tive stress more so than the mature brain [250]. H2O2 accumulation has also been associated 
with increased injury in the superoxide dismutase-overexpressing neonatal murine brain, and 
greater cell death is seen when immature neurons are exposed to H2O2 than with mature neu-
rons. Increased H2O2 accumulation may be the result of relative insufficiency of the endogenous 
enzyme GSHPx.
Under physiologic circumstances, the brain has efficient antioxidant defense mechanisms, 
including GSHPx, which converts potentially harmful H2O2 to oxygen and water at the 
expense of reduced GSH. Under oxidative stress, in the immature brain, endogenous levels 
of GSHPx may be inadequate for converting excess H2O2. Transgenic mice that overexpress 
GSHPx (hGPx-tg), when subjected to hypoxia-ischemia (HI), have less histologic brain injury 
than their WT littermates [19]. In addition, the cortex exhibits increased GSHPx enzyme activ-
ity at 24 h, whereas GSHPx activity remains unaltered in the WT brain. In addition, neu-
rons cultured from the hGPx-tg brain are resistant to injury from exogenously applied H2O2 
[251]. Neurons cultured from the hippocampus and cortex that are transfected (transfection 
describes the introduction of foreign material into eukaryotic cells) with genes for catalase 
and GSHPx also show protection from neurotoxic insults and a corresponding decrease in 
H2O2 accumulation [252]. These findings indicate that adequate GSHPx activity can amelio-
rate injury to the immature brain from oxidative stress due to H2O2.
It is well established that a previous stress to the brain can induce tolerance to subsequent injury, 
a phenomenon called personality change (PC). In neonatal rodents, protection against HI brain 
injury has been induced by PC with a period of hypoxia before the induction of HI [253]. The 
mechanisms of this protection have yet to be fully determined, but it has been established that a 
large number of genes are induced in response to hypoxia [254]. Many of these genes are regu-
lated by the transcription factor hypoxia-inducible factor-1α (HIF-1α), perhaps most importantly 
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vascular endothelial growth factor (VEGF) and erythropoietin (EPO). VEGF is upregulated after 
focal ischemic injury in the neonatal rat, in parallel with the induction of HIF-1α [255].
9. Current opportunities and future prospects towards personalized 
medicine
Neurological disorders are diseases that affect the central and peripheral nervous systems. 
They can affect an entire neurological pathway or a single neuron; the neurodegeneration 
describes the loss of neuronal structure and function [256]. They are caused by genetic muta-
tions present during embryo or fetal development, although they may be observed later 
in life [257–259]. The mutations may be inherited from a parent’s genome, or they may be 
acquired in utero. The risk factors for the diseases are diverse, including age, genetics, life-
style, etc. Inflammatory conditions represent a major causative factor in numerous medically 
significant disorders. It can result from a range of stimuli from outside or within the body. 
However, these stimuli trigger cells and physiological processes within a host environment. 
It is believed that environmental exposures increase the risk of developing the disease. Even 
in inherited cases, exposure to toxins or other environmental factors may influence when 
symptoms of the disease appear or how the disease progresses [258, 260, 261].
With an increase in life span and decrease in death rate, the prevalence of these chronic recur-
ring condition are rising all over the world. Moreover, no direct therapy/treatment is avail-
able now, which can reverse or retard the pathophysiological processes permanently. The 
medication (drug) regimen needs to be well integrated with healthy diet and lifestyle to attain 
high-quality and longer lives [262]. Therefore, the complex physiopathological mechanisms 
must now be clarified, and the immunological and genetical causes to neurological diseases 
must be investigated. New research on gene changes linked and gene therapy to neurological 
disorders is helping scientists better understand the disease, in which DNA or RNA is used 
as the pharmacological agent, defined as gene therapy [263]. Both genetic and environmental 
factors are known to influence susceptibility to diseases. Therefore, environmental factors 
may also have a protective effect.
The role of free radicals is well established in etiopathogenesis of neurological disorders. Some 
of the known antioxidants, which can prevent oxidation chronic recurring condition, have 
been studied [38, 39]. Recent developments in basic research have confirmed the relationship 
between etiopathogenesis and supplementation therapy with vitamins and trace elements. 
Supplementation therapy studies should be conducted. We need more clinical experience 
and a longer follow-up period with our neurological disorder patients receiving antioxidant 
therapy to reach more final conclusions concerning efficacy in the control of optimal develop-
ment. Studies are now looking at the possible effects of these compounds more closely to 
develop related compounds that are even more potent and might be used as dietary supple-
ments. However, so far, most research suggests that a balanced diet is of greater benefit than 
taking these substances as dietary supplements.
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10. Personalized medicine approaches
Neurological diseases cannot be managed by using one single approach. These disorders, 
like all chronic diseases, are a complex metabolic system that is related to the way a patient’s 
genes interact with their individual environment. Therefore, precise and reliable testing 
methods are needed including patient biomarkers, age, and genetic history. Oxidative stress 
has been linked to dozens of chronic conditions [264, 265]. Identifying the cause of oxidative 
stress such as emotional stressors, poor diet, smoking, metal toxicity [266], chemical exposure, 
and pesticides can be of help [266, 267]. To balance free radicals may require lifestyle and diet 
modifications such as antioxidant supplementation [268, 269].
There is no doubt that the nervous system is involved in the etiopathogenesis of various 
pathological states and diseases. Interactions between the nervous, endocrine, and immune 
systems might represent the anatomical and functional basis for understanding the pathways 
and mechanisms that enable the brain to modulate the progression of disease. For example, 
an increasing number of pharmacogenetic association studies in DS are being reported [270, 
273]. Personalized medicine is an evidence-based, individualized medicine that delivers the 
right care to the right patient at the right time and results in measurable improvements in out-
comes and a reduction on healthcare costs. However, in order to make personalized medicine 
effective, genomic techniques must be standardized and integrated into health systems and 
clinical workflow. Though personalizing drug treatment on the basis of individual genotype 
rather than ethnicity may be more appropriate, differences in allele frequencies across conti-
nents should be considered when designing clinical trials of new drugs [270]. For example, 
new therapies for treating DS require quality of life measurement, such as the use of stem 
cells in order to develop treatments which may improve the intelligence of those affected with 
the syndrome [274]. Other methods being studied include the use of antioxidants, gamma 
secretase inhibition, adrenergic agonists, and memantine [275–279].
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Abstract
Oxidative stress has been implicated in epilepsy and various neurodegenerative disor-
ders. In this review, we elaborate oxidative stress-mediated neuronal loss and assess 
the role of selenium in some neurological disorders including epilepsy. Selenium as 
an essential trace element has attracted the attention of many researchers because of its 
potentialities in human health. It has an important role in the brain, immune response, 
defense against tissue damage, and thyroid function. Selenium forms part of the active 
site of the peroxide-destroying enzyme glutathione peroxidase (GSHPx), and it also has 
other functions, for example in biotransformation and detoxification. Functional and 
clinical consequences of selenium deficiency states in neurological diseases have been 
described, and the selenium requirement, which is influenced by various processes, has 
been discussed. Wide variations have been found in selenium status in different parts 
of the world, and populations or groups of patients exposed to marginal deficiency are 
more numerous than was previously thought. Chronic diseases, such as neurological 
disorders, heart disease, diabetes, cancer, aging, and others, are reported to associate 
with markers of oxidative damage. It is, therefore, not unreasonable to suggest that 
antioxidants would alleviate the oxidative damage, resulting in health improvements. 
In recent years, accumulated evidence in nutrigenomics, laboratory experiments, clinical 
trials, and epidemiological data have established the role of selenium in a number of 
conditions. Most of these effects are related to the function of selenium in the antioxidant 
enzyme systems. Current research activities in the field of human medicine and nutrition 
are devoted to the possibilities of using selenium as an adjuvant for the treatment of 
degenerative or free radical diseases such as neurological disorders, inflammatory dis-
eases, and cancer.
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disorders
© 2020 The Author(s). Licensee IntechOpen. Distributed under the terms of the Creative Commons Attribution-
NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/), which permits use, distribution
and reproduction for non-commercial purposes, provided the original is properly cited.
Chapter 9
Reactive Oxygen Species and Selenium in Epilepsy and
in Other Neurological Disorders
Erkki Antila, Tuomas Westermarck, Arno Latvus and
Faik Atroshi




© 2016 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons  
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,  
distribution, and reproduction in any medium, provided the original work is properly cited. 
cti   ci s  l i  i  il s   
in ther eurological isorders
r i  til , s  st r rc , r  L tv s  
i   i
dditional infor ation is available at the end of the chapter
Abstract
Oxidative stress has been implicated in epilepsy and various neurodegenerative disor-
ders. In this review, we elaborate oxidative stress-mediated neuronal loss and assess 
the role of selenium in some neurological disorders including epilepsy. Selenium as 
an essential trace element has attracted the attention of many researchers because of its 
potentialities in human health. It has an important role in the brain, immune response, 
defense against tissue damage, and thyroid function. Selenium forms part of the active 
site of the peroxide-destroying enzyme glutathione peroxidase (GSHPx), and it also has 
other functions, for example in biotransformation and detoxification. Functional and 
clinical consequences of selenium deficiency states in neurological diseases have been 
described, and the selenium requirement, which is influenced by various processes, has 
been discussed. Wide variations have been found in selenium status in different parts 
of the world, and populations or groups of patients exposed to marginal deficiency are 
more numerous than was previously thought. Chronic diseases, such as neurological 
disorders, heart disease, diabetes, cancer, aging, and others, are reported to associate 
with markers of oxidative damage. It is, therefore, not unreasonable to suggest that 
antioxidants would alleviate the oxidative damage, resulting in health improvements. 
In recent years, accumulated evidence in nutrigenomics, laboratory experiments, clinical 
trials, and epidemiological data have established the role of selenium in a number of 
conditions. Most of these effects are related to the function of selenium in the antioxidant 
enzyme systems. Current research activities in the field of human medicine and nutrition 
are devoted to the possibilities of using selenium as an adjuvant for the treatment of 
degenerative or free radical diseases such as neurological disorders, inflammatory dis-
eases, and cancer.
Keywords: selenium, antioxidants, oxidative stress, pathogenesis of neurological 
disorders
© 2020 The Author(s). Licensee IntechOpen. Distributed under the terms of the Creative Commons Attribution-
NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/), which permits use, distribution
and reproduction for non-commercial purposes, provided the original is properly cited.
1. Introduction
Selenium is a trace mineral essential to human health, which has an important role in the 
immune response, defense against tissue damage, and thyroid function. Improving sele-
nium status could help protect against overwhelming tissue damage and infection in criti-
cally ill adults [1–4]. Selenium is incorporated into proteins to make selenoproteins, which 
are important antioxidant enzymes. The antioxidant properties of selenoproteins help pre-
vent cellular damage from free radicals. Free radicals are natural by-products of oxygen 
metabolism that may contribute to the development of chronic diseases such as cancer and 
heart disease [5, 6]. There is evidence that selenium deficiency may contribute to develop-
ment of a form of hypothyroidism and a weakened immune system. Specific diseases have 
been associated with selenium deficiency such as Keshan and Kashin-Beck disease, which 
results in osteoarthropathy and myxedematous endemic cretinism, which results in mental 
retardation [7, 8].
In recent years, considerable evidence has emerged implicating a role for oxygen free radicals 
in the initiation of cellular injury which can lead to the development of several neurological 
disorders. The neonatal brain, with its high concentrations of unsaturated fatty acids (lipid 
content), high rate of oxygen consumption, and low concentrations of antioxidants, is particu-
larly vulnerable to oxidative damage. Thus, increased oxidative stress has been implicated in 
various neurological disorders such as seizures, ischemia-reperfusion injury, and neurode-
generative diseases [9, 10] such as Alzheimer’s, Parkinson’s, and Lou Gehrig’s disease. Free 
radical damage has been implicated in the initiation and propagation of seizure activity as 
well as the accompanying seizure-induced neuronal damage [11]. Therefore, antioxidants 
could play an important role in modulating susceptibility to seizure activity and seizure-
induced neuronal injury.
The use of selenium as a supplement in neurological disorders has been reported. The ratio-
nale for selenium supplementation comes from the nutrient’s role as an antioxidant [12], 
working primarily as a component of glutathione peroxidase, an important cellular protector 
against free radical damage. Furthermore, selenium deficiency is known to result in neu-
romuscular disease. Attempts have been taken to relate selenium to different neurological 
disorders as epilepsy, phenylketonuria and maple syrup urine disease, Parkinson’s disease, 
amyotrophic lateral sclerosis, neuronal ceroid lipofuscinoses, myotonic dystrophy, multiple 
sclerosis, Down syndrome (DS), and Alzheimer’s disease [13, 14]. The relevant connection 
between selenium and the majority of these disorders rests on clinical observations during 
selenium supplementation alone or in combination with other antioxidants.
2. Selenium distribution in humans
Due to the uneven geographic distribution of selenium in soil, the amount of whole-body sele-
nium in adult humans was reported to differ in different countries [15–18]. At normal dietary 
levels, the highest selenium concentration was detected in reindeer liver and kidney, followed 
Personalized Medicine, in Relation to Redox State, Diet and Lifestyle162
by the spleen, pancreas, heart, brain, lung, bone, and skeletal muscle. Selenium concentration 
in the human body was also found to vary with age. For instance, selenium concentration 
in fetal brain decreased with age but increased with age postnatally. Blood selenium levels 
were negatively correlated with age in healthy adults, and the same was documented for 40 
patients with dementia of the Alzheimer type (DAT). Furthermore, Ejima et al. [19] reported 
that selenium concentrations varied in different adult human brain regions.
3. Selenium in the brain
Neurochemical aspects of selenium have been widely reported. In this approach to the etio-
pathogenetic role of selenium in CNS diseases, teleological ideas are explicitly correlated to 
the paradigm of oxygen toxicity. The brain differs from many other tissues, being a highly 
aerobic and totally oxygen-dependent tissue. Oxygen reduction produces reactive radical 
intermediates, i.e., singlet oxygen, a superoxide radical which is thought to be a major agent of 
oxygen toxicity. Hydrogen peroxide, H2O2, is formed through dismutation of a singlet oxygen 
catalyzed by Cu-Zn and Mn forms of superoxide dismutase, both found in CNS tissues. Other 
hydrogen peroxide-generating enzymes are associated with d- and l-amino acid oxidase, 
monoamine oxidase, a-hydroxyacid oxidase, xanthine oxidase, and cytochrome P-450 system.
Unlike charged oxygen radicals being a rather unreactive and stable, H2O2 rapidly crosses cell 
membranes. Cellular damage is accomplished when H2O2 decomposes to the highly reactive 
hydroxyl radical in iron(II) or copper(I) catalyzed reactions. Scavenging of H2O2 and contem-
poraneous prevention of hydroxyl radical formation occurs predominantly at two cellular 
sites, in the peroxisomes and in the cytoplasm by catalase and GSHPx (GSHPx, glutathione/
hydrogen peroxide oxidoreductase, EC 1.11.1.9), respectively. If this is not done, the hydroxyl 
radical may attack the fatty acid side chains and start a chain reaction of lipid peroxidation. 
Lipid peroxidation causes gradual loss of membrane fluidity and membrane potential and 
increases membrane permeability to ions. Radical attack may also destroy membrane-bound 
enzymes and receptors, e.g., the binding of serotonin is decreased. Oxidative degradation 
and polymerization of lipids leads to the accumulation of lipofuscin, the age pigment. The 
presence of catalytic iron and copper complexes in human CSF, and the high iron content of 
brain, suggests that they are very sensitive to oxygen radical generation.
The crucial role of selenium as a trace element in the nervous tissue has been associated 
with a selenoenzyme glutathione peroxidase. Selenium is thought to be present at the 
active site of GSHPx in its selenolate form as selenocysteine [20]. The fairly homogenous 
distribution of selenium in the human brain corresponds well with the regions of the high-
est and lowest GSHPx activity found in the rat brain. However, estimates of the amounts 
of selenium in rat brain have indicated that GSHPx may account for only 1/5 of the total Se 
found in the brain [21]. Most of the selenium is bound to proteins and not to amino acids or 
nucleic acids [22]. Selenoproteins, other than GSHPx, found in the brain and the reproduc-
tive and the endocrine organs seem to serve as a priority pathway of the element during 
inadequate selenium intake. The function of selenium in proteins has been explained in 
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terms of semiconduction [23]. It is possible although not yet proven that selenium may have 
this or some other special functions outside of GSHPx too.
Observations suggest that free radical intermediates may be involved in the coupling between 
depolarization of the plasma membrane, Ca2+ fluxes, and neurotransmitter release [24]. In gen-
eral, cellular redox adjustments regulate functional sulfhydryl groups of proteins. Therefore, 
cellular prooxidant states may be involved in the generation of physiological responses. This 
means that the adjustment of redox equilibrium in CNS is a far more delicate phenomenon 
than just a tendency to a normal balance.
The regulation of GSH level (GSH/GSSG) through pentose phosphate pathway producing 
NADPH, GSH-reductase, and GSHPx contributes to the overall redox state of cells in the 
brain [25]. The brain tends to need radical reactions as well as to possess specific or high 
endogenous levels of free radical scavengers such as dopamine, norepinephrine, and cat-
echol estrogens, taurine and carnosine [26], in neurons. Carnosine is involved with GSBA 
activity in the brain, and a study by Takahashi [27] demonstrated that homocarnosine levels 
were high in patients who responded to antiepileptic drugs. The functional balance between 
various free radical scavenger systems in the brain seems reasonable. Significant positive 
correlations between catalase and SOD levels have been reported in tissues of normal sub-
jects excluding erythrocytes. Factors concomitantly influencing the variation of the activities 
of SOD, catalase, and GHSPx have been reported. Enzymes frequently called a protective 
should rather be envisaged as being regulatory, controlling the levels of different states of 
oxygen reduction.
4. Brain antioxidant homeostasy in relation to selenium and GSHPx
As a trace element in nature, the availability of selenium may be limited. GSHPx activity has 
been shown to reflect selenium status in deficient and adequate states [6]. On the other hand, 
protection against toxicity is likely to involve the alterations in GSH metabolism that occur 
in nutritional Se deficiency. High concentrations of erythrocyte glutathione in patients with 
neurological disorders have been reported [28]. However, regulatory mechanisms apparently 
exist which ensure that during periods of insufficient selenium intake, the content of the ele-
ment is kept up above all in the brain and the reproductive and endocrine organs.
Yoshida et al. [29] reported a comprehensive method for identifying the selenium-binding 
proteins using PenSSeSPen as a model of the selenium metabolite, selenotrisulfide (RSSeSR, 
STS), which was applied to a complex cell lysate generated from the rat brain. The authors 
stated that a thiol-containing protein at m/z 15155 in the brain cell lysate was identified as the 
cystatin-12 precursor (CST12) from a rat protein database search and a tryptic fragmentation 
experiment. CST12 belongs to the cysteine proteinase inhibitors of the cystatin superfamily 
that are of interest in mechanisms regulating the protein turnover and polypeptide produc-
tion in the central nervous system and other tissues. Consequently, CST12 is suggested to be 
one of the cytosolic proteins responsible for the selenium metabolism in the brain [29].
Personalized Medicine, in Relation to Redox State, Diet and Lifestyle164
Selenium seems to be somehow involved in the regulation of oxygen metabolism through its 
influence on a variety of enzymes. In concentrations of 6 × 10−7 to × 10−6 M, selenite induces a 
30-fold increase of GSHPx activity in neuroblast cells in vitro. Other studies with the rat liver 
have suggested that Se status regulates the level of GSHPx mRNA as well as regulates GSHPx 
protein concentration and GSHPx activity [30]. In concentrations of 0.7–2 × 10−5 M, Se in rat 
liver increases the activities of g-glutamylcysteine synthetase, the first rate-limiting enzyme in 
GSH biosynthesis, and GSSG-reductase, which catalyzes the reduction of GSSG to GSH [31]. In 
some species the induction of GSH-S-transferase has been shown to occur as a result of Se defi-
ciency. H2O2 as the most stable and diffusible of the oxygen reduction intermediates may exert 
an influence on the expression of SOD, catalase, and GSHPx activities. GSHPx, which exists in 
several forms that differ in their primary structure and localization, catalyzes the reduction of 
hydrogen peroxide and organic hydroperoxide by glutathione and functions in the protection 
of cells against oxidative damage [32]. The homeostasy in the oxidative metabolism and oxygen 
reduction may be distorted by different means, either inherent or acquired. Depending on the 
spatial and temporal occurrence of the distortion, various neurological states are expressed.
The developing brain is particularly susceptible to oxidative stress, more so than the mature 
brain [33]. H2O2 accumulation has also been associated with increased injury in superoxide 
dismutase-overexpressing neonatal murine brain, and greater cell death is seen when imma-
ture neurons are exposed to H2O2 than mature neurons. Increased H2O2 accumulation may be 
the result of relative insufficiency of the endogenous enzyme GSHPx.
Under physiologic circumstances, the brain has efficient antioxidant defense mechanisms, 
including GSHPx, which converts potentially harmful H2O2 to oxygen and water at the 
expense of reduced GSH. Under oxidative stress, in the immature brain, endogenous levels 
of GSHPx may be inadequate for converting excess H2O2. Transgenic mice that overexpress 
GSHPx (hGPx-tg), when subjected to hypoxic-ischemic (HI), have less histologic brain injury 
than their Wt littermates [25]. In addition, the cortex exhibits increased GSHPx enzyme activ-
ity at 24 h, whereas GSHPx activity remains unaltered in the Wt brain. In addition, neu-
rons cultured from GSHPx-tg brain are resistant to injury from exogenously applied H2O2 
[34]. Neurons cultured from the hippocampus and cortex that are transfected (transfection 
describes the introduction of foreign material into eukaryotic cells) with genes for catalase 
and GSHPx also show protection from neurotoxic insults and a corresponding decrease in 
H2O2 accumulation [35]. These findings indicate that adequate GSHPx activity can ameliorate 
injury to the immature brain from oxidative stress due to H2O2.
It is well established that previous stress to the brain can induce tolerance to subsequent 
injury, a phenomenon called personality change (PC). In neonatal rodents, protection against 
HI brain injury has been induced by PC with a period of hypoxia before the induction of 
HI [36]. The mechanisms of this protection have yet to be fully determined, but it has been 
established that a large number of genes are induced in response to hypoxia [37]. Several 
of these genes are regulated by the transcription factor hypoxia-inducible factor-1α (HIF-1α) 
and perhaps most importantly vascular endothelial growth factor (VEGF) and erythropoietin 
(EPO). VEGF is upregulated after focal ischemic injury in the neonatal rat, in parallel with 
induction of HIF-1α [38, 39].
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terms of semiconduction [23]. It is possible although not yet proven that selenium may have 
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STS), which was applied to a complex cell lysate generated from the rat brain. The authors 
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cystatin-12 precursor (CST12) from a rat protein database search and a tryptic fragmentation 
experiment. CST12 belongs to the cysteine proteinase inhibitors of the cystatin superfamily 
that are of interest in mechanisms regulating the protein turnover and polypeptide produc-
tion in the central nervous system and other tissues. Consequently, CST12 is suggested to be 
one of the cytosolic proteins responsible for the selenium metabolism in the brain [29].
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5. Aging, dementia, and Alzheimer’s disease
Major interest in CNS selenium is related to aspects of oxidative stress and aging. The 
decrease in cerebral blood flow, glucose utilization, and oxygen consumption common to 
many dementias results from abnormalities of brain structure with a high oxidative capacity. 
During mental activity, regional cerebral oxidative metabolism and regional cerebral blood 
flow increase in several areas of the brain. In dementia of the Alzheimer type, brain blood flow 
and oxidative metabolism are reduced. This situation may lead to loss of balance between 
prooxidants and antioxidants [40]. The role of H2O2 in the etiology of Alzheimer’s disease 
has been reported [41, 42]. Furthermore, the activities of catalase and GSHPx decrease with 
aging in intact animals. Some reports suggest that the SOD activity is significantly greater in 
Alzheimer cell fibroblasts. Both GSHPx and SOD activities in the erythrocytes of AD have 
been reported to be normal, while other studies show significantly higher erythrocyte SOD 
level in AD [43]. It remains to be seen whether oxidative damage will still be related to the 
accumulation of aluminum silicates in the brain as well as to that of the senile plaques and 
tangles. Experiments have indicated that aluminum salts may not only accelerate Fe(II)-
induced peroxidation of membrane lipids but do this especially in the brain [44, 45].
In order to evaluate the peroxidative stress in dementias, autopsy brain samples should be 
studied for GSHPx, SOD, catalase, and selenium. A direct causal relationship between brain 
antioxidant defenses and dementia in aging and Alzheimer’s disease is hard to demonstrate 
because of the extremely slow process. Interestingly a high proportion of Down syndrome 
patients develop the neuropathological and clinical changes of AD, suggesting a close patho-
genetic relationship between these disorders. Thus, the correction of antioxidant balance in 
AD by Se supplementation should be demonstrated by other means so as to direct it preven-
tatively to those with a high risk of developing AD.
In Alzheimer’s disease the H2O2 molecule should be considered a therapeutic target for treat-
ment of the oxidative stress associated with the disease. The actions of H2O2 include modifica-
tion of DNA, proteins, and lipids, all of which are effects seen in an Alzheimer’s disease brain, 
possibly contributing to the loss of synaptic function characteristic of the disease. Future 
research and development of agents that specifically target the H2O2 molecule or enzymes 
involved in its metabolism may provide the future route to Alzheimer’s disease therapy [42].
6. Down syndrome
Trisomy 21 (Down syndrome) is the most common genetic cause of learning disability in 
humans [46], occurring in about 1 per 1000 babies born each year [47]. Postmortem studies 
have reported neuronal depletion and structural abnormalities of the brain during late gesta-
tion and early postnatal life [48]. Down syndrome was found to have increased activity of 
superoxide dismutase without a compensatory increase in glutathione peroxidase activity 
[49]. However, there is no evidence to support the use of antioxidant or folinic acid supple-
ments in children with Down syndrome [50].
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Increased primary gene products which may contribute to the pathology of DS include cyto-
plasmic CuZn-superoxide dismutase (SOD). Consistent with the gene dosage effect, SOD 
activity is increased by 50%, leading to noxious concentrations of H2O2, while brain GSHPx 
remains normal. The overall redox state in other tissues is corrected by an adaptive increase 
of GSHPx activity. This means that the brain is especially susceptible to oxygen free radical 
stress. Our primary survey of specific antioxidant therapy with selenium [51] rests on this 
theory.
The whole-body retention of 5–8 kBq 75Se-sodium selenite with 0.4 g Se as carrier/kg body 
weight in DS patients has been earlier estimated to be 53.3 + 21.1%. Stable Se supplementation 
increased 75Se elimination, indicating a saturated Se pool in the body. Twenty-four patients 
aged 1–41 years were either given selenium supplements of 0.025 mg Se/kg/d in the form of 
sodium selenite or given placebo or no preparation. The serum levels of selenium indicated no 
real deficiency as compared to the normal healthy population. However, the mean compensa-
tory increase of erythrocyte GSHPx activity before supplementation was lower than expected. 
Because of difficulties in obtaining brain biopsies, variables found in the plasma and erythro-
cyte samples were used as indicators of antioxidant balance. Sinet et al. [52] have reported a 
high positive correlation between erythrocyte GSHPx values and the intelligence quotient in DS 
patients. Because of this and the difficulties in testing changes of IQ which is one of the most deci-
sive clinical goals of therapy, we found it reasonable to follow changes of E-GSHPX. Selenium 
supplementation increased E-GSHPx activity by 28% (59.9% above normal). The correction is 
sensitive to adequate Se supplementation as indicated by SOD/GSHPx index which decreased 
by 23.9% (P < 0.01) [51]. Interestingly the primarily high serum and blood mononuclear cell 
levels of cupric and ferrous ions decreased, and that of zinc ions increased during supplementa-
tion. In conclusion we believe that the patients have benefited from the selenium supplementa-
tion through optimization of their antioxidant protection by GSHPx.
7. Selenium and epilepsy
An epilepsy syndrome is a complex of signs and symptoms defining a unique condition [53]. 
Oxidative stress and generation of reactive oxygen species are strongly implicated in a num-
ber of neuronal and neuromuscular disorders, including epilepsy. The functions of selenium 
as an antioxidant trace element are believed to be carried out by selenoproteins that possess 
antioxidant activities and the ability to promote neuronal cell survival. Selenoproteins are 
important for normal brain function, and decreased function of selenoproteins may lead to 
impaired cognitive function and neurological disorders [54].
Free radicals and lipoperoxidation reactions seem to be involved in epileptic seizure devel-
oping after brain hemorrhage of different kinds. There is an association between hemosid-
erin deposition and post-traumatic epilepsy. An extravasation of blood and hemolysis of 
erythrocytes result in the decompartmentalization of free iron and accelerate the rates of 
lipoperoxidation and superoxide-dependent formation of OH radicals, which are propagated 
by reperfusion and reoxygenation in postischemic tissue injury. Simultaneously the activity 
of GSHPx in the ischemic tissue is decreasing. Selenium and other antioxidants have been 
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observed to prevent synergistically the lipoperoxidation in animals and in man. Pretreatment 
of rats with vitamin E and selenium prior to iron injections has been shown to prevent the 
development of seizures to a high degree in a large percentage of experimental rats [55]. 
There are also reports of the normalization of the EEG of patients with the juvenile type of 
neuronal ceroid lipofuscinosis (JNCL) after vitamin E and sodium selenite supplementation. 
In addition, the onset of epilepsy is significantly earlier among JNCL patients not given this 
antioxidant therapy (11.1 year) than patients receiving antioxidant therapy (13.6 year) [56].
Numerous evidences suggest that selenium may ameliorate some of the adverse metabolic 
consequences of valproic acid. Valproic acid therapy has been shown to deplete plasma sele-
nium levels, a cofactor required for glutathione peroxidase activity. Selenium supplement 
may help lower ammonia level in patients with valproate-induced hyperammonemia over 
long-term treatment. Selenium deficiency may lead to the loss of seizure control, even when 
the patient is remained on the same dose of valproic acid [57, 58]. Furthermore, Ashrafi et al. 
[59] concluded that the measurement of serum selenium in patients with intractable epilepsy 
should be considered.
8. Juvenile type of neuronal ceroid lipofuscinosis
The neuronal ceroid lipofuscinoses (NCL) are a group of recessively inherited neurodegener-
ative-lysosomal storage diseases of infancy, with an estimated occurrence of 1 in 12,500 live 
births [60–62]. Characteristics of the diseases are deposits of ceroid and lipofuscin pigments 
in the tissues, particularly in the neural tissue, visual failure, and progressive mental retarda-
tion. Depending on the age of onset and clinical, electrophysiological, and neuropathological 
features, the NCLs can be subdivided into the infantile, the late infantile, the juvenile, and the 
adult type of NCL. The pathogenesis of NCL is unknown. The polyenic acid level with low 
levels of linoleic acid and an inverse relationship between GSHPx activity and the level of 
eicosatrienoic acid has been observed in JNCL [63].
The occurrence of the fluorescent pigments suggested the peroxidation of lipids in the etiology of 
NCL. It is likely that the diseased tissues peroxidize more rapidly than normal tissues and cyto-
toxic end products of lipoperoxidation cause secondary damage. On a weight basis, ceroid seen 
in JNCL patients binds five times more iron than the lipofuscin seen in normal elderly individu-
als. The increased levels of aluminum salts greatly enhance iron-dependent damage to mem-
branes. Heiskala et al. [64] have confirmed the presence of complexable iron and copper in the 
CSF of patients with NCL and other neurological disorders, and when the pH value of the assay 
for iron was lowered, the NCL group had substantially more complexable iron in their CSFs. 
Interestingly aluminum has been observed in CSF and in ceroid lipofuscin pigments of the brain 
of NCL patients [65]. It is well established that damaged tissue releases metals from protein-
bound sites and these metals stimulate peroxidative damage to lipids and other biomolecules.
One of the most essential enzymes counteracting lipoperoxidation is the selenium-containing 
GSHPx. Two independent reports have demonstrated that erythrocyte GSHPx activity is 
decreased in JNCL patients [66, 67]. This low GSHPx activity was reversed to normal level by 
selenium supplementation.
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The evaluation of sodium selenite absorption and losses before supplementation of JNCL 
patients has been studied by using total body counting for 75Se detection. These studies showed 
that in three JNCL patients, about 55% of the administered 75Se was eliminated during the 
first 11 days in the feces and about 10% in the urine [68]. Compared to healthy controls (n = 
2, percentages 42% and 7%, respectively), findings indicate a reduced absorption of selenium 
in JNCL patients contrary to a previous report. The low GSHPx activity in NCL patients may 
indeed reflect a low selenium intake, most probably due to a disturbed absorption of selenium 
and secondary phenomena due to an inborn error of metabolism. Apart from the low selenium 
status, also very low vitamin E levels are found in the serum of advanced and hospitalized 
NCL patients. This can be explained by the recent finding of a pronounced reduction of apo-
protein B as well as the whole fraction of very low density lipoprotein (VLDL) in JNCL patients.
JNCL patients (genetically subgroups) have been given daily supplementation of sodium 
selenite (0.05–0.1 mg/Se/kg of b.w.), vitamin E (α-tocopherol acetate 0.014–0.05 g/kg b.w.), 
vitamin B2 (0.025–0.05 mg/kg b.w.), and vitamin B6 (0.63–0.8 mg/kg b.w.). The benefits of 
the therapy are corroborated by the significant negative correlation of GSHPx activity with 
neurological dysfunction of motor performance, balance, coordination, and speech [69]. The 
mean age at death has been extended by 4 years as compared to that at the beginning of 
the century. As the best responders to antioxidant therapy show no neurological dysfunc-
tion at the age of over 20 years, there is no doubt that the life expectancy of JNCL patients 
receiving antioxidants, including selenium, will be significantly prolonged in the future [70]. 
Complications of the antioxidant therapy have been few and not severe. Six patients have 
experienced vomiting and nausea when the serum concentration of selenium reached the 
level of 4.5–5 M. Serum levels up to 4.0 M were usually well tolerated as well as when the 
sodium selenite was changed to EbselenR (2-Phenyl-1,2-benzoselenazol-3-one).
9. Multiple sclerosis (MS)
Multiple sclerosis is a severe neurodegenerative disease of polygenic etiology affecting the 
central nervous system. Low levels of polyenic acids are involved in the pathogenesis of both 
MS and JNCL [71, 72]. In 1972 Thompson et al. found decreased levels of serum linoleate as 
well as unsaturated fatty acids of brain phospholipids in MS patients. It has also been shown 
that supplementation with essential fatty acids may improve the clinical status of young MS 
patients diagnosed early. As in NCL, the selenium may by activating GSHPx (scavenger of 
organic peroxides) regulate the metabolic transformation of essential fatty acids and biotrans-
formation of these to prostaglandins, thromboxanes, and leukotrienes. Curiously decreased 
GSHPx activities in erythrocytes have been found in female but not in male MS patients [73].
Blood selenium levels have been reported to be lower in MS patients than in healthy con-
trols [74–76]. However, selenium concentration has been shown to be normal in plasma and 
erythrocytes but lowered in platelets of MS patients. Impaired Se status has been found in 
MS largely in the connection of severe protein-calorie malnutrition. Treatment of MS with Se 
supplementation does not seem warranted in the absence of demonstrated deficiency. Thus, 
in the reported selenium-containing antioxidant treatments, the clinical benefit to the course 
of MS has remained open to speculation.
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The evaluation of sodium selenite absorption and losses before supplementation of JNCL 
patients has been studied by using total body counting for 75Se detection. These studies showed 
that in three JNCL patients, about 55% of the administered 75Se was eliminated during the 
first 11 days in the feces and about 10% in the urine [68]. Compared to healthy controls (n = 
2, percentages 42% and 7%, respectively), findings indicate a reduced absorption of selenium 
in JNCL patients contrary to a previous report. The low GSHPx activity in NCL patients may 
indeed reflect a low selenium intake, most probably due to a disturbed absorption of selenium 
and secondary phenomena due to an inborn error of metabolism. Apart from the low selenium 
status, also very low vitamin E levels are found in the serum of advanced and hospitalized 
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9. Multiple sclerosis (MS)
Multiple sclerosis is a severe neurodegenerative disease of polygenic etiology affecting the 
central nervous system. Low levels of polyenic acids are involved in the pathogenesis of both 
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MS largely in the connection of severe protein-calorie malnutrition. Treatment of MS with Se 
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Mercury is well known for its severe toxicity especially by inhalation [77]. People exposure 
to Hg is mainly due to environmental pollution and the consumption of fish or other aquatic 
product [78]. Chronic mercury poisoning is characterized by neurological and psychological 
symptoms, such as tremor, restlessness, personality changes, anxiety, sleep disturbance, and 
depression. Symptoms are reversible after cessation of exposure. Because of the blood-brain 
barrier, there is no central nervous involvement related to inorganic mercury exposure [79]. 
Selenium interacts in the body with a wide range of toxic metals such as arsenic, cadmium, 
mercury, copper, silver, and lead. It has been shown to be highly effective in animals in pre-
venting brain damage of organic and inorganic mercury. In postmortem brain samples from 
persons exposed to mercury vapors, mercury and selenium were found at a molar ratio of 
approximately 1. This indicates that the brain is the target organ in human exposure to mer-
cury vapors. Mercury and selenium react in various ways. The role of brain selenium in inor-
ganic heavy metal toxicity is thought to be minimal [80, 81]. Mercuric ion bound to selenium 
is proposed to form a biologically inert complex, leading to increased body burden of both 
elements. This reaction seems to take place only when a threshold of mercury exposure is 
exceeded. Selenium influences the oxidation rate of elemental mercury in cases of low GSHPx 
activity; decreased mercury oxidation may lead to increased brain uptake. Selenium may also 
together with vitamin E counteract mercury-induced lipid peroxidation.
11. Other CNS diseases related to selenium
11.1 Parkinson’s disease
Parkinson’s disease (PD) is a chronic and progressive movement disorder, meaning that 
symptoms continue and worsen over time. Oxidative stress is also thought to have a patho-
genic role in Parkinson’s disease [82, 83]. Selenium protects cellular elements from oxidative 
damage and may participate in redox-type reactions. Low plasma selenium concentrations 
are associated with subtle neurological impairments reflected in soft neurological signs [84, 
85]. Plasma Se was the only statistically significant difference of up to 16 elements identified 
for PD patients [86] relative to Alzheimer's disease patients. Redox-active role is evidenced 
by an increased lipid peroxidation and reduced glutathione levels [87] and high concentra-
tion of iron and free radical generation via autocatalytic mechanisms within neuromelanin-
containing catecholaminergic neurons in the substantia nigra. In addition, the observation 
that exogenous administration of cysteine, N-acetyl cysteine, or glutathione decreased the 
neurotoxic effects of 6-hydroxydopamine in vitro and in vivo reinforces this hypothesis [88].
11.2 Tardive dyskinesia
Tardive dystonia (TD), a rarer side effect after longer exposure to antipsychotics, is character-
ized by local or general, sustained, involuntary contraction of a muscle or muscle group, with 
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twisting movements, generally slow, which may affect the limbs, trunk, neck, or face [89, 90]. 
This condition is characterized by involuntary movements. These abnormal movements most 
often occur around the mouth. The disorder may range from mild to severe. For some people, 
it cannot be reversed, while others recover partially or completely. Tardive dyskinesia is seen 
most often after long-term treatment with antipsychotic medications. Other names for this 
specific disorder are linguofacial dyskinesia, oral-facial dyskinesia, tardive dystonia, tardive 
oral dyskinesia, and TD. Many preclinical and clinical studies have investigated the possible 
role of selenium and other antioxidants. These studies suggest that free radicals are probably 
involved in the pathogenesis of TD and that vitamin E and selenium could be efficacious in 
its treatment.
11.3 Duchenne muscular dystrophy
Muscular dystrophy (MD) is a group of genetic diseases involving progressive weakness and 
degeneration of the muscles that control movement. In some forms of MD, the heart muscles 
and other involuntary muscles, as well as other organs, are also affected. There are nine 
distinct types of MD, with myotonic the most common form among adults and Duchenne 
the most common form among children, primarily affecting males. MD is an incurable, often 
fatal disease. It is usually obvious by the age of 5 and evolves progressively until it causes 
disablement and death, around the age of 20. Death commonly results from involvement of 
the respiratory muscles. It is recessively inherited and linked to sex, and the gene determin-
ing DMD has been mapped in the Xp-21 locus. It has an incidence of 1/3000–1/3500 male 
births, and one third of the cases come from new mutation. Some affected individuals may 
develop intellectual disturbance due to unknown mechanism, so far. The sister of an affected 
individual has a 50% chance of carrying the defective gene. The result of the dystrophic locus 
on the gene is the absence of dystrophin, a rod-shaped protein that is part of the muscle 
cytoskeleton.
The genetic alteration produces abnormality in the membrane of the muscular fibers that con-
sists of a disturbance in the calcium transport (Ca2+), inside the muscular fibers, which is the base 
mechanism of cellular degeneration and necrosis. There is fiber necrosis and replacement of fibers 
by fat. A nucleotide degradation, and decreased muscle ATP and ADP content, has been reported. 
The ATP is necessary to drive the Na+/K+ pump, which maintains ionic gradients across the sar-
colemma; re-sequester the Ca2+ into the cisternae; and have power contraction. The production of 
ATP can be the result of anaerobic respiration, which breaks glucose down into ATP and lactic 
acid, or aerobic respiration when ATP, carbon dioxide, and water are formed. A second immediate 
reserve of energy exists in the form of creatine phosphate, which can donate phosphate to ADP 
to form ATP, becoming itself creatine. In the resting muscle, glucose is stored as glycogen, and in 
such a muscle aerobic respiration synthesizes ATP from glucose or fatty acids.
Therapy of DMD has been an elusive goal. Studies with isolated myocytes have shown that lipid 
peroxidation with an enhanced free radical production can be activated by increasing Ca concen-
tration. Low oxygen saturation in the muscle tissue may stimulate the Il-6 production, a cytokine, 
which is produced by contracting muscles and released into the blood. The blood circulation of 
the older Duchenne patients is particularly disturbed. Pedersen et al. [91] have demonstrated 
that Il-6 affects the metabolic genes, induction of lipolysis, inhibition of insulin resistance, and 
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stimulation of cortisol production. In addition, carbohydrate supplementation during exercise 
was shown to inhibit the release of Il-6 from contracting muscle. Thus carnitine supplementation 
is indicated to the Duchenne patients, to make sure that the energy supply will be good.
Johansson et al. [92] hypothesized that increased production of interleukin-6 (IL-6) and tumor 
necrosis factor-alpha (TNF-alpha) may be important underlying mechanisms in myotonic 
dystrophy. Patients with high body fat mass had significantly increased insulin levels and 
decreased morning levels of cortisol, ACTH, and testosterone. IL-6 and TNF-alpha levels are 
increased, and adrenocortical hormone regulation is disturbed in MD. Adiposity may con-
tribute to these disturbances, which may be of importance for decreased adrenal androgen 
hormone production and metabolic, muscular, and neuropsychiatric dysfunction in MD [92]. 
Henríquez-Olguín et al. [93] reported that IL-6 is a key metabolic modulator that is released 
by the skeletal muscle to coordinate a multisystemic response (liver, muscle, and adipocytes) 
during physical exercise; the alteration of this response in dystrophic muscles may contribute 
to an abnormal response to contraction and exercise.
Thus, several kinds of antioxidants have been proposed as a treatment since increased levels 
of thiobarbituric acid (TBA) reactive material have been found in the muscles and blood of 
DMD boys [94]. Increased amounts of pentane are expelled by the DMD patients [95]. We 
have previously reported that the biological half-life of 75Se in DMD patients was significantly 
shorter than in healthy controls [96]. We also reported that patients with myotonic muscular 
dystrophy, the most common form of muscular dystrophy in adults, show improvement in 
muscular force and function when treated with selenium and vitamin E [97].
Shimomura et al. [98] observed a group of trained animals, part of which were coenzyme 
Q10 treated and had to exercise for 30 min on treadmill, in downhill position. CoQ10-
treated animals had higher level of CoQ10 In their muscles, and the early rise in creatine 
kinase and lactic dehydrogenase plasma levels, due to the exercise, was evident at a 
remarkably significant lower extent, in the treated ones. Similar observations were also 
made in humans [99]. Therefore we have been treating the Duchenne patients with CoQ10. 
We have been given two siblings of whom the elder one got practically no antioxidants and 
the younger one whose antioxidant treatment started at the age of 6 years. Nutrient supple-
ment protocol for DMD patients included sodium selenite  0.05-0.1 mg Se kg−1 b.w. day−1 
; alpha-tocopherol, 10-20 mg kg−1 b.w. day−1;  vitamin B2, 0.2 mg kg−1 b.w. day−1;  vitamin 
B6, 5 mg kg−1 b.w. day−1; L-carnitine 10–20 mg kg−1 b.w. day−1; ubiquinone-10 (coenzyme 
Q10) 3 mg kg−1 b.w. day−1 [100]. In the future the therapy may be by producing functional 
amounts of dystrophin by skipping the mutated exon like what has been done in the mdx 
dystrophic mouse [101].
12. Personalized gene therapy
The analytical power of modern methods for DNA analysis has outstripped our capability to 
interpret and understand the data generated. It is vital that we understand the mechanisms 
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through which mutations affect biochemical pathways and physiological systems [102]: 
major bcr-abl mRNA nucleic acid amplification assay, genetic analysis of progressive mus-
cular dystrophy, genetic analysis of rearranged immunoglobulin gene, and genetic analy-
sis of malignant tumor. The promise of personalized medicines is enormous, particularly 
for rare disease [103, 104]. The genetic diversity of Emery-Dreifuss muscular dystrophy 
(EDMD) predicts that a cure will ultimately depend upon the individual’s defect at the 
gene level, making this an ideal candidate for a precision medicine approach [105]. Ataluren 
known as PTC124 is a drug for the treatment of Duchenne muscular dystrophy caused by 
a nonsense mutation (nmDMD) and cystic fibrosis caused by a nonsense mutation (nmCF). 
PTC124 can lead to restoration of some dystrophin expression in human Duchenne mus-
cular dystrophy muscles with mutations resulting in premature stops [106]. Eteplirsen, a 
phosphoramidite morpholino sequence complementary to a portion of exon 51, is designed 
to force the exclusion of exon 51 from the mature DMD mRNA. Similar drugs targeting 
other DMD exons are under development and could theoretically restore reading frame 
in majority of patients. The fact that such drugs rely on specific sequence information and 
target the proximate cause of the disease makes these one of the first examples of precision 
genetic medicine [104, 107].
A common denominator to the spectrum of neurological disorders and selenium seems to 
be oxygen toxicity. Difficulties exist in giving proper weight to the interaction of the com-
ponents of a complex system like the brain’s antioxidant defense. The presence of multiple 
and contemporaneous control mechanisms means that a dysregulated system is impaired 
not only  in one but more regulatory or homeostatic mechanism. Supplementation by a 
single factor like selenium or together with other antioxidants may to a limited extent sus-
tain these mechanisms. However, much more basic research should be done before these 
complexities can be better understood. The neurological diseases reviewed above have 
provided the theoretical framework for the continued investigation of the efficacy of the 
pharmacological manipulation of glutathione concentration and synthesis in treatment of 
these diseases [108–110].
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Cu-Zn SOD copper zinc superoxide dismutase
ROS reactive oxygen species
CNS central nervous system
DHP enzyme dehydropeptidase










E-GSHPx erythrocyte glutathione peroxidase
EEG electroencephalogram activation: EEG is an essential component in the 
evaluation of epilepsy
CSF cerebrospinal fluid
JNCL juvenile neuronal ceroid lipofuscinosis
MS multiple sclerosis
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Abstract
The essential role of zinc in human health was first suggested by our studies in growth-
retarded Iranian villagers in 1961. Our later studies in 1963 established conclusively that 
zinc was essential for human and that zinc deficiency resulted in severe growth retarda-
tion, hypogonadism in males, immune dysfunctions, and cognitive function impairment. 
The suggestion that zinc was an essential element for humans remained very controver-
sial, but in 1974, the USA National Academy of Sciences declared zinc as an essential 
element for humans and established the recommended dietary allowances. In 1978, the 
FDA and other regulatory agencies made it mandatory to include zinc in total parenteral 
nutrition fluids, which resulted in saving many lives. During the past five decades, tre-
mendous progress has been made in the understanding of the biochemical role of zinc, 
and we now know that zinc therapy has impacted significantly on human health and 
diseases. In this review, I plan to present a brief historical review of the discovery of 
zinc as an essential element for humans, the clinical manifestations of zinc deficiency, its 
therapeutic impact on human health and diseases, biomarkers of human zinc deficiency, 
and its biochemical role.
Keywords: zinc, anti-inflammatory agent, antioxidant agent, oxidative stress, 
inflammatory cytokines
1. Historical review
In 1869, Raulin [1] reported for the first time that zinc was essential for the growth of Aspergillus 
niger. In 1926, it was reported that zinc was required for the growth of the plants, and in 1934, 
it was shown to be a growth factor for the rats [2].
I received my training in medicine as a clinical scientist under Professor Cecil James Watson 
at the University of Minnesota Medical School. The purpose of this training was to train 
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physicians not only in clinical medicine but also in basic sciences so that the clinical scientists 
could investigate the bedside clinical problems in research laboratories and to understand the 
basic mechanisms involved in clinical disorders [1–4].
Following the completion of my training under Dr. Watson in 1958, I was contacted by 
Professor Hobart Reimann, Chief of Medicine, Jefferson Medical College in Philadelphia. 
Professor Reimann who was a personal friend of the Shah of Iran had just accepted a position 
as Chief of Medicine at Shiraz University, Iran, and he offered me a position at the Shiraz 
Medical School to set up a medical curriculum for students and physicians in training on an 
American pattern. Although I was initially very reluctant, I did accept this offer and arrived 
in Shiraz, Iran, in July 1958.
The story of zinc began when an Iranian physician presented to me a severely anemic 
21-year-old male, who looked like a 10-year-old boy, at the medical school grand round. His 
genitalia were infantile. He had rough and dry skin, was mentally lethargic, and had hepa-
tosplenomegaly. He ate only bread made of whole wheat flour, he had no intake of animal 
protein, and in addition he ate 1 pound of clay every day. His severe anemia was due to iron 
deficiency but he had no blood loss. Iron deficiency in adult males without blood loss is a 
very unusual phenomenon.
Iron deficiency alone could not account for the severe growth retardation and infantile genitalia 
as these features are not seen in iron-deficient experimental animals. An examination of the 
periodic table suggested to me that deficiency of another transitional element, perhaps zinc, 
may also have been present, which could account for growth retardation and hypogonadism. 
We considered the possibility that a high phosphate content of the diet and clay may have 
decreased the availability of both iron and zinc which resulted in their deficiencies [3].
Our studies in Egypt later documented that zinc deficiency occurred in humans and that zinc 
supplementation resulted in 5–6 in. of longitudinal growth in 1 year and the genitalia became 
normal within 3–6 months of zinc supplementation [5].
The details of circumstances leading to the discovery of human zinc deficiency have been 
published recently [6].
2. Clinical manifestations of human zinc deficiency
The clinical manifestations of a moderate deficiency of zinc as described in the Middle East 
included growth retardation, hypogonadism in the males, rough skin, poor appetite, mental 
lethargy, delayed wound healing, cell-mediated immune dysfunctions, and abnormal neuro-
sensory changes. These manifestations were reported in subjects with nutritional deficiency 
of zinc [5, 6] and in subjects with conditional deficiency of zinc [7, 8].
It is now apparent that a nutritional deficiency of zinc in humans is globally widespread, par-
ticularly in areas where cereal proteins are primarily consumed. Their diets are high in phy-
tate, an organic phosphate compound which complexes both zinc and iron, and this deficiency 
may be affecting nearly 2 billion subjects in the world [7, 8].
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Zinc deficiency is also prevalent in females in the developing world. Cavdar et al. [9] 
observed decreased plasma zinc levels in almost 30% of the low-socioeconomic-status 
pregnant women in Turkey. Maternal zinc deficiency was associated with severe con-
genital malformation of the central nervous system in the fetuses and increased maternal 
morbidity [9].
In 1973, Barnes and Moynahan [10] reported a 2-year-old girl with severe acrodermatitis 
enteropathica (AE) who was being treated with diiodohydroxyquinoline and a lactose-defi-
cient synthetic diet, but she was unresponsive to this management. The serum zinc level was 
low and this prompted the physicians to administer zinc sulfate. Surprisingly this resulted in 
complete recovery of this patient. This observation was quickly confirmed by others through-
out the world, and many lives were saved by zinc therapy of AE patients.
AE used to be a lethal disease. This is caused by an autosomal recessive genetic disorder 
which usually occurs in infants of Italian, Armenian, or Iranian lineage [7, 8]. The disease 
manifests in the early months of life soon after weaning from breastfeeding. The dermatologic 
manifestations of severe zinc deficiency in AE patients include bullous pustular dermatitis of 
the extremities and the oral, anal, and genital areas around the orifices, paronychia, and alo-
pecia. Ophthalmic signs include blepharitis, conjunctivitis, photophobia, and corneal opaci-
ties. Neuropsychiatric signs include irritability, emotional instability, tremors, and cerebellar 
ataxia. Other manifestations include growth retardation, weight loss, and male hypogonad-
ism. Congenital malformation of fetuses and infants born of pregnant women with AE has 
been frequently observed [7, 8].
AE patients have increased susceptibility to infections. Immune dysfunction is due to abnor-
mal Th1 functions. Clinical course is downhill with failure to thrive and complicated by inter-
current bacterial, viral, fungal, or parasitic infections. The disease if unrecognized is fatal. 
Zinc therapy is very effective and is curative.
AE gene has been identified as SCL39A4 and is localized to a ~3.5cm region on 8q24.3 chromo-
some. The gene encodes a histidine-rich protein which is now referred to as ZIP-4, which is a 
member of a large family of transmembrane proteins, known as zinc transporters. In patients 
with AE, mutations in this gene have been demonstrated [11]. So far 31 different mutations 
or variants of the SCL39A4 gene have been identified in AE patients throughout the world 
[12–14].
Covering about 4.5 kb of chromosomal region 8q24.3, the human SLC39A4 gene is composed 
of 12 exons ranging from 55 bP (exon 9) to 292 bP (exon 1) in size and 11 introns ranging from 
76 bP (intron 7) to 506 bP (intron 1). The SLC39A4 gene encodes a 647-amino acid protein 
of about 68 kDa. This protein, which is designated as ZIP-4, belongs to the family of 14 
members of specific ZIP zinc transporters (for zinc-/iron-regulated transporter-like protein) 
which facilitate zinc influx from outside the cell to cellular compartments into the cytoplasm 
[11–14]. We have previously reported a new mutation in exon 3 of the SCL39A4 gene in a 
Tunisian family with severe AE [14], and recently we have observed two new mutations 
(unpublished), one in a United Arab Emirate (UAE) family, which showed a mutation in 
exon 7, Gly 409→Arg, and the other in a patient from Turkey, which showed the mutation in 
exon 7 Leu 415→Pro.
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3. Severe zinc deficiency in total parenteral nutrition (TPN) patients
Kay and Tasman-Jones reported the occurrence of severe zinc deficiency in subjects receiv-
ing TPN without zinc for prolonged periods [15]. Okada et al. [16] also reported similar 
observations in 1976. The clinical features were similar to those reported in AE patients. 
These complications of TPN fluids were completely prevented after 1978 when it was made 
mandatory to include zinc in TPN fluids. In 1976 we reported a severe deficiency of zinc in 
a patient with Wilson’s disease who was treated with penicillamine and eventually became 
severely deficient of zinc due to chelation therapy. The manifestations were similar to AE 
patients [17].
We developed an experimental model of mild deficiency of zinc in human volunteers in 1978 
[18]. The details of dietary preparation and experimental model studies have been published 
in detail before [18]. A semi-purified diet which supplied all essential nutrients in RDA 
amounts except zinc which was restricted to approximately 3.0–5.0 mg of zinc daily was used 
to induce zinc deficiency [18].
In this model as a result of specific mild deficiency of zinc, we observed decreased serum tes-
tosterone level, oligospermia, decreased natural killer (NK) cell activity, decreased IL-2 (inter-
leukin-2) activity of T helper cells, decreased serum thymulin activity, hyperammonemia, 
hypogeusia, decreased dark adaptation, and decreased lean body mass [18–21]. Our study 
clearly established that even a mild deficiency of zinc in humans adversely affects clinical, 
biochemical, and immunological functions.
4. Biomarkers of zinc deficiency
In the Middle East, we assayed zinc in plasma, red blood cells, 24-h urine, and hair by dithi-
zone technique [4]. This technique was very difficult and labor intensive but there was noth-
ing easier available. Extreme precautions were taken to avoid contamination. We also utilized 
Zn65 to study zinc metabolism in our subjects [4].
Zinc levels were decreased in plasma, red blood cells, 24-h urine, and hair in the growth-
retarded subjects in comparison to the controls. The plasma zinc turnover rate was greater, 
and the 24-h zinc exchangeable pool was decreased significantly in the dwarfs. The cumula-
tive excretion of zinc in urine and stool in 13 days was decreased in the dwarfs, in comparison 
to the controls, indicating body conservation of zinc in the zinc-deficient subjects. We con-
cluded from these results that the dwarfs were zinc deficient. This was the first demonstration 
that zinc deficiency in humans occurred [4].
On daily oral supplementation with 15 mg zinc as sulfate, the growth rate was 5–6 in. 
per year in the dwarfs, and the external genitalia became adult like within 6 months of 
supplementation [5].
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5. Atomic absorption spectrophotometric assay for zinc (AAS)
In 1965 we published the first technique of zinc measurement in plasma and blood cells by 
the use of atomic absorption spectrophotometer (AAS), and this technique is currently being 
used all over the world [22].
At present plasma zinc by AAS is being widely used as a biomarker of zinc deficiency glob-
ally. The machine is expensive, needs careful maintenance, and is not easily available in 
developing countries. Furthermore, plasma zinc assay is not a specific biomarker of zinc defi-
ciency in humans inasmuch as the plasma zinc pool changes as a result of infections, exercise, 
and stress. Also, even slight hemolysis increases the plasma zinc inasmuch as the red cells 
are very rich in zinc.
6. Biomarkers of zinc deficiency in experimental human zinc 
deficiency model
We used a semi-purified diet based on texturized soy protein which provided all nutrients 
in RDA amounts except for zinc which was 3–5 mg/d. The RDA for zinc is 12–15 mg/d. The 
details of experimental model studies have been published before [18].
In this model we studied the effect of zinc deficiency on zinc levels in plasma, blood cells, 
zinc-dependent enzymes, and immunological functions.
We observed that the assay of ecto 5’ nucleotidase (5’NT), a zinc-dependent enzyme, which 
is present in plasma membrane of lymphocytes and is a marker of cell maturity, was a very 
sensitive test for human zinc deficiency [23]. We observed that the activity of 5’NT decreased 
during early zinc depletion phase (4–8 weeks). Plasma zinc did not change until 24 weeks of 
zinc restriction.
We also assayed serum zinc thymulin activity in our experimental model of human zinc 
deficiency subjects [21]. Thymulin is a thymic hormone which requires zinc for its activity. 
Thymulin is required for the development and differentiation of T helper cells. In our sub-
jects, we observed that serum thymulin activity decreased within 8–12 weeks following zinc-
restricted diet, suggesting that this test was also a very sensitive biomarker of zinc deficiency. 
This correlated well with our observation that the generation of IL-2 and its mRNA were also 
decreased during the early zinc depletion phase, 8–12 weeks after initiation of zinc-restricted 
diet [20, 24, 25].
Thus, our studies revealed that the assay of immunological markers is perhaps the most sensi-
tive biomarker of human zinc deficiency. We have published that the assay of IL-2 mRNA in 
peripheral blood mononuclear cells by RT-PCR was a very good indicator of zinc deficiency 
in humans [25].
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7. Endogenous excretion of zinc as a biomarker of zinc deficiency
Humans maintain zinc homeostasis by increasing efficacy of zinc absorption and decreasing 
endogenous excretion of zinc when they are subjected to short-term dietary zinc restriction. 
However, a mild deficiency of zinc in humans is usually an outcome of chronic exposure to 
low dietary zinc for many months and years.
We, therefore, assessed the efficiency of zinc absorption as well as endogenous zinc excretion 
during a 6-month period of dietary zinc restriction by the use of Zn70. Our studies showed that 
the efficiency of zinc absorption was not sustained and decreased in the volunteers when the 
zinc-restricted diet was continued for 6 months [26]. On the other hand, prolonged dietary 
zinc restriction did not impair the functional role of endogenous zinc excretion in zinc homeo-
stasis. We observed a significant reduction of endogenous zinc excretion by restricting dietary 
zinc for 6 months. Our studies thus showed that the measurement of endogenous zinc excre-
tion may also be a sensitive biomarker of human zinc deficiency.
In collaboration with Dr. Chris Fredrickson, we are currently developing a cost-effective, 
exportable instrument which uses laser-induced background spectroscopy (LIBS) for the 
measurement of zinc in tissue, plasma, and blood cells. Our preliminary studies have shown 
that measurement of zinc by LIBS technique in nails is an excellent technique for assessing 
chronic zinc deficiency in humans.
8. Therapeutic impact of zinc
8.1. Acute diarrhea in children
Zinc supplementation has been shown to prevent and treat diarrhea in children under 5 years 
of age decreasing both diarrhea and mortality [27, 28]. Zinc deficiency is also correlated with 
risk of respiratory tract infections, but the benefits of supplementation appears to be limited 
to more severe episodes and in populations with high incidence of zinc deficiency [28].
Diarrhea causes damage to absorptive mucosa of the intestines and decreases absorption of 
nutrients including zinc. Children with low plasma zinc were observed to be more susceptible 
to diarrhea, thus resulting in a vicious cycle of zinc deficiency and infection.
In 2004 the World Health Organization (WHO) issued a global recommendation for the daily 
supplementation of 20 mg zinc in children ≥6 months for 10–14 days upon diarrheal onset [28].
Meta-analysis of routine supplementation for up to 3 months in seven studies providing one 
to two times RDA elemental zinc five to seven times per week found an 18% reduction in 
diarrheal incidence, or 25% decrease in diarrhea prevalence, and a 33% reduction in persis-
tent diarrhea episodes among supplemented children in comparison to those who received 
placebo [28]. A meta-analysis of three randomized controlled trials providing short course 
of zinc supplementation with two to four times the daily RDA for 2 weeks following the 
onset of acute or persistent diarrhea was also reported. The pooled analysis showed an 11% 
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decrease in diarrhea incidence and a 34% decrease in diarrhea prevalence during 3 months 
of observation.
8.2. Zinc for the treatment of common cold
Common cold is one of the most frequently occurring diseases in the world [29]. More than 
20 viruses cause common cold, and these include rhinoviruses, corona viruses, adenoviruses, 
respiratory syncytial viruses, and parainfluenza viruses. In the USA, adults may suffer of 
common cold two to four times and children six to eight times per year. The morbidity and 
subsequent financial loss resulting from absenteeism from work are considerable. Previous 
treatments have not resulted in a consistent relief of symptoms.
We tested the efficacy of zinc acetate lozenges in common cold in 50 volunteers who were 
recruited within 24 h of the onset of common cold symptoms, and we carried out a double-
blind placebo-controlled trial [29]. Participants took one lozenge containing 12-8 mg zinc (as 
acetate) or placebo every 2–3 h while awake as soon as they developed common cold symp-
toms. Subjective symptom scores for sore throat, nasal discharge, nasal congestion, sneezing, 
cough, scratchy throat, hoarseness, muscle ache, fever, and headache were recorded daily for 
12 d. Plasma zinc and pro-inflammatory cytokines were assayed on day 1 and at the end when 
subjects were well.
Compared to the placebo group, the zinc group had shorter overall duration of cold symp-
toms (4.5 d vs 8.1 d, p < 0.01), nasal discharge (4.1 d vs 5.8 d, p = 0.02), and decreased total 
severity scores for all symptoms (p = 0.02).
In another study, we recruited 50 ambulatory volunteers within 24 h of the onset of common 
cold for randomized placebo-controlled trial of zinc lozenges [30]. Each lozenge contained 
13.3 mg of zinc as acetate. Plasma zinc, soluble interleukin (IL-1) receptor antagonist (sIL-
1ra), soluble tumor necrosis factor receptor-1, and soluble vascular endothelial cell adhesion 
molecule (SICAM)-1 were assayed on days 1 and 5 [30].
Compared with the placebo group, the zinc group had a shorter mean duration of common 
cold (4.0 d vs 7.1 d, p = 0.001), shorter duration of cough (2.1 d vs 5.0 d, p < 0.001), and nasal 
discharge (3.0 d vs 4.5 d, p = 0.02). The mean changes between zinc and the placebo groups 
(before vs after therapy) showed significant difference in sIL-1-ra (interleukin-1 receptor 
antagonist) (p = 0.033) and sICAM-1 (p = 0.04). Both decreased in the zinc group, and the 
mean changes between zinc and placebo group (before vs after therapy) showed significant 
differences (p < 0.001). Our results suggest that zinc decreased oxidative stress of monocytes 
and macrophages induced by the common cold viruses.
Human rhinovirus type 24 “docks” at ICAM-1 on the surface of the somatic cells [30]. Our 
results showed that zinc may have acted as an antiviral agent by reducing the ICAM-1 levels. 
We have also reported earlier that zinc downregulates NF-κB activity which is involved in 
gene regulation of ICAM-1 [30].
We conclude that zinc acetate lozenges are effective in decreasing the duration and severity 
of common cold symptoms. We also conclude that these beneficial effects of zinc on common 
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cold symptoms are due to the anti-inflammatory and antioxidant effect of zinc. A meta-anal-
ysis published by Cochrane has confirmed our results and conclusions [31].
8.3. Zinc deficiency in sickle cell disease (SCD)
Our extensive studies have documented the occurrence of zinc deficiency in SCD adult 
patients [31]. Growth retardation, male hypogonadism, hyperammonemia, abnormal dark 
adaptation, and cell-mediated immune dysfunctions in SCD patients have been related to 
a deficiency of zinc. Zinc deficiency was associated with decreased levels of zinc in plasma, 
erythrocytes, lymphocytes, and hair; hyperzincuria; decreased activity of zinc-dependent 
enzymes such as carbonic anhydrase activity in erythrocytes, alkaline phosphatase activity 
in granulocytes, and deoxythymidine kinase activity in newly synthesizing collagen con-
nective tissue; and hyperammonemia [32]. Zinc supplementation to SCD patients resulted 
in significant improvement in growth; secondary sexual characteristics; normalization of 
plasma ammonia levels; correction of dark adaptation; increased zinc levels in plasma, 
erythrocytes, lymphocytes, and granulocytes; and expected response of zinc on zinc-
dependent enzymes [32, 33]. Zinc supplementation also corrected impaired delayed-type 
hypersensitivity (DTH).
A recent Cochrane review has concluded that zinc is the only therapeutic modality which 
results in decreased incidence of infections and pain crises [34].
8.4. Zinc therapy for Wilson’s disease (WD)
Wilson’s disease is an inherited autosomal disorder due to copper accumulation. The excre-
tion of liver copper in the bile is deceased which leads to the decreased loss of copper in the 
stool. This leads to accumulation of copper in the liver. Eventually copper accumulates in the 
brain, kidneys, and other organs. Patients present with liver disease, neurological disease 
(movement disorder), or psychiatric disturbance in the second to fourth decades of life. In 
many cases the diagnosis is missed by the physician [35].
The genetic mutation of Wilson’s disease gene leads to a defective generation of a protein 
called ATP 7B which is responsible for a key step in biliary excretion of copper [35–37]. The 
disease is recessive, and thus both copies of the ATP 7B gene have to be mutated to cause 
the disease. A large number of mutations in this gene causing Wilson’s disease have been 
reported.
Early diagnosis of Wilson’s disease is important inasmuch as effective therapy may prevent 
toxic accumulation of copper and damage to organs.
Ninety percent of the WD patients have low levels of ceruloplasmin and ceruloplasmin-bound 
copper, but non-ceruloplasmin copper is elevated in the plasma. Twenty four hour urinary 
copper is markedly elevated and this is a helpful diagnostic tool. Urinary copper, however, 
may be elevated also in patients with obstructive liver disease.
A slit lamp examination for copper deposits in the cornea (Kayser-Fleischer rings) is a very 
useful noninvasive diagnostic test for WD. This is positive in nearly 50% of the cases.
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Several years ago, we were using 150 mg elemental zinc in six divided doses as an effective 
anti-sickling agent for the treatment of patients with sickle cell disease (SCD) [38]. At this level 
of zinc therapy, we observed that we induced copper deficiency in SCD patients [38]. This led 
Brewer et al. [35–37] to develop zinc as an effective anti-copper drug for WD.
Zinc competes with copper for similar binding sites, and oral doses of zinc efficiently decrease 
the uptake of copper [39]. Zinc may act by inducing intestinal metallothionein (MT) which has 
a high affinity for binding copper. This prevents the serosal transfer of copper into the blood 
pool. The intestinal cells turn over rapidly and take the complexed copper in stool for excre-
tion. Zinc not only blocks food copper but also the copper which is endogenously excreted 
via salivary, gastric, and other gastrointestinal juices. Thus zinc is effective in producing a 
negative balance of copper.
Fifty milligrams of zinc (as acetate) is given orally three times a day to WD patients. Zinc 
must be given in a fasting or post absorptive state. The only side effect of zinc is that nearly 
10% of the subjects may experience mild gastric discomfort. This can be avoided if zinc is 
administered between breakfast and lunch or after dinner before going to bed.
Zinc is the drug of choice for maintenance therapy. Zinc has no toxicity and is non-teratogenic, 
and it can be prescribed to subjects of all ages and even to pregnant women. Zinc has been 
approved by the FDA for the treatment of WD patients.
8.5. Zinc and age-related macular degeneration (AMD)
Age-related macular degeneration (AMD) affects nearly 25% of the subjects over 65 years of 
age, and late stage of disease accounts for nearly 50% of legal blindness in Europe and North 
America [40]. Newsome et al. [40] reported for the first time that zinc concentration is reduced 
in the human eye in patients with AMD, and they suggested that zinc deficiency may have led 
to oxidative stress and retinal damage.
The Age-Related Eye Disease Study (AREDS) group, supported by the National Eye Institute, 
NIH, conducted a double-blind clinical trial in patients with dry-type AMD in 11 centers [41]. 
They enrolled 3640 patients for trial. Their ages ranged from 55 to 80 years, and the average 
follow-up period was 6.3 years. Participants were assigned randomly to receive orally one 
of the following: (1) antioxidants (vitamin C, 500 mg; vitamin E, 400 IU; and beta carotene, 
15 mg); (2) zinc 80 mg as zinc oxide and copper 2 mg as copper oxide, to prevent copper 
deficiency induced by zinc; (3) antioxidants plus zinc; or (4) placebo.
The group taking the antioxidant plus zinc reduced the risk of developing advanced AMD by 
about 25% and the vision loss by 19%.
The group taking zinc alone reduced the risk of developing advanced AMD by about 21% 
and the vision loss by 11%. In the group taking the vitamins alone, the risk of developing 
advanced AMD was decreased by 17%, and the vision loss was decreased by 10%. Only the 
zinc-supplemented group showed increased longevity [42, 43]. The risk of mortality was 
reduced by 27% in subjects who received only zinc. In a later publication, the AREDS group 
reported that a decrease in mortality was due to a decrease in the adverse cardiovascular 
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cold symptoms are due to the anti-inflammatory and antioxidant effect of zinc. A meta-anal-
ysis published by Cochrane has confirmed our results and conclusions [31].
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Our extensive studies have documented the occurrence of zinc deficiency in SCD adult 
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adaptation, and cell-mediated immune dysfunctions in SCD patients have been related to 
a deficiency of zinc. Zinc deficiency was associated with decreased levels of zinc in plasma, 
erythrocytes, lymphocytes, and hair; hyperzincuria; decreased activity of zinc-dependent 
enzymes such as carbonic anhydrase activity in erythrocytes, alkaline phosphatase activity 
in granulocytes, and deoxythymidine kinase activity in newly synthesizing collagen con-
nective tissue; and hyperammonemia [32]. Zinc supplementation to SCD patients resulted 
in significant improvement in growth; secondary sexual characteristics; normalization of 
plasma ammonia levels; correction of dark adaptation; increased zinc levels in plasma, 
erythrocytes, lymphocytes, and granulocytes; and expected response of zinc on zinc-
dependent enzymes [32, 33]. Zinc supplementation also corrected impaired delayed-type 
hypersensitivity (DTH).
A recent Cochrane review has concluded that zinc is the only therapeutic modality which 
results in decreased incidence of infections and pain crises [34].
8.4. Zinc therapy for Wilson’s disease (WD)
Wilson’s disease is an inherited autosomal disorder due to copper accumulation. The excre-
tion of liver copper in the bile is deceased which leads to the decreased loss of copper in the 
stool. This leads to accumulation of copper in the liver. Eventually copper accumulates in the 
brain, kidneys, and other organs. Patients present with liver disease, neurological disease 
(movement disorder), or psychiatric disturbance in the second to fourth decades of life. In 
many cases the diagnosis is missed by the physician [35].
The genetic mutation of Wilson’s disease gene leads to a defective generation of a protein 
called ATP 7B which is responsible for a key step in biliary excretion of copper [35–37]. The 
disease is recessive, and thus both copies of the ATP 7B gene have to be mutated to cause 
the disease. A large number of mutations in this gene causing Wilson’s disease have been 
reported.
Early diagnosis of Wilson’s disease is important inasmuch as effective therapy may prevent 
toxic accumulation of copper and damage to organs.
Ninety percent of the WD patients have low levels of ceruloplasmin and ceruloplasmin-bound 
copper, but non-ceruloplasmin copper is elevated in the plasma. Twenty four hour urinary 
copper is markedly elevated and this is a helpful diagnostic tool. Urinary copper, however, 
may be elevated also in patients with obstructive liver disease.
A slit lamp examination for copper deposits in the cornea (Kayser-Fleischer rings) is a very 
useful noninvasive diagnostic test for WD. This is positive in nearly 50% of the cases.
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Several years ago, we were using 150 mg elemental zinc in six divided doses as an effective 
anti-sickling agent for the treatment of patients with sickle cell disease (SCD) [38]. At this level 
of zinc therapy, we observed that we induced copper deficiency in SCD patients [38]. This led 
Brewer et al. [35–37] to develop zinc as an effective anti-copper drug for WD.
Zinc competes with copper for similar binding sites, and oral doses of zinc efficiently decrease 
the uptake of copper [39]. Zinc may act by inducing intestinal metallothionein (MT) which has 
a high affinity for binding copper. This prevents the serosal transfer of copper into the blood 
pool. The intestinal cells turn over rapidly and take the complexed copper in stool for excre-
tion. Zinc not only blocks food copper but also the copper which is endogenously excreted 
via salivary, gastric, and other gastrointestinal juices. Thus zinc is effective in producing a 
negative balance of copper.
Fifty milligrams of zinc (as acetate) is given orally three times a day to WD patients. Zinc 
must be given in a fasting or post absorptive state. The only side effect of zinc is that nearly 
10% of the subjects may experience mild gastric discomfort. This can be avoided if zinc is 
administered between breakfast and lunch or after dinner before going to bed.
Zinc is the drug of choice for maintenance therapy. Zinc has no toxicity and is non-teratogenic, 
and it can be prescribed to subjects of all ages and even to pregnant women. Zinc has been 
approved by the FDA for the treatment of WD patients.
8.5. Zinc and age-related macular degeneration (AMD)
Age-related macular degeneration (AMD) affects nearly 25% of the subjects over 65 years of 
age, and late stage of disease accounts for nearly 50% of legal blindness in Europe and North 
America [40]. Newsome et al. [40] reported for the first time that zinc concentration is reduced 
in the human eye in patients with AMD, and they suggested that zinc deficiency may have led 
to oxidative stress and retinal damage.
The Age-Related Eye Disease Study (AREDS) group, supported by the National Eye Institute, 
NIH, conducted a double-blind clinical trial in patients with dry-type AMD in 11 centers [41]. 
They enrolled 3640 patients for trial. Their ages ranged from 55 to 80 years, and the average 
follow-up period was 6.3 years. Participants were assigned randomly to receive orally one 
of the following: (1) antioxidants (vitamin C, 500 mg; vitamin E, 400 IU; and beta carotene, 
15 mg); (2) zinc 80 mg as zinc oxide and copper 2 mg as copper oxide, to prevent copper 
deficiency induced by zinc; (3) antioxidants plus zinc; or (4) placebo.
The group taking the antioxidant plus zinc reduced the risk of developing advanced AMD by 
about 25% and the vision loss by 19%.
The group taking zinc alone reduced the risk of developing advanced AMD by about 21% 
and the vision loss by 11%. In the group taking the vitamins alone, the risk of developing 
advanced AMD was decreased by 17%, and the vision loss was decreased by 10%. Only the 
zinc-supplemented group showed increased longevity [42, 43]. The risk of mortality was 
reduced by 27% in subjects who received only zinc. In a later publication, the AREDS group 
reported that a decrease in mortality was due to a decrease in the adverse cardiovascular 
Zinc in Human Health
http://dx.doi.org/10.5772/intechopen.92005
193
events [43]. These results of zinc supplementation in the elderly are remarkable and suggest 
that the anti-inflammatory effect of zinc may be beneficial in patients with atherosclerosis.
8.6. Zinc deficiency in the elderly
The daily intake of zinc in the elderly in the Western world including the USA is only approxi-
mately 8–10 mg, whereas the RDA as reported in 1974 is 15 mg [44]. Frequently the elderly do 
not routinely eat three meals a day. Many live alone and do not cook a proper meal.
Our study in Detroit showed that 35% of the well-to-do ambulatory elderly subjects may have 
a deficiency of zinc [44–46]. Results of the third National Health and Nutrition Examination 
Survey (1988–1994) also reported that the elderly subjects >71 years were at great risk of inad-
equate zinc intake.
Oxidative stress and increased inflammatory cytokines have been recognized as important 
contributing factors for several chronic diseases attributed to aging, such as atherosclerosis 
and related cardiovascular disorders, mutagenesis and cancer, neurodegenerative disorders, 
type 2 diabetes, and Alzheimer’s disease. Together, O2−, H2O2, and OH·− radicals are known 
as reactive oxygen species (ROS), and excessive generation of ROS causes oxidative stress. 
Inflammatory cytokines such as TNF-α, IL-1β, and IL-6 generated by activated monocytes and 
macrophages are also known to generate excessive ROS.
We have shown that zinc supplementation to subjects ages 20–50 decreased oxidative stress 
markers such as malondialdehyde (MDA), 4-hydroxy-alkelans (HAE), and 8-hydroxydeoxy-
guanine in the plasma and downregulated the ex vivo induction of TNF-α and IL-1β mRNA 
in mononuclear cells (MNCs) by decreasing TNF-α induced NF-κB induction [46]. We have 
also reported that in the promyelocytic leukemia cell line HL60, which differentiates to the 
monocyte and macrophage phenotype in response to phorbol-12-myristate-13 acetate (PMA), 
zinc upregulated the expression of A20 and the binding of A20 to trans-activating factor to 
DNA which resulted in the inhibition of NF-κB activation [45, 46].
We carried out a randomized placebo-controlled trial of zinc supplementation in 50 healthy 
elderly subjects (55–87 y) of both sexes and all ethnic groups in Detroit, MI. Exclusion criteria 
were life expectancy of <8 mo, progressive neoplastic disease, severe cardiac dysfunction, sig-
nificant renal disease, significant liver disease, and subjects who were mentally incompetent. 
Zinc supplementation consisted of 45 mg elemental zinc as gluconate daily for 12 mo.
A comparison of our baseline data in the elderly with the younger adults showed that in the 
elderly, plasma zinc was lower and the percentage of cells producing IL-1β and TNF-α and the 
generated cytokines were significantly higher [45, 46]. IL-10 generated by Th2 cells which is 
known to downregulate IL-2 generation from Th1 cells was significantly higher in the elderly. 
The oxidative stress markers were also significantly higher in the elderly than the younger 
adults [45].
The mean incidence of infections was lower (p < 0.01) in the zinc-supplemented group 
(1.4 ± 0.95) vs placebo group (20.29 ± 0.46). The plasma zinc increased, and ex vivo generation 
of TNF-α and IL-10 significantly decreased in the zinc group in comparison to the placebo 
group [45, 46]. Oxidative stress markers in the plasma also decreased in the zinc group in 
comparison to the placebo group [46].
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In MNCs isolated from zinc-deficient elderly subjects, zinc supplementation increased the 
ex vivo PHA induced IL-2 mRNA expression and plasma zinc concentration when compared 
to the placebo group.
Thus our study showed that zinc supplementation to the elderly subjects decreased the 
incidence of infection by nearly 66%. Following zinc supplementation the oxidative stress 
markers and the generation of inflammatory cytokines which were increased prior to supple-
mentation significantly declined. These are very significant effects of zinc supplementation 
and may imply that zinc may prove to be an excellent agent for prevention of some of the 
chronic diseases in the elderly.
8.7. Biochemical mechanisms of zinc
When I started my studies in zinc metabolism in the early sixties, I knew of only three 
enzymes which required zinc for their functions. These were carbonic anhydrase, carboxy-
peptidase, and alcohol dehydrogenase. Now we understand that there is hardly any cellular 
process that does not depend upon zinc in some way. Zinc is a constituent of at least 2800 
human protein structures, enzymatic catalysis, and cellular regulation. The largest group of 
zinc metalloenzymes is proteinases [47]. Zinc has a major role in the structural organization 
of protein domains that interact with DNA/RNA, other proteins, and lipids. Several dozen 
proteins control cellular and subcellular zinc homeostasis and redistribution. This control is 
essential for regulatory functions of free zinc (II) ions.
Free zinc intracellularly regulates the activity of several kinases, phosphatases, phosphodies-
terases, caspases, and transcription factors.
8.8. Zinc and growth
IGF-1 is a zinc-dependent growth factor. Zinc is required for generation of IGF-1, and its 
receptor tyrosine kinase requires zinc for phosphorylation. IGF-1 intracellularly upregulates 
thymidine uptake by the nucleus which is converted to dTMP and dTTP for DNA synthesis. 
The enzyme deoxy thymidine kinase (TK) is required for the synthesis of TTP. Our studies 
have shown that zinc is required for the gene expression of TK. Thus zinc is involved at vari-
ous steps for DNA synthesis and cell proliferation. Other enzymes such as DNA polymerase 
and RNA polymerase are also zinc dependent.
8.9. Zinc and immune cells
Zinc is a second messenger for immune cells, and intracellular zinc participates in signaling 
events [21, 48–51]. Hirano et al. [48, 49] have shown that a decrease in intracellular free zinc 
in T cells is essential for LPS-mediated CD4+ activation by dendritic cells (DCs). LPS binds to 
TLR-4 on DCs and activates Myd88 and TRIF-mediated signaling [48]. TRIF-mediated signal-
ing upregulates ZnT-5 mRNA and downregulates ZIP-6 mRNA, resulting in a decrease of 
intracellular free zinc in DCs. Reduction in intracellular free zinc increases the expression of 
MHC class II molecules which is required for the activation of CD4+ T cells [48].
Zinc activates monocytes-macrophages in several ways. Zinc is required for the develop-
ment of monocytes-macrophages and regulates its functions such as phagocytosis and 
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events [43]. These results of zinc supplementation in the elderly are remarkable and suggest 
that the anti-inflammatory effect of zinc may be beneficial in patients with atherosclerosis.
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The daily intake of zinc in the elderly in the Western world including the USA is only approxi-
mately 8–10 mg, whereas the RDA as reported in 1974 is 15 mg [44]. Frequently the elderly do 
not routinely eat three meals a day. Many live alone and do not cook a proper meal.
Our study in Detroit showed that 35% of the well-to-do ambulatory elderly subjects may have 
a deficiency of zinc [44–46]. Results of the third National Health and Nutrition Examination 
Survey (1988–1994) also reported that the elderly subjects >71 years were at great risk of inad-
equate zinc intake.
Oxidative stress and increased inflammatory cytokines have been recognized as important 
contributing factors for several chronic diseases attributed to aging, such as atherosclerosis 
and related cardiovascular disorders, mutagenesis and cancer, neurodegenerative disorders, 
type 2 diabetes, and Alzheimer’s disease. Together, O2−, H2O2, and OH·− radicals are known 
as reactive oxygen species (ROS), and excessive generation of ROS causes oxidative stress. 
Inflammatory cytokines such as TNF-α, IL-1β, and IL-6 generated by activated monocytes and 
macrophages are also known to generate excessive ROS.
We have shown that zinc supplementation to subjects ages 20–50 decreased oxidative stress 
markers such as malondialdehyde (MDA), 4-hydroxy-alkelans (HAE), and 8-hydroxydeoxy-
guanine in the plasma and downregulated the ex vivo induction of TNF-α and IL-1β mRNA 
in mononuclear cells (MNCs) by decreasing TNF-α induced NF-κB induction [46]. We have 
also reported that in the promyelocytic leukemia cell line HL60, which differentiates to the 
monocyte and macrophage phenotype in response to phorbol-12-myristate-13 acetate (PMA), 
zinc upregulated the expression of A20 and the binding of A20 to trans-activating factor to 
DNA which resulted in the inhibition of NF-κB activation [45, 46].
We carried out a randomized placebo-controlled trial of zinc supplementation in 50 healthy 
elderly subjects (55–87 y) of both sexes and all ethnic groups in Detroit, MI. Exclusion criteria 
were life expectancy of <8 mo, progressive neoplastic disease, severe cardiac dysfunction, sig-
nificant renal disease, significant liver disease, and subjects who were mentally incompetent. 
Zinc supplementation consisted of 45 mg elemental zinc as gluconate daily for 12 mo.
A comparison of our baseline data in the elderly with the younger adults showed that in the 
elderly, plasma zinc was lower and the percentage of cells producing IL-1β and TNF-α and the 
generated cytokines were significantly higher [45, 46]. IL-10 generated by Th2 cells which is 
known to downregulate IL-2 generation from Th1 cells was significantly higher in the elderly. 
The oxidative stress markers were also significantly higher in the elderly than the younger 
adults [45].
The mean incidence of infections was lower (p < 0.01) in the zinc-supplemented group 
(1.4 ± 0.95) vs placebo group (20.29 ± 0.46). The plasma zinc increased, and ex vivo generation 
of TNF-α and IL-10 significantly decreased in the zinc group in comparison to the placebo 
group [45, 46]. Oxidative stress markers in the plasma also decreased in the zinc group in 
comparison to the placebo group [46].
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ex vivo PHA induced IL-2 mRNA expression and plasma zinc concentration when compared 
to the placebo group.
Thus our study showed that zinc supplementation to the elderly subjects decreased the 
incidence of infection by nearly 66%. Following zinc supplementation the oxidative stress 
markers and the generation of inflammatory cytokines which were increased prior to supple-
mentation significantly declined. These are very significant effects of zinc supplementation 
and may imply that zinc may prove to be an excellent agent for prevention of some of the 
chronic diseases in the elderly.
8.7. Biochemical mechanisms of zinc
When I started my studies in zinc metabolism in the early sixties, I knew of only three 
enzymes which required zinc for their functions. These were carbonic anhydrase, carboxy-
peptidase, and alcohol dehydrogenase. Now we understand that there is hardly any cellular 
process that does not depend upon zinc in some way. Zinc is a constituent of at least 2800 
human protein structures, enzymatic catalysis, and cellular regulation. The largest group of 
zinc metalloenzymes is proteinases [47]. Zinc has a major role in the structural organization 
of protein domains that interact with DNA/RNA, other proteins, and lipids. Several dozen 
proteins control cellular and subcellular zinc homeostasis and redistribution. This control is 
essential for regulatory functions of free zinc (II) ions.
Free zinc intracellularly regulates the activity of several kinases, phosphatases, phosphodies-
terases, caspases, and transcription factors.
8.8. Zinc and growth
IGF-1 is a zinc-dependent growth factor. Zinc is required for generation of IGF-1, and its 
receptor tyrosine kinase requires zinc for phosphorylation. IGF-1 intracellularly upregulates 
thymidine uptake by the nucleus which is converted to dTMP and dTTP for DNA synthesis. 
The enzyme deoxy thymidine kinase (TK) is required for the synthesis of TTP. Our studies 
have shown that zinc is required for the gene expression of TK. Thus zinc is involved at vari-
ous steps for DNA synthesis and cell proliferation. Other enzymes such as DNA polymerase 
and RNA polymerase are also zinc dependent.
8.9. Zinc and immune cells
Zinc is a second messenger for immune cells, and intracellular zinc participates in signaling 
events [21, 48–51]. Hirano et al. [48, 49] have shown that a decrease in intracellular free zinc 
in T cells is essential for LPS-mediated CD4+ activation by dendritic cells (DCs). LPS binds to 
TLR-4 on DCs and activates Myd88 and TRIF-mediated signaling [48]. TRIF-mediated signal-
ing upregulates ZnT-5 mRNA and downregulates ZIP-6 mRNA, resulting in a decrease of 
intracellular free zinc in DCs. Reduction in intracellular free zinc increases the expression of 
MHC class II molecules which is required for the activation of CD4+ T cells [48].
Zinc activates monocytes-macrophages in several ways. Zinc is required for the develop-
ment of monocytes-macrophages and regulates its functions such as phagocytosis and 
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pro-inflammatory cytokine production [50, 51]. LPS stimulation of zinc-sufficient monocytes 
results in downregulation of inflammatory cytokines such as TNF-α, IL-6, IL-1β, and IL-8. 
Zinc inhibits the cell membrane phosphodiesterase (PDE), which results in elevated levels of 
second messenger cGMP, which is followed by decreased activation of NF-κB and decreased 
generation of inflammatory cytokines [50, 51]. We have shown that zinc induces A-20, a zinc 
finger transcription factor protein, which inhibits NF-κB signaling via TNF receptor-associated 
pathways, resulting in downregulation of mRNAs of inflammatory cytokines [52, 53]. Based 
on these we propose that zinc is an important anti-inflammatory agent.
Infection or other stresses activate NADPH oxidase in monocytes-macrophages, which 
upregulates the generation of free radicals (O∙−2). Zinc is an inhibitor of NADPH oxidase. In 
the next step, the free radical is converted to H2O2, and the enzyme involved in this process is 
superoxide dismutase, a zinc- and copper-dependent enzyme. H2O2 generates ∙OH ions. Free 
radicals, H2O2 and ∙OH ions, are known as collectively reactive oxygen species (ROS). By the 
above mechanisms, zinc functions as an important antioxidant.
Zinc deficiency adversely affects Th1 functions [29]. Serum thymulin activity and generation 
of Th1 cytokine IL-2 and IFN-γ were adversely affected within 8–12 weeks of institution of 
zinc-restricted diet (3–5 mg daily) in human volunteers, whereas plasma zinc decreased later 
after 20–24 weeks of the institution of the experimental diet. These studies showed that Th1 
cells are very sensitive to zinc restriction. Th2 cytokines were not affected in subjects who 
received experimental zinc-deficient diet. Thymulin is a zinc containing nonapeptide and is 
essential for the development and proliferation of Th cells.
Our studies also showed that several transcription factors such as NF-κB, AP-1, and SP-1 
were zinc dependent and their binding to the DNA of IL-2 gene were decreased, resulting 
in decreased generation of IL-2 [24, 25]. A similar effect of zinc was also seen in generation 
of IFN-γ. Decreased IL-2 resulted in decreased NK and cytolytic T cell activity. Decreased 
IFN-γ along with decreased IL-12, another zinc-dependent cytokine generated by monocyte-
macrophages, results in decreased phagocytosis by monocyte-macrophages.
In Th0, a human malignant lymphoblastoid cell line HUT-78, we showed that in zinc-sufficient 
cells, mRNA levels of IFN-γ, IL-12 Rβ2, and T-bet in PMA-/PHA-stimulated cells were increased 
in comparison to zinc-deficient cells [54]. Although intracellular free zinc increased only 
slightly in PMA-/PHA-stimulated cells, in Con-A stimulated cells in zinc-sufficient medium, 
there was an increased and sustained level of intracellular free zinc in comparison to the zinc-
deficient cells [54]. We hypothesized that in stimulation of cells by Con-A via TCR, there was a 
release of intracellular free zinc which resulted in signal transduction for generation of IFN-γ 
and T-bet, IL-12 Rβ2, and STAT-4 mRNAs which participated in Th-1 cell differentiation.
8.10. Zinc transporters
Zinc transporters maintain intracellular zinc homeostasis very tightly. Ten ZnT (SLC 30) fam-
ily of zinc transporters lower intracellular zinc concentration through export of zinc or by 
import into cellular compartment organelles such as Golgi, intracellular vesicles, mitochon-
dria, or nucleus.
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Fourteen ZIP (SLC 39) transporters are responsible for increasing intracellular zinc concentra-
tion through zinc import into cells or export from intracellular organelles.
In humans, ZIP 4 mutation in AE is known to result in severe deficiency of zinc, which is 
fatal if not recognized and properly treated with zinc. This entity has been discussed in a 
previous section.
A detailed study of Ehlers-Danlos syndrome characterized by progressive kyphoscoliosis, joint 
hypermobility, hyperelasticity of the skin, and severe hypotonicity of skeletal muscles has shown 
that these patients are homozygous for a 9 bp in-frame deletion of exon 4 of SLC 39 A 13 [55].
Bone morphogenetic protein (BMP)/transforming growth factor β (TGF-β) enters the mes-
enchymal cells, fibroblasts, osteoblasts, chondrocytes, etc. for generation of collagen, Max 2, 
hard connective tissue of bone, teeth, and cartilage, etc. Intracellularly BMP/TGF-β activates 
Smad which is then involved in gene expression of collagen, bone, and cartilage. Zinc is 
required for activation of Smad. ZIP-13 mutation, however, affects the activation of Smad by 
zinc, and these results in Ehlers-Danlos syndrome.
In prostate cancer cells, ZIP-1 and ZIP-2 are mutated, and this decreases the intracellular 
zinc concentration of prostate cancer cells. This results in activation of NF-κB, which leads 
to upregulation of anti-apoptotic genes and growth factors and proliferation of cancer cells, 
which leads to progression of prostate cancer. It is possible that proper supplementation of 
zinc in these patients may have a beneficial effect in patients with prostate cancer.
9. Conclusion
The essentiality of zinc for humans was established in 1963. The National Academy of Sciences 
and the US Congress established recommended dietary allowance for zinc in 1974, and the 
FDA made it mandatory to include zinc in the total parenteral nutrition in 1978.
The major clinical effects of zinc deficiency in humans include growth retardation in young 
ages, cell-mediated immune dysfunction, neurosensory disorders, delayed wound healing, 
and cognitive impairment. Currently it is the estimate of the WHO that nearly 2 billion sub-
jects in the developing world may be zinc deficient. This is due to the fact that these popula-
tions mainly subsist on cereal proteins mainly and their diet has high levels of phytate which 
makes zinc unavailable for absorption.
Over 300 enzymes require zinc for their structure stability and activity, and over 2000 tran-
scription factors are zinc dependent. Zinc is a molecular signal for immune and neuronal 
cells. Zinc is essential for thymulin, a thymic hormone which is required for T helper cell dif-
ferentiation and proliferation. Zinc is essential for gene expression of Th1 cytokines. We have 
now documented that several transcription factors such as NF-кB, AP-1, SP-1, A20, T-bet, and 
STAT 4 are zinc dependent and are adversely affected by zinc deficiency. Zinc is required for 
DNA synthesis and cell proliferation, and we have shown that the gene expression of deoxy 
thymidine kinase (TK) is zinc dependent. Zinc not only improves cell-mediated immune 
functions, but it is also an antioxidant and anti-inflammatory agent.
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pro-inflammatory cytokine production [50, 51]. LPS stimulation of zinc-sufficient monocytes 
results in downregulation of inflammatory cytokines such as TNF-α, IL-6, IL-1β, and IL-8. 
Zinc inhibits the cell membrane phosphodiesterase (PDE), which results in elevated levels of 
second messenger cGMP, which is followed by decreased activation of NF-κB and decreased 
generation of inflammatory cytokines [50, 51]. We have shown that zinc induces A-20, a zinc 
finger transcription factor protein, which inhibits NF-κB signaling via TNF receptor-associated 
pathways, resulting in downregulation of mRNAs of inflammatory cytokines [52, 53]. Based 
on these we propose that zinc is an important anti-inflammatory agent.
Infection or other stresses activate NADPH oxidase in monocytes-macrophages, which 
upregulates the generation of free radicals (O∙−2). Zinc is an inhibitor of NADPH oxidase. In 
the next step, the free radical is converted to H2O2, and the enzyme involved in this process is 
superoxide dismutase, a zinc- and copper-dependent enzyme. H2O2 generates ∙OH ions. Free 
radicals, H2O2 and ∙OH ions, are known as collectively reactive oxygen species (ROS). By the 
above mechanisms, zinc functions as an important antioxidant.
Zinc deficiency adversely affects Th1 functions [29]. Serum thymulin activity and generation 
of Th1 cytokine IL-2 and IFN-γ were adversely affected within 8–12 weeks of institution of 
zinc-restricted diet (3–5 mg daily) in human volunteers, whereas plasma zinc decreased later 
after 20–24 weeks of the institution of the experimental diet. These studies showed that Th1 
cells are very sensitive to zinc restriction. Th2 cytokines were not affected in subjects who 
received experimental zinc-deficient diet. Thymulin is a zinc containing nonapeptide and is 
essential for the development and proliferation of Th cells.
Our studies also showed that several transcription factors such as NF-κB, AP-1, and SP-1 
were zinc dependent and their binding to the DNA of IL-2 gene were decreased, resulting 
in decreased generation of IL-2 [24, 25]. A similar effect of zinc was also seen in generation 
of IFN-γ. Decreased IL-2 resulted in decreased NK and cytolytic T cell activity. Decreased 
IFN-γ along with decreased IL-12, another zinc-dependent cytokine generated by monocyte-
macrophages, results in decreased phagocytosis by monocyte-macrophages.
In Th0, a human malignant lymphoblastoid cell line HUT-78, we showed that in zinc-sufficient 
cells, mRNA levels of IFN-γ, IL-12 Rβ2, and T-bet in PMA-/PHA-stimulated cells were increased 
in comparison to zinc-deficient cells [54]. Although intracellular free zinc increased only 
slightly in PMA-/PHA-stimulated cells, in Con-A stimulated cells in zinc-sufficient medium, 
there was an increased and sustained level of intracellular free zinc in comparison to the zinc-
deficient cells [54]. We hypothesized that in stimulation of cells by Con-A via TCR, there was a 
release of intracellular free zinc which resulted in signal transduction for generation of IFN-γ 
and T-bet, IL-12 Rβ2, and STAT-4 mRNAs which participated in Th-1 cell differentiation.
8.10. Zinc transporters
Zinc transporters maintain intracellular zinc homeostasis very tightly. Ten ZnT (SLC 30) fam-
ily of zinc transporters lower intracellular zinc concentration through export of zinc or by 
import into cellular compartment organelles such as Golgi, intracellular vesicles, mitochon-
dria, or nucleus.
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Fourteen ZIP (SLC 39) transporters are responsible for increasing intracellular zinc concentra-
tion through zinc import into cells or export from intracellular organelles.
In humans, ZIP 4 mutation in AE is known to result in severe deficiency of zinc, which is 
fatal if not recognized and properly treated with zinc. This entity has been discussed in a 
previous section.
A detailed study of Ehlers-Danlos syndrome characterized by progressive kyphoscoliosis, joint 
hypermobility, hyperelasticity of the skin, and severe hypotonicity of skeletal muscles has shown 
that these patients are homozygous for a 9 bp in-frame deletion of exon 4 of SLC 39 A 13 [55].
Bone morphogenetic protein (BMP)/transforming growth factor β (TGF-β) enters the mes-
enchymal cells, fibroblasts, osteoblasts, chondrocytes, etc. for generation of collagen, Max 2, 
hard connective tissue of bone, teeth, and cartilage, etc. Intracellularly BMP/TGF-β activates 
Smad which is then involved in gene expression of collagen, bone, and cartilage. Zinc is 
required for activation of Smad. ZIP-13 mutation, however, affects the activation of Smad by 
zinc, and these results in Ehlers-Danlos syndrome.
In prostate cancer cells, ZIP-1 and ZIP-2 are mutated, and this decreases the intracellular 
zinc concentration of prostate cancer cells. This results in activation of NF-κB, which leads 
to upregulation of anti-apoptotic genes and growth factors and proliferation of cancer cells, 
which leads to progression of prostate cancer. It is possible that proper supplementation of 
zinc in these patients may have a beneficial effect in patients with prostate cancer.
9. Conclusion
The essentiality of zinc for humans was established in 1963. The National Academy of Sciences 
and the US Congress established recommended dietary allowance for zinc in 1974, and the 
FDA made it mandatory to include zinc in the total parenteral nutrition in 1978.
The major clinical effects of zinc deficiency in humans include growth retardation in young 
ages, cell-mediated immune dysfunction, neurosensory disorders, delayed wound healing, 
and cognitive impairment. Currently it is the estimate of the WHO that nearly 2 billion sub-
jects in the developing world may be zinc deficient. This is due to the fact that these popula-
tions mainly subsist on cereal proteins mainly and their diet has high levels of phytate which 
makes zinc unavailable for absorption.
Over 300 enzymes require zinc for their structure stability and activity, and over 2000 tran-
scription factors are zinc dependent. Zinc is a molecular signal for immune and neuronal 
cells. Zinc is essential for thymulin, a thymic hormone which is required for T helper cell dif-
ferentiation and proliferation. Zinc is essential for gene expression of Th1 cytokines. We have 
now documented that several transcription factors such as NF-кB, AP-1, SP-1, A20, T-bet, and 
STAT 4 are zinc dependent and are adversely affected by zinc deficiency. Zinc is required for 
DNA synthesis and cell proliferation, and we have shown that the gene expression of deoxy 
thymidine kinase (TK) is zinc dependent. Zinc not only improves cell-mediated immune 
functions, but it is also an antioxidant and anti-inflammatory agent.
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Currently plasma zinc assay by AAS is used globally as a biomarker of zinc deficiency in 
humans. In our experience, this assay is not very sensitive nor specific for zinc deficiency. The 
immunological assays such as measurement of thymulin activity, assay of IL-2 mRNA and 
protein following PHA stimulation of mononuclear cells, and assay of lymphocyte ecto 5’ 
nucleotidase are very specific and sensitive biomarkers of zinc deficiency.
Therapeutic impact of zinc has been tremendous in several conditions. These include treat-
ment of diarrhea in infants and children globally resulting in saving millions of lives, devel-
opment of zinc therapy for Wilson’s disease, common cold, prevention of blindness in elderly 
subjects with AMD, decreasing the incidence of infections and the incidences of adverse car-
diovascular events in the elderly, successful treatment of carbon-monoxide poisoning, and 
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